CA2095633C - Enrichment method for variant proteins with altered binding properties - Google Patents
Enrichment method for variant proteins with altered binding properties Download PDFInfo
- Publication number
- CA2095633C CA2095633C CA002095633A CA2095633A CA2095633C CA 2095633 C CA2095633 C CA 2095633C CA 002095633 A CA002095633 A CA 002095633A CA 2095633 A CA2095633 A CA 2095633A CA 2095633 C CA2095633 C CA 2095633C
- Authority
- CA
- Canada
- Prior art keywords
- hgh
- phage
- binding
- gene
- phagemid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormones [GH] (Somatotropin)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/61—Growth hormones [GH] (Somatotropin)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/802—Protein-bacteriophage conjugates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
Abstract
A method for selecting novel proteins such as growth hormone and antibody fragment variants having altered bind-ing properties for their respective receptor molecules is pro-vided. The method comprises fusing a gene encoding a protein of interest to the carboxy terminal domain of the gene III coat protein of the filamentous phage M13. The gene fusion is mu-tated to form a library of structurally related fusion proteins that are expressed in low quantity on the surface of a phagem-id particle. Biological selection and screening are employed to identify novel ligands useful as drug candidates. Disclosed are preferred phangemid expression vectors and selected human growth hormone variants.
Description
WO 92/09690 ~ ~ ~ ~ PCT/US91 /09133 ENRK:HAAENT IAETHOD FOR YARiANT PROTE~IS WITH ALTERED BINDING PROPERTIES
FIELD OF THE INVENTION
This invention relates to the preparation and systematic selection of novel binding proteins having altered binding properties for a target molecule. Specifically, this irwentan relates to methods for producing foreign polypeptides mimicking the binding activity of naturally occurring binding partners. In preferred embodiments, the invention is directed to the preparation of therapeutic or diagnostic compounds that mimic proteins or nonpeptidyl mole~es such a hormones, dings and other smaN
moleales, particularly biologically active molea~les such as growth hormone.
BACKGROUND OF THE INVENTION
Binding partners are substances chat speafically bind to one another, usually through noncovalent interactions. Examples of binding partners inGude ligand-receptor, antibody-antigen, drug-target, and enzyme-substrate interactions. Binding partners are extremely useful in both therapeutic and diagnostic fields.
Binding partners have been produced in the past by a variety of methods including; harvesting them from nature (e.g., antibody-antigen, and ligand-receptor pairings) and by adventitious identification (e.g.
traditional drug development empbying random screening of candidate molecules). In some instances these two approaches have been combined. For example, variants of proteins or pdypeptides, such as polypeptide fragments, have been made that contain key functional residues that participate in binding. These polypeptide fragments, in tum, have been derivatized by methods akin to traditional drug development. M example of such derivitization would include strategies such as cyclization to confortnationally constrain a polypeptide fragment to produce a novel candidate binding partner.
The problem wish prior art methods is that naturally occurring ligands may not have proper characteristics for all therapeutic applications. Additionally, polypeptide Ggands may not even be available for some target substances. Furthermore, methods for making non~naturally occurring synthetic binding partners are often expensive and difficult, usually requiring complex synthetic methods to produce each candidate. The inability to characterize the structure of the resulting candidate so that rational drug design methods can be applied for further optimizatan of candidate molecules further hampers these methods.
In an attempt to overcome these problems, Geysen (Geysen, Immun. Todav. 6:364-369 [1985]); and (Geysen et al., ~~p~p" 23:709-715 [1986J) has proposed the use of polypeptide synthesis to provide a framework for systematic iterative binding partner identification and preparation. According to Geysen et al., Ibid, short polypeptides, such as dipeptides, are first screened for the ability to bind to a target molecule. The most active dipeptides are then selected for an additional round of testing comprising linking, to the starting dipeptide, an additional residue (or by internally modifying the components of the original starting dipeptide) and then screening this set of candidates for the desired activity. This process is reiterated until the Minding partner having the desired properties is identified.
The Geysen et at. method suffers from the disadvantage that the chemistry upon which it is based, peptide synthesis, produces molecules with ill-defined or variable secondary and tertiary structure. As rounds of iterative selection progress, random interactions accelerate among the various substituent groups of the polypeptide so that a true random population of interactive molecules having reproducible higher order structure becomes lays arid less adainabla. For example, inleractians beMleen side drains of amino acki5. which are sequentiasy widely aeparathd but which are spatialH nelgt,mrs. freely ocax.
Furihertnore, sequences that do not taa~tate confartnationally stable secondary sbuGtureS ~~ ~P~x t~et~-ddectr3in interactions wtxcn may prevent sideChaln in6eracifons of a given amino dad with tyre target motearle.
Such complex interactions are -g taalitated by the Nexittility of die polyamlde back 8t ttta pdypeptide candidates. Additionally, rrandldates may exist In numerous aontormAliOrts mafdn9 it dlmCult to identity the oarfartner shat interacts or binds to the target with greatesl alenity or speatrcity eamplicating rational drug des'sgn-A final problem with the ipsrative polypeptide method of Geyttett is that, at presenl, there are r~
practical medrods with which a great diversity of dllferent peptides can be pnvduoed. screened and analyzed. i3y 10 using the Iwenty naturatty Qoaming amino acids, the total number of all oambinatbrrs of hexapeptides that must be synthesized is 64,t>00,000. Even having prepared such a dversity at peptides, there are no methods avrailabte with which mixtrxes of sub a diversity of peptides aan ~ raP~Y Keened to selea those pepdde5'havir~g a high atkniiy for the target molecule. At present, each 'adtrerent' peptide must be recovered in amounts large enough tQ cony out protein sequenoin9~
15 To overcome marry et the problems inherent in the ~y~n aPP~ ~~i~l selection and 5aeenlng was ciwsen as an attemadve. Biological selections and saeens are Powerful foals to probe Protein function and to isolate variant proteins with desirable properties (Shortle, plpi!»Dg. Oxender and Fox, ads., A.R. Liss, Inc., NY, pp.103~108 [1988]) and 8ovne et or.. ., ~T:1306-1310 [199D)).
However, a given selection or gcreen is appliGabIB t0 only Dne or a small number of related proteins.
20 Recendy, umilh and coworkers (Smith. ~~. x:1315~1317 [1985)) arKi Parmley and Smith. ~.
7a:3a5-318 [1985] have der~nstrated that small protein tra9ments (10~50 amino adds) can be 'displayed' etfidently on the surface of iilamentous pf~ge by inserting Short gene lsagmerns Into genQ III of the td phage (~tusion phage'). The gene Ill minor coat protein (present in abo~ 3 ~Ples at one end at the virion) is important for proper pttage assembly and tar infection by attachment to the pill of E
Colt (see Ranched et at. , 25 gsy"50: a01-427 [1886]). Recently, 'fusion pttage' have been shown to be useful for displaying start mutated peptide sequences for identifying peptides Ihat may react with anUbadies (Scott et 8i., 249: 386-390, [1990] -..)and Gwirla et tit., prn~ Na_N, p,ad t A 87: 638~6382. [1990[).or a foreign protein (Llevlin et al"
~~' ,pig, 24~: 404-406 [t990)).
There are, trowever, several important limitations In using tttxh'fusian ptrage' to ider>diy altered 30 pepCides or proteins with new or enhanced birxJitlg fxapeTt~s. Frst, it has teen shown (Parmldy et al., one. 73:
305-318. [1998]) that fusion phage are useful only br displaying proteins of less Ihan tOQ arid preferably less than 50 amino aad residues, becauso large inserts presumably disrupt the krrction of Gene Ill and ii~refore phage assembly and intectivity. Second, prior art methods have been unable b select pep4des from a Gtxary having the highest binding aeiNty for a target molecule. For example, attar exhaustive panning of a random peptide litxary 35 with an antr~ endorphin monoGOrral antiltcdy, t~lrla et al., supra could not separate moderate adinity peptides (icd - 10 wM) from higher affinity peptides (Kd -d.4 ~M) fused id phage. Moreover, the Parent ~_ endorphin peptide sequence which has very trigh aftirtity (iCd ~ 7nMj, was not Padre from the epitope library.
Ladner WO 9010x802 discloses a method for selecting novel birxkrtg proteins displayed on the ouoer surface of cells arid viral particles where it is contemplated drat the heharobgorss proteins may have up to 1 B4 WO 92/09690 ~ ~ ~ PCT/U591 /09133 3 >._ amino acrd residues . The method cont~nplates isolating and amplifying the c~splayed proteins to engineer a new family of Minding proteins having desired affinity for a target moleade. More sped6calty, Ladner discloses a 'fusion phage' displaying proteins having 'initial protein finding domains' ranging from 46 residues (cramt~n) to 164 residues (T4 lysozyme) fused to the M13 gene III coat protein. Ladner beaches the use of proteins'no larger than necessary t~erause it is easier to arrange restriction sites in smaNer amino add sequences and prefers the 58 amino add residue bovine pancreatic trypsin inhibitor (BPTI). Small tusan proteins, such as BPTI, are preferred when the target is a protein or macromolecule, while larger fusion proteins, such as T4 lysozyme, are preferred for small target molecules such as sterads because such large proteins have clefts and grooves into which small molecules can fit. The preferred protein, BPTI, is proposed to be fused b gene III at the site disclosed by Smith et al. or de la Cruz et al., J. Biol. Chgm" 263: 4318,4322 [1988), or to one of the terminii, along with a second synthetic copy of gene III so that'some' unaltered gene III protein will be present. Ladner does not address the problem of successfully panning high affinity peptides from the random peptide library which plagues the biological selection and screening methods of the prig art.
Human growth hormone (hGH) partidpates in much of the regulation of normal human growth and development. This 22,000 dalton ptuitary hormone exhibits a multitude of biological effects including linear growth (somatogenesis), lactation, activation of macrophages, insulin-like and diabetogenic effects among others (Chawla, R, K. (1983) 911p ev. Med. fig, 519; Edwards, C. K et al. (1988) ,~,p~,~Q, 769; Thomer, M. 0., et al.
(1988) J. Clip. Invest gl, 745). Growth hormone defiaency in children leads to dwarfism which has been successfully treated for more than a decade by exogenous administratan of hGH.
hGH is a member of a family of 2 0 homologous hormones that include placenhal lactogens, prolactins, and other genetic and spades variants or growth hormone (Nicoll, C. S., efal., (1986) ~ocrine Reviews 2,169). hGH is unusual among these in that it exhibits broad species spedfidty and binds to either the dor~ed somatogenic (Leung, D. W., et aL, [1987] ~g ~,,3,Q, 537) or prolactin receptor (Boutin, J. M.,et al., [1988] fig; ,~, 69). The doped gene for hGH has been expressed in a secreted forth in ~j (Ctrarg, C. N., et al., [i987] ~;~,189) and its DNA and amino add sequence has been reported (Goeddel, etal., p979] ~,~, 544; Gray, etal., [1985] ~,3$, 247).
The three-dimensional stnxture of hGH is not available. However, the three-dimensional folding pattern for porcine growth hormone (pGH) has been reported at moderate resolution and reffr~ement (Abdel-Meguid, S. S., et al., [1987j Proc-Natl.Natl.
e~~d. Sci. USA $4, 6434). Human growth hormone's receptor and antibody epitopes have been identified by homolog-scanning mutagenesis (Cunningham etal., Saenoe Zq$;1330,1989). The structure of novel amino terminal methionyl bovine growth hormone contair>ing a spliced-in sequerxe of human growl hormone including histidine 18 and histidine 21 has been shown (U.S. Patent 4,880,910) Human growth hormone (hGH) cages a variety of physiological and metabolic effects in various ar>imal models including linear bone growth, lactation, activation of macrophages, insulin-like and diabetogenic effects and others (R. K. Chawla etal., Anna. Rev. Mad. 34, 519 (1983); 0. G. P. Isaksson etat., Mrw. Rev. Phys'rot. 47, 483 (1985); C. K. Edwards etal., Science 239, 769 (1988); M. 0. Thomer and M. L.
Vance, J. Clip. Invest. 82, 745 (1988); J. P. Hughes and H. G. Friesen, Mn. Rev. Physiol. 47, 469 (1985)).
These biological effects dertve from the interaction between hGH and spedfic cellular receptors..
Accordingly, it is an object of this invention to provide a rapid and effective method for the systematic preparation of candidate binding substances.
It is another object of this invention to prepare candidate Minding substances displayed on surface of a phagemid particle that are conformationally stable.
It is another object of this invention to prepare candidate tending substances comprising fusion proteins of a phage coat protein and a heterologous polypeptide where the polypeptide is greater than 100 amino acids in length and may be more than one subur>;t and is displayed on a phagemid particle where the polypeptide is encoded by the phagemid genome.
It is a further object of this invention to provide a method for tt~e preparation and selection of binding substances that is suffiaently versatile to present, or display, all peptidyl moieties that could potentially particlpate in a nonoovalent binding interaction, and to present these moieties in a fashion that is sterically confined.
Still another object of the invention is the production of growth hormone variants that exhibit stronger affinity for growth hormone receptor and binding protein.
It is yet another ot~ject of this invention to produce expressan vector phagemids that contain a suppressible termination oodon tunc6onally bcated between the heterok~gous polypeptide and the phage coat protein such that detectable fusion protein is produced in a host suppressor cell and only the heterologous polypeptide is produced in a non-suppresser host cell.
Fnally, it is an object of this invention to produce a phagemid particle that rarely displays more than one copy of candidate binding proteins on the outer surface of the phagemid particle so that efficient selection of high affinity tHnding proteins can be achieved.
These and other objects of this irnention wit be apparent from consideration of the invention as a whole.
These objectives have been achieved by providing a method for seleding novel binding polypeptides comprising: (a) constructing a replicable expression vector comprising a first gene encoding a polypeptide, a second gene encoding at least a portion of a natural or wild-type phage coat protein wherein the first and second 2 5 genes are heterologous, and a transcription regulatory element operady linked to the first and second genes, thereby forming a gene fusion erxxxfing a fusion protein; (b) mutating the vector at one or more selected positions within the first gene thereby forming a family of related plasmids; (c) transforming suitable host peas with the plasmids; (d) infecting the transformed host cells with a helper phage having a gene encoding the phage coat protein; (e) culturing the transformed infected host cells under conditions suitable for forming recombinant phagemid particles containing at least a portion of the plasmid and capable of transforming the host, the conditions adjusted so that no more than a minor amount of ph~emid particles display more than one copy of the fusion protein on the surface of the particle; (f) contacting the phagemid particles with a target molecule so that at least a portion of the phagemid particles find to the target molecule; and (g) separating the phagemid particles that bind from those that do not. Preferably, the method further comprises transforming suitable host cells with recombinant phagemid particles that bind to the target molecule and repeating steps (d) through (g) one or more times.
Additionally, the method for selecting novel binding proteins where the proteins are composed of more than one subunit is ad~ieved by selecting novel binding peptides comprising constructing a replicable expression vector comprising a transcription regulatory element operably linked to DNA
erxoding a protein of interest WO 92/09690 ~ ~~ ~ ~ ~ ~ ~ PC1'/US91/09133 _ containing one or more subunits, wherein the DNA encoding at least one of the subunits is fused to the DNA
encoding at least a portion of a phage coat protein;mutating the DNA encoding the protein of interest at one or more selected positions thereby fomring a family of related vectors;
transforming suitable host cells with the vectors; iMecting the transformed host cells with a helper phage having a gene encoding the phage coat protein;
5 culturing the transformed infected host cells under conditions suitable for forming recombinant phagemid particles containing at least a portion of the plasmid and capable of transforming the host, the conditions adjusted so that no more than a minor amours of phagemid particles display more than one copy of the fusion protein on the surface of the particle; contacting the phagemid particles with a target molecule so that at least a portion of the phagemid particles bind to the target molecule; and separating the phagemid particles that hind from those that do not.
Preferably in the method of Ihis invention the plasmid is under tght control of the transcription regulatory element, and the culturing conditions are adjusted so that the amount or number of phagemid particles displaying more than one copy of the fusion protein on the surface of the particle is less than about 1 %. Also preferably, amount of phagemid particles displaying more than one copy of the fusion protein is less than f0% the amount of phagemid particles displaying a single copy of the tusan protein.
Most preferably the amount is less than 20°x.
Typically, in the method of this invention, the expression vector will further contain a secretory signal sequences fused to the DNA enaxling each subunit of the polypeptide, and the transcription regulatory element will be a promoter system. Preferred promoter systems are selected from; Lac Z, a,pL, TAC, T 7 polymerise, tryptophan, and alkaline phosphatase promoters and combinatans thereof.
Also typically, the first gene will encode a mammalian protein, preferably the protein will be selected from; human growth hormone(hGHj, N-metfionyl human growth hormone, bovine growth homrone, parathyroid hormone, thyro>one, insulin A-drain, insulin B~chain, proinsuWn, rolaxin A~hain, relaxin B-chain, prorelaxin, glycoprotein hormones such as follicle stimulating hormone(FSH), thyroid stimulating hormone(TSH), and leutinizing hormone(LH), glycoprotein hormone receptors, caldtonin, glucagon, factor VIII, an antibody, lung surtactant, urokinase, streptokinase, human tissue-type plasminogen activator (t-PA), bombesin, factor IX, thrombin, hemopoietic growth factor, tumor r~sis factor-alpha and -beta, enkephalinase, human serum albumin, mullerian-inhibiting substance, mouse gonadotropin-associated peptide, a microbial protein, such as betalactamase, tissue factor protein, inhibin, activin, vascular endothelial growth factor, receptors for hormones or growth factors; integrin, thrombopoietin, protein A or D, rheumatoid factors, nerve growth factors such as NGF-)3, platelet~rowth factor, transforming growth factors (TGFj such as TGF,alpha and TGF-beta, insuiin-like growth factor-I and -II, insulin-like growth factor binding proteins , CD-4, DNase, latency assodated peptide, erythropoietin, osteoinductive factors, interferons such as interferon-alpha, -beta, and -gamma, colony stimulating factors (CSFs) such as M-CSF, GM-CSF, and G-CSF, interleukins (ILs) such as IL-1, IL-2, IL-3, IL-4, superoxide dismutase; decay accelerating factor, viral antigen, HIV
envelope proteins such as GP120, GPt40, atrial natriuretic peptides A, B or C, immunoglobulins, and fragments of any of the above-listed proteins.
Preferably the first gene will encode a polypeptide of one or more subunits containing more than about 100 amino add residues and will be folded to form a plurality of rigid secondary structures displaying a plurality of amino acids capable of interacting with the target. Preferably the first gene will be mutated at codons corresponding to only the amino acids capable of interacting with the target so that the integrity of the rigid secondary strur.~ures will be preserved.
Normally, the method of this invention will empby a helper phage selected from; M13K07, M13R408, M13-VCS, and Phi X 174. The preferred helper phage is M13K07, and the preferred coat protein is the M13 Phage gene III coat protein. The preferred host is E. cbli, and protease deffdent strains of E. coli. Novel hGH
variants selected by the method of the present irnentan have been detected.
Phagemid expression vectors were constnxted that contain a suppresside termination colon functionally located between the nucleic acids encoding the polypeptide and the phage coat protein.
BRIEF DESCRIPTION OF THE FIGURES
FIGURE 1. Strategy for displaying large proteins on the surface of filamenbous phage and enriching for altered receptor binding properties. A plasmid, phGH-Ml3glll was consrruucted that fuses the entire coding sequence of hGH to the carboxyl terminal domain of M13 gene III. Transcription of the fusion protein is under control of the lac promoberloperator sequence, and secretion is directed by the stll signal sequence. Phagemid partices are produced by infection with the 'helper phage, M13K07, and particles displaying hGH can be enriched by twining to an affinity ma~ix contakring the hGH receptor. The wild-type gene III (derived from the M13K07 phage) is diagramed by 4-5 copies of the multiple arrows on the tip of the phage, and the fusion protein (derived from the phagemid, phGH-Ml3glll) is indicated schematicatiy by the folding diagram of hGH repladng the arrow head.
FIGURE 2 knmunot~lot of whole phage particles shows that hGH comigrates with phage. Phagemid 2 0 particles purified in a cesium chloride gradient were loaded into duplicate wells and electrophoresed through a 1 agarose gel in 375 mM Tris, 40 mM glycne pH 9.6 buffer. The gel was soaked in transfer buffer (25 mM Tris, pH
8.3, 200 mM glyane, 20% methanol) containing 2% SDS and 296 ~-mercaptoethanol for 2 hours, then rinsed in transfer buffer for 6 hours. The proteins in the gel were then electrobbtted onto immot>ilon membranes (Millipore). The membrane containing one set of samples was stained with Coomassie blue to show the position of the phage proteins (A). The duplicate membrane was immures-stained for hGH by reacting the membrane with polydonal rabbit anti-hGH antibodies folbwed by reaction with horseradish peroxidase conjugated goat anti-rabbit IgG antibodies (B). Lane 1 contains Ifrre M13K07 parent phage and is viside only in the Coomassie blue stained membrane, since it lacks hGH. Lanes 2 and 3 contain separate preparations of the hormone phagemid partiGes which is visible both by Coomassie and hGH immuno-stairang. The difference in mgration distance between the parent M13K07 phage and hormone phagemid particles reflects the different size genomes that are packaged within (8.7 kb vs. 5.1 kb, respectively).
FIGURE 3. Summary diagram of steps in the selection process for an hGH-phage library randomized at colons 172,174,176, and 178. The template molecules, pH0415, containing a unique Kpnl restriction site and the hGH(Rt78G,1179T) gene was mutagenized as described in the text and electrotransfonned into E. cofi strain WJM101 to obtain the initial phagemid library, Library 1. An aliquot (approximately 2%) from Ubrary 1 was used directly in an initial selection round as described in the text to yield Litxary 1 G. Meanwhile, double-stranded DNA
(dsDNA) was prepared from Library I, digested with restriction enzyme Kpnl to eliminate template badkground, and electrotransformed into WJM101 to yield Library 2. Subsequent rounds of selection (or Kpnl digestion, shaded boxes) followed by phagemid propagation were carried out as indicated by the arrows, according to the WO 92/09690 ~ '~ ,-~~ ~ ~ ~ ~ PCT/US91 /09133 ..
procedure described in the text. Four independent doves from litxary 4G4 and tour independent Bones from library 5G6 were sequenced by dideoxy sequendng. All of these Bones had the identical DNA sequence, corresponding 1o the hGH mutant (Glu 174 Ser, Phe 176 Tyr).
FIGURE 4. Structural model of hGH derived from a 2.8 la folding diagram of porcine growth hormone determined aystallographically. t-ovation of residues in hGH that strongly modulate its binding to the hGH-binding protein are within the shaded drde. Alanine substitutions that cause a greater than tenfold reduction(~), a four- to tenfold reduction (~), or increase (O), or a two- to fourfold reduction (~), in tending affinity are indicated. Helical wheel projections in the regions of a-helix reveal their amptupathic quality.
Blackened, shaded, or noruhaded residues are charged, polar, or nonpolar, respedavely. In helix-4 the most important residues for mutation are on the hydrophilic face.
FIGURE 5. Amino acrd substitutions at positions 172,174,176 and 178 of hGH
(The notation, e.g.
KSYR, denotes hGH mutant 172KI174SI176Y/178R.) found after sequencng a number of doves from rounds 1 and 3 of tt~e selection process for the pathways indicated (hGH elution;
Glycine elution; or Glydne elution after pre-adsorption). Non-functional sequences (i.e. vector badkground, or other prematurely terminated andlor frame-shifted mutarns) are shown as'NF'. Fkxrctional sequences which contained a non-silent, spurious mutation (i.e. outside the set of target residues) are marked with a '+'. Protein sequences which appeared more than once among all the sequerxed doves, but with different DNA sequences, are marked with a '~". Protein sequerxes wtych appeared more than once among the sequenced Bones and with the same DNA
sequence are marked with a "'. Note that after three rounds of selection, 2 different contaminating sequences were found; these Bones did not correspond to cassette mutants, but to previously constructed hormone phage. The pS0643 contaminant corresponds to wild-type hGH-phage (hGH 'KEFR'). The pH0457 contaminant, which dominates the third-round glycine-selected pool of phage, corresponds to a previously identified mutant of hGH, 'KSYR.' The amplification of these contaminants emphasizes the agility of the hormone-phage selection process to select for rarely oocurting mutants. The convergence of sequences is also striking in all three pathways: R or K occurs most often at positions 172 and 178; Y or F occurs most often at position 176; and S, T, A, and other residues occur at position 174.
FIGURE 6. Sequences from phage selected on hPRLbp-beads in the presence of zinc. The notation is as described in Figure. 5. Here, the convergerxe of sequerxes is not predictable, but there appears to be a bias towards hydrophotMC sequences under the most sfringent (Glydne) seledion conditions; L ,W and P residues are 3 0 frequently found in this pool.
FIGURE 7. Se~errces from phage selected on hPRLbp-beads in the absence of zinc. The notation is as described in Figure 5. In contrast to the sequences of Fgure. 6, these sequences appear more hydrophilic. After 4 rounds of selection using hGH elution, two clones (ANHQ, and TLDTI171V) dominate the pool.
FIGURE 8. Sequences from phage selected on blank beads. The notation is as described in Fg. 5. After three rounds of selection with glycine elution, no siblings were observed and a badkground level of non-functional sequences remained.
FIGURE 9. Construction of phagemid fl on from pH0415. This vector for cassette mutagenesis and expression of the hGH-gene III fusion protein was constnxted as follows.
Plasmid pS0643 was constructed by oligonudeotide-directed mutagenesis of pS0132, which contains pBR322 and f1 origins of replication and WO 92/09690 PC1'/US91/09133 expresses an hGH-gene III fusion protein (hGH residues 1-191, folbwed by a single Gly residue, fused to Pro-198 of gene III) under the control of the ~ )~ promoter. Mutagenesis was carried out with the oligonuGeotide 5'-GGC-AGC-TGT-GGC-TTC-TAG-AGT-GGC-GGC-GGC-TCT-GGT-3', which introduced a ~
site (underlined) and an amber stop colon (TAG) following Phe-191 of hGH.
FIGURE 10. A. Diagram of plasmid pDH188 insert containing the DNA encoding the Ight chain and heavy chain (variable and constant domain 1 ) of the Fab humanized antibody directed to the HER-2 receptor. V~
and VH are the variable regions for the Ight and heavy chains, respectively.
Ck is the constant region of the human kappa light chain. CH1G1 is the first constant region of the human gamma 1 chain. Both coding regions start with the bacterial st II signal sequence. B. A schematic diagram of the entire plasma pDH188 containing the insert described in 5A. After transformation of the plasmid into E. cbli SR101 cells and the addition of helper phage, the plasmid is packaged into phage particles. Some of these particles display the Fab-p III fusion (where p III is the protein enk~ded by the M13 gene III DNA). The segments in the plasmid figure correspond to the insert shown in 5A.
FIGURE 11 A through C are cdlectJvely referred to here as Figure 11. The nucleotide (Seq. ID No. 25) sequerxe of the DNA encoding the 4D5 Fab molecule expressed on the phagemid surface. The amino acid sequerx;e of the light chain is also shown (Seq. ID No. 26), as is the amino acct sequence of the heavy chain p III fusion (Seq. ID
No. 27).
FIGURE 12 Enrichment of wild-type 4D5 F~ phagemid from variant Fab phagemid.
Mixtures of wild-type phagemid and variant 4D5 Fab phagemid in a ratio of 1:1,000 were selected on plates coated with the extra-cellular domain protein of the HER-2 receptor. After each round of selection, a portion of the eluted phagemid were infected into E. Qoli and plasmid DNA was prepared. This plasmid DNA was then digested with Eco RV and Pst I, separated on a 5% polyakxylamide gel, and stained with ethidium bromide. The bands were visualized under UV light. The bands due to the wild-type and variant plasmids are marked with arrows. The first round of selection was eluted only under acid conditions; subsequent rounds were eluted with either an acct elution (left side of Figure) or with a humanized 4D5 antibody wash step prior to acid elution (right side of Figure) using methods desalted in Example VIII. Three variant 4D5 Fab molecules were made:
H9t A (amino aad histidine at position 91 on the V~ chain mutated to alanine; indicated as 'A' lanes in Figure), Y49A (amino acid tyrosine at position 49 on the V~ chain mutated to alanine; indicated as'B' lanes in the Figure), and Y92A (amino acid tyrosine at position 92 on the V~ chain mutated to alanine; indicated as'C' lanes in the Fgure). Amino acct position numbering is according to Kabat et al.,(Sequences of proteins of immunological interest, 4th ed., U.S. Dept of Health and Human Services, Public Health Service, Nat'I. Institute of Health, Bethesda, MD (1987]).
FIGURE 13. The Scatchard analysis of the RIA affinity determination described in Experimental Protocols is shovm here. The amount of labeled ECD antigen that is bound is shown on the x-axis while the amount that is bound divided by the amount that is free is shown on the y-axis. The slope of the line indicates the Ka; the 3 5 calculated Kd is l ll(a.
WO 92/09690 2 ~ ~ ~ ~ J 3 PCT/US91/09i33 DETAILED DESCRIPTION OF THE INVENTION
The foNowing discussion will be best iurderstood by referring to Figure t. in its simplest torm, the method of the instant invention comprises a method for selecting novel binding polypeptides, such as protein Igands, having a desired, usuaay high, aiffnity for a target molecule from a library of stnxturally related bindirg polypeptides. The lilxary of structurally related polypeptides, fused Do a phage coat protein, is produced by mutagenesis and, preferably, a single copy of each related polypeptide is displayed on the surface of a phagemid particle containing DNA encoding that polypepade. These phagemid particles are then contacted with a target molecule and those particles having the highest affinity for the target are separated from those of lower affinity.
The high atfir>ity binders are then amplified by infection of a bacterial host and the competitive binding step is repeated. This process is reiterated until polypeptides of the desired affinity are obtained.
The novel binding polypeptides or ligands produced by the method of this invention are useful per se as diagnostics or therapeutics ( eg. agonists or antagonists) used in treatment of biological organisms. Structural analysis of the selected polypeptides may also be used to fadlitate rational drug design.
By 'binding polypeptide' as used herein is meant any polypeptide that binds with a selectable affinity to a target molecule. Preferably the polypeptide will be a protein that most preferably contains more than about 100 amino add residues. Typically the polypeptide will be a t~onnone or an antibody or a fragment thereof.
By 'high affinity' as used herein is meant an affinity constant (Kd ) of <t0-5 M and preferably <10'~M
under physalogical conditions.
By 'target molea~le' as used herein is meant any molecule, rat necessarily a pr~ein, for which it is desirable to produce a ligand. Preferably, however, the target will be a protein and most preferably the target will be a receptor, such as a hormone receptor.
By 'humanized antibody' as used herein is meant an antitxxly in wtich the oomplementarity~ietermining regions (CDRs) of a mouse or other ron-human antibody are graffed onto a human antibody framework. By human antibody framework is meant the entire human antibody excluding the CDRs.
L
The first step in the method of this invention is to choose a polypeptide having rigid secondary structure exposed to the surface of the polypeptide for display on the surface of a phage.
By'polypeptide' as used herein is meant any molecule whose expressan can be directed by a specific DNA sequence. The polypeptides of ttws invention may comprise more than one subunit, where each subunit is 3 0 encoded by a separate DNA sequerxe.
By 'rigid secondary structure' as used herein is meant any polypeptide segment exhibiting a regular repeated structure such as is found in; a-helices, 3fp helices, n-heMces, parallel and antiparallel ~-sheets, and reverse toms. Certain 'non~rdered' structures that lack recognizable geometric order are also included in the definition of rigid secondary structure provided they form a domain or'patch' of amino acid residues capable of interaction with a target and that the overall shape of the stnxture is not destroyed by replacement of an amino acid within the structure . h is believed that some non-ordered structures are comt~inations of reverse turns. The geometry of these rigid secondary structures is well defined by ~ and ~r torsional angles about the a-carbons of the peptide 'backbone'.
WO 92/09690 2 ~ ~ ~ ~ ~ J PCT/US91/09133 The requirement that the secondary stmct~xe be exposed to the surface of the polypeptide is to provide a domain or'patch' of amino aad residues that can be exposed to and bind with a target molecule. It is primarily these amino aad residues that are replaced by mutagenesis that form the 'library' of structurally related (mutant) Minding polypeptides that are displayed on the surface of the phage and from which novel 5 polypeptide ligands are selected. Mutagenesis or replacement of amino acid residues directed toward the interior of the polypeptide is generally avoided so that the overall stinxture of the rigid secondary structure is preserved.
Some replacement of amino acids on the interior region of the rigid secondary stnxriues, especlally with hydrophobic amino aad residues, may be tolerated since these conservative substitutions are unlikely to distort the overall structure of the polypeptide.
10 Repeated cycles of'polypeptide' selection are used to select for higher and higher affinity Minding by the phagemid selection of multiple amino aad changes which are selected by multiple selection cyGes. Following a first round of phagemid selection, involving a first region or selection of amino aclds in the ligand polypeptide, additional rounds of phagemid selection in other regions or amino aads of the ligand potypeptide are conducted.
The cycles of phagemid selection are repeated until the desired affinity properties of the ligand polypeptide are achieved. To illustrate this process, Example VIII phagemid selection of hGH
was conducted in cycles. In the first cycle hGH amino aads 172,174,176 and 178 were mutated and phagemid selected.
In a second cycle hGH amino aads 167,171,175 and 179 were phagemid selected. In a third cycle hGH amino acids 10,14,18 and 21 were phagemid selected. Optimum amino aad changes from a previous cycle may be irxorporated into the polypeptide before the next cycle of selection. For example, hGH amino aclds substitutan 174 (serine) and 176 (tyrosine) were irxorporated into the hGH before the phagemid selection of hGH amino aads 167,171,175 and 179.
From the forgoing it will be appreciated that the amino aad residues that form the binding domain of the polypeptide will not be sequentially linked and may reside on different suburuts of the polypeptide. That is, the Minding domain tracks with the particular secorxiary stnxture at the binding site and not the primary stmcture. Thus, generally, mutations will be introduced into colons erxoding amino acids within a particular secondary structure at sites directed away from the interior of the polypeptide so that they will have the potential to interact with the target. By way of illustration, Figure 2 shows the location of residues in hGH that are known to strongly modulate its t~ir~ding to the hGH-binding protein (Cunningham etaL, 247:1461-1465 (1990]). Thus representative sites suitable for mutagerresis would include residues 172, 174, 176, and 178 on helix-4, as well as residue 64 located in a 'non-ordered' secondary structure.
There is no requirement that the polypeptide chosen as a ligand to a target normally hind to that target.
Thus, for example, a glycoprotein hormone such as TSH can be chosen as a ligand for the FSH receptor and a library of mutant TSH molecules are employed in the method of this invention to produce novel drug candidates.
This invention thus contemplates any polypeptide that hinds to a target molecule, and inGudes antibodies. Preferred polypeptides are those that have pharmaceutical utility.
More preferred polypeptides 3 5 include; a growth hormone, including human growth hormone, des-N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroid stimulating hormone; thyroxine;
insulin A~chain; insulin B~hain;
proinsulin; follicle stimulating hormone; calcltorun; leutinizing hormone;
glucagon; factor VIII; an antibody; lung surfactant; a plasminogen activator, such as urokinase or human tissue-type plasminogen activator (t-PA);
t~ombesin; factor IX, thromt~in; hemopoietic growth factor; tumor necrosis factor-alpha and -beta; enkephalinase; a WO 92/09690 ~ ~ ~'~ ~ ~ ~ PCT/US91/09133 saran albumin such as txunan seem albumin; mullerian-intibiting substance;
rela~dn A~chain; relaxin B~chain;
prorelaxin; mouse gorradotropn-assoaatsd peptide; a microbial protein, such as beidta~tamase; tissue factor protein; inhibin; activin; vascular endothelial growth factor; receptors for hormones or growth factors; integrin;
thrombopoietin; protein A or D; rheumatoid factors; nerve growth factor such as NGF-J3; platelet~erived growth factor; 6broblast growth factor such as aFGF and bFGF; epidermal growth factor; transforming growth factor (TGF) such as TGF-alpha and TGF-beta; insulin-like growth factor-I and -II;
insulin-like growth factor binding proteins; CD-4; DNase; latency assodated peptide; eryttxopoietin;
osteoinductive factors; an interferon such as interteron-alpha, -beta, and -gamma; colony stimulating factors (CSFs), e.g., M-CSF, GM-CSF, and G-CSF;
interfeukins (ILs), e.g., IL-1, IL-2, IL-3, IL-4, etc.; superoxide dismutase;
decay accelerating factor; atrial natriuretic peptides A, B or C; viral antigen such as, for example, a portion of the HIV ernebpe; immunoglobulins;
and fragments of any of the above-listed polypeptides. In addition, one or more predetermined amino add residues on the polypeptide may be substituted, inserted, or deleted, for example, to produce products with improved tMOlogical properties. Further, fragments of these polypeptides, espedally biologically active fragments, are inducted. Yet more preferted polypeptides of this invention are human growth hormone , and atrial naturetic peptides A, B, and C, endotoxin, subtilisin, trypsin and Other serine proteases.
StiA more preferred are polypeptide hormones that can be defined as any amino add sequence produced in a first cell that binds spedfically to a receptor on the same cell type (autocrine hormones) or a second cell type (non-autocrine) and causes a physiobgical response characteristic of the receptor-bearing cell. Among such polypeptide hormones are cytokines, lymphokines, neurotrophic homnones and aderx>hypophyseal pdypeptide hormones such as growth hormone, prdactin, placer>tal lactogen, luteinizing hormone, follicle-stimulating hormone, thyrotropn, chorbnic gonadotropin, corticotropn, a or ~-melanocyte-stimulating hormone, J3-lipotropin, Y-lipotropin and the endorphins; hypothalmic release-inhibiting honnones such as corticotropin-release factor, growth hormone release-inhibiting hormone, growth hormone-release factor; and other polypeptide hormones such as atrial natriuretiC peptides A, B or C.
IL
The gene encoding the desired polypeptide (i.e., a polypeptide with a rigid secondary structure) can be obtained by methods known in the art (see generally, Samtxook et al. , J
olecular BiojQgw: A Labora~p~"~ap~[, Cold Spring Harbor Press, Cold Spring Harbor, New Yak [19139]). If the sequence of the gene is known, the DNA encoding the gene may be d~emically synthesized (Merrfieki, J. Am. Chem.
Soc.., 85 X149 [1963]). If the 3 0 sequence of the gene is not known, cr if the gene has rot previously been isolated, it may be cloned from a d7NA
litxary (made from RNA obtained from a suitable tissue in which the desired gene is expressed) or from a suitable genomic DNA library. The gene is then isolated using an appropriate probe. For cDNA libraries, suitable probes include monodortal or polydonal antibodies (provided that the cDNA library is an expression library), oiigonudeotides, and complementary or homologous cDNAs or fragments ri~ereof.
The probes that may be used to isolate the gene of interest from genomic DNA litxaries include cDNAs or fragments thereof that encode the same or a similar gene, homobgous genomic DNAs a DNA fragments, and oligorxxleotides. Screening the cDNA or genomic library with the selected probe is conducted using standard procedures as described in d~apters 10-12 of Samtxook et al., supra.
An alternative means to isolating the gene encoding the protein of interest is to use polymerase chain reaction methodobgy (PCR) as described in section 14 of Samlxook et al., sera.
This method requires the use of oligonudeotides that will hybridize to the gene of interest; thus, at least some of the DNA sequence for this gene must be known in order to generate the oGgonudeotides.
After the gene has been isolated, it may be inserted into a suitable vector (preferably a plasmid) for amplification, as described generally in Sambrook et al., supra.
While several types of vectors are available and may be used to practice this invention, plasmid vectors are the preferred vectors for use herein, as they may be constructed with relative ease, and can be readily amplfied. Plasmid vectors generally contain a variety of components including promoters, signal sequences, phenotypic selectan genes, origin of replication sites, and other necessary components as are known to those of ordinary skill in the art.
Promoters most commonly used in prokaryotic vectors include the )~ Z promoter system, the alkaline phosphatase p~ A promoter, the bacteriophage A,PL promoter (a temperature sensitive promoter), the ~
promoter (a hylxid ~-~ promoter that is regulated by the ~ repressor), the Iryptophan promoter, and the bacteriophage T7 promoter. For general descriptions of promoters, see section 17 of Sambrook et al. supra .
While these are the most commonly used promoters, other suitable microbial promoters may be used as well.
Preferred promoters for practicing this inventan are those that can be tightly regulated such that expression of the fusan gene can be controlled. It is believed that the problem that went unrecognized in the prior art was that display of multiple copies of the fusion protein on the surface of the phagemid particle lead to multipoint attachment of the phagemid with the target. It is believed this effect, referred to as the 'chelate effect', results in selection of false 'high affinity' polypeptides when m~dtiple copies of the fusion protein are displayed on the phagemid particle in dose proximity to one another so that the target was'chelated'. When multipoint attachment occurs, the effective or apparent Kd may be as high as the product of the individual Kds for each copy of the displayed fusan protein. This effect may be the reason Cwirla and coworkers supra were unable to separate moderate affinity peptides from higher affinity peptides.
It has been discovered that by tightly regulating expressan of the fusion protein so that ra more than a minor amount, i.e. fewer than about 1 °~, of the phagemid particles contain multiple copies of the fusion protein the 'chelate effect' is overcome allowing proper selection of high affinity polypeptides. Thus, depending on the 3 0 promoter, culturing conditions of the fast are adjusted to maximize the number of phagemid particles containing a single copy of the fusion protein and mirimize the number of phagemid particles containing multiple copies of the tusion protein.
Preferred promoters used to practice this invention are the l~ Z promoter and the ~ A promoter.
The !~ Z promoter is regulated by the lac repressor protein j~ f, and thus transcription of the fusion gene can be controlled by manipulation of the level of the lac repressor protein. By way of illustration, the phagemid containing the )~ Z promotor is grown in a ceu strain that contains a copy of the )~ f repressor gene, a repressor for the l~ Z promotor. Exemplary cell strains containing the )~ f gene include JM 101 and XL1-blue. In the alternative, the host cell can be cotransfected with a plasmid containing Moth the repressor !~ f and the I3~ Z promotor.
Occasionally both of the above techniques are used simultaneously, that is, phagmide particles containing the l~ Z
WO 92/09690 ~ ~ ,~ ~ ~ PfT/fJS91/09133 promoter are grown in oeti strains containing the ~ i gene and the ceu strains are catransfected with a plasmid containing both tt~e ~ Z and )~ i genes. Normally when one wishes to express a gene, to the transfected host above one would ~d an inducer such as isopropylthiogalacboside (IPTG). In the present invention however, this step is omitted to (a) minimize the expression of the gene III fusion protein thereby minimizing the copy number (i.e. the number of gene III iusans per phagemid number) and to (b) prevent poor or improper packaging of the phagemid caused by induoers such as IPTG even at bw corxentrations. Typcally, when no inducer is ceded, the number of fusion proteins per phagemid partide is about 0.1 (number of bulk fusion proteinslnumber of phagemid partides). The most preferred promoter used to practice this invention is p~
A. This promoter is believed to be regulated by the level of inorganic phosphate in the cell where the phosphate acts to down-regulate the activity of the promoter. Thus, by depleting cells of phosphate, the activity of the promoter can be increased. The desired result is achieved by grovhng cells in a phosphate enriched medium such as 2n or LB thereby controlling the expression of the gene III fusion.
One other useful component of vectors used to practice tNs invention is a signal sequence. This sequence is typically located immediately 5' to the gene encoding the fusion protein, and will thus be transcribed at the amino terminus of the fusan protein. However, in certain cases, the signal sequence has been demonstrated to be located at positions other 5' to the gene encoding the protein to be secreted. This sequence targets the protein to which it is attad~ed across the imer membrane of the bacterial cell. The DNA
encoding the signal sequer~e may be obtained as a restriction erxionucease fragment from any gene encoding a protein that has a signal sequence.
Suitable prokaryotic sisal sequences may be obtained from genes encoding, for example, Lama or OmpF (along et al, t~, 68:193 [1983j), MaIE, PhoA and other genes. A preferred prokaryotic signal sequence for practidng this invention is the E. cbli heat-stale enterotoxin II (STII) signal sequence as described by Chang ef a!. , ~g,pg, 55: 189 [ 1987j.
Another useful component of the vectors used to practice this invention is phenotypic selection genes.
Typical phenotypic selection genes are chose encoding proteins chat confer antibiotic resistance upon the host cell.
By way of illustration, the ampicillin resistance gene (~), and the tetracydine resistance gene (t~ are readily employed for this purpose.
Construction of suitable vectors comprising the aforementioned components as weU as the gene encoding the desired polypeptide (gene 1 ) are prepared using standard recombinant DNA
procedures as described in Samtxook et al. supra. Isolated DNA fragments to be combined m form the vector are cleaved, tailored, and 3 0 ligated together in a spedfic order and orientation to generate the desired vector.
The ONA is deaved using the appropria~ restriction enzyme or enzymes in a suitable buffer. In general, about 0.2-1 ~g of plasmid or DNA fragments is used with about 1-2 units of the appropriate restriction enzyme in about 20 p.1 of buffer solution. Appropriate buffers, DNA concentrations, and incubation times and temperatures are sped5ed by the manufacturers of the restriction enzymes.
Generally, incubation times of about one or iwo hours at 3TC are adequate, although several enzymes require higher temperatures. After incubation, the enzymes and other contaminants are removed by extraction of the digestion solution with a mixture of phenol and chloroform, and the DNA is recovered from the aqueous fraction by precipitation with ethanol.
To ligate the DNA fragments together to form a functional vector, the ends of the DNA fragments must be compatible with each other. In some cases, the ends will be directly compatible after endonudease WO 92/09690 ~ ~ ~ ~ ~ j ~~ PCT/US91/09133 digestion. However, it may be necessary to first convert the sticky ends commoNy produced by endonudease digestion to blunt ends to make them compatible for Ggation. To blunt the ends, the DNA is treated in a suitable buffer for at least 15 minutes at 15'C with 10 units of of the Klenow fragment of DNA polymerise I (Klenow) in the presence of the four deoxynudeotide triphosphates. The DNA is then purified by phenol-chloroform extraction and ethanol predptatan.
The deaved DNA fragments may be size-separated and selected using DNA gel electrophoresis. The DNA may be electrophoresed through either an agarose or a polyacrylamide matrix. The selection of the matrix will depend on the size of the DNA fragments to be separated. After electrophoresis, the DNA is extracted from the matrix by electroelutan, or, if low-melting agarose has been used as the matrix, by melting the agarose and extracting the DNA from it, as described in sections 6.30-6.33 of Sambrook et aL, supra.
The DNA fragments that are to be ligated together (previously digested with the appropriate restriction enzymes such that the ends of each fragment to be ligated are compatible) are put in solution in about equimolar amounts. The solution will also contain ATP, ligase buffer and a ligase such as T4 DNA ligase at about 10 units per 0.5 ug of DNA. If the DNA fragment is to be ligated into a vector, the vector is at first linearized by , cutting with the appropriate restriction endonudease(s). The linearized vector is then treated with alkaline phosphatase or calf intestinal phosphatase. The phosphatasing prevents self-ligation of the vector during the Iigation step.
After ligation, the vector with the foreign gene now inserted is transformed into a suitable host cell.
Prokaryotes are the preferred host cells for this invention. Suitable prokaryotic host cells inducts E. colt strain JM101, E. colt K12 strain 294 (ATCC number 31,446), E. colt strain W3110 (ATCC
number 27,325), E. colt X1776 (ATCC number 31,537), E. colt XL-1 Blue (stratagene), and E colt B;
however many other strains of E.
colt, such as H8101, NM522, NM538, NM539, and many other species and genera of prokaryotes may be used as well. In addition to the E. aoli strains listed above, badlli such as ~(~j~, other enterobacteriaceae such as m a and various p,~speaes may all be used as hosts.
Transformation of prokaryotic cells is readily accomplished using the caldum chloride method as described in section 1.82 of Sambrook et al., supra. Alternatively, electroporation (Neumann etaL, EMBO J..J..
1:841 [1982J) may be used to transform these cells. The transformed cells are selected by growth on an antit~iotic, commonly tetracydine (tet) or ampidllin (amp), to which they are rendered resistant due to the presence of tet and/or amp resistance genes on the vector.
After selection of the transformed cells, these cells are grown in culture and the plasmid DNA (or other vector with the foreign gene inserted) is then isolated. Plasmid DNA can be isolated using methods known in the art. Two suitable methods are the small scale preparation of DNA and the large-scale preparation of DNA as described in sections 1.25-1.33 of Sambrook et al., supra. The isolated DNA
can be purified by methods known in the art such as that described in section 1.40 of Sambrook etal., supra. This purified plasmid DNA is then analyzed by restriction mapping andlor DNA sequendng. DNA sequendng is generally pertormed by either the method of Messing et al. ~gg3" 9:309 [1981 J or by the method of Maxim et aL
~Qg~pty~j" 65:
ass [ls6oJ.
!V.
This invention contemplates fusing the gene erxlosing the desired polypeptide (gene t ) to a second gene (gene 2) such that a fusion protein is generated during transcription. Gene 2 is typically a coat protein gene of a phage, and preferably it is the phage M13 gene III coat protein, or a fragment thereof. Fusan of genes t and 2 may 5 be accomplished by inserting gene 2 inb a parGaa~aar site on a plasmid that contains gene 1, or by inserting gene 1 into a particular site on a plasmid that contains gene 2.
Insertion of a gene into a ptasmid requires that the plasmid be cut at the precise locatan that the gene is to be inserted. Thus, there must be a restriction erxionudease sibs at this bcation (preferably a unique site such that the plasmid will only be cut at a single location during restriction endorx~dease digestion). The plasmid is 10 digested, phosphatased, and purified as described above. The gene is then inserted into this linearized plasmid by ligatirg the two DNAs together. Ligatan can be accomplished if the ends of the plasmid are compatible with the ends of the gene to be inserted. If the restriction enzymes are used to cut the plasmid and isolate the gene to be inserted create blunt ends or compatible sticky ends, the DNAs can be ligated together directly using a ligase such as bacteriophage T4 DNA ligase and irxubating the mixture at 16'C for t ~4 hours in the presence of ATP
15 and Ngase buffer as described in section 1.68 of Sambrook et aL, ~. If the ends are rat compatible, they must first be made Bunt by using the Klenow fragment of DNA polymerase I or bacteriophage T4 DNA polymerase, both of which require the four deoxyribonudeotide triphosphates to fill-in overhanging single-stranded ends of the digested DNA Alternatively, the ends may be Bunted using a nuclease such as nuclease S1 a mung-bean rn~clease, both of which function by cutting back the overtranging single strands of DNA. The DNA is then 2 0 religated using a ligase as described above. In some cases, it may not be possible 6o Bunt the ends of the gene to be inserted, as the reading frame of the coding region will be altered. To overcome this problem, o6gonuGeotide linkers may be used. The linkers serve as a bridge to connect the plasmid m the gene to be inserted. These linkers can be made synthetically as double stranded or single stranded DNA using standard methods. The linkers have one end that is compatible with the ends of the gene b be inserted; the IiNcers are first ligated to this gene using Igation methods described above. The other end of the linkers is desgned to be compatible with the plasmid for ligation. In designing the linkers, care must be taken to not destroy the reading frame of the gene to be inserted or the reading frame of the gene contained on the plasmid. In some cases, it may be necessary to design the linkers such that they code for part of an amino acrd, or such that they code fa one or more amino aads.
Between gene 1 and gene 2, DNA encoding a termination colon may be inserted, such termination colons are UAG( amber), UAA (odder) and UGA (opal). (Microbiology, Davis et al.
Harper l~ Row, New York,1980, pages 237, 245-47 and 274). The termination colon expressed in a wild type host cell results in the synthesis of the gene t protein product without the gene 2 protein attached. However, growth in a suppressor host cell results in the synthesis of detectable quantities of fused protein. Such suppressor host cells contain a tRNA
modified to insert an amino acrd in the termination colon position of the mRNA
thereby resulting in production of detectible amounts of the fusion protein. Such suppressor host cells are well known and described, such as E.coli suppressor strain (Bullock et al., BioTechnioues 5, 376-379 [i987)). Any acceptable method may be used to place such a termination colon into the mRNA erxxxiing the fusion polypeptide.
The suppressible colon may be inserted between the first gene erxoding a polypeptide, and a second gene encoding at least a portion of a phage coat protein. Alternatively, the suppressible termination colon may be WO 92/09690 PCl'/US91/09133 2~~~5~~ ,s inserted adjacent to the fusion site by replacing the last amino acid triplet in the polypeptide or the first amino acrd in the phage coat protein. When the phagemid containing ttre suppressible colon is grown in a suppressor host cell, it results in the detectable production of a tusan polypeptide containing the polypeptide and the coat protein. When the phagemid is grown in a non-suppressor host cell, the polypeptide is synthesized substantially without fusion to the phage coat protein due to termination at the inserted suppressible triplet encoding UAG, UAA, or UGA. In the non-suppressor cell the polypeptide is synthesized and secreted from the host cell due to the absence of the fused phage coat protein which otherwise anchored it to the host cell.
V.
Gene 1, erxoding the desired poiypeptide, may be altered at one or more selected colons. An alteration , 0 is defined as a substitution, deletion, or insertion of one or more colons in the gene encoding the polypeptide that results in a change in the amino acid sequence of the polypeptide as compared with the unaltered or native sequence of the same polypeptide. Preferably, the alterations will be by substitution of at least one amino acid with any other amino acid in one a more regions of the molecule. The alterations may be produced be a variety of methods knoHm in the art. These methods include but are not limited to oligonudeotide-mediated mutagenesis and cassette mutagerresis.
81~
Oligonucleotide -mediated mutagenesis is preferred method for preparing substitution, deletion, and insertion variants of gene 1. This techr~que is weA knorm in the art as described by Zoller et al. Nucleic Aads Res.
IQ: 6487504 [1987]. Briefly, gene 1 is altered by hybridizing an oligonuGeotide encoding the desired mutation to a DNA template, where the 0emplate is the single-stranded form of the plasmid containing the unaltered or native DNA sequence of gene t. After hybridization, a DNA polymerise is used to synthesize an entire second complementary strand of the template will thus incorporate the oligonudeotide primer, and will code for the selected alteration in gene 1.
Generally, oligonuGeotides of at least 25 nucleotides in length are used. An optimal oligonuGeotide will have 12 to 15 nuGeotides that are completely complementary to the template on either side of the nudeotide(s) coding for the mutation. This ensures that the oligonuGeotide will hybridize properly to the single-stranded DNA
template molecule. The digonudeotides are readily synthesized using techniques IQrowrr in the art such as chat described by Crea et al. Proc. Nat,. Acid. Sa. USA 75: 5765 [1978].
The DNA template can only be generated by those vectors that are either derived from bacteriophage M13 vectors (the commercially available M13mp18 and M13mp19 vectors are suitable), or those vectors that contain a single-stranded phage orgin of replication as described by Viera et aL x,",53: 3 [1987].
Thus, the DNA that is to be mutated must be inserted into one of these vectors in order to generate single-stranded template. Production of the single-stranded template is described in sections 4.21-4.41 of Sambrook et al., supra.
To alter the native DNA sequence, the oligonudeotide is hybridized to the single stranded template under suitable hybridization conditions. A DNA polymerizing enzyme, usually the Klenow fragment of DNA
polymerise I, is then added to synthesize the complementary strand of the template using the oligonucleotide as a primer for synthesis. A heteroduplex molecule is thus formed such that one strand of DNA encodes the mutated form of gene 1, and the other strand (the original template) encodes the native, unaltered sequence of gene t .
WO 92/09690 ~ ~ !~ ~ PCT/US91/09133 This heterodupex molecule is then transformed into a suitable host cell, usually a prokaryote such as E. Coil JM101. After growing the cells, they are plated onto agarose plates and screened using the oGgonudeotide primer radiolabelled with 32-Phosphate to identify the bacterial colonies that contain the mutated DNA.
The method described immediately above may be modified such U~at a homoduplex molecule is created wherein both strands of the plasmid contain the mutation(s). The modifications are as follows: The single-stranded oGgonucleotide is ar~aied to the single-stranded template as described above. A mixture of three deoxyribonudeotides, deoxyriboadenosine (dATP), deoxyriboguanosine (dGTP), and deoxyribohymidine (dTTP), is combined with a modified thio~deoxyribocytosine called dCTP-(aS) (which can be obtained from Amersham).
This mixture is added to the template-o~gonudeotide complex. Upon addition of DNA polymerise to this mixture, a strand of DNA identical bo the template except for the mutated bases is generated. h addition, this new strand of DNA will contain dCTP-(aS) instead of dCTP, which serves to protect it from restriction endonudease digestion. After the template strand of the double-stranded heteroduplex is nicked with an appropriate restriction enzyme, the template strand can be digested with Exolll nudease or another appropriate nuGease past the region that contains the sites) to be mutagenized. The reaction is then stopped to leave a molecule that is only partially single-stranded. A complete double-stranded DNA homoduplex is then formed using DNA
polymerise in the presence of all lour deoxyribonudeotide triphosphates, ATP, and DNA Ggase. This homoduplex molecule can then be transformed hto a suitade host cell such as E. colt JM101, as described above:
Mutants witty more than one amino acrd to be substituted may be generated in one of several ways. 1f the amino aids are boated dose together h the pdypeptide chain, they may be mutated simultaneously u~rg one 2 0 oligonudeotide that codes for all of the desired amino acrd substitutions.
If, however, the amino acids are located some distance from each other (separated by more than about ten amino acids), it is more difficult to generate a single digonudeotide that encodes all of the desired changes. Instead, one of two alternative methods may be employed.
In the first method, a separate oligonudeotide is generated for each amino add to be substituted. The oligonudeotides are then amealed to the single-strarxJed template DNA
simultaneously, and the second strand of DNA that is synthesized from Use template wil encode all of the desired amino add substitutions. The alternative method involves two or more rounds of mutagenesis to produce the desired mutant. The first round is as described for the single mutants: wild-type DNA is used for the template, an oliganudeotide encoding the first desired amino acid substitutions) is annealed to this template, and the heteroduplex DNA molecule is then generated. The second round of mutagenesis utilizes the mutated DNA produced in the first round of mutagenesis as the template. Thus, this template already contains one or more mutations. The oligonucleotide encoding the additional desired amino acid substitutions) is then annealed to this template, and the resulting strand of DNA now encodes mutations from both the first and second rounds of mutagenesis. This resultant DNA
can be used as a template in a third round of mutagenesis, and so on.
B.
This method is also a preferred method for preparing substitution, delet'ron, and insertan variants of gene 1. The method is based on that described by Wells et at. ~,, 34:315 [1985].. The starting material is the plasmid (or other vector) comprising gene 1, the gene to be mutated. The codon(s) in gene 1 to be mutated are identified. There must be a unique restriction endorwdease site on each side of the identified mutation site(s). If ~' '~" f a 18 ~~.~~..~ a.~~~
no such restriction sites exist, they may be generated using the above~iesaibed olgonudeotide-mediated mutagenesis method to introduce them at appropriate locations in gene 1. After the restriction sites have been introduced into the plasmid, the plasmid is cut at these sires to linearize it. A double-stranded oligonudeotide encoding the sequence of the DNA between the restriction sites but containing the desired mutations) is synthesized using standard prooe~res. The two strands are synthesized separately and then hybridized together using standard techniques. This double-stranded oligonudeotide is referred to as the cassette. This cassette is designed to have 3' and 5' ends that are compatide with the ends of the linearized plasmid, such that it can be directly ligated 1o the plasmid. This ptasmid now contains the muhated DNA sequence of gene 1.
VI.
In an altemadve embodiment, this invention contemplates production of variants of a desired protein containing one or more subunits. Each subur~t is typically encoded by separate gene. F~ch gene encoding each subunit can be obtained by methods knovm in the art (see, for example, Section II). In some instances, it may be necessary to obtain the gene encoding the various subunits using separate techniques selected from any of the methods described in Section II.
When constmcting a replicable expression vector where the protein of interest contains more than one subunit, all subunits can be regulated by the same promoter, typically located 5' to the DNA encoding the subunits, or each may be regulated by separate promoter suitably oriented in the vector so that each promoter is operably linked to the DNA it is intended to regulate . Selection of promoters is carried out as described in Section III
above.
In constructing a repNcade expression vector aoMaining DNA encoding the protein of interest having multiple subunits, the reader is referred to Figure 10 where, by way of illustration, a vector is diagrammed showing DNA encoding each subunit of an antibody fragment. This figure shows that, generally, one of the subunits of the protein of interest will be fused to a phage coat protein such as M13 gene III. This gene fusion generally will contain its own sgnal sequence. A separate gene encodes the other subunit or suburits, and it is 2 5 apparent that each subur~it generally has its own signal sequerxe. Fgure 10 also shows that a single promoter can regulate the expression of both subunits. Alternatively, each subunit may be independently regulated by a different promoter. The protein of interest subunit-phage coat protein fusion construct can be made as described in Section IV above.
When constructing a famtly of variants of the desired multi-subunit protein, DNA encoding each subunit 3 0 in the vector may mutated in one or more positions in each suburut. When multi-subunit antibody variants are constructed, preferred sites of mutagenesis correspond to colons encoding amino acid residues located in the complementarily-determining regions (CDR) of either the light chain, the heavy chain, or both chains. The CDRs are commonly referred to as the hypervariable regrons. Methods for mutagenizing DNA encoding each subunit of the protein of interest are conducted essentially as described in Section V
above.
VII.
Target proteins, such as receptors, may be isolated from natural sources or prepared by recomt~inant methods by procedures known in the art. By way of illustration, glycoprotein hormone receptors may be prepared by the technique described by McFarland et al., 245:494-499 [1989J, norglycosylated forms expressed WO 92/09690 ~ ~ ~ ~, ~ ~ PCT/US91 /09I 33 in E. colt are described by Fuh et al. J. Biol. Chem 265:3111-3115 [1990]
Otter receptors can be prepared by standard methods.
The purified target protein may be attached to a suitable matrix such as agarose beads, acrylamide beads, glass beads, cellulose, various acxytic copdymers, hydroxylalkyl methaaylate gels, polyaaylic and polymethacrylic copolymers, nylon, neutral and ionic carriers, and the ike.
Attachment of the target protein to the matrix may be accomplished by methods described in ~p~p~, 44 (1976j, or by other means known in the art.
After attachment of the target protein to the matrix, the immobilized target is contacted with the library of phagemid particles under conditions suitable for binding of at least a portan of tf~e phagemid particles with the immobilized target. Nortnaliy, the conditions, including pH, ionic strength, temperature and the like will mimic physiological conditions.
Bound phagemid particles ('binders') having high affinity br the immobilized target are separated from those having a low affinity (and thus do not hind to the target) by washing. Binders may be dissociated from the immot~ilized target by a variety of methods. These methods include competitive dissodation using the wild-type ligand, altering pH arKilor ionic strength, and methods known in the art.
Suitable host cells are infected with the hinders and helper phage, and the host cells are cultured under conditans stable for amplification of the phagemid particles. The phagemid particles are then collected and the selection process is repeated one or more times unto hinders having the desired affinity for the target molecule are selected.
Optionally the library of phagemid particles may be sequentially contacted with more than one immolHlized target to improve selectivity for a particular target. For example, it is often the case that a ligand such as hGH has more than one r~at~al receptor. h the case of hGH, both the growth hormone receptor and tte prolaetin receptor bind the hGH ligand. ft may be desirable to improve the selectivity of hGH for the growth hormone receptor over the prolactin receptor. This can be achieved by ffrst contacting the library of phagemid particles with immot~ilized prolactin receptor, eluting those with a tow affinity (i.e. lower than wild type hGH) for tt~e prolactin receptor and then contacting the bw affinity prolactin 'binders' or non-hinders with the immobilized growth hormone receptor, and selecting for high affinity growth hormone receptor binders. In this case an hGH mutant having a lower affinity for the prolactin receptor would have therapeutic utility even if the affhity for the growth hormone receptor were somewhat lower than that of wild type hGH. This same strategy may be employed to improve selectivity of a particular hormone or protein for its primary function receptor over its clearance receptor.
In another embodiment of tfys invention, an improved substrate amino acid sequence can be obtained.
These may be useful for making better 'cut sites' for protein linkers, or for better protease substratesl~r~ihitors. h this embodiment, an immobitizable molea~e (e.g. hGH-receptor, biotin-avidin, or one capable of covalent linkage with a matrix) is fused to gene III through a linker. The linker will preferably be from 3 to 10 amino aads h length and will act as a substrate for a protease. A
phagemid wiU be constructed as described above where the DNA encoding the linker region is randomly mutated to produce a randomized library of phagemid particles with different amino acid sequences at the linking site. The library of phagemid particles are then immobilized on a matrix and exposed to a desired protease. Phagemid particles having preferred or better substrate amira acld ~ In the liner region kx the desired protease wAi be ekrted, fret pradudrtp an enriched pod of P~9em'd P~des er~adl~p prererred linkers. these phapemid tides are then cycled several mare limes lo t~ epos of particles an~n9 tense seqtrsnve(s) (~ epos Xlll and XIV~.
lltlt. ~Ge.YHdiIO~.A~d~, The domed gene for trGH rtes teen expressed ~ a seaetad tons in Fteals (G~4, C. rb, et al., (1987) hem ~5..i 89) and as oNn and amino add sequsnpa h~ been reported (Goeddel. er ~. [1 s79) ~Q.1.
544; Gray et af., l19&5] ~33~ 247?. The present inversion desaibss navel hGH
variants Prad~d u~n9 die p~~;d ~~pn methods. Human growth hormone verierss ~ fak p'°~~ns 10,14,18, 21, 187,171,172. l 74, 175,176,178 and 179 have been drd~ T~~ ~~rD trigher txndlng affinities are 10 deSCa'Ib6d ~ Tables VII, Xllt irld KiV. The amino acid rl~erl~t~ ~r deSCl~irlp 1119 Var~r~ is flow.
Growth honronB variants may be admlrtlstsred aM ~ ~ ~ s~ ~ "~"~r t~'"~
h°n"one. The growth hormone variants of the present invention may be expressed in any recomt~inanl system which is capable of expressing dative or met hGH.
T~~utic i4rmulafions of hGH for therapeutic admiryistration are prepared for storage by mixing 15 hGH having the desired degr~ of purity with opnonal physialogicatly atxeptable Carriers, exGipients, or stabilizers (13~71nnlon's Pita(m$~C~,L$C1~ ~~~ ~~ A.. ~d., (19801., in ~ form of tyoptw6ied cake or a4uevug ~lutions. Acceptable carriers, exoit>ienls or stabilizers era nontoxic bo reripiants at the dosages and C9n0enbailOns em~l6yEd, and irSClllde bllflta5 ~ 88 pfb"~, a~dte, arid DI~IBr Organic acids; ~tibbxid3nt5 inGuding asoabic sad; kyw mo'lsatlar weight pass than about 10 residues) poiypeptides; proteins. s~h as serum 2 o altxJmin. gelatin. or Immmogk~Gns: hydrnph~ic polymers auc+r as t~PYmolndone; amino atdds s~d~ as glycir~e, glutamine, asparagina, arginine, or lysine: monosaccharides, dis~rides, and other cart#tydrates including glucose. rnamose, or dexuins; chelating agents such as EDTA; divaler>t metal ions such as zinc, cobalt or copper:
sugar altohofs such as rnarrstol or sorbital; salt~tortning txsunlerions such as sodium; anchor norikmic suriacranls such as Tween; Pluronies~r po>yefhytene gtycot (isEG). Fortnulatior>s of the present invention may additionally 25 contain a phartnaaeuticallY aooeptable.butter, amino add, bulking agent arrdror non-ionic siufactant. These include, for example, buffers. tdieiating agents, antibxidarlLS, preservatives, cosotvent5, arid the like; spetxtic examples 9t these could include, trimethylamakte salts ('iris butter"), and dtsot8txn sdetate. Ttte phapemids of the present Invention may ba used to produce qttantitiefi bf the htahl verlar115 free of the phage pr018m. To expra35s ttGH
variants free of the gene III portion Of tt~a fusion, pS0643 and derivatives can simply be grown in a rtorr 30 suppressor strain such as i6C9. In ttris case, the amber colon (TAG) leads to tetrnlr>ation of iralnslation, which yields tree homtlxte, vntllout the need for an independent DNA consinxtion.
The frGH variant is setxeted from the host and may be isdated from the collars med'nim.
One or mbre of the e(ght hGH amino adds F10, M14, HiB, ill. Rt87, D171, T175 and 1179 may be raped by any amino tad other than the one found in that position (n r~turs~y rig hGH
as ~dicated. Thereiore,1, 2, 35 3, 4, 5, ti, 7, a a0 t3 of the indicated amino acids, F10, M14, H18, H21, Rtfi7,17171, T175 and 1179, may he replaced by any or the other 19 amino acids out of the 20 amino acids listed below. tn a preferred embodunerlt, as eight listed amino acids are replaced by another amino aid. The most preferred eight amino acids to be substituted are indicated in Table XIV in Example XII.
*trarlemark 2, An,ho add nomr~cla~re.
Ala (A) Arg (R) Asn (N) Asp (D) Cys (C) Gln (0) Glu (E) p Giy (G) His (H) Ile (I) Leu (L) Lys (K) Met (M) Phe (F) Pro (P) Ser (S) Thr (T) Trp (W) Tyr (Y) Val (V) The one letter hGH variant nomendadxe first gives the hGH amino acrd deleted, for example glutamate 179; then the amino acid inserted; for example, serine; resulting in (E1795S).
EXAMPLES
Without further desaiptan, it is believed that one of ordinary skill in the art can, using the preceding description and illustrative examples, make and utilize the present invention to the fullest extent. The follov~ng working examples therefore speafically point out preferred embodiments of the present invention, and are not to 3 0 be construed as limiting in any way of the remainder of the disclosure.
EXAMPLE I
Plasrrdd Cor~uciJons and Preparation o1 Mali-phagerr~ld Parfides The plasmid phGH-Ml3glll (Fig.1 ), was oonstnxted from M13K077 and the hGH
producing plasmid, pB0473 (Cunningham, B. C., et aL , ~jg~, 243:1330-1336, [1989]). A synthetic oligonucleotide 5'-AGC
TGT-GGC-TTC-GGG'CCC-TTA-GCA-TTT-AAT-GCG-GTA-3' was used to introduce a unique Apal restriction sib (underlined) into p80473 after the final Phel9t colon of hGH.
The oligonudeotide 5'-TTC-ACA-AAC-GAA-GGGCCC-CTA-ATT-AAA-GCC-AGA-3' was used to introduce a unique Apal restriction site (underlined), and a GIut97-to-amber stop oodon (bold lettering) into M13K07 gene III. The oligonuGeotide 5'-CAA-TAA-TAA-CGG-~'C~ T-AGC-CAA-AAG-AAC-TGG-3' introduces a unique Nhel site (underlined) after the 3' end of the gene III coding sequence. The resulting 650 base pair (bp) Apal-Nhel fragment from the doubly mutated M13K07 gene III was doped into the large Apal-Nhel fragment of pB0473 to create the plasmid, pS0132. This fuses the carboxyl terminus of hGH (Phe191 ) to the Pro198 residue of the gene III protein with the insertan of a glydne residue errcoded from the Apal site and places the fusion protein under control of the E. coG
alkaline phosphatase (ptaA) promoter and stll secretion signal sequence (Chang, C. N., et al. , ~gpg, 55:189-196, [1987)). For indudble expression of the fusion protein in rich media, we replaced the phoA promoter with the lac promoter and operabr. A 138 by EcoRl-Xbal fragment containing the lac promoter, operator, and Cap binding site was produced by PCR of plasmid pUC119 using the oligonudeotides 5'-CACGACAGAATTCCCGACTGGAAA-3' and 5'-CTGTT TCTAGAGTGAAATTGTTA-3' that flank the desired lac sequences and introduce the EcoRl and Xbal restriction sites (underlined).
Ttws lac fragment was gel pur'rfied and ligated into the large EcbRl-X6al fragment of pS0132 to create the plasmid, phGH-Ml3glll. The sequences of all taibred DNA junctions were verified by the dideoxy sequerxe method (Sanger, F., et aL Proc. Nail. Acad.
~j,~,~,g, 74:5463-5467, [1977)). The R64A variant hGH phagemid was constructed as follows: the Nsil-Bglll mutated fragment of hGH (Cunninghamet al. supra ) erxading the Arg64 to Ala substitution (R64A) (Cunningham, B. C., Wells, J. A., ~jgp~, 244:1081-1085, [1989]) was Boned between the corresponding restriction sites in the phGH-Ml3glll plasmid (Fig. 1) to replace the wild-type hGH sequence. The R64A hGH
phagemid particles were propagated and titered as described bebw for the wild-type hGH-phagemid.
Plasmids were transformed into a male strain of E. cali (JM101 ) and selected on carbenidllin plates. A
single transformant was grown in 2 ml 2n medium for 4 h at 3TC and infected with 50 W of Mt3K07 helper phage. The infected culture was diluted into 30 ml 2YT, grown overnight, and phagemid particles were harvested by predpitation with polyethylene glycol (Vierra, J., Messing, J. ,153:3-11, (1987]).
Typical phagemid particle titers ranged from 2 to 5 x 1011 cfu/ml. The particles were purified to homogeneity by CsCI density oentrrfugation (Day, L.A. J. Mol. Biol., 3965-277, (1969]) to remove any fusion protein not attached to virions.
hsrnnOd>e~al Analyses Of hGH m the Futon Phape Rabbit polydonal antibodies to hGH were purified with protein A, and coated onto microtiter plates (Nuns) at a corxernration of 2 Irglml in 50 mM sodium carbonate buffer (pH 10) at 4'C for 16-20 hours. After washing in PBS containing 0.05% Tween 20, hGH or hGH-phagemid particles were senialty diluted from 2.0 -0.002 nM in buffer A (50 mM Tris (pH 7.5), 50 mM NaCI, 2 mM EDTA, 5 mglml bovine serum albumin, and 0.05%
Tween 20). After 2 hours at room temperature (rt), the plates were washed well and the indicated Mab (Cunninghamet al. supra ) was added at 1 Nglml in buffer A for 2 hours at rt.
Following washing, horseradish peroxidase conjugated goat anti-mouse IgG antibody was bound at rt for 1 hour.
After a final wash, the peroxidase activity was assayed with the substrate, o~phenylenediamine.
3 5 FxAMPLE IA
Coupling of the hGH Binding Rolein bo Pdyaaylamlde Beads and Binding Eryichments Oxirane polyacrylamide beads (Sigma) were conjugated to the purified extracellular domain of the hGH
receptor (hGHbp) (Fuh, G., etal., J. Biol. Chem., 265:3111-3115 (1990)) containing an extra cysteine residue introduced by site-directed mutagenesis at positron 237 that does not affect binding of hGH (J. Wells, WO 92/09690 ~ ~ ~~ PCT/US91 /09133 unpublished). The hGHbp was corrugated as recommended by the supplier to a level of 1.7 pmol hGHbplmg dry oxirane bead, as measured by binding of [tag hGH b the resin. Subsequendy, any unreacted oxirane groups were blocked with BSA and Tris. As a control for non-specific binding of phagemid particles, BSA was similarly coupled to the beads. Buffer for adsorption and washing contained 10 mM
Tris~HCl (pH 7.5),1 mM EDTA, 50 mM
NaG,1 mglml BSA, and 0.0296 Tween 20. Elution buffers contained wash buffer plus 200 nM hGH or 0.2 M
glyclne (pH 2.1). Parental phage M13K07 was mixed with hGH phagemid particles at a rata of nearly 3000:1 (original mixture) and tumded for 8-12 h with a 5 N.I aliquot (0.2 mg of aaylamide beads) of either absorbent in a 50 p.1 volume at room temperature. The beads were peueted by oen~ifugation and the supemate carefully removed. The beads were resuspended in Z00 W wash buffer and tumbled at room temperatrue for 4 hours (wash t). After a second wash (wash 2), the beads were eluted twice with 200 nM hGH for 6-10 hours each (eluate 1, eluate 2). The final elution was with a glyclne buffer (pH 2.1 ) for 4 hours to remove remaining hGH
phagemid particles (eluate 3). Each fraction was diluted appropriately in 2n media, mixed with fresh JM101, incubated at 3TC for 5 minutes, and plated with 3 ml of 2n soft agar an LB or LB carbeniclllin plates.
iD(AMPLE IV
Cor~nrcUan of hGH.phagemld ParOd~ wlth a Mbct~e of Gene 11 Products The gene III protein is composed of 410 residues divided into two domains that are separated by a flexible linker sequence (Armstrong, J., elal., FEES Lett..135:167-172, [1981)). The amino-terrnir~al domain is required for attachment to the pill of E. cori, while the carboxyl-terminal domain is imbedded in the phage coat and required for proper phage assembly (Crissman, J. W., Smith, G. P., Viroloav.
132:445-455. [1984]). The signal 2 0 sequerxe and amino-terminal domain of gene Ill was replaced with the stll signal and entire hGH gene (Chang et al.
supra) by fusion to residue 198 in the carboxyl-terminal domain of gene III
(Fig.1 ). The hGH~ene III fusion was placed under control of the lac promoterloperator in a plasmid (phGH-M13g111;
Fg. 1) containing the pBR322 ~-lactamase gene and Col Et replication origin, and the phage ft intergenic region. The vector can be easily mair><ained as a small plasmid vector by selection on carber~allin, which avoids relying on a functional gene III fusion for propagation. Alternatively, the plasmid can be ef6clently packaged into virions (called phagemid particles) by infection with helper phage such as M13K07 (Yera et al.. supra ) which avoids problems of phage assembly.
Phagemid infectivity titers based upon transduction to carbeniclllin resistance in this system varied from 2-5 x 1011colony forming units (cfu~ml. The titer of the M13K07 helper phage in these phagemid stocks is ~1010 plaque forming units (pfu)Iml.
lAfith this system we confirmed previous studies (Parmiey, Smith supra) that homogeneous expression of large proteins fused to gene III is deleterious to phage production (data not shown). For example, induction of the lac promoter in phGH-Ml3glll by addition of IPTG produced low phagemid titers.
Moreover, phagemid particles produced by oo-infection with M13K07 contairurg an amber mutation in gene III
gave very low phagemid titers (<t010 ciulml). We believed that multiple copies of the gene 111 fusion attached to the phagemid surface could lead to multiple point attachment (the 'chelate effect') of the fusion phage to the immobilized target protein.
Therefore to control the fusion protein copy number we limited transcription of the hGH-gene III fusion by culturing the plasmid in E. colt JM101 (iacl~) which contains a oonstitutively high level of the lac repressor protein.
The E. colt JM101 cultures containing phGH-Ml3glll were best propagated and infected with M13K07 in the absence of the lac operon inducer (IPTG); however, this system is flexible so that co~xpression of other gene III
2~~5~3.3 24 tusan proteins can be balanced. We estimate that about 10°~ of the phagemid particles contain one copy of the hGH gene III fusion protein from the ratio of the amount of hGH per virion (based on hGH immures-reactive material in CsCI gradient purified phagemid). Therefore, the titer of fusion phage displaying the hGH gene III fusion is about 2 - 5 x 1010hn1. This number is much greater than the titer of E. aoli (-108 to l0glml) in the culture from which they are derived. Thus, on average every E. ooli cell produces 10-100 copies of phage decorated with an hGH gene III fusion protein.
EXAMPLE V
Structural Inteprtty of the hGH~ene II Fusion Immunoblot analysis (Fg. 2) of the hGH~ene III phagemid show that hGH aoss-reactive material comigrates with phagemid particles in agarose gels. This indicates that the hGH is tightly assoclated with phagemid particles. The hGH-gene III fusion protein from the phagemid particles runs as a single immuno-stained band showing that there is little degradation of the hGH when it is attached to gene III. Hfild-type gene III protein is dearly present because about 25% of the phagemid particles are infectious.
This is comparable to specific infectivity estimates made for wild-type M13 phage that are similarly purified (by CsCI density gradients) and concentrations estimated by UV absorbance (Smith, G. P. supra and Parmley, Smith supra) Thus, both wild-type gene III and the hGH-gene III fusion proteins are displayed in the phage pool.
It was important to confirm that the tertiary structure of the displayed hGH
was maintained. in order to have confidence that results from Minding selections will translate to the native protein. We used monoclonal antibodies (blabs) to hGH bo evaluate the sUuctural integrity of the displayed hGH gene III fusion protein (Table I).
TABLE L Binding of Eight Different Monoclonal AnfIbodles (Mab"s) to hGH end hGH Phagemld Particles' IC50 (nM) blab hGH hGH-phagemid __________..___________._..._______.________________._______....._________...__ ____ 1 0.4 0.4 2 0.04 0.04 3 0.2 0.2 4 0.1 0.1 5 0.2 >2.0 6 0.07 0.2 7 0.1 0.1 8 0.1 0.1 'Values given represent ~e oorxentrationGH or hGH-phagemid particles (nM) of h to give half-maximal binding to the particular Mab. Standard errors in these measurements are typically at or below 30%
of the reported value.
See Materials and Methods for further details.
The epitopes on hGH for these blabs have been mapped (Cunringham et al..
supra) and Minding for 7 of 8 blabs requires that hGH be properly folded. The IC50 values for all blabs were equivalent to wild-type hGH
except for Mab 5 and 6 . Both blabs 5 and 6 are known to have tHnding determinants near the carboxyl-terminus of hGH which is blocked in the gene III fusion protein. The relative IC50 value for Mabt which reacts with Moth native and denatured hGH is urxhanged oompan;d to the confortnationally sensitive blabs 2-5, 7 and 8. Thus, Mab1 serves as a good internal control for any errors in matching the concentration of the hGH standard to that of the hGH~ene 111 fusion.
WO 92/09690 ~ ~ ~ ~ ~, ~ ~ PCT/US91/09133 EXAMPLE VI
Bin~ng Enrldnferwa on Raoepbor AtANty BeHds Previous workers (Partnley, Smith supra ; Scott, Smith supra; Cwirla et al.
supra; and DeNin et al.
5 supra) have fractionated phage by panning with streptavidin coated polystyrene petri dishes or miaotiter plates.
However, chromatographic systems would allow more efficient fractionation of phagemid particles displaying mutant proteins with different binding affinities. We chose non-porous oxirane beads (Sigma) to avoid trapping of phagemid particles in the chromatographic resin. Furthermore, these beads have a small partite size (1 N.m) to maximize the surface area to mass ratio. The extracellular domain of the hGH
receptor (hGHbp) (Fuh ef al. , 10 supra) containing a free cysteira residue was effiaently coupled m these beads and phagemid particles showed very low non-specific bin ding to beads coupled oMy to bovine serum albumin (Table II).
TABLE II.
15 Specific Binding of Hormone Phage to hGHbp-coated Beads Provides an Enrichment for hGH-phage over M13K07 Phage' Sample Absorbent$ Total pfu Total cfu Ratio (cfu/pfu) Enrichment~
20 Original mixturet 8.3 x 1011 2.9 x 1p8 3.5 x 10'4 (1) Supernatant BSA 7.4 x 1011 2.8 x 108 3.8 x 10'4 1.1 hGHbp 7.6 x 1011 3.3 x 108 4.3 x 10'4 1.2 Wash 1 BSA 1.1 x 1010 6.0 x 106 5.5 x 10'4 1.6 hGHbp 1.9 x 1010 1.7 x 107 8.9 x 10'4 2.5 25 Wash 2 BSA 5.9 x 107 2.8 x 104 4.7 x 10'4 1.3 hGHbp 4.9 x 107 2.7 x 106 5.5 x 10'2 1.6 x 102 Eluate 1 (hGH)BSA t .1 x 106 1.9 x 103 1,7 x 10'3 4.9 hGHbp 1.2 x 106 2.1 x 106 1.8 5.1 x 103 Eluate 2 (hGH)BSA 5.9 x 105 1.2 x 103 2.0 x 10'3 5.7 hGHbp 5.5 x 105 1.3 x 106 2.4 6.9 x 103 Eluate 3 (pH 2.1 )BSA4.6 x 105 2.0 x 103 4.3 x 10'3 12.3 hGHbp 3.8 x 105 4.0 x 106 10.5 3.0 x 104 'The titers of M13K07 and hGH-phagemid particles in each fraction was determined by multiplying the number of plaque forming units (pfu) or carbenicillin resistant colony forming units (cfu) by the dilution factor, respectively. See Example IV for details.
tThe ratio of M13K07 to hGH-phagemid particles was adjusted to 3000:1 in the original mixture.
$Absorbents were conjugated with BSA or hGHbp.
~Enrichments are calculated by dividing the cfu/pfu ratio after each step by cfu/pfu ratio in the original mixture.
In a typical enrichment experiment (Table II), one part of hGH phagemid was mixed with >3,000 parts M13K07 phage. After one cyGe of binding and elution,106 phage were recovered and the ratio of phagemid to M13K07 phage was 2 to 1. Thus, a single binding selection step gave >5000-~Id enrichment. Additional elutions with free hGH or acid treatment to remove remaining phagemids produced even greater enrichments. The enrichments are comparable to those obtained by Smith and coworkers using batch elution from coated polystyrene plates (Smith, G.P. supra and Parmely, Smith sypra ) however much smaller volumes are used on the WO 92/09690 N Q ~ ~ b ~y ~~ PCT/US91/09133 beads (200 W vs. 6 ml). There was almost no enrichment for the hGH phagemid over M13K07 when we used beads linked only to BSA. The slight enrictxnent observed for control beads (-10-fold for pH 2.t elution; Table 2) may result firom trace contaminants of bovine growth hormone t>;n<ling protein present in the BSA linked to the bead. Nevertheless these data show the enrichmer><s for the hGH phage depend ion the presence of the hGHbp on the bead suggesting Minding oxurs by specific interactan between hGH and the hGHbp.
We evaluated the enrichment for wild-type hGH over a weaker bir»dirg variant of the hGH on fusion phagemids to further demonstrate enrichment speafiaty, and to Nnk the reduction in binding affinity for the purffied hormones to ervichment factors after panrwng fusion phagemids. A
fusion phagemid was constmcted with an hGH mutant in which Arg64 was substituted with Ala (R64A). The R64A
variant hormone is about 20-fold reduced in receptor binding affinity compared to hGH (Kd values of 7.t nM
and 0.34 nM, respectively [Cunningham, Wells, supra )). The titers of the R64A hGHt~ene III fusan phagemid were comparable to those of wild-type hGH phagemid. After one round of binding and elution (Table III) the wild-type hGH phagemid was enriched from a mixture of the two phagemids plus M13K07 by 8-fold relative to the phagemid R64A, and 104 relative to M13K07 helper phage.
TABLE WI. hGHbp~ooated Beads Select fa hGH PhaperNds Over a Weaker B4~np hGH Variant tfiapemld Sample enrichment j~ enrichment total phagemid for WT/R64A total phagemid for VIrT/R6~4A
Original mixture 8/20 (1) 8/20 (1) Supernatant ND - 4/10 1.0 Elution 1 (hGH) 7J20 0.8 17120 8.5$
Elution 2 (pH 2.1 ) 11 /20 1.8 21 /27 5.2 'The parent M13K07 phage, wild-type hGH phagemid and R64A pt~agemid particles were mixed at a ratio of 104:0.4.6. Binding selections were carried out using beads linked with BSA
(control beads) or with the hGHbp (hGHbp beads) as described in Table II and the Materials and Methods After each step, plasmid DNA was isolated(&mboim, H. C., Doly, J. , Nucleic Acids Res., T:1513-1523, [1979]) from carbeniallin resistant colonies and analyzed by restriction analysis to determine if it contained the wild-type hGH or the R64A hGH gene III
fusion.
tThe enrichment for wild-type hGH phagemid over R64A mutant was ca~ulated from the rata of hGH phagemid present after each step to that present in the original mixture (8120), divided by the coresponding ratio for R64A phagemids. WT = wild-type; ND = not determined.
$The enrichment for phagemid over total M13K07 parental phage was -104 after this step.
4 0 By displaying a mixture of wild-type gene III and the gene 111 fusion protein on phagemid particles one can assemble and propagate virions that display a large and proper folded protein as a fusion to gene III. The copy number of the gene III fusion protein can be effectively controlled to avoid'chelate effects' yet maintained at high enough levels in the phagemid pool to permit panning of large epitope libraries (>1010). We have shown that hGH
(a 22 kD protein) can be displayed in its native folded torm. Binding selections performed on receptor affinity beads eluted with free hGH, efficiently enriched for wild-type hGH phagemids over a mutant hGH phagemid shown to gave reduced receptor binding affinity. Thus, it is possible to sort phagemid particles whose binding constants are doom in the r~anomolar range.
WO 92/09690 ~ 9 j ~ 3 ~ PCT/US91 /09133 Proteirrprotein and antibody-antigen interactions are dominated by discontinuous epitopes (Janin, J., et al. , J.J. MoLBiol..Biol.. 204:155-164, (1988]; Argos, P., Prot Ena., 2a01-113, (19881; Barlow, D.J.,etaL , ~,, 322:747-748, [1987); and Davies, D.R., et at. , ,(,,Biol. Chem.. 263:10541-10544, [1988)); that is the residues directly involved in binding are dose in tertiary structure but separated by residues not involved in binding. The screening system presented here should albw one to analyze more conveniently protein-receptor interactions and isolate disoont~uous epitopes in proteins with new and high affinity binding properties.
S~don d hGH from a IJbrary Rundomtaed at hGH Colons 172,174,176,178 i 0 Constructi~~n of template A mutant of the hGH~ene III fusion protein was constructed using the method of Kunkel.,et aL fuj~.
Fp~,154, 367-382 [1987]. Template DNA was prepared by growing the plasmid pS0132 (containing the natural hGH gene fused to the carboxy-terminal half of M13 gene III, under control of the alkaline phosphatase promoter) in CJ236 cells with M13-K07 phage added as helper. Single-stranded, uradl-containing DNA was prepared for mutagenesis to introduce (1) a mutation in hGH which would greatly reduce binding to the hGH
binding protein (hGHbp); and (2) a unique restriction site (Kpnl) which could be used for assaying for -- and selecting against - parental background phage. Oligonudeotide-directed mutagenesis was carried out using T7 DNA polymerise and the foNowing digodeoxy-nucleotide:
Gly Thr hGH colon: 178 179 5' -G ACA TTC CTG S-aGT A~.C GTG CAG T-3' < KpnI >
This oligo introduces the Kpnl site as shown, along with mutations (R178G,1179T) ~ hGH. These mutations are predicted to reduce binding of hGH to hGHbp by more than 30-fold. Clones from the mutagenesis were screened by Kpnl digestion and confirmed by dideoxy DNA sequencing. The resulting constrict, b be used as a template for random mutagenesis, was designated pH04t5.
~ ~ggpn Ihel6c~l of hCt( Colons 172,174,176,178 were targeted for random mutagenesis in hGH, again using the method of Kunkel. Single-strarxied template from pH0415 was prepared as above and mutagenesis was carried ouf using 3 0 the following pool of oligos:
hGH colon: 172 174 5'- GC TTC AGG AAG GAC ATG GAC ~ GTC )~ ACA-Ile .5. CTG ~ ATC GTG CAG TGC CGC TCT GTG G-3' As shown, this oligo pool reverts colon 179 to wtid-type (tie), destroys the unique Kpnl site of pH0415, and introduces random colons (NNS, where N= A,G,C, or T and S= G or C) at positions 172,174,176, and 178. Using this colon selection in the context of the above sequence, no additional Kpnl sites can be seated. The choice of the NNS degenerate sequence yields 32 possible colons (inducting one 'stop' colon, and at least one colon for each amino add) at 4 sites, for a total of (32)4= 1,048,576 possible nudeotide sequences (12°~ of which contain at least one stop colon), or (20)4= 160,000 possible polypeptide sequences plus 34,481 prematurely terminated sequences (i.e. sequerxes contair>ing at least one stop colon).
PSg~,~geffon of tnlfjat Ilbrarv WO 92/09690 ~ ~ ~ C~ ~ J ~ PCT/US91/09133 The mutagenesis products were extracted twice with phenolxtrloroform (50:50) and ethanol precpitated with an excess of carrier tRNA 6o avoid adding salt that would confound the subsequent electroporation step. Approximately 50 ng (15 fmols) of DNA was electroporated into WJM101 cells (2.8 x 101 ~
oeIIsImL) in 45 N.L btal volume in a 0.2 an cuvette at a voltage setting of 2.49 kV with a single pulse (time constant = 4.7 msec.).
The ceNs were aNowed to recover 1 hour at 37oC with shaking, then mixed with 25 mL 2YT medium,100 ~glmL carbenicllin, and M13-K07 (multiplicity of infection = 1000). Plating of serial dilutions from this culture onto carbenialGn~onta~ing media indicated that 8.2 x 106 electrotransformarris were obtained. After 10' at 23oC, the culture was incubated overnight (15 hours) at 37oC with shaking.
After ovemght incubation, the cells were pelleted, and double-stranded DNA
(dsDNA), designated pLIB1, was prepared by the alkaline lysis method. The supernatant was spun again to remove any remaining cells, and the phage, designated phage pool ~1, were PEG-precipitated and resuspended in 1 mL STE buffer (10 mM
Tris, pH 7.6, 1 mM EDTA, 50 mM NaCI). Phage titers were measured as colony-formirg units (CFU) for the recombinant phagemid containing hGH~3p gene III fusion (hGH~) plasmid, and plaque-forming units (PFU) for 1 S the M13-K07 helper phage.
1. BINDING: M aliquot of phage pool ~1 (6 x 109 CFU, 6 x 107 PFU) was diluted 4.5-fold in buffer A
(Phosphate-buffered saline, 0.5% BSA, 0.05°~ Tween-20, 0.01°k thimerosal) and mixed with a 5 uL suspension of oxirane-polyacrylamide beads coupled to the hGHbp containing a Ser237 Cys mutation (350 fmols) in a 1.5 mL
silated polypropylene tube. As a control, an equivalent aNquot of phage were mixed in a separate tube with beads that had been coated with BSA only. The phage were allowed to hind to the beads by incubating 3 hours at room temperature (23oC) with slow rotation (approximately 7 RPM). Subsequent steps were carried out with a constant volume of 200~L and at room temperature.
2. WASH: The beads were spun 15 sec., and the supernatant was removed (Sup.1 ). To remove phage/phagemid not specifically bound, the beads were washed twice by resuspending in buffer A, then pelleting.
A final wash consisted of rotating the beads in buffer A for 2 tours.
3. hGH ELUTION: Phagelphagemid Minding weakly to the beads were removed by stepwise elution with hGH. In the first step, the beads were rotated with buffer A containing 2 nM
hGH. After 17 hours , the beads were pelleted and resuspended in buffer A containing 20 nM hGH and rotated for 3 hours, then pelleted. In the 3 0 final hGH wash, the beads were suspended in buffer A containing 200 nM hGH
and rotated for 3 tours then pelleted.
4. GLYCINE ELUTION: To remove the tightest-binding phagemid (i.e. those still bound after the hGH
washes), beads were suspended in Glycne buffer (1 ~Glycine, pH 2.0 with HCI), rotated 2 hours and pelleted.
The supernatant (fraction 'G'; 200~.L) was neutralized by adding 30 Nl. of 1 M
Tris base.
Fraction G eluted from the hGHbp-beads (1 x 106 CFU, 5 x 104 PFU) was not substantially enriched for phagemid over K07 helper phage. We believe this resulted from the fact that K07 phage packaged during propagation of the recombinant phagemid display the hGH-gap fusion.
WO 92/09690 ~ ~ 9 ~ ~ ~ ~ PCT/US91/09133 However, when compared with fraction G eluted from the BSAcoated control beads, the hGHbp-beads yielded 14 times as many CFU's. This reflects the enrichment of tight-binding hGH~displaying phagemid over nonspedfically-binding phagemid.
5. PROPAGATION: M aliquot (4.3 x 105 CFU) of fractan G ekited from the hGHbp-beads was used to infect log-phase WJM101 cells. Transductans were cartied out by mixing 100 N.L fractan G with 1 mL WJM101 cells, incubating 20 min. at 37oC, then adding K07 (multiplidty of infection=1000). Cultures (25 mL 2YT plus carberudllin) were grown as described above and the second pool of phage (Library 1G, for first glydne elution) were prepared as described above.
Phage from library 1 G (Fig. 3) were selected for tlinding to hGHbp beads as described above. Fraction G eluted from hGHbp beads contained 30 times as many CFU's as fir~tion G
eluted from BSA-beads in this selectan. Again, an aliquot of fraction G was propagated in WJM101 cells to yield library 1G2 (indicating that this library had been twice selected by glyane elution). Double-stranded DNA
(pLIB 1 G2) was also prepared from this culture.
To reduce the level of background (Kpnl+) template, an aliquot (about 0.5 p.g) of pLIB 1G2 was digested with Kpnl and electroporated into WJM101 cells. These cells were grown in the presence of K07 (multiplidty of infection= i00) as described for the initial library, and a new phage pool, pLIB 3, was prepared (Fig. 3).
In addition, an aliquot (about 0.5 fig) of dsDNA from the initial library (pLIB1) was digested with Kpnl and electroporated directly into WJM101 cells. Transfortnants were allowed to recover as above, infected with M13-K07, and grown overnight to obtain a new Gtxary of phage, designated phage Library 2 (Fig. 3).
Phagemid binding, elution, and propagation were carried out in successive rounds for phagemid derived from both pLIB 2 and pLIB 3 (Fig. 3) as described above, except that (1) an excess (10-fold over CFU) of p~xified K07 pfrage (not ~sptaying hGH) was added in the bead-binding cocktail, and (2) the hGH stepwise elutions were n;plaoed with txief washings of buffer A alone. Also, in some cases, XL1-Blue cells were used for phagemid propagation.
An additional digestion of dsDNA with Kpnl was carried out on pLIB 2G3 and on pLlB 3G5 before the final round of bead-binding selection (Fg. 3).
Four independently isolated doves from LIB 4G4 and bur indeperxiently isolated doves from LIB 5G6 were sequenced by dideoxy sequendng. All eight of these doves had identical DNA sequences:
hGH colon: 172 174 176 178 5' -AAG GTC TCC ACA TAC CTG AGG ATC-3' Thus, all these encode the same mutant of hGH: (E174S, F176Y). Residue 172 in these Bones is Lys as in wild-type. The colon selected for 172 is also identical to wild-type hGH. This is not surprising since AAG is the only lysine~odon possible from a degenerate 'NNS' colon set. Residue 178-Arg is also the same as wild-type, but here, the colon selected from the library was AAG instead of CGC as is found in wild-type hGH, even though the latter colon is also possible using the'NNS' colon set.
p 30 The multipliclty of infection of K07 infection is an important parameter in the propagation of recomtHnant phagemids. The K07 multiplidty of infection must be high enough to insure that virtually all cells transformed or transfected with phagemid are able to package new phagemid particles. Furthermore, the concentration of wild-type gene III in each cell should be kept high Eo reduce the possibility of multiple hGH-gene III
fusion molecules being displayed on each phagemid particle, thereby reduarg chelate effects in binding. However, if the K07 multiplidty of infection is too high, the packaging of K07 will compete with that of recombinant phagemid. We find that aooeptabfe phagemid yields, vhth oMy 1-10% badc~ound K07 phage, are obtained when the K07 mutGplidty of infection is 100.
Table IV.
Phage Pool moi (K07) Enrichment hGHbpIBSA beads Fraction Kpnl CFUIPFU
LIB 1 1000 ND 14 0.44 LIB 1G 1000 ND 30 0.57 LIB 3 100 ND 1.7 0.26 LIB 3G3 10 ND 8.5 0.18 LIB 3G4 100 460 220 0.13 LIB 2 100 ND 1.7 <0.05 LIB 2G 10 ND 4.1 <0.10 LIB 2G2 100 1000 27 0.18 Phage pools are labelled as shown (Fig. 3). The multiplidty of infection (moi) refers to the multiplidty of K07 infection (PFUlcells) in the propagation of ptragemid. The enrictunent of CFU
over PFU is shown in those cases where purified K07 was added in the binding step. The rata of CFU eluting from hGHbp-beads over CFU eluting from BSA-beads is shown. The fraction of Kpnl-containing template (i.e., pH0415) remaining in the pool was determined by digesting dsDNA with Kpnl plus EcoRl, running the products on a 1°k agarose gel, and laser-scanning a negative of the ethidium bromide-stained DNA.
R~'gp~tor-blndina aftlnHp~r of fhe hormone hGH(E174S. F176Y1 The fact that a single done was isolated from iwo different pathways of selection (Fig. 3) suggested that the double mutant (E174S,F176Y) hinds strongly to hGHbp. To determine the affinity of this mutant of hGH for hGHbp, we constructed this mutant of hGH by site~irected mutagenesis, using a plasmid (pB0720) which contains the wild-type hGH gene as template and the following oligonuGeotide which changes colons 174 and hGH colon: 172 174 176 178 Lys Ser Tyr Arg 5'- ATG GAC AAG GTR ~G ACA T8C CTG CGC ATC GTG -3' The resulting construct, pH0458B, was transformed into E. coli strain 16C9 for expression of the mutant hormone. Scatchard analysis of competitive tHnding of hGH(E174S,F176Y) versus 1251-hGH to hGHbp indicated that the (E174S,F176Y) mutant has a Minding affinity at least 5.0-fold tighter than that of wild-type hGH.
EXAMPLE VUI
SELECTION OF hGH VAFBANTS FROM A
Human growth hormone variants were produced by the method of the present irnention using the phagemid desaibed in figure 9.
We designed a vector for cassette mutagenesis (Wells et al., ~, 34, 315-323 [1985)) and expression of the hGH-gene III fusion probin with the objectives of (1 ) improving the wnkage between hGH and the gene I II
moiety to more favorably display the hGH moiety on the phage (2) limiting expression of the fusion protein to obtain essentially 'monovaleM display,' (3) allowing for restriction rxidease selection against the starting vector, (4) eliminating expression of fusion protein from the starting vector, and (5) achieving taale expression of the corresponding free hormone from a given hGH-gene III fusion mutant.
Plasmid pS0643 was constructed by oligonuGeotide-directed mutagenesis (Kunkel et al., Fp~,154, 367-382 [1987J) of pS0132, which contains pBR322 and fi origins of repbcation and expresses an hGH-gene III fusion protein (hGH residues 1-191, followed by a single Gly residue, fused to Pro-198 of gene III) under the control of the F,,~ p(ZQ6 promoter (Bass et al., Proteins 8, 309-314 [1990])(Figure 9). Mutagenesis was carried out with the oligonuGeotide 5'-GGC-AGC-TGT-GGC-TT_r,~AG-AGT-GGC-GGC-GGC-TCT-GGT-3', which introduces a ~[ site (underlined) and an amber stop colon (TAG) foNowing Phe-19t of hGH. In the resulting construct, pS0643, a portion of gene III was deleted, and two silent mutations (underlined) occurred, yielding the folbwing junction between hGH and gene III:
__ ~ _______.__________.> geae » >
2 5 1B7 188 18B 190 181 am' 249 2!!0 261 2:3~ 2S3 264 t9Q Gars G19 P>'e (;fin tsa Cdr G~ Gf;Y ~' ~9 GGC AOC TGT GGA ThC TAG ~IGT O0~ (ifs'T' C1GC TCT GiG1' This shortens the total size of tire fusion protein firom 401 residues ~
pS0132 to 350 residues in 3 0 pS0643. Experiments using monoclonal antibodies against hGH have demonstrated that the hGH portion of the new fusion protein, assemded on a phage particle, is more acoesside than was the previous, longer fusion.
For propagation of hormone-displaying phage, pS0643 and derivatives can be grown in a amber-suppressor strain of ~, such as JM101 or XL1-Blue (Bullock et al., BioTecbpj~
5, 376-379 [1987j). Shown above is substitution of Glu at the amt~er colon which occurs in ;~ suppressor strains. Suppression with other 3 5 amino acids is also possible in various available sUair~s of ~,,~ well known and publicalty available.
To express hGH (or mutants) tree of the gene III portion of the fusion, pS0643 and derivatives can simply be groHm in a non-suppressor strain such as 16C9. ~ ihis case, the amber colon (TAG) leads to termination of translation, which yields free hormone, without the need for an independent DNA construction.
To create sites for cassette mutagenesis, pS0643 was mutated with the oligonucJeotides (1 ) 5'-CGG-40 ACT-GGG-CAG-ATA-TTC-AAG-CAG-ACC-3', which destroys the unique $q(1[ site of pS0643; (2) 5'-CTC-AAG-AAC-TAC-GGG-TTA-CCC-TGA-CTG-CTT-CAG-GAA-GG-3', which inserts a unique ~j site, a single-base (rameshift, and a non-amber stop colon (TGA); and (3) 5'-CGC-ATC-GTG-CAG-TGC-AGA-TCT-GTG-GAG-GGC-3', which introduces a new ~ site, to yield the starting vector, pH0509. The addition of a frameshift along with a TGA stop colon insures that no genelll-fusion can be produced from the startirg vector.
WO 92/09690 ~ Q ~ PCT/LJS91/09133 The ~[[ - ~[[1 segment is cut out of pH0509 and replaced with a DNA cassette, mutated at the colons of interest. Other restriction sites for cassette mutagenesis at other locatans in hGH have also been introduced into the hormone-phage vector.
Colons 172,174, 176 and 178 of hGH were targeted for random mutagenesis because they all lie on or near the surface of hGH and contribute significantly to receptor-binding (Cunningham and Wells, 244, 1081-1085 (1989]); they all we within a well-defined structure, occupying 2'tums' on the same side of helix 4;
and they are each substituted by at least one amino aad among krawn evolutionary variants of hGH.
We chose to s~stitute NNS (N=A/G/C/T; S=G/C) at each of the target residues.
The choice of the NNS degenerate sequence yields 32 possible codor~s (including at least one colon for each amino aad) at 4 sites, for a total of (32)4= 1,048,576 possible nucleotide sequences, or (20)4=
160,000 possible polypeptide sequences. Only one stop colon, amber (TAG), is albwed by this choice of colons, and this colon is suppressible as Glu in ~ strains of ~.
Two degenerate oligonudeotides, with NNS at colons 172,174,176, and 178, were synthesized, phosphorylated, and annealed to construct the mutagenic cassette: 5'-GT-TAC-TCT-ACT-GCT-TTC-AGG-AAG-GAC-ATG-GAC-NNS-GTC-NNS-ACA-NNS-CTG-NNS-ATC-GTG-CAG-TGC-A-3', and 5'-GA-TCT-GCA-CTG-CAC-GAT-SNN-CAG-SNN-TGT-SNN-GAC-SNN-GTC-CAT-GTC-CTT-CCT-GAA-GCA-GTA-GA-3'.
The vector was prepared by digesting pH0509 with followed by ~[[j. The products were run on a 1% agarose gel and the large fragment exased, phenol-extracted, and ethanol precipitated. This fragment was treated with calf intestinal phosphatase (Boehringer), then phenol:chloroform extracted, ethanol preapitated, and resuspended for ligatan with the mutagenic cassette.
rr~~umn uu: nnu~ nu~~r m w~rw~ ma Following ligation, the reaction products were again digested with , then phenol:chloroform extracted, ethanol precipitated and resuspended in water. (A g~j1 recognition site (GGTNACC) is created within cassettes which contain a ~ at position 3 of colon 172 and an ~ (Thr) colon at 174. However, treatment with ~stEll at this step should not select against any of the possible mutagenic cassettes, because virtually all cassettes will be heteroduplexes, which cannot be Geaved by the enzyme.) Approximately 150 ng (45 fmols) of DNA was electroporated into XL1-Blue cells (1.8 x 109 cells in 0.045 mL) in a 0.2 an cuvette at a voltage setting of 2.49 kV with a single pulse (time constant = 4.7 msec.).
The cells were allowed to recover 1 hour at 37oC in S.O.C meda with shaking, then mixed with 25 mL
2YT medium,100 mg/mL carbenicillin, and M13-K07 (moi= 100). After 10' at 23oC, the culture was incubated overnight (15 hours) at 37oC with shaking. Plating of serial dilutions from this culture onto carbenicillin-containing media indicated that 3.9 x 107 electrotransformants were obtained.
After overnight incubation, the cells were pelleted, and double-strarxied DNA
(dsDNA), designated pH0529E (the initial library), was prepared by the alkaline lysis method. The supernatant was spun again to remove any remaining cells, and the phage, designated phage pool ~H0529E (the initial lilxary of phage), were PEG-precipitated and resuspended in 1 mL STE buffer (10 mM Tris, pH 7.6, 1 mM
EDTA, 50 mM NaCI). Phage WO 92/09690 ~ j ~ ~ ~ PCT/US91/09133 titers were measured as cobny-forming units (CFU) for the recombinant phagemid containing hGH-gap.
Approximately 4.5 x 1013 CFU were obtained from the starting library.
From the pool of electrotransformants, 58 doves were sequenced in the region of the ~-gq(j[
cassette. Of these, 17% corresponded to the starting vector,17% contained at least one frame shift, and 7°~6 contained a non-silent (non-terminating) mutation outside the four target colons. We conclude that 41°~ of the doves were defective by one of the above measures, leaving a botat functional pool of 2.0 x 107 initial transfortnants. This number stiN exceeds the possible number of DNA sequences by nearly 20-fold. Therefore, we are confident of having all possible sequences represented in the starting litxary.
We examined the sequences of non-selected phage to evaluate the degree of colon bias in the mutager~esis (Table V). The results indicated that, although some colons (and amino adds) are under- or over-represented relative to the random expectation, the library is extremely diverse, with no evidence of large-scale 'sibling' degeneracy (Table VI).
Table V.
Colon distributan (per 188 colons) of non-selected hormone phage. Cbnes were sequenced from the starting library (pFt0529E). All colons were tabulated, inducting those from Bones which contained spurious mutations andlor frameshifts. ' Note: the amber stop colon (TAG) is suppressed as Glu in XLt-Blue cells. Highlighted colons were ovedunder-represented by 50% or more.
leu 17.6 18 1.0 Ser 17.6 26 1.5 A r g 17.6 10 0.57 Pro 11.8 16 1.4 Thr 11.8 14 1.2 Ala 11.8 13 1.1 Gly 11.8 16 1.4 Val 11.8 4 0.3 1e 5.9 2 0.3 Met 5.9 1 0.2 Ty r 5.9 1 0.2 Ws 5.9 2 0.3 Trp 5.9 2 0.3 Phe 5.9 5 0.9 4 Cys 5.9 5 0.9 Gln 5.9 7 1.2 Asn 5.9 14 2.4 Lys 5.9 11 1.9 Asp 5.9 9 1.5 Glu 5.9 6 1.0 amber' 5.9 6 1.0 WO 92/09690 ~ ~ ~ ~ ~ PCT/US91/09133 Table VI.
Non-selected (pH0529E) clones with an open reading frame.
The notation, e.g. TWGS, denotes the hGH mutant 172TI174WI176G/178S. Amber (TAG) colons, translated as GIu in XL1-Blue cells are shown as E.
Ke NT KTEQ CVLQ
TWGS NNCR EASL
Pe ER FPCL SSKE
LPPS NSDF ALLL
SLDP HRPS PSHP
OQSN LSLE SYAP
GSKT NGSK ASNG
TPVT LTTE EANN
RSRA PSGG KNAK
LCGL LWFP SRGK
TGRL PAGS GLDG
AKAS GRAK NDPI
GNDD GTNG
Immobilized hGHbp ('hGHbp-beads') was prepared as described (Bass et al., Proteins 8, 309-314 [1990]), except that wild-type hGHbp (Fuh et al., ~, Biol. Chem. 265, 3111-3115 [1990]) was used. Competitive binding experiments with [1251] hGH indicated that 58 fmols of turxtional hGHbp were coupled per uL of bead Immobilized hPRLbp ('hPRlbp-beads') was prepared as above, using the 211-residue extraoelluiar domain of the prolactin receptor (Cunningham et al., ~jg~ 250,1709-1712 [1990]). Competitive binding experiments with [1251] hGH in the presence of 50 l,t~ zinc indicated that 2.1 fmols of functional hPRLbp were 3 0 coupled per N.L of bead suspension.
'Blank beads' were prepared by treating the oxirane-acrylamide beads with 0.6 M etharalamine (pH
FIELD OF THE INVENTION
This invention relates to the preparation and systematic selection of novel binding proteins having altered binding properties for a target molecule. Specifically, this irwentan relates to methods for producing foreign polypeptides mimicking the binding activity of naturally occurring binding partners. In preferred embodiments, the invention is directed to the preparation of therapeutic or diagnostic compounds that mimic proteins or nonpeptidyl mole~es such a hormones, dings and other smaN
moleales, particularly biologically active molea~les such as growth hormone.
BACKGROUND OF THE INVENTION
Binding partners are substances chat speafically bind to one another, usually through noncovalent interactions. Examples of binding partners inGude ligand-receptor, antibody-antigen, drug-target, and enzyme-substrate interactions. Binding partners are extremely useful in both therapeutic and diagnostic fields.
Binding partners have been produced in the past by a variety of methods including; harvesting them from nature (e.g., antibody-antigen, and ligand-receptor pairings) and by adventitious identification (e.g.
traditional drug development empbying random screening of candidate molecules). In some instances these two approaches have been combined. For example, variants of proteins or pdypeptides, such as polypeptide fragments, have been made that contain key functional residues that participate in binding. These polypeptide fragments, in tum, have been derivatized by methods akin to traditional drug development. M example of such derivitization would include strategies such as cyclization to confortnationally constrain a polypeptide fragment to produce a novel candidate binding partner.
The problem wish prior art methods is that naturally occurring ligands may not have proper characteristics for all therapeutic applications. Additionally, polypeptide Ggands may not even be available for some target substances. Furthermore, methods for making non~naturally occurring synthetic binding partners are often expensive and difficult, usually requiring complex synthetic methods to produce each candidate. The inability to characterize the structure of the resulting candidate so that rational drug design methods can be applied for further optimizatan of candidate molecules further hampers these methods.
In an attempt to overcome these problems, Geysen (Geysen, Immun. Todav. 6:364-369 [1985]); and (Geysen et al., ~~p~p" 23:709-715 [1986J) has proposed the use of polypeptide synthesis to provide a framework for systematic iterative binding partner identification and preparation. According to Geysen et al., Ibid, short polypeptides, such as dipeptides, are first screened for the ability to bind to a target molecule. The most active dipeptides are then selected for an additional round of testing comprising linking, to the starting dipeptide, an additional residue (or by internally modifying the components of the original starting dipeptide) and then screening this set of candidates for the desired activity. This process is reiterated until the Minding partner having the desired properties is identified.
The Geysen et at. method suffers from the disadvantage that the chemistry upon which it is based, peptide synthesis, produces molecules with ill-defined or variable secondary and tertiary structure. As rounds of iterative selection progress, random interactions accelerate among the various substituent groups of the polypeptide so that a true random population of interactive molecules having reproducible higher order structure becomes lays arid less adainabla. For example, inleractians beMleen side drains of amino acki5. which are sequentiasy widely aeparathd but which are spatialH nelgt,mrs. freely ocax.
Furihertnore, sequences that do not taa~tate confartnationally stable secondary sbuGtureS ~~ ~P~x t~et~-ddectr3in interactions wtxcn may prevent sideChaln in6eracifons of a given amino dad with tyre target motearle.
Such complex interactions are -g taalitated by the Nexittility of die polyamlde back 8t ttta pdypeptide candidates. Additionally, rrandldates may exist In numerous aontormAliOrts mafdn9 it dlmCult to identity the oarfartner shat interacts or binds to the target with greatesl alenity or speatrcity eamplicating rational drug des'sgn-A final problem with the ipsrative polypeptide method of Geyttett is that, at presenl, there are r~
practical medrods with which a great diversity of dllferent peptides can be pnvduoed. screened and analyzed. i3y 10 using the Iwenty naturatty Qoaming amino acids, the total number of all oambinatbrrs of hexapeptides that must be synthesized is 64,t>00,000. Even having prepared such a dversity at peptides, there are no methods avrailabte with which mixtrxes of sub a diversity of peptides aan ~ raP~Y Keened to selea those pepdde5'havir~g a high atkniiy for the target molecule. At present, each 'adtrerent' peptide must be recovered in amounts large enough tQ cony out protein sequenoin9~
15 To overcome marry et the problems inherent in the ~y~n aPP~ ~~i~l selection and 5aeenlng was ciwsen as an attemadve. Biological selections and saeens are Powerful foals to probe Protein function and to isolate variant proteins with desirable properties (Shortle, plpi!»Dg. Oxender and Fox, ads., A.R. Liss, Inc., NY, pp.103~108 [1988]) and 8ovne et or.. ., ~T:1306-1310 [199D)).
However, a given selection or gcreen is appliGabIB t0 only Dne or a small number of related proteins.
20 Recendy, umilh and coworkers (Smith. ~~. x:1315~1317 [1985)) arKi Parmley and Smith. ~.
7a:3a5-318 [1985] have der~nstrated that small protein tra9ments (10~50 amino adds) can be 'displayed' etfidently on the surface of iilamentous pf~ge by inserting Short gene lsagmerns Into genQ III of the td phage (~tusion phage'). The gene Ill minor coat protein (present in abo~ 3 ~Ples at one end at the virion) is important for proper pttage assembly and tar infection by attachment to the pill of E
Colt (see Ranched et at. , 25 gsy"50: a01-427 [1886]). Recently, 'fusion pttage' have been shown to be useful for displaying start mutated peptide sequences for identifying peptides Ihat may react with anUbadies (Scott et 8i., 249: 386-390, [1990] -..)and Gwirla et tit., prn~ Na_N, p,ad t A 87: 638~6382. [1990[).or a foreign protein (Llevlin et al"
~~' ,pig, 24~: 404-406 [t990)).
There are, trowever, several important limitations In using tttxh'fusian ptrage' to ider>diy altered 30 pepCides or proteins with new or enhanced birxJitlg fxapeTt~s. Frst, it has teen shown (Parmldy et al., one. 73:
305-318. [1998]) that fusion phage are useful only br displaying proteins of less Ihan tOQ arid preferably less than 50 amino aad residues, becauso large inserts presumably disrupt the krrction of Gene Ill and ii~refore phage assembly and intectivity. Second, prior art methods have been unable b select pep4des from a Gtxary having the highest binding aeiNty for a target molecule. For example, attar exhaustive panning of a random peptide litxary 35 with an antr~ endorphin monoGOrral antiltcdy, t~lrla et al., supra could not separate moderate adinity peptides (icd - 10 wM) from higher affinity peptides (Kd -d.4 ~M) fused id phage. Moreover, the Parent ~_ endorphin peptide sequence which has very trigh aftirtity (iCd ~ 7nMj, was not Padre from the epitope library.
Ladner WO 9010x802 discloses a method for selecting novel birxkrtg proteins displayed on the ouoer surface of cells arid viral particles where it is contemplated drat the heharobgorss proteins may have up to 1 B4 WO 92/09690 ~ ~ ~ PCT/U591 /09133 3 >._ amino acrd residues . The method cont~nplates isolating and amplifying the c~splayed proteins to engineer a new family of Minding proteins having desired affinity for a target moleade. More sped6calty, Ladner discloses a 'fusion phage' displaying proteins having 'initial protein finding domains' ranging from 46 residues (cramt~n) to 164 residues (T4 lysozyme) fused to the M13 gene III coat protein. Ladner beaches the use of proteins'no larger than necessary t~erause it is easier to arrange restriction sites in smaNer amino add sequences and prefers the 58 amino add residue bovine pancreatic trypsin inhibitor (BPTI). Small tusan proteins, such as BPTI, are preferred when the target is a protein or macromolecule, while larger fusion proteins, such as T4 lysozyme, are preferred for small target molecules such as sterads because such large proteins have clefts and grooves into which small molecules can fit. The preferred protein, BPTI, is proposed to be fused b gene III at the site disclosed by Smith et al. or de la Cruz et al., J. Biol. Chgm" 263: 4318,4322 [1988), or to one of the terminii, along with a second synthetic copy of gene III so that'some' unaltered gene III protein will be present. Ladner does not address the problem of successfully panning high affinity peptides from the random peptide library which plagues the biological selection and screening methods of the prig art.
Human growth hormone (hGH) partidpates in much of the regulation of normal human growth and development. This 22,000 dalton ptuitary hormone exhibits a multitude of biological effects including linear growth (somatogenesis), lactation, activation of macrophages, insulin-like and diabetogenic effects among others (Chawla, R, K. (1983) 911p ev. Med. fig, 519; Edwards, C. K et al. (1988) ,~,p~,~Q, 769; Thomer, M. 0., et al.
(1988) J. Clip. Invest gl, 745). Growth hormone defiaency in children leads to dwarfism which has been successfully treated for more than a decade by exogenous administratan of hGH.
hGH is a member of a family of 2 0 homologous hormones that include placenhal lactogens, prolactins, and other genetic and spades variants or growth hormone (Nicoll, C. S., efal., (1986) ~ocrine Reviews 2,169). hGH is unusual among these in that it exhibits broad species spedfidty and binds to either the dor~ed somatogenic (Leung, D. W., et aL, [1987] ~g ~,,3,Q, 537) or prolactin receptor (Boutin, J. M.,et al., [1988] fig; ,~, 69). The doped gene for hGH has been expressed in a secreted forth in ~j (Ctrarg, C. N., et al., [i987] ~;~,189) and its DNA and amino add sequence has been reported (Goeddel, etal., p979] ~,~, 544; Gray, etal., [1985] ~,3$, 247).
The three-dimensional stnxture of hGH is not available. However, the three-dimensional folding pattern for porcine growth hormone (pGH) has been reported at moderate resolution and reffr~ement (Abdel-Meguid, S. S., et al., [1987j Proc-Natl.Natl.
e~~d. Sci. USA $4, 6434). Human growth hormone's receptor and antibody epitopes have been identified by homolog-scanning mutagenesis (Cunningham etal., Saenoe Zq$;1330,1989). The structure of novel amino terminal methionyl bovine growth hormone contair>ing a spliced-in sequerxe of human growl hormone including histidine 18 and histidine 21 has been shown (U.S. Patent 4,880,910) Human growth hormone (hGH) cages a variety of physiological and metabolic effects in various ar>imal models including linear bone growth, lactation, activation of macrophages, insulin-like and diabetogenic effects and others (R. K. Chawla etal., Anna. Rev. Mad. 34, 519 (1983); 0. G. P. Isaksson etat., Mrw. Rev. Phys'rot. 47, 483 (1985); C. K. Edwards etal., Science 239, 769 (1988); M. 0. Thomer and M. L.
Vance, J. Clip. Invest. 82, 745 (1988); J. P. Hughes and H. G. Friesen, Mn. Rev. Physiol. 47, 469 (1985)).
These biological effects dertve from the interaction between hGH and spedfic cellular receptors..
Accordingly, it is an object of this invention to provide a rapid and effective method for the systematic preparation of candidate binding substances.
It is another object of this invention to prepare candidate Minding substances displayed on surface of a phagemid particle that are conformationally stable.
It is another object of this invention to prepare candidate tending substances comprising fusion proteins of a phage coat protein and a heterologous polypeptide where the polypeptide is greater than 100 amino acids in length and may be more than one subur>;t and is displayed on a phagemid particle where the polypeptide is encoded by the phagemid genome.
It is a further object of this invention to provide a method for tt~e preparation and selection of binding substances that is suffiaently versatile to present, or display, all peptidyl moieties that could potentially particlpate in a nonoovalent binding interaction, and to present these moieties in a fashion that is sterically confined.
Still another object of the invention is the production of growth hormone variants that exhibit stronger affinity for growth hormone receptor and binding protein.
It is yet another ot~ject of this invention to produce expressan vector phagemids that contain a suppressible termination oodon tunc6onally bcated between the heterok~gous polypeptide and the phage coat protein such that detectable fusion protein is produced in a host suppressor cell and only the heterologous polypeptide is produced in a non-suppresser host cell.
Fnally, it is an object of this invention to produce a phagemid particle that rarely displays more than one copy of candidate binding proteins on the outer surface of the phagemid particle so that efficient selection of high affinity tHnding proteins can be achieved.
These and other objects of this irnention wit be apparent from consideration of the invention as a whole.
These objectives have been achieved by providing a method for seleding novel binding polypeptides comprising: (a) constructing a replicable expression vector comprising a first gene encoding a polypeptide, a second gene encoding at least a portion of a natural or wild-type phage coat protein wherein the first and second 2 5 genes are heterologous, and a transcription regulatory element operady linked to the first and second genes, thereby forming a gene fusion erxxxfing a fusion protein; (b) mutating the vector at one or more selected positions within the first gene thereby forming a family of related plasmids; (c) transforming suitable host peas with the plasmids; (d) infecting the transformed host cells with a helper phage having a gene encoding the phage coat protein; (e) culturing the transformed infected host cells under conditions suitable for forming recombinant phagemid particles containing at least a portion of the plasmid and capable of transforming the host, the conditions adjusted so that no more than a minor amount of ph~emid particles display more than one copy of the fusion protein on the surface of the particle; (f) contacting the phagemid particles with a target molecule so that at least a portion of the phagemid particles find to the target molecule; and (g) separating the phagemid particles that bind from those that do not. Preferably, the method further comprises transforming suitable host cells with recombinant phagemid particles that bind to the target molecule and repeating steps (d) through (g) one or more times.
Additionally, the method for selecting novel binding proteins where the proteins are composed of more than one subunit is ad~ieved by selecting novel binding peptides comprising constructing a replicable expression vector comprising a transcription regulatory element operably linked to DNA
erxoding a protein of interest WO 92/09690 ~ ~~ ~ ~ ~ ~ ~ PC1'/US91/09133 _ containing one or more subunits, wherein the DNA encoding at least one of the subunits is fused to the DNA
encoding at least a portion of a phage coat protein;mutating the DNA encoding the protein of interest at one or more selected positions thereby fomring a family of related vectors;
transforming suitable host cells with the vectors; iMecting the transformed host cells with a helper phage having a gene encoding the phage coat protein;
5 culturing the transformed infected host cells under conditions suitable for forming recombinant phagemid particles containing at least a portion of the plasmid and capable of transforming the host, the conditions adjusted so that no more than a minor amours of phagemid particles display more than one copy of the fusion protein on the surface of the particle; contacting the phagemid particles with a target molecule so that at least a portion of the phagemid particles bind to the target molecule; and separating the phagemid particles that hind from those that do not.
Preferably in the method of Ihis invention the plasmid is under tght control of the transcription regulatory element, and the culturing conditions are adjusted so that the amount or number of phagemid particles displaying more than one copy of the fusion protein on the surface of the particle is less than about 1 %. Also preferably, amount of phagemid particles displaying more than one copy of the fusion protein is less than f0% the amount of phagemid particles displaying a single copy of the tusan protein.
Most preferably the amount is less than 20°x.
Typically, in the method of this invention, the expression vector will further contain a secretory signal sequences fused to the DNA enaxling each subunit of the polypeptide, and the transcription regulatory element will be a promoter system. Preferred promoter systems are selected from; Lac Z, a,pL, TAC, T 7 polymerise, tryptophan, and alkaline phosphatase promoters and combinatans thereof.
Also typically, the first gene will encode a mammalian protein, preferably the protein will be selected from; human growth hormone(hGHj, N-metfionyl human growth hormone, bovine growth homrone, parathyroid hormone, thyro>one, insulin A-drain, insulin B~chain, proinsuWn, rolaxin A~hain, relaxin B-chain, prorelaxin, glycoprotein hormones such as follicle stimulating hormone(FSH), thyroid stimulating hormone(TSH), and leutinizing hormone(LH), glycoprotein hormone receptors, caldtonin, glucagon, factor VIII, an antibody, lung surtactant, urokinase, streptokinase, human tissue-type plasminogen activator (t-PA), bombesin, factor IX, thrombin, hemopoietic growth factor, tumor r~sis factor-alpha and -beta, enkephalinase, human serum albumin, mullerian-inhibiting substance, mouse gonadotropin-associated peptide, a microbial protein, such as betalactamase, tissue factor protein, inhibin, activin, vascular endothelial growth factor, receptors for hormones or growth factors; integrin, thrombopoietin, protein A or D, rheumatoid factors, nerve growth factors such as NGF-)3, platelet~rowth factor, transforming growth factors (TGFj such as TGF,alpha and TGF-beta, insuiin-like growth factor-I and -II, insulin-like growth factor binding proteins , CD-4, DNase, latency assodated peptide, erythropoietin, osteoinductive factors, interferons such as interferon-alpha, -beta, and -gamma, colony stimulating factors (CSFs) such as M-CSF, GM-CSF, and G-CSF, interleukins (ILs) such as IL-1, IL-2, IL-3, IL-4, superoxide dismutase; decay accelerating factor, viral antigen, HIV
envelope proteins such as GP120, GPt40, atrial natriuretic peptides A, B or C, immunoglobulins, and fragments of any of the above-listed proteins.
Preferably the first gene will encode a polypeptide of one or more subunits containing more than about 100 amino add residues and will be folded to form a plurality of rigid secondary structures displaying a plurality of amino acids capable of interacting with the target. Preferably the first gene will be mutated at codons corresponding to only the amino acids capable of interacting with the target so that the integrity of the rigid secondary strur.~ures will be preserved.
Normally, the method of this invention will empby a helper phage selected from; M13K07, M13R408, M13-VCS, and Phi X 174. The preferred helper phage is M13K07, and the preferred coat protein is the M13 Phage gene III coat protein. The preferred host is E. cbli, and protease deffdent strains of E. coli. Novel hGH
variants selected by the method of the present irnentan have been detected.
Phagemid expression vectors were constnxted that contain a suppresside termination colon functionally located between the nucleic acids encoding the polypeptide and the phage coat protein.
BRIEF DESCRIPTION OF THE FIGURES
FIGURE 1. Strategy for displaying large proteins on the surface of filamenbous phage and enriching for altered receptor binding properties. A plasmid, phGH-Ml3glll was consrruucted that fuses the entire coding sequence of hGH to the carboxyl terminal domain of M13 gene III. Transcription of the fusion protein is under control of the lac promoberloperator sequence, and secretion is directed by the stll signal sequence. Phagemid partices are produced by infection with the 'helper phage, M13K07, and particles displaying hGH can be enriched by twining to an affinity ma~ix contakring the hGH receptor. The wild-type gene III (derived from the M13K07 phage) is diagramed by 4-5 copies of the multiple arrows on the tip of the phage, and the fusion protein (derived from the phagemid, phGH-Ml3glll) is indicated schematicatiy by the folding diagram of hGH repladng the arrow head.
FIGURE 2 knmunot~lot of whole phage particles shows that hGH comigrates with phage. Phagemid 2 0 particles purified in a cesium chloride gradient were loaded into duplicate wells and electrophoresed through a 1 agarose gel in 375 mM Tris, 40 mM glycne pH 9.6 buffer. The gel was soaked in transfer buffer (25 mM Tris, pH
8.3, 200 mM glyane, 20% methanol) containing 2% SDS and 296 ~-mercaptoethanol for 2 hours, then rinsed in transfer buffer for 6 hours. The proteins in the gel were then electrobbtted onto immot>ilon membranes (Millipore). The membrane containing one set of samples was stained with Coomassie blue to show the position of the phage proteins (A). The duplicate membrane was immures-stained for hGH by reacting the membrane with polydonal rabbit anti-hGH antibodies folbwed by reaction with horseradish peroxidase conjugated goat anti-rabbit IgG antibodies (B). Lane 1 contains Ifrre M13K07 parent phage and is viside only in the Coomassie blue stained membrane, since it lacks hGH. Lanes 2 and 3 contain separate preparations of the hormone phagemid partiGes which is visible both by Coomassie and hGH immuno-stairang. The difference in mgration distance between the parent M13K07 phage and hormone phagemid particles reflects the different size genomes that are packaged within (8.7 kb vs. 5.1 kb, respectively).
FIGURE 3. Summary diagram of steps in the selection process for an hGH-phage library randomized at colons 172,174,176, and 178. The template molecules, pH0415, containing a unique Kpnl restriction site and the hGH(Rt78G,1179T) gene was mutagenized as described in the text and electrotransfonned into E. cofi strain WJM101 to obtain the initial phagemid library, Library 1. An aliquot (approximately 2%) from Ubrary 1 was used directly in an initial selection round as described in the text to yield Litxary 1 G. Meanwhile, double-stranded DNA
(dsDNA) was prepared from Library I, digested with restriction enzyme Kpnl to eliminate template badkground, and electrotransformed into WJM101 to yield Library 2. Subsequent rounds of selection (or Kpnl digestion, shaded boxes) followed by phagemid propagation were carried out as indicated by the arrows, according to the WO 92/09690 ~ '~ ,-~~ ~ ~ ~ ~ PCT/US91 /09133 ..
procedure described in the text. Four independent doves from litxary 4G4 and tour independent Bones from library 5G6 were sequenced by dideoxy sequendng. All of these Bones had the identical DNA sequence, corresponding 1o the hGH mutant (Glu 174 Ser, Phe 176 Tyr).
FIGURE 4. Structural model of hGH derived from a 2.8 la folding diagram of porcine growth hormone determined aystallographically. t-ovation of residues in hGH that strongly modulate its binding to the hGH-binding protein are within the shaded drde. Alanine substitutions that cause a greater than tenfold reduction(~), a four- to tenfold reduction (~), or increase (O), or a two- to fourfold reduction (~), in tending affinity are indicated. Helical wheel projections in the regions of a-helix reveal their amptupathic quality.
Blackened, shaded, or noruhaded residues are charged, polar, or nonpolar, respedavely. In helix-4 the most important residues for mutation are on the hydrophilic face.
FIGURE 5. Amino acrd substitutions at positions 172,174,176 and 178 of hGH
(The notation, e.g.
KSYR, denotes hGH mutant 172KI174SI176Y/178R.) found after sequencng a number of doves from rounds 1 and 3 of tt~e selection process for the pathways indicated (hGH elution;
Glycine elution; or Glydne elution after pre-adsorption). Non-functional sequences (i.e. vector badkground, or other prematurely terminated andlor frame-shifted mutarns) are shown as'NF'. Fkxrctional sequences which contained a non-silent, spurious mutation (i.e. outside the set of target residues) are marked with a '+'. Protein sequences which appeared more than once among all the sequerxed doves, but with different DNA sequences, are marked with a '~". Protein sequerxes wtych appeared more than once among the sequenced Bones and with the same DNA
sequence are marked with a "'. Note that after three rounds of selection, 2 different contaminating sequences were found; these Bones did not correspond to cassette mutants, but to previously constructed hormone phage. The pS0643 contaminant corresponds to wild-type hGH-phage (hGH 'KEFR'). The pH0457 contaminant, which dominates the third-round glycine-selected pool of phage, corresponds to a previously identified mutant of hGH, 'KSYR.' The amplification of these contaminants emphasizes the agility of the hormone-phage selection process to select for rarely oocurting mutants. The convergence of sequences is also striking in all three pathways: R or K occurs most often at positions 172 and 178; Y or F occurs most often at position 176; and S, T, A, and other residues occur at position 174.
FIGURE 6. Sequences from phage selected on hPRLbp-beads in the presence of zinc. The notation is as described in Figure. 5. Here, the convergerxe of sequerxes is not predictable, but there appears to be a bias towards hydrophotMC sequences under the most sfringent (Glydne) seledion conditions; L ,W and P residues are 3 0 frequently found in this pool.
FIGURE 7. Se~errces from phage selected on hPRLbp-beads in the absence of zinc. The notation is as described in Figure 5. In contrast to the sequences of Fgure. 6, these sequences appear more hydrophilic. After 4 rounds of selection using hGH elution, two clones (ANHQ, and TLDTI171V) dominate the pool.
FIGURE 8. Sequences from phage selected on blank beads. The notation is as described in Fg. 5. After three rounds of selection with glycine elution, no siblings were observed and a badkground level of non-functional sequences remained.
FIGURE 9. Construction of phagemid fl on from pH0415. This vector for cassette mutagenesis and expression of the hGH-gene III fusion protein was constnxted as follows.
Plasmid pS0643 was constructed by oligonudeotide-directed mutagenesis of pS0132, which contains pBR322 and f1 origins of replication and WO 92/09690 PC1'/US91/09133 expresses an hGH-gene III fusion protein (hGH residues 1-191, folbwed by a single Gly residue, fused to Pro-198 of gene III) under the control of the ~ )~ promoter. Mutagenesis was carried out with the oligonuGeotide 5'-GGC-AGC-TGT-GGC-TTC-TAG-AGT-GGC-GGC-GGC-TCT-GGT-3', which introduced a ~
site (underlined) and an amber stop colon (TAG) following Phe-191 of hGH.
FIGURE 10. A. Diagram of plasmid pDH188 insert containing the DNA encoding the Ight chain and heavy chain (variable and constant domain 1 ) of the Fab humanized antibody directed to the HER-2 receptor. V~
and VH are the variable regions for the Ight and heavy chains, respectively.
Ck is the constant region of the human kappa light chain. CH1G1 is the first constant region of the human gamma 1 chain. Both coding regions start with the bacterial st II signal sequence. B. A schematic diagram of the entire plasma pDH188 containing the insert described in 5A. After transformation of the plasmid into E. cbli SR101 cells and the addition of helper phage, the plasmid is packaged into phage particles. Some of these particles display the Fab-p III fusion (where p III is the protein enk~ded by the M13 gene III DNA). The segments in the plasmid figure correspond to the insert shown in 5A.
FIGURE 11 A through C are cdlectJvely referred to here as Figure 11. The nucleotide (Seq. ID No. 25) sequerxe of the DNA encoding the 4D5 Fab molecule expressed on the phagemid surface. The amino acid sequerx;e of the light chain is also shown (Seq. ID No. 26), as is the amino acct sequence of the heavy chain p III fusion (Seq. ID
No. 27).
FIGURE 12 Enrichment of wild-type 4D5 F~ phagemid from variant Fab phagemid.
Mixtures of wild-type phagemid and variant 4D5 Fab phagemid in a ratio of 1:1,000 were selected on plates coated with the extra-cellular domain protein of the HER-2 receptor. After each round of selection, a portion of the eluted phagemid were infected into E. Qoli and plasmid DNA was prepared. This plasmid DNA was then digested with Eco RV and Pst I, separated on a 5% polyakxylamide gel, and stained with ethidium bromide. The bands were visualized under UV light. The bands due to the wild-type and variant plasmids are marked with arrows. The first round of selection was eluted only under acid conditions; subsequent rounds were eluted with either an acct elution (left side of Figure) or with a humanized 4D5 antibody wash step prior to acid elution (right side of Figure) using methods desalted in Example VIII. Three variant 4D5 Fab molecules were made:
H9t A (amino aad histidine at position 91 on the V~ chain mutated to alanine; indicated as 'A' lanes in Figure), Y49A (amino acid tyrosine at position 49 on the V~ chain mutated to alanine; indicated as'B' lanes in the Figure), and Y92A (amino acid tyrosine at position 92 on the V~ chain mutated to alanine; indicated as'C' lanes in the Fgure). Amino acct position numbering is according to Kabat et al.,(Sequences of proteins of immunological interest, 4th ed., U.S. Dept of Health and Human Services, Public Health Service, Nat'I. Institute of Health, Bethesda, MD (1987]).
FIGURE 13. The Scatchard analysis of the RIA affinity determination described in Experimental Protocols is shovm here. The amount of labeled ECD antigen that is bound is shown on the x-axis while the amount that is bound divided by the amount that is free is shown on the y-axis. The slope of the line indicates the Ka; the 3 5 calculated Kd is l ll(a.
WO 92/09690 2 ~ ~ ~ ~ J 3 PCT/US91/09i33 DETAILED DESCRIPTION OF THE INVENTION
The foNowing discussion will be best iurderstood by referring to Figure t. in its simplest torm, the method of the instant invention comprises a method for selecting novel binding polypeptides, such as protein Igands, having a desired, usuaay high, aiffnity for a target molecule from a library of stnxturally related bindirg polypeptides. The lilxary of structurally related polypeptides, fused Do a phage coat protein, is produced by mutagenesis and, preferably, a single copy of each related polypeptide is displayed on the surface of a phagemid particle containing DNA encoding that polypepade. These phagemid particles are then contacted with a target molecule and those particles having the highest affinity for the target are separated from those of lower affinity.
The high atfir>ity binders are then amplified by infection of a bacterial host and the competitive binding step is repeated. This process is reiterated until polypeptides of the desired affinity are obtained.
The novel binding polypeptides or ligands produced by the method of this invention are useful per se as diagnostics or therapeutics ( eg. agonists or antagonists) used in treatment of biological organisms. Structural analysis of the selected polypeptides may also be used to fadlitate rational drug design.
By 'binding polypeptide' as used herein is meant any polypeptide that binds with a selectable affinity to a target molecule. Preferably the polypeptide will be a protein that most preferably contains more than about 100 amino add residues. Typically the polypeptide will be a t~onnone or an antibody or a fragment thereof.
By 'high affinity' as used herein is meant an affinity constant (Kd ) of <t0-5 M and preferably <10'~M
under physalogical conditions.
By 'target molea~le' as used herein is meant any molecule, rat necessarily a pr~ein, for which it is desirable to produce a ligand. Preferably, however, the target will be a protein and most preferably the target will be a receptor, such as a hormone receptor.
By 'humanized antibody' as used herein is meant an antitxxly in wtich the oomplementarity~ietermining regions (CDRs) of a mouse or other ron-human antibody are graffed onto a human antibody framework. By human antibody framework is meant the entire human antibody excluding the CDRs.
L
The first step in the method of this invention is to choose a polypeptide having rigid secondary structure exposed to the surface of the polypeptide for display on the surface of a phage.
By'polypeptide' as used herein is meant any molecule whose expressan can be directed by a specific DNA sequence. The polypeptides of ttws invention may comprise more than one subunit, where each subunit is 3 0 encoded by a separate DNA sequerxe.
By 'rigid secondary structure' as used herein is meant any polypeptide segment exhibiting a regular repeated structure such as is found in; a-helices, 3fp helices, n-heMces, parallel and antiparallel ~-sheets, and reverse toms. Certain 'non~rdered' structures that lack recognizable geometric order are also included in the definition of rigid secondary structure provided they form a domain or'patch' of amino acid residues capable of interaction with a target and that the overall shape of the stnxture is not destroyed by replacement of an amino acid within the structure . h is believed that some non-ordered structures are comt~inations of reverse turns. The geometry of these rigid secondary structures is well defined by ~ and ~r torsional angles about the a-carbons of the peptide 'backbone'.
WO 92/09690 2 ~ ~ ~ ~ ~ J PCT/US91/09133 The requirement that the secondary stmct~xe be exposed to the surface of the polypeptide is to provide a domain or'patch' of amino aad residues that can be exposed to and bind with a target molecule. It is primarily these amino aad residues that are replaced by mutagenesis that form the 'library' of structurally related (mutant) Minding polypeptides that are displayed on the surface of the phage and from which novel 5 polypeptide ligands are selected. Mutagenesis or replacement of amino acid residues directed toward the interior of the polypeptide is generally avoided so that the overall stinxture of the rigid secondary structure is preserved.
Some replacement of amino acids on the interior region of the rigid secondary stnxriues, especlally with hydrophobic amino aad residues, may be tolerated since these conservative substitutions are unlikely to distort the overall structure of the polypeptide.
10 Repeated cycles of'polypeptide' selection are used to select for higher and higher affinity Minding by the phagemid selection of multiple amino aad changes which are selected by multiple selection cyGes. Following a first round of phagemid selection, involving a first region or selection of amino aclds in the ligand polypeptide, additional rounds of phagemid selection in other regions or amino aads of the ligand potypeptide are conducted.
The cycles of phagemid selection are repeated until the desired affinity properties of the ligand polypeptide are achieved. To illustrate this process, Example VIII phagemid selection of hGH
was conducted in cycles. In the first cycle hGH amino aads 172,174,176 and 178 were mutated and phagemid selected.
In a second cycle hGH amino aads 167,171,175 and 179 were phagemid selected. In a third cycle hGH amino acids 10,14,18 and 21 were phagemid selected. Optimum amino aad changes from a previous cycle may be irxorporated into the polypeptide before the next cycle of selection. For example, hGH amino aclds substitutan 174 (serine) and 176 (tyrosine) were irxorporated into the hGH before the phagemid selection of hGH amino aads 167,171,175 and 179.
From the forgoing it will be appreciated that the amino aad residues that form the binding domain of the polypeptide will not be sequentially linked and may reside on different suburuts of the polypeptide. That is, the Minding domain tracks with the particular secorxiary stnxture at the binding site and not the primary stmcture. Thus, generally, mutations will be introduced into colons erxoding amino acids within a particular secondary structure at sites directed away from the interior of the polypeptide so that they will have the potential to interact with the target. By way of illustration, Figure 2 shows the location of residues in hGH that are known to strongly modulate its t~ir~ding to the hGH-binding protein (Cunningham etaL, 247:1461-1465 (1990]). Thus representative sites suitable for mutagerresis would include residues 172, 174, 176, and 178 on helix-4, as well as residue 64 located in a 'non-ordered' secondary structure.
There is no requirement that the polypeptide chosen as a ligand to a target normally hind to that target.
Thus, for example, a glycoprotein hormone such as TSH can be chosen as a ligand for the FSH receptor and a library of mutant TSH molecules are employed in the method of this invention to produce novel drug candidates.
This invention thus contemplates any polypeptide that hinds to a target molecule, and inGudes antibodies. Preferred polypeptides are those that have pharmaceutical utility.
More preferred polypeptides 3 5 include; a growth hormone, including human growth hormone, des-N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroid stimulating hormone; thyroxine;
insulin A~chain; insulin B~hain;
proinsulin; follicle stimulating hormone; calcltorun; leutinizing hormone;
glucagon; factor VIII; an antibody; lung surfactant; a plasminogen activator, such as urokinase or human tissue-type plasminogen activator (t-PA);
t~ombesin; factor IX, thromt~in; hemopoietic growth factor; tumor necrosis factor-alpha and -beta; enkephalinase; a WO 92/09690 ~ ~ ~'~ ~ ~ ~ PCT/US91/09133 saran albumin such as txunan seem albumin; mullerian-intibiting substance;
rela~dn A~chain; relaxin B~chain;
prorelaxin; mouse gorradotropn-assoaatsd peptide; a microbial protein, such as beidta~tamase; tissue factor protein; inhibin; activin; vascular endothelial growth factor; receptors for hormones or growth factors; integrin;
thrombopoietin; protein A or D; rheumatoid factors; nerve growth factor such as NGF-J3; platelet~erived growth factor; 6broblast growth factor such as aFGF and bFGF; epidermal growth factor; transforming growth factor (TGF) such as TGF-alpha and TGF-beta; insulin-like growth factor-I and -II;
insulin-like growth factor binding proteins; CD-4; DNase; latency assodated peptide; eryttxopoietin;
osteoinductive factors; an interferon such as interteron-alpha, -beta, and -gamma; colony stimulating factors (CSFs), e.g., M-CSF, GM-CSF, and G-CSF;
interfeukins (ILs), e.g., IL-1, IL-2, IL-3, IL-4, etc.; superoxide dismutase;
decay accelerating factor; atrial natriuretic peptides A, B or C; viral antigen such as, for example, a portion of the HIV ernebpe; immunoglobulins;
and fragments of any of the above-listed polypeptides. In addition, one or more predetermined amino add residues on the polypeptide may be substituted, inserted, or deleted, for example, to produce products with improved tMOlogical properties. Further, fragments of these polypeptides, espedally biologically active fragments, are inducted. Yet more preferted polypeptides of this invention are human growth hormone , and atrial naturetic peptides A, B, and C, endotoxin, subtilisin, trypsin and Other serine proteases.
StiA more preferred are polypeptide hormones that can be defined as any amino add sequence produced in a first cell that binds spedfically to a receptor on the same cell type (autocrine hormones) or a second cell type (non-autocrine) and causes a physiobgical response characteristic of the receptor-bearing cell. Among such polypeptide hormones are cytokines, lymphokines, neurotrophic homnones and aderx>hypophyseal pdypeptide hormones such as growth hormone, prdactin, placer>tal lactogen, luteinizing hormone, follicle-stimulating hormone, thyrotropn, chorbnic gonadotropin, corticotropn, a or ~-melanocyte-stimulating hormone, J3-lipotropin, Y-lipotropin and the endorphins; hypothalmic release-inhibiting honnones such as corticotropin-release factor, growth hormone release-inhibiting hormone, growth hormone-release factor; and other polypeptide hormones such as atrial natriuretiC peptides A, B or C.
IL
The gene encoding the desired polypeptide (i.e., a polypeptide with a rigid secondary structure) can be obtained by methods known in the art (see generally, Samtxook et al. , J
olecular BiojQgw: A Labora~p~"~ap~[, Cold Spring Harbor Press, Cold Spring Harbor, New Yak [19139]). If the sequence of the gene is known, the DNA encoding the gene may be d~emically synthesized (Merrfieki, J. Am. Chem.
Soc.., 85 X149 [1963]). If the 3 0 sequence of the gene is not known, cr if the gene has rot previously been isolated, it may be cloned from a d7NA
litxary (made from RNA obtained from a suitable tissue in which the desired gene is expressed) or from a suitable genomic DNA library. The gene is then isolated using an appropriate probe. For cDNA libraries, suitable probes include monodortal or polydonal antibodies (provided that the cDNA library is an expression library), oiigonudeotides, and complementary or homologous cDNAs or fragments ri~ereof.
The probes that may be used to isolate the gene of interest from genomic DNA litxaries include cDNAs or fragments thereof that encode the same or a similar gene, homobgous genomic DNAs a DNA fragments, and oligorxxleotides. Screening the cDNA or genomic library with the selected probe is conducted using standard procedures as described in d~apters 10-12 of Samtxook et al., supra.
An alternative means to isolating the gene encoding the protein of interest is to use polymerase chain reaction methodobgy (PCR) as described in section 14 of Samlxook et al., sera.
This method requires the use of oligonudeotides that will hybridize to the gene of interest; thus, at least some of the DNA sequence for this gene must be known in order to generate the oGgonudeotides.
After the gene has been isolated, it may be inserted into a suitable vector (preferably a plasmid) for amplification, as described generally in Sambrook et al., supra.
While several types of vectors are available and may be used to practice this invention, plasmid vectors are the preferred vectors for use herein, as they may be constructed with relative ease, and can be readily amplfied. Plasmid vectors generally contain a variety of components including promoters, signal sequences, phenotypic selectan genes, origin of replication sites, and other necessary components as are known to those of ordinary skill in the art.
Promoters most commonly used in prokaryotic vectors include the )~ Z promoter system, the alkaline phosphatase p~ A promoter, the bacteriophage A,PL promoter (a temperature sensitive promoter), the ~
promoter (a hylxid ~-~ promoter that is regulated by the ~ repressor), the Iryptophan promoter, and the bacteriophage T7 promoter. For general descriptions of promoters, see section 17 of Sambrook et al. supra .
While these are the most commonly used promoters, other suitable microbial promoters may be used as well.
Preferred promoters for practicing this inventan are those that can be tightly regulated such that expression of the fusan gene can be controlled. It is believed that the problem that went unrecognized in the prior art was that display of multiple copies of the fusion protein on the surface of the phagemid particle lead to multipoint attachment of the phagemid with the target. It is believed this effect, referred to as the 'chelate effect', results in selection of false 'high affinity' polypeptides when m~dtiple copies of the fusion protein are displayed on the phagemid particle in dose proximity to one another so that the target was'chelated'. When multipoint attachment occurs, the effective or apparent Kd may be as high as the product of the individual Kds for each copy of the displayed fusan protein. This effect may be the reason Cwirla and coworkers supra were unable to separate moderate affinity peptides from higher affinity peptides.
It has been discovered that by tightly regulating expressan of the fusion protein so that ra more than a minor amount, i.e. fewer than about 1 °~, of the phagemid particles contain multiple copies of the fusion protein the 'chelate effect' is overcome allowing proper selection of high affinity polypeptides. Thus, depending on the 3 0 promoter, culturing conditions of the fast are adjusted to maximize the number of phagemid particles containing a single copy of the fusion protein and mirimize the number of phagemid particles containing multiple copies of the tusion protein.
Preferred promoters used to practice this invention are the l~ Z promoter and the ~ A promoter.
The !~ Z promoter is regulated by the lac repressor protein j~ f, and thus transcription of the fusion gene can be controlled by manipulation of the level of the lac repressor protein. By way of illustration, the phagemid containing the )~ Z promotor is grown in a ceu strain that contains a copy of the )~ f repressor gene, a repressor for the l~ Z promotor. Exemplary cell strains containing the )~ f gene include JM 101 and XL1-blue. In the alternative, the host cell can be cotransfected with a plasmid containing Moth the repressor !~ f and the I3~ Z promotor.
Occasionally both of the above techniques are used simultaneously, that is, phagmide particles containing the l~ Z
WO 92/09690 ~ ~ ,~ ~ ~ PfT/fJS91/09133 promoter are grown in oeti strains containing the ~ i gene and the ceu strains are catransfected with a plasmid containing both tt~e ~ Z and )~ i genes. Normally when one wishes to express a gene, to the transfected host above one would ~d an inducer such as isopropylthiogalacboside (IPTG). In the present invention however, this step is omitted to (a) minimize the expression of the gene III fusion protein thereby minimizing the copy number (i.e. the number of gene III iusans per phagemid number) and to (b) prevent poor or improper packaging of the phagemid caused by induoers such as IPTG even at bw corxentrations. Typcally, when no inducer is ceded, the number of fusion proteins per phagemid partide is about 0.1 (number of bulk fusion proteinslnumber of phagemid partides). The most preferred promoter used to practice this invention is p~
A. This promoter is believed to be regulated by the level of inorganic phosphate in the cell where the phosphate acts to down-regulate the activity of the promoter. Thus, by depleting cells of phosphate, the activity of the promoter can be increased. The desired result is achieved by grovhng cells in a phosphate enriched medium such as 2n or LB thereby controlling the expression of the gene III fusion.
One other useful component of vectors used to practice tNs invention is a signal sequence. This sequence is typically located immediately 5' to the gene encoding the fusion protein, and will thus be transcribed at the amino terminus of the fusan protein. However, in certain cases, the signal sequence has been demonstrated to be located at positions other 5' to the gene encoding the protein to be secreted. This sequence targets the protein to which it is attad~ed across the imer membrane of the bacterial cell. The DNA
encoding the signal sequer~e may be obtained as a restriction erxionucease fragment from any gene encoding a protein that has a signal sequence.
Suitable prokaryotic sisal sequences may be obtained from genes encoding, for example, Lama or OmpF (along et al, t~, 68:193 [1983j), MaIE, PhoA and other genes. A preferred prokaryotic signal sequence for practidng this invention is the E. cbli heat-stale enterotoxin II (STII) signal sequence as described by Chang ef a!. , ~g,pg, 55: 189 [ 1987j.
Another useful component of the vectors used to practice this invention is phenotypic selection genes.
Typical phenotypic selection genes are chose encoding proteins chat confer antibiotic resistance upon the host cell.
By way of illustration, the ampicillin resistance gene (~), and the tetracydine resistance gene (t~ are readily employed for this purpose.
Construction of suitable vectors comprising the aforementioned components as weU as the gene encoding the desired polypeptide (gene 1 ) are prepared using standard recombinant DNA
procedures as described in Samtxook et al. supra. Isolated DNA fragments to be combined m form the vector are cleaved, tailored, and 3 0 ligated together in a spedfic order and orientation to generate the desired vector.
The ONA is deaved using the appropria~ restriction enzyme or enzymes in a suitable buffer. In general, about 0.2-1 ~g of plasmid or DNA fragments is used with about 1-2 units of the appropriate restriction enzyme in about 20 p.1 of buffer solution. Appropriate buffers, DNA concentrations, and incubation times and temperatures are sped5ed by the manufacturers of the restriction enzymes.
Generally, incubation times of about one or iwo hours at 3TC are adequate, although several enzymes require higher temperatures. After incubation, the enzymes and other contaminants are removed by extraction of the digestion solution with a mixture of phenol and chloroform, and the DNA is recovered from the aqueous fraction by precipitation with ethanol.
To ligate the DNA fragments together to form a functional vector, the ends of the DNA fragments must be compatible with each other. In some cases, the ends will be directly compatible after endonudease WO 92/09690 ~ ~ ~ ~ ~ j ~~ PCT/US91/09133 digestion. However, it may be necessary to first convert the sticky ends commoNy produced by endonudease digestion to blunt ends to make them compatible for Ggation. To blunt the ends, the DNA is treated in a suitable buffer for at least 15 minutes at 15'C with 10 units of of the Klenow fragment of DNA polymerise I (Klenow) in the presence of the four deoxynudeotide triphosphates. The DNA is then purified by phenol-chloroform extraction and ethanol predptatan.
The deaved DNA fragments may be size-separated and selected using DNA gel electrophoresis. The DNA may be electrophoresed through either an agarose or a polyacrylamide matrix. The selection of the matrix will depend on the size of the DNA fragments to be separated. After electrophoresis, the DNA is extracted from the matrix by electroelutan, or, if low-melting agarose has been used as the matrix, by melting the agarose and extracting the DNA from it, as described in sections 6.30-6.33 of Sambrook et aL, supra.
The DNA fragments that are to be ligated together (previously digested with the appropriate restriction enzymes such that the ends of each fragment to be ligated are compatible) are put in solution in about equimolar amounts. The solution will also contain ATP, ligase buffer and a ligase such as T4 DNA ligase at about 10 units per 0.5 ug of DNA. If the DNA fragment is to be ligated into a vector, the vector is at first linearized by , cutting with the appropriate restriction endonudease(s). The linearized vector is then treated with alkaline phosphatase or calf intestinal phosphatase. The phosphatasing prevents self-ligation of the vector during the Iigation step.
After ligation, the vector with the foreign gene now inserted is transformed into a suitable host cell.
Prokaryotes are the preferred host cells for this invention. Suitable prokaryotic host cells inducts E. colt strain JM101, E. colt K12 strain 294 (ATCC number 31,446), E. colt strain W3110 (ATCC
number 27,325), E. colt X1776 (ATCC number 31,537), E. colt XL-1 Blue (stratagene), and E colt B;
however many other strains of E.
colt, such as H8101, NM522, NM538, NM539, and many other species and genera of prokaryotes may be used as well. In addition to the E. aoli strains listed above, badlli such as ~(~j~, other enterobacteriaceae such as m a and various p,~speaes may all be used as hosts.
Transformation of prokaryotic cells is readily accomplished using the caldum chloride method as described in section 1.82 of Sambrook et al., supra. Alternatively, electroporation (Neumann etaL, EMBO J..J..
1:841 [1982J) may be used to transform these cells. The transformed cells are selected by growth on an antit~iotic, commonly tetracydine (tet) or ampidllin (amp), to which they are rendered resistant due to the presence of tet and/or amp resistance genes on the vector.
After selection of the transformed cells, these cells are grown in culture and the plasmid DNA (or other vector with the foreign gene inserted) is then isolated. Plasmid DNA can be isolated using methods known in the art. Two suitable methods are the small scale preparation of DNA and the large-scale preparation of DNA as described in sections 1.25-1.33 of Sambrook et al., supra. The isolated DNA
can be purified by methods known in the art such as that described in section 1.40 of Sambrook etal., supra. This purified plasmid DNA is then analyzed by restriction mapping andlor DNA sequendng. DNA sequendng is generally pertormed by either the method of Messing et al. ~gg3" 9:309 [1981 J or by the method of Maxim et aL
~Qg~pty~j" 65:
ass [ls6oJ.
!V.
This invention contemplates fusing the gene erxlosing the desired polypeptide (gene t ) to a second gene (gene 2) such that a fusion protein is generated during transcription. Gene 2 is typically a coat protein gene of a phage, and preferably it is the phage M13 gene III coat protein, or a fragment thereof. Fusan of genes t and 2 may 5 be accomplished by inserting gene 2 inb a parGaa~aar site on a plasmid that contains gene 1, or by inserting gene 1 into a particular site on a plasmid that contains gene 2.
Insertion of a gene into a ptasmid requires that the plasmid be cut at the precise locatan that the gene is to be inserted. Thus, there must be a restriction erxionudease sibs at this bcation (preferably a unique site such that the plasmid will only be cut at a single location during restriction endorx~dease digestion). The plasmid is 10 digested, phosphatased, and purified as described above. The gene is then inserted into this linearized plasmid by ligatirg the two DNAs together. Ligatan can be accomplished if the ends of the plasmid are compatible with the ends of the gene to be inserted. If the restriction enzymes are used to cut the plasmid and isolate the gene to be inserted create blunt ends or compatible sticky ends, the DNAs can be ligated together directly using a ligase such as bacteriophage T4 DNA ligase and irxubating the mixture at 16'C for t ~4 hours in the presence of ATP
15 and Ngase buffer as described in section 1.68 of Sambrook et aL, ~. If the ends are rat compatible, they must first be made Bunt by using the Klenow fragment of DNA polymerase I or bacteriophage T4 DNA polymerase, both of which require the four deoxyribonudeotide triphosphates to fill-in overhanging single-stranded ends of the digested DNA Alternatively, the ends may be Bunted using a nuclease such as nuclease S1 a mung-bean rn~clease, both of which function by cutting back the overtranging single strands of DNA. The DNA is then 2 0 religated using a ligase as described above. In some cases, it may not be possible 6o Bunt the ends of the gene to be inserted, as the reading frame of the coding region will be altered. To overcome this problem, o6gonuGeotide linkers may be used. The linkers serve as a bridge to connect the plasmid m the gene to be inserted. These linkers can be made synthetically as double stranded or single stranded DNA using standard methods. The linkers have one end that is compatible with the ends of the gene b be inserted; the IiNcers are first ligated to this gene using Igation methods described above. The other end of the linkers is desgned to be compatible with the plasmid for ligation. In designing the linkers, care must be taken to not destroy the reading frame of the gene to be inserted or the reading frame of the gene contained on the plasmid. In some cases, it may be necessary to design the linkers such that they code for part of an amino acrd, or such that they code fa one or more amino aads.
Between gene 1 and gene 2, DNA encoding a termination colon may be inserted, such termination colons are UAG( amber), UAA (odder) and UGA (opal). (Microbiology, Davis et al.
Harper l~ Row, New York,1980, pages 237, 245-47 and 274). The termination colon expressed in a wild type host cell results in the synthesis of the gene t protein product without the gene 2 protein attached. However, growth in a suppressor host cell results in the synthesis of detectable quantities of fused protein. Such suppressor host cells contain a tRNA
modified to insert an amino acrd in the termination colon position of the mRNA
thereby resulting in production of detectible amounts of the fusion protein. Such suppressor host cells are well known and described, such as E.coli suppressor strain (Bullock et al., BioTechnioues 5, 376-379 [i987)). Any acceptable method may be used to place such a termination colon into the mRNA erxxxiing the fusion polypeptide.
The suppressible colon may be inserted between the first gene erxoding a polypeptide, and a second gene encoding at least a portion of a phage coat protein. Alternatively, the suppressible termination colon may be WO 92/09690 PCl'/US91/09133 2~~~5~~ ,s inserted adjacent to the fusion site by replacing the last amino acid triplet in the polypeptide or the first amino acrd in the phage coat protein. When the phagemid containing ttre suppressible colon is grown in a suppressor host cell, it results in the detectable production of a tusan polypeptide containing the polypeptide and the coat protein. When the phagemid is grown in a non-suppressor host cell, the polypeptide is synthesized substantially without fusion to the phage coat protein due to termination at the inserted suppressible triplet encoding UAG, UAA, or UGA. In the non-suppressor cell the polypeptide is synthesized and secreted from the host cell due to the absence of the fused phage coat protein which otherwise anchored it to the host cell.
V.
Gene 1, erxoding the desired poiypeptide, may be altered at one or more selected colons. An alteration , 0 is defined as a substitution, deletion, or insertion of one or more colons in the gene encoding the polypeptide that results in a change in the amino acid sequence of the polypeptide as compared with the unaltered or native sequence of the same polypeptide. Preferably, the alterations will be by substitution of at least one amino acid with any other amino acid in one a more regions of the molecule. The alterations may be produced be a variety of methods knoHm in the art. These methods include but are not limited to oligonudeotide-mediated mutagenesis and cassette mutagerresis.
81~
Oligonucleotide -mediated mutagenesis is preferred method for preparing substitution, deletion, and insertion variants of gene 1. This techr~que is weA knorm in the art as described by Zoller et al. Nucleic Aads Res.
IQ: 6487504 [1987]. Briefly, gene 1 is altered by hybridizing an oligonuGeotide encoding the desired mutation to a DNA template, where the 0emplate is the single-stranded form of the plasmid containing the unaltered or native DNA sequence of gene t. After hybridization, a DNA polymerise is used to synthesize an entire second complementary strand of the template will thus incorporate the oligonudeotide primer, and will code for the selected alteration in gene 1.
Generally, oligonuGeotides of at least 25 nucleotides in length are used. An optimal oligonuGeotide will have 12 to 15 nuGeotides that are completely complementary to the template on either side of the nudeotide(s) coding for the mutation. This ensures that the oligonuGeotide will hybridize properly to the single-stranded DNA
template molecule. The digonudeotides are readily synthesized using techniques IQrowrr in the art such as chat described by Crea et al. Proc. Nat,. Acid. Sa. USA 75: 5765 [1978].
The DNA template can only be generated by those vectors that are either derived from bacteriophage M13 vectors (the commercially available M13mp18 and M13mp19 vectors are suitable), or those vectors that contain a single-stranded phage orgin of replication as described by Viera et aL x,",53: 3 [1987].
Thus, the DNA that is to be mutated must be inserted into one of these vectors in order to generate single-stranded template. Production of the single-stranded template is described in sections 4.21-4.41 of Sambrook et al., supra.
To alter the native DNA sequence, the oligonudeotide is hybridized to the single stranded template under suitable hybridization conditions. A DNA polymerizing enzyme, usually the Klenow fragment of DNA
polymerise I, is then added to synthesize the complementary strand of the template using the oligonucleotide as a primer for synthesis. A heteroduplex molecule is thus formed such that one strand of DNA encodes the mutated form of gene 1, and the other strand (the original template) encodes the native, unaltered sequence of gene t .
WO 92/09690 ~ ~ !~ ~ PCT/US91/09133 This heterodupex molecule is then transformed into a suitable host cell, usually a prokaryote such as E. Coil JM101. After growing the cells, they are plated onto agarose plates and screened using the oGgonudeotide primer radiolabelled with 32-Phosphate to identify the bacterial colonies that contain the mutated DNA.
The method described immediately above may be modified such U~at a homoduplex molecule is created wherein both strands of the plasmid contain the mutation(s). The modifications are as follows: The single-stranded oGgonucleotide is ar~aied to the single-stranded template as described above. A mixture of three deoxyribonudeotides, deoxyriboadenosine (dATP), deoxyriboguanosine (dGTP), and deoxyribohymidine (dTTP), is combined with a modified thio~deoxyribocytosine called dCTP-(aS) (which can be obtained from Amersham).
This mixture is added to the template-o~gonudeotide complex. Upon addition of DNA polymerise to this mixture, a strand of DNA identical bo the template except for the mutated bases is generated. h addition, this new strand of DNA will contain dCTP-(aS) instead of dCTP, which serves to protect it from restriction endonudease digestion. After the template strand of the double-stranded heteroduplex is nicked with an appropriate restriction enzyme, the template strand can be digested with Exolll nudease or another appropriate nuGease past the region that contains the sites) to be mutagenized. The reaction is then stopped to leave a molecule that is only partially single-stranded. A complete double-stranded DNA homoduplex is then formed using DNA
polymerise in the presence of all lour deoxyribonudeotide triphosphates, ATP, and DNA Ggase. This homoduplex molecule can then be transformed hto a suitade host cell such as E. colt JM101, as described above:
Mutants witty more than one amino acrd to be substituted may be generated in one of several ways. 1f the amino aids are boated dose together h the pdypeptide chain, they may be mutated simultaneously u~rg one 2 0 oligonudeotide that codes for all of the desired amino acrd substitutions.
If, however, the amino acids are located some distance from each other (separated by more than about ten amino acids), it is more difficult to generate a single digonudeotide that encodes all of the desired changes. Instead, one of two alternative methods may be employed.
In the first method, a separate oligonudeotide is generated for each amino add to be substituted. The oligonudeotides are then amealed to the single-strarxJed template DNA
simultaneously, and the second strand of DNA that is synthesized from Use template wil encode all of the desired amino add substitutions. The alternative method involves two or more rounds of mutagenesis to produce the desired mutant. The first round is as described for the single mutants: wild-type DNA is used for the template, an oliganudeotide encoding the first desired amino acid substitutions) is annealed to this template, and the heteroduplex DNA molecule is then generated. The second round of mutagenesis utilizes the mutated DNA produced in the first round of mutagenesis as the template. Thus, this template already contains one or more mutations. The oligonucleotide encoding the additional desired amino acid substitutions) is then annealed to this template, and the resulting strand of DNA now encodes mutations from both the first and second rounds of mutagenesis. This resultant DNA
can be used as a template in a third round of mutagenesis, and so on.
B.
This method is also a preferred method for preparing substitution, delet'ron, and insertan variants of gene 1. The method is based on that described by Wells et at. ~,, 34:315 [1985].. The starting material is the plasmid (or other vector) comprising gene 1, the gene to be mutated. The codon(s) in gene 1 to be mutated are identified. There must be a unique restriction endorwdease site on each side of the identified mutation site(s). If ~' '~" f a 18 ~~.~~..~ a.~~~
no such restriction sites exist, they may be generated using the above~iesaibed olgonudeotide-mediated mutagenesis method to introduce them at appropriate locations in gene 1. After the restriction sites have been introduced into the plasmid, the plasmid is cut at these sires to linearize it. A double-stranded oligonudeotide encoding the sequence of the DNA between the restriction sites but containing the desired mutations) is synthesized using standard prooe~res. The two strands are synthesized separately and then hybridized together using standard techniques. This double-stranded oligonudeotide is referred to as the cassette. This cassette is designed to have 3' and 5' ends that are compatide with the ends of the linearized plasmid, such that it can be directly ligated 1o the plasmid. This ptasmid now contains the muhated DNA sequence of gene 1.
VI.
In an altemadve embodiment, this invention contemplates production of variants of a desired protein containing one or more subunits. Each subur~t is typically encoded by separate gene. F~ch gene encoding each subunit can be obtained by methods knovm in the art (see, for example, Section II). In some instances, it may be necessary to obtain the gene encoding the various subunits using separate techniques selected from any of the methods described in Section II.
When constmcting a replicable expression vector where the protein of interest contains more than one subunit, all subunits can be regulated by the same promoter, typically located 5' to the DNA encoding the subunits, or each may be regulated by separate promoter suitably oriented in the vector so that each promoter is operably linked to the DNA it is intended to regulate . Selection of promoters is carried out as described in Section III
above.
In constructing a repNcade expression vector aoMaining DNA encoding the protein of interest having multiple subunits, the reader is referred to Figure 10 where, by way of illustration, a vector is diagrammed showing DNA encoding each subunit of an antibody fragment. This figure shows that, generally, one of the subunits of the protein of interest will be fused to a phage coat protein such as M13 gene III. This gene fusion generally will contain its own sgnal sequence. A separate gene encodes the other subunit or suburits, and it is 2 5 apparent that each subur~it generally has its own signal sequerxe. Fgure 10 also shows that a single promoter can regulate the expression of both subunits. Alternatively, each subunit may be independently regulated by a different promoter. The protein of interest subunit-phage coat protein fusion construct can be made as described in Section IV above.
When constructing a famtly of variants of the desired multi-subunit protein, DNA encoding each subunit 3 0 in the vector may mutated in one or more positions in each suburut. When multi-subunit antibody variants are constructed, preferred sites of mutagenesis correspond to colons encoding amino acid residues located in the complementarily-determining regions (CDR) of either the light chain, the heavy chain, or both chains. The CDRs are commonly referred to as the hypervariable regrons. Methods for mutagenizing DNA encoding each subunit of the protein of interest are conducted essentially as described in Section V
above.
VII.
Target proteins, such as receptors, may be isolated from natural sources or prepared by recomt~inant methods by procedures known in the art. By way of illustration, glycoprotein hormone receptors may be prepared by the technique described by McFarland et al., 245:494-499 [1989J, norglycosylated forms expressed WO 92/09690 ~ ~ ~ ~, ~ ~ PCT/US91 /09I 33 in E. colt are described by Fuh et al. J. Biol. Chem 265:3111-3115 [1990]
Otter receptors can be prepared by standard methods.
The purified target protein may be attached to a suitable matrix such as agarose beads, acrylamide beads, glass beads, cellulose, various acxytic copdymers, hydroxylalkyl methaaylate gels, polyaaylic and polymethacrylic copolymers, nylon, neutral and ionic carriers, and the ike.
Attachment of the target protein to the matrix may be accomplished by methods described in ~p~p~, 44 (1976j, or by other means known in the art.
After attachment of the target protein to the matrix, the immobilized target is contacted with the library of phagemid particles under conditions suitable for binding of at least a portan of tf~e phagemid particles with the immobilized target. Nortnaliy, the conditions, including pH, ionic strength, temperature and the like will mimic physiological conditions.
Bound phagemid particles ('binders') having high affinity br the immobilized target are separated from those having a low affinity (and thus do not hind to the target) by washing. Binders may be dissociated from the immot~ilized target by a variety of methods. These methods include competitive dissodation using the wild-type ligand, altering pH arKilor ionic strength, and methods known in the art.
Suitable host cells are infected with the hinders and helper phage, and the host cells are cultured under conditans stable for amplification of the phagemid particles. The phagemid particles are then collected and the selection process is repeated one or more times unto hinders having the desired affinity for the target molecule are selected.
Optionally the library of phagemid particles may be sequentially contacted with more than one immolHlized target to improve selectivity for a particular target. For example, it is often the case that a ligand such as hGH has more than one r~at~al receptor. h the case of hGH, both the growth hormone receptor and tte prolaetin receptor bind the hGH ligand. ft may be desirable to improve the selectivity of hGH for the growth hormone receptor over the prolactin receptor. This can be achieved by ffrst contacting the library of phagemid particles with immot~ilized prolactin receptor, eluting those with a tow affinity (i.e. lower than wild type hGH) for tt~e prolactin receptor and then contacting the bw affinity prolactin 'binders' or non-hinders with the immobilized growth hormone receptor, and selecting for high affinity growth hormone receptor binders. In this case an hGH mutant having a lower affinity for the prolactin receptor would have therapeutic utility even if the affhity for the growth hormone receptor were somewhat lower than that of wild type hGH. This same strategy may be employed to improve selectivity of a particular hormone or protein for its primary function receptor over its clearance receptor.
In another embodiment of tfys invention, an improved substrate amino acid sequence can be obtained.
These may be useful for making better 'cut sites' for protein linkers, or for better protease substratesl~r~ihitors. h this embodiment, an immobitizable molea~e (e.g. hGH-receptor, biotin-avidin, or one capable of covalent linkage with a matrix) is fused to gene III through a linker. The linker will preferably be from 3 to 10 amino aads h length and will act as a substrate for a protease. A
phagemid wiU be constructed as described above where the DNA encoding the linker region is randomly mutated to produce a randomized library of phagemid particles with different amino acid sequences at the linking site. The library of phagemid particles are then immobilized on a matrix and exposed to a desired protease. Phagemid particles having preferred or better substrate amira acld ~ In the liner region kx the desired protease wAi be ekrted, fret pradudrtp an enriched pod of P~9em'd P~des er~adl~p prererred linkers. these phapemid tides are then cycled several mare limes lo t~ epos of particles an~n9 tense seqtrsnve(s) (~ epos Xlll and XIV~.
lltlt. ~Ge.YHdiIO~.A~d~, The domed gene for trGH rtes teen expressed ~ a seaetad tons in Fteals (G~4, C. rb, et al., (1987) hem ~5..i 89) and as oNn and amino add sequsnpa h~ been reported (Goeddel. er ~. [1 s79) ~Q.1.
544; Gray et af., l19&5] ~33~ 247?. The present inversion desaibss navel hGH
variants Prad~d u~n9 die p~~;d ~~pn methods. Human growth hormone verierss ~ fak p'°~~ns 10,14,18, 21, 187,171,172. l 74, 175,176,178 and 179 have been drd~ T~~ ~~rD trigher txndlng affinities are 10 deSCa'Ib6d ~ Tables VII, Xllt irld KiV. The amino acid rl~erl~t~ ~r deSCl~irlp 1119 Var~r~ is flow.
Growth honronB variants may be admlrtlstsred aM ~ ~ ~ s~ ~ "~"~r t~'"~
h°n"one. The growth hormone variants of the present invention may be expressed in any recomt~inanl system which is capable of expressing dative or met hGH.
T~~utic i4rmulafions of hGH for therapeutic admiryistration are prepared for storage by mixing 15 hGH having the desired degr~ of purity with opnonal physialogicatly atxeptable Carriers, exGipients, or stabilizers (13~71nnlon's Pita(m$~C~,L$C1~ ~~~ ~~ A.. ~d., (19801., in ~ form of tyoptw6ied cake or a4uevug ~lutions. Acceptable carriers, exoit>ienls or stabilizers era nontoxic bo reripiants at the dosages and C9n0enbailOns em~l6yEd, and irSClllde bllflta5 ~ 88 pfb"~, a~dte, arid DI~IBr Organic acids; ~tibbxid3nt5 inGuding asoabic sad; kyw mo'lsatlar weight pass than about 10 residues) poiypeptides; proteins. s~h as serum 2 o altxJmin. gelatin. or Immmogk~Gns: hydrnph~ic polymers auc+r as t~PYmolndone; amino atdds s~d~ as glycir~e, glutamine, asparagina, arginine, or lysine: monosaccharides, dis~rides, and other cart#tydrates including glucose. rnamose, or dexuins; chelating agents such as EDTA; divaler>t metal ions such as zinc, cobalt or copper:
sugar altohofs such as rnarrstol or sorbital; salt~tortning txsunlerions such as sodium; anchor norikmic suriacranls such as Tween; Pluronies~r po>yefhytene gtycot (isEG). Fortnulatior>s of the present invention may additionally 25 contain a phartnaaeuticallY aooeptable.butter, amino add, bulking agent arrdror non-ionic siufactant. These include, for example, buffers. tdieiating agents, antibxidarlLS, preservatives, cosotvent5, arid the like; spetxtic examples 9t these could include, trimethylamakte salts ('iris butter"), and dtsot8txn sdetate. Ttte phapemids of the present Invention may ba used to produce qttantitiefi bf the htahl verlar115 free of the phage pr018m. To expra35s ttGH
variants free of the gene III portion Of tt~a fusion, pS0643 and derivatives can simply be grown in a rtorr 30 suppressor strain such as i6C9. In ttris case, the amber colon (TAG) leads to tetrnlr>ation of iralnslation, which yields tree homtlxte, vntllout the need for an independent DNA consinxtion.
The frGH variant is setxeted from the host and may be isdated from the collars med'nim.
One or mbre of the e(ght hGH amino adds F10, M14, HiB, ill. Rt87, D171, T175 and 1179 may be raped by any amino tad other than the one found in that position (n r~turs~y rig hGH
as ~dicated. Thereiore,1, 2, 35 3, 4, 5, ti, 7, a a0 t3 of the indicated amino acids, F10, M14, H18, H21, Rtfi7,17171, T175 and 1179, may he replaced by any or the other 19 amino acids out of the 20 amino acids listed below. tn a preferred embodunerlt, as eight listed amino acids are replaced by another amino aid. The most preferred eight amino acids to be substituted are indicated in Table XIV in Example XII.
*trarlemark 2, An,ho add nomr~cla~re.
Ala (A) Arg (R) Asn (N) Asp (D) Cys (C) Gln (0) Glu (E) p Giy (G) His (H) Ile (I) Leu (L) Lys (K) Met (M) Phe (F) Pro (P) Ser (S) Thr (T) Trp (W) Tyr (Y) Val (V) The one letter hGH variant nomendadxe first gives the hGH amino acrd deleted, for example glutamate 179; then the amino acid inserted; for example, serine; resulting in (E1795S).
EXAMPLES
Without further desaiptan, it is believed that one of ordinary skill in the art can, using the preceding description and illustrative examples, make and utilize the present invention to the fullest extent. The follov~ng working examples therefore speafically point out preferred embodiments of the present invention, and are not to 3 0 be construed as limiting in any way of the remainder of the disclosure.
EXAMPLE I
Plasrrdd Cor~uciJons and Preparation o1 Mali-phagerr~ld Parfides The plasmid phGH-Ml3glll (Fig.1 ), was oonstnxted from M13K077 and the hGH
producing plasmid, pB0473 (Cunningham, B. C., et aL , ~jg~, 243:1330-1336, [1989]). A synthetic oligonucleotide 5'-AGC
TGT-GGC-TTC-GGG'CCC-TTA-GCA-TTT-AAT-GCG-GTA-3' was used to introduce a unique Apal restriction sib (underlined) into p80473 after the final Phel9t colon of hGH.
The oligonudeotide 5'-TTC-ACA-AAC-GAA-GGGCCC-CTA-ATT-AAA-GCC-AGA-3' was used to introduce a unique Apal restriction site (underlined), and a GIut97-to-amber stop oodon (bold lettering) into M13K07 gene III. The oligonuGeotide 5'-CAA-TAA-TAA-CGG-~'C~ T-AGC-CAA-AAG-AAC-TGG-3' introduces a unique Nhel site (underlined) after the 3' end of the gene III coding sequence. The resulting 650 base pair (bp) Apal-Nhel fragment from the doubly mutated M13K07 gene III was doped into the large Apal-Nhel fragment of pB0473 to create the plasmid, pS0132. This fuses the carboxyl terminus of hGH (Phe191 ) to the Pro198 residue of the gene III protein with the insertan of a glydne residue errcoded from the Apal site and places the fusion protein under control of the E. coG
alkaline phosphatase (ptaA) promoter and stll secretion signal sequence (Chang, C. N., et al. , ~gpg, 55:189-196, [1987)). For indudble expression of the fusion protein in rich media, we replaced the phoA promoter with the lac promoter and operabr. A 138 by EcoRl-Xbal fragment containing the lac promoter, operator, and Cap binding site was produced by PCR of plasmid pUC119 using the oligonudeotides 5'-CACGACAGAATTCCCGACTGGAAA-3' and 5'-CTGTT TCTAGAGTGAAATTGTTA-3' that flank the desired lac sequences and introduce the EcoRl and Xbal restriction sites (underlined).
Ttws lac fragment was gel pur'rfied and ligated into the large EcbRl-X6al fragment of pS0132 to create the plasmid, phGH-Ml3glll. The sequences of all taibred DNA junctions were verified by the dideoxy sequerxe method (Sanger, F., et aL Proc. Nail. Acad.
~j,~,~,g, 74:5463-5467, [1977)). The R64A variant hGH phagemid was constructed as follows: the Nsil-Bglll mutated fragment of hGH (Cunninghamet al. supra ) erxading the Arg64 to Ala substitution (R64A) (Cunningham, B. C., Wells, J. A., ~jgp~, 244:1081-1085, [1989]) was Boned between the corresponding restriction sites in the phGH-Ml3glll plasmid (Fig. 1) to replace the wild-type hGH sequence. The R64A hGH
phagemid particles were propagated and titered as described bebw for the wild-type hGH-phagemid.
Plasmids were transformed into a male strain of E. cali (JM101 ) and selected on carbenidllin plates. A
single transformant was grown in 2 ml 2n medium for 4 h at 3TC and infected with 50 W of Mt3K07 helper phage. The infected culture was diluted into 30 ml 2YT, grown overnight, and phagemid particles were harvested by predpitation with polyethylene glycol (Vierra, J., Messing, J. ,153:3-11, (1987]).
Typical phagemid particle titers ranged from 2 to 5 x 1011 cfu/ml. The particles were purified to homogeneity by CsCI density oentrrfugation (Day, L.A. J. Mol. Biol., 3965-277, (1969]) to remove any fusion protein not attached to virions.
hsrnnOd>e~al Analyses Of hGH m the Futon Phape Rabbit polydonal antibodies to hGH were purified with protein A, and coated onto microtiter plates (Nuns) at a corxernration of 2 Irglml in 50 mM sodium carbonate buffer (pH 10) at 4'C for 16-20 hours. After washing in PBS containing 0.05% Tween 20, hGH or hGH-phagemid particles were senialty diluted from 2.0 -0.002 nM in buffer A (50 mM Tris (pH 7.5), 50 mM NaCI, 2 mM EDTA, 5 mglml bovine serum albumin, and 0.05%
Tween 20). After 2 hours at room temperature (rt), the plates were washed well and the indicated Mab (Cunninghamet al. supra ) was added at 1 Nglml in buffer A for 2 hours at rt.
Following washing, horseradish peroxidase conjugated goat anti-mouse IgG antibody was bound at rt for 1 hour.
After a final wash, the peroxidase activity was assayed with the substrate, o~phenylenediamine.
3 5 FxAMPLE IA
Coupling of the hGH Binding Rolein bo Pdyaaylamlde Beads and Binding Eryichments Oxirane polyacrylamide beads (Sigma) were conjugated to the purified extracellular domain of the hGH
receptor (hGHbp) (Fuh, G., etal., J. Biol. Chem., 265:3111-3115 (1990)) containing an extra cysteine residue introduced by site-directed mutagenesis at positron 237 that does not affect binding of hGH (J. Wells, WO 92/09690 ~ ~ ~~ PCT/US91 /09133 unpublished). The hGHbp was corrugated as recommended by the supplier to a level of 1.7 pmol hGHbplmg dry oxirane bead, as measured by binding of [tag hGH b the resin. Subsequendy, any unreacted oxirane groups were blocked with BSA and Tris. As a control for non-specific binding of phagemid particles, BSA was similarly coupled to the beads. Buffer for adsorption and washing contained 10 mM
Tris~HCl (pH 7.5),1 mM EDTA, 50 mM
NaG,1 mglml BSA, and 0.0296 Tween 20. Elution buffers contained wash buffer plus 200 nM hGH or 0.2 M
glyclne (pH 2.1). Parental phage M13K07 was mixed with hGH phagemid particles at a rata of nearly 3000:1 (original mixture) and tumded for 8-12 h with a 5 N.I aliquot (0.2 mg of aaylamide beads) of either absorbent in a 50 p.1 volume at room temperature. The beads were peueted by oen~ifugation and the supemate carefully removed. The beads were resuspended in Z00 W wash buffer and tumbled at room temperatrue for 4 hours (wash t). After a second wash (wash 2), the beads were eluted twice with 200 nM hGH for 6-10 hours each (eluate 1, eluate 2). The final elution was with a glyclne buffer (pH 2.1 ) for 4 hours to remove remaining hGH
phagemid particles (eluate 3). Each fraction was diluted appropriately in 2n media, mixed with fresh JM101, incubated at 3TC for 5 minutes, and plated with 3 ml of 2n soft agar an LB or LB carbeniclllin plates.
iD(AMPLE IV
Cor~nrcUan of hGH.phagemld ParOd~ wlth a Mbct~e of Gene 11 Products The gene III protein is composed of 410 residues divided into two domains that are separated by a flexible linker sequence (Armstrong, J., elal., FEES Lett..135:167-172, [1981)). The amino-terrnir~al domain is required for attachment to the pill of E. cori, while the carboxyl-terminal domain is imbedded in the phage coat and required for proper phage assembly (Crissman, J. W., Smith, G. P., Viroloav.
132:445-455. [1984]). The signal 2 0 sequerxe and amino-terminal domain of gene Ill was replaced with the stll signal and entire hGH gene (Chang et al.
supra) by fusion to residue 198 in the carboxyl-terminal domain of gene III
(Fig.1 ). The hGH~ene III fusion was placed under control of the lac promoterloperator in a plasmid (phGH-M13g111;
Fg. 1) containing the pBR322 ~-lactamase gene and Col Et replication origin, and the phage ft intergenic region. The vector can be easily mair><ained as a small plasmid vector by selection on carber~allin, which avoids relying on a functional gene III fusion for propagation. Alternatively, the plasmid can be ef6clently packaged into virions (called phagemid particles) by infection with helper phage such as M13K07 (Yera et al.. supra ) which avoids problems of phage assembly.
Phagemid infectivity titers based upon transduction to carbeniclllin resistance in this system varied from 2-5 x 1011colony forming units (cfu~ml. The titer of the M13K07 helper phage in these phagemid stocks is ~1010 plaque forming units (pfu)Iml.
lAfith this system we confirmed previous studies (Parmiey, Smith supra) that homogeneous expression of large proteins fused to gene III is deleterious to phage production (data not shown). For example, induction of the lac promoter in phGH-Ml3glll by addition of IPTG produced low phagemid titers.
Moreover, phagemid particles produced by oo-infection with M13K07 contairurg an amber mutation in gene III
gave very low phagemid titers (<t010 ciulml). We believed that multiple copies of the gene 111 fusion attached to the phagemid surface could lead to multiple point attachment (the 'chelate effect') of the fusion phage to the immobilized target protein.
Therefore to control the fusion protein copy number we limited transcription of the hGH-gene III fusion by culturing the plasmid in E. colt JM101 (iacl~) which contains a oonstitutively high level of the lac repressor protein.
The E. colt JM101 cultures containing phGH-Ml3glll were best propagated and infected with M13K07 in the absence of the lac operon inducer (IPTG); however, this system is flexible so that co~xpression of other gene III
2~~5~3.3 24 tusan proteins can be balanced. We estimate that about 10°~ of the phagemid particles contain one copy of the hGH gene III fusion protein from the ratio of the amount of hGH per virion (based on hGH immures-reactive material in CsCI gradient purified phagemid). Therefore, the titer of fusion phage displaying the hGH gene III fusion is about 2 - 5 x 1010hn1. This number is much greater than the titer of E. aoli (-108 to l0glml) in the culture from which they are derived. Thus, on average every E. ooli cell produces 10-100 copies of phage decorated with an hGH gene III fusion protein.
EXAMPLE V
Structural Inteprtty of the hGH~ene II Fusion Immunoblot analysis (Fg. 2) of the hGH~ene III phagemid show that hGH aoss-reactive material comigrates with phagemid particles in agarose gels. This indicates that the hGH is tightly assoclated with phagemid particles. The hGH-gene III fusion protein from the phagemid particles runs as a single immuno-stained band showing that there is little degradation of the hGH when it is attached to gene III. Hfild-type gene III protein is dearly present because about 25% of the phagemid particles are infectious.
This is comparable to specific infectivity estimates made for wild-type M13 phage that are similarly purified (by CsCI density gradients) and concentrations estimated by UV absorbance (Smith, G. P. supra and Parmley, Smith supra) Thus, both wild-type gene III and the hGH-gene III fusion proteins are displayed in the phage pool.
It was important to confirm that the tertiary structure of the displayed hGH
was maintained. in order to have confidence that results from Minding selections will translate to the native protein. We used monoclonal antibodies (blabs) to hGH bo evaluate the sUuctural integrity of the displayed hGH gene III fusion protein (Table I).
TABLE L Binding of Eight Different Monoclonal AnfIbodles (Mab"s) to hGH end hGH Phagemld Particles' IC50 (nM) blab hGH hGH-phagemid __________..___________._..._______.________________._______....._________...__ ____ 1 0.4 0.4 2 0.04 0.04 3 0.2 0.2 4 0.1 0.1 5 0.2 >2.0 6 0.07 0.2 7 0.1 0.1 8 0.1 0.1 'Values given represent ~e oorxentrationGH or hGH-phagemid particles (nM) of h to give half-maximal binding to the particular Mab. Standard errors in these measurements are typically at or below 30%
of the reported value.
See Materials and Methods for further details.
The epitopes on hGH for these blabs have been mapped (Cunringham et al..
supra) and Minding for 7 of 8 blabs requires that hGH be properly folded. The IC50 values for all blabs were equivalent to wild-type hGH
except for Mab 5 and 6 . Both blabs 5 and 6 are known to have tHnding determinants near the carboxyl-terminus of hGH which is blocked in the gene III fusion protein. The relative IC50 value for Mabt which reacts with Moth native and denatured hGH is urxhanged oompan;d to the confortnationally sensitive blabs 2-5, 7 and 8. Thus, Mab1 serves as a good internal control for any errors in matching the concentration of the hGH standard to that of the hGH~ene 111 fusion.
WO 92/09690 ~ ~ ~ ~ ~, ~ ~ PCT/US91/09133 EXAMPLE VI
Bin~ng Enrldnferwa on Raoepbor AtANty BeHds Previous workers (Partnley, Smith supra ; Scott, Smith supra; Cwirla et al.
supra; and DeNin et al.
5 supra) have fractionated phage by panning with streptavidin coated polystyrene petri dishes or miaotiter plates.
However, chromatographic systems would allow more efficient fractionation of phagemid particles displaying mutant proteins with different binding affinities. We chose non-porous oxirane beads (Sigma) to avoid trapping of phagemid particles in the chromatographic resin. Furthermore, these beads have a small partite size (1 N.m) to maximize the surface area to mass ratio. The extracellular domain of the hGH
receptor (hGHbp) (Fuh ef al. , 10 supra) containing a free cysteira residue was effiaently coupled m these beads and phagemid particles showed very low non-specific bin ding to beads coupled oMy to bovine serum albumin (Table II).
TABLE II.
15 Specific Binding of Hormone Phage to hGHbp-coated Beads Provides an Enrichment for hGH-phage over M13K07 Phage' Sample Absorbent$ Total pfu Total cfu Ratio (cfu/pfu) Enrichment~
20 Original mixturet 8.3 x 1011 2.9 x 1p8 3.5 x 10'4 (1) Supernatant BSA 7.4 x 1011 2.8 x 108 3.8 x 10'4 1.1 hGHbp 7.6 x 1011 3.3 x 108 4.3 x 10'4 1.2 Wash 1 BSA 1.1 x 1010 6.0 x 106 5.5 x 10'4 1.6 hGHbp 1.9 x 1010 1.7 x 107 8.9 x 10'4 2.5 25 Wash 2 BSA 5.9 x 107 2.8 x 104 4.7 x 10'4 1.3 hGHbp 4.9 x 107 2.7 x 106 5.5 x 10'2 1.6 x 102 Eluate 1 (hGH)BSA t .1 x 106 1.9 x 103 1,7 x 10'3 4.9 hGHbp 1.2 x 106 2.1 x 106 1.8 5.1 x 103 Eluate 2 (hGH)BSA 5.9 x 105 1.2 x 103 2.0 x 10'3 5.7 hGHbp 5.5 x 105 1.3 x 106 2.4 6.9 x 103 Eluate 3 (pH 2.1 )BSA4.6 x 105 2.0 x 103 4.3 x 10'3 12.3 hGHbp 3.8 x 105 4.0 x 106 10.5 3.0 x 104 'The titers of M13K07 and hGH-phagemid particles in each fraction was determined by multiplying the number of plaque forming units (pfu) or carbenicillin resistant colony forming units (cfu) by the dilution factor, respectively. See Example IV for details.
tThe ratio of M13K07 to hGH-phagemid particles was adjusted to 3000:1 in the original mixture.
$Absorbents were conjugated with BSA or hGHbp.
~Enrichments are calculated by dividing the cfu/pfu ratio after each step by cfu/pfu ratio in the original mixture.
In a typical enrichment experiment (Table II), one part of hGH phagemid was mixed with >3,000 parts M13K07 phage. After one cyGe of binding and elution,106 phage were recovered and the ratio of phagemid to M13K07 phage was 2 to 1. Thus, a single binding selection step gave >5000-~Id enrichment. Additional elutions with free hGH or acid treatment to remove remaining phagemids produced even greater enrichments. The enrichments are comparable to those obtained by Smith and coworkers using batch elution from coated polystyrene plates (Smith, G.P. supra and Parmely, Smith sypra ) however much smaller volumes are used on the WO 92/09690 N Q ~ ~ b ~y ~~ PCT/US91/09133 beads (200 W vs. 6 ml). There was almost no enrichment for the hGH phagemid over M13K07 when we used beads linked only to BSA. The slight enrictxnent observed for control beads (-10-fold for pH 2.t elution; Table 2) may result firom trace contaminants of bovine growth hormone t>;n<ling protein present in the BSA linked to the bead. Nevertheless these data show the enrichmer><s for the hGH phage depend ion the presence of the hGHbp on the bead suggesting Minding oxurs by specific interactan between hGH and the hGHbp.
We evaluated the enrichment for wild-type hGH over a weaker bir»dirg variant of the hGH on fusion phagemids to further demonstrate enrichment speafiaty, and to Nnk the reduction in binding affinity for the purffied hormones to ervichment factors after panrwng fusion phagemids. A
fusion phagemid was constmcted with an hGH mutant in which Arg64 was substituted with Ala (R64A). The R64A
variant hormone is about 20-fold reduced in receptor binding affinity compared to hGH (Kd values of 7.t nM
and 0.34 nM, respectively [Cunningham, Wells, supra )). The titers of the R64A hGHt~ene III fusan phagemid were comparable to those of wild-type hGH phagemid. After one round of binding and elution (Table III) the wild-type hGH phagemid was enriched from a mixture of the two phagemids plus M13K07 by 8-fold relative to the phagemid R64A, and 104 relative to M13K07 helper phage.
TABLE WI. hGHbp~ooated Beads Select fa hGH PhaperNds Over a Weaker B4~np hGH Variant tfiapemld Sample enrichment j~ enrichment total phagemid for WT/R64A total phagemid for VIrT/R6~4A
Original mixture 8/20 (1) 8/20 (1) Supernatant ND - 4/10 1.0 Elution 1 (hGH) 7J20 0.8 17120 8.5$
Elution 2 (pH 2.1 ) 11 /20 1.8 21 /27 5.2 'The parent M13K07 phage, wild-type hGH phagemid and R64A pt~agemid particles were mixed at a ratio of 104:0.4.6. Binding selections were carried out using beads linked with BSA
(control beads) or with the hGHbp (hGHbp beads) as described in Table II and the Materials and Methods After each step, plasmid DNA was isolated(&mboim, H. C., Doly, J. , Nucleic Acids Res., T:1513-1523, [1979]) from carbeniallin resistant colonies and analyzed by restriction analysis to determine if it contained the wild-type hGH or the R64A hGH gene III
fusion.
tThe enrichment for wild-type hGH phagemid over R64A mutant was ca~ulated from the rata of hGH phagemid present after each step to that present in the original mixture (8120), divided by the coresponding ratio for R64A phagemids. WT = wild-type; ND = not determined.
$The enrichment for phagemid over total M13K07 parental phage was -104 after this step.
4 0 By displaying a mixture of wild-type gene III and the gene 111 fusion protein on phagemid particles one can assemble and propagate virions that display a large and proper folded protein as a fusion to gene III. The copy number of the gene III fusion protein can be effectively controlled to avoid'chelate effects' yet maintained at high enough levels in the phagemid pool to permit panning of large epitope libraries (>1010). We have shown that hGH
(a 22 kD protein) can be displayed in its native folded torm. Binding selections performed on receptor affinity beads eluted with free hGH, efficiently enriched for wild-type hGH phagemids over a mutant hGH phagemid shown to gave reduced receptor binding affinity. Thus, it is possible to sort phagemid particles whose binding constants are doom in the r~anomolar range.
WO 92/09690 ~ 9 j ~ 3 ~ PCT/US91 /09133 Proteirrprotein and antibody-antigen interactions are dominated by discontinuous epitopes (Janin, J., et al. , J.J. MoLBiol..Biol.. 204:155-164, (1988]; Argos, P., Prot Ena., 2a01-113, (19881; Barlow, D.J.,etaL , ~,, 322:747-748, [1987); and Davies, D.R., et at. , ,(,,Biol. Chem.. 263:10541-10544, [1988)); that is the residues directly involved in binding are dose in tertiary structure but separated by residues not involved in binding. The screening system presented here should albw one to analyze more conveniently protein-receptor interactions and isolate disoont~uous epitopes in proteins with new and high affinity binding properties.
S~don d hGH from a IJbrary Rundomtaed at hGH Colons 172,174,176,178 i 0 Constructi~~n of template A mutant of the hGH~ene III fusion protein was constructed using the method of Kunkel.,et aL fuj~.
Fp~,154, 367-382 [1987]. Template DNA was prepared by growing the plasmid pS0132 (containing the natural hGH gene fused to the carboxy-terminal half of M13 gene III, under control of the alkaline phosphatase promoter) in CJ236 cells with M13-K07 phage added as helper. Single-stranded, uradl-containing DNA was prepared for mutagenesis to introduce (1) a mutation in hGH which would greatly reduce binding to the hGH
binding protein (hGHbp); and (2) a unique restriction site (Kpnl) which could be used for assaying for -- and selecting against - parental background phage. Oligonudeotide-directed mutagenesis was carried out using T7 DNA polymerise and the foNowing digodeoxy-nucleotide:
Gly Thr hGH colon: 178 179 5' -G ACA TTC CTG S-aGT A~.C GTG CAG T-3' < KpnI >
This oligo introduces the Kpnl site as shown, along with mutations (R178G,1179T) ~ hGH. These mutations are predicted to reduce binding of hGH to hGHbp by more than 30-fold. Clones from the mutagenesis were screened by Kpnl digestion and confirmed by dideoxy DNA sequencing. The resulting constrict, b be used as a template for random mutagenesis, was designated pH04t5.
~ ~ggpn Ihel6c~l of hCt( Colons 172,174,176,178 were targeted for random mutagenesis in hGH, again using the method of Kunkel. Single-strarxied template from pH0415 was prepared as above and mutagenesis was carried ouf using 3 0 the following pool of oligos:
hGH colon: 172 174 5'- GC TTC AGG AAG GAC ATG GAC ~ GTC )~ ACA-Ile .5. CTG ~ ATC GTG CAG TGC CGC TCT GTG G-3' As shown, this oligo pool reverts colon 179 to wtid-type (tie), destroys the unique Kpnl site of pH0415, and introduces random colons (NNS, where N= A,G,C, or T and S= G or C) at positions 172,174,176, and 178. Using this colon selection in the context of the above sequence, no additional Kpnl sites can be seated. The choice of the NNS degenerate sequence yields 32 possible colons (inducting one 'stop' colon, and at least one colon for each amino add) at 4 sites, for a total of (32)4= 1,048,576 possible nudeotide sequences (12°~ of which contain at least one stop colon), or (20)4= 160,000 possible polypeptide sequences plus 34,481 prematurely terminated sequences (i.e. sequerxes contair>ing at least one stop colon).
PSg~,~geffon of tnlfjat Ilbrarv WO 92/09690 ~ ~ ~ C~ ~ J ~ PCT/US91/09133 The mutagenesis products were extracted twice with phenolxtrloroform (50:50) and ethanol precpitated with an excess of carrier tRNA 6o avoid adding salt that would confound the subsequent electroporation step. Approximately 50 ng (15 fmols) of DNA was electroporated into WJM101 cells (2.8 x 101 ~
oeIIsImL) in 45 N.L btal volume in a 0.2 an cuvette at a voltage setting of 2.49 kV with a single pulse (time constant = 4.7 msec.).
The ceNs were aNowed to recover 1 hour at 37oC with shaking, then mixed with 25 mL 2YT medium,100 ~glmL carbenicllin, and M13-K07 (multiplicity of infection = 1000). Plating of serial dilutions from this culture onto carbenialGn~onta~ing media indicated that 8.2 x 106 electrotransformarris were obtained. After 10' at 23oC, the culture was incubated overnight (15 hours) at 37oC with shaking.
After ovemght incubation, the cells were pelleted, and double-stranded DNA
(dsDNA), designated pLIB1, was prepared by the alkaline lysis method. The supernatant was spun again to remove any remaining cells, and the phage, designated phage pool ~1, were PEG-precipitated and resuspended in 1 mL STE buffer (10 mM
Tris, pH 7.6, 1 mM EDTA, 50 mM NaCI). Phage titers were measured as colony-formirg units (CFU) for the recombinant phagemid containing hGH~3p gene III fusion (hGH~) plasmid, and plaque-forming units (PFU) for 1 S the M13-K07 helper phage.
1. BINDING: M aliquot of phage pool ~1 (6 x 109 CFU, 6 x 107 PFU) was diluted 4.5-fold in buffer A
(Phosphate-buffered saline, 0.5% BSA, 0.05°~ Tween-20, 0.01°k thimerosal) and mixed with a 5 uL suspension of oxirane-polyacrylamide beads coupled to the hGHbp containing a Ser237 Cys mutation (350 fmols) in a 1.5 mL
silated polypropylene tube. As a control, an equivalent aNquot of phage were mixed in a separate tube with beads that had been coated with BSA only. The phage were allowed to hind to the beads by incubating 3 hours at room temperature (23oC) with slow rotation (approximately 7 RPM). Subsequent steps were carried out with a constant volume of 200~L and at room temperature.
2. WASH: The beads were spun 15 sec., and the supernatant was removed (Sup.1 ). To remove phage/phagemid not specifically bound, the beads were washed twice by resuspending in buffer A, then pelleting.
A final wash consisted of rotating the beads in buffer A for 2 tours.
3. hGH ELUTION: Phagelphagemid Minding weakly to the beads were removed by stepwise elution with hGH. In the first step, the beads were rotated with buffer A containing 2 nM
hGH. After 17 hours , the beads were pelleted and resuspended in buffer A containing 20 nM hGH and rotated for 3 hours, then pelleted. In the 3 0 final hGH wash, the beads were suspended in buffer A containing 200 nM hGH
and rotated for 3 tours then pelleted.
4. GLYCINE ELUTION: To remove the tightest-binding phagemid (i.e. those still bound after the hGH
washes), beads were suspended in Glycne buffer (1 ~Glycine, pH 2.0 with HCI), rotated 2 hours and pelleted.
The supernatant (fraction 'G'; 200~.L) was neutralized by adding 30 Nl. of 1 M
Tris base.
Fraction G eluted from the hGHbp-beads (1 x 106 CFU, 5 x 104 PFU) was not substantially enriched for phagemid over K07 helper phage. We believe this resulted from the fact that K07 phage packaged during propagation of the recombinant phagemid display the hGH-gap fusion.
WO 92/09690 ~ ~ 9 ~ ~ ~ ~ PCT/US91/09133 However, when compared with fraction G eluted from the BSAcoated control beads, the hGHbp-beads yielded 14 times as many CFU's. This reflects the enrichment of tight-binding hGH~displaying phagemid over nonspedfically-binding phagemid.
5. PROPAGATION: M aliquot (4.3 x 105 CFU) of fractan G ekited from the hGHbp-beads was used to infect log-phase WJM101 cells. Transductans were cartied out by mixing 100 N.L fractan G with 1 mL WJM101 cells, incubating 20 min. at 37oC, then adding K07 (multiplidty of infection=1000). Cultures (25 mL 2YT plus carberudllin) were grown as described above and the second pool of phage (Library 1G, for first glydne elution) were prepared as described above.
Phage from library 1 G (Fig. 3) were selected for tlinding to hGHbp beads as described above. Fraction G eluted from hGHbp beads contained 30 times as many CFU's as fir~tion G
eluted from BSA-beads in this selectan. Again, an aliquot of fraction G was propagated in WJM101 cells to yield library 1G2 (indicating that this library had been twice selected by glyane elution). Double-stranded DNA
(pLIB 1 G2) was also prepared from this culture.
To reduce the level of background (Kpnl+) template, an aliquot (about 0.5 p.g) of pLIB 1G2 was digested with Kpnl and electroporated into WJM101 cells. These cells were grown in the presence of K07 (multiplidty of infection= i00) as described for the initial library, and a new phage pool, pLIB 3, was prepared (Fig. 3).
In addition, an aliquot (about 0.5 fig) of dsDNA from the initial library (pLIB1) was digested with Kpnl and electroporated directly into WJM101 cells. Transfortnants were allowed to recover as above, infected with M13-K07, and grown overnight to obtain a new Gtxary of phage, designated phage Library 2 (Fig. 3).
Phagemid binding, elution, and propagation were carried out in successive rounds for phagemid derived from both pLIB 2 and pLIB 3 (Fig. 3) as described above, except that (1) an excess (10-fold over CFU) of p~xified K07 pfrage (not ~sptaying hGH) was added in the bead-binding cocktail, and (2) the hGH stepwise elutions were n;plaoed with txief washings of buffer A alone. Also, in some cases, XL1-Blue cells were used for phagemid propagation.
An additional digestion of dsDNA with Kpnl was carried out on pLIB 2G3 and on pLlB 3G5 before the final round of bead-binding selection (Fg. 3).
Four independently isolated doves from LIB 4G4 and bur indeperxiently isolated doves from LIB 5G6 were sequenced by dideoxy sequendng. All eight of these doves had identical DNA sequences:
hGH colon: 172 174 176 178 5' -AAG GTC TCC ACA TAC CTG AGG ATC-3' Thus, all these encode the same mutant of hGH: (E174S, F176Y). Residue 172 in these Bones is Lys as in wild-type. The colon selected for 172 is also identical to wild-type hGH. This is not surprising since AAG is the only lysine~odon possible from a degenerate 'NNS' colon set. Residue 178-Arg is also the same as wild-type, but here, the colon selected from the library was AAG instead of CGC as is found in wild-type hGH, even though the latter colon is also possible using the'NNS' colon set.
p 30 The multipliclty of infection of K07 infection is an important parameter in the propagation of recomtHnant phagemids. The K07 multiplidty of infection must be high enough to insure that virtually all cells transformed or transfected with phagemid are able to package new phagemid particles. Furthermore, the concentration of wild-type gene III in each cell should be kept high Eo reduce the possibility of multiple hGH-gene III
fusion molecules being displayed on each phagemid particle, thereby reduarg chelate effects in binding. However, if the K07 multiplidty of infection is too high, the packaging of K07 will compete with that of recombinant phagemid. We find that aooeptabfe phagemid yields, vhth oMy 1-10% badc~ound K07 phage, are obtained when the K07 mutGplidty of infection is 100.
Table IV.
Phage Pool moi (K07) Enrichment hGHbpIBSA beads Fraction Kpnl CFUIPFU
LIB 1 1000 ND 14 0.44 LIB 1G 1000 ND 30 0.57 LIB 3 100 ND 1.7 0.26 LIB 3G3 10 ND 8.5 0.18 LIB 3G4 100 460 220 0.13 LIB 2 100 ND 1.7 <0.05 LIB 2G 10 ND 4.1 <0.10 LIB 2G2 100 1000 27 0.18 Phage pools are labelled as shown (Fig. 3). The multiplidty of infection (moi) refers to the multiplidty of K07 infection (PFUlcells) in the propagation of ptragemid. The enrictunent of CFU
over PFU is shown in those cases where purified K07 was added in the binding step. The rata of CFU eluting from hGHbp-beads over CFU eluting from BSA-beads is shown. The fraction of Kpnl-containing template (i.e., pH0415) remaining in the pool was determined by digesting dsDNA with Kpnl plus EcoRl, running the products on a 1°k agarose gel, and laser-scanning a negative of the ethidium bromide-stained DNA.
R~'gp~tor-blndina aftlnHp~r of fhe hormone hGH(E174S. F176Y1 The fact that a single done was isolated from iwo different pathways of selection (Fig. 3) suggested that the double mutant (E174S,F176Y) hinds strongly to hGHbp. To determine the affinity of this mutant of hGH for hGHbp, we constructed this mutant of hGH by site~irected mutagenesis, using a plasmid (pB0720) which contains the wild-type hGH gene as template and the following oligonuGeotide which changes colons 174 and hGH colon: 172 174 176 178 Lys Ser Tyr Arg 5'- ATG GAC AAG GTR ~G ACA T8C CTG CGC ATC GTG -3' The resulting construct, pH0458B, was transformed into E. coli strain 16C9 for expression of the mutant hormone. Scatchard analysis of competitive tHnding of hGH(E174S,F176Y) versus 1251-hGH to hGHbp indicated that the (E174S,F176Y) mutant has a Minding affinity at least 5.0-fold tighter than that of wild-type hGH.
EXAMPLE VUI
SELECTION OF hGH VAFBANTS FROM A
Human growth hormone variants were produced by the method of the present irnention using the phagemid desaibed in figure 9.
We designed a vector for cassette mutagenesis (Wells et al., ~, 34, 315-323 [1985)) and expression of the hGH-gene III fusion probin with the objectives of (1 ) improving the wnkage between hGH and the gene I II
moiety to more favorably display the hGH moiety on the phage (2) limiting expression of the fusion protein to obtain essentially 'monovaleM display,' (3) allowing for restriction rxidease selection against the starting vector, (4) eliminating expression of fusion protein from the starting vector, and (5) achieving taale expression of the corresponding free hormone from a given hGH-gene III fusion mutant.
Plasmid pS0643 was constructed by oligonuGeotide-directed mutagenesis (Kunkel et al., Fp~,154, 367-382 [1987J) of pS0132, which contains pBR322 and fi origins of repbcation and expresses an hGH-gene III fusion protein (hGH residues 1-191, followed by a single Gly residue, fused to Pro-198 of gene III) under the control of the F,,~ p(ZQ6 promoter (Bass et al., Proteins 8, 309-314 [1990])(Figure 9). Mutagenesis was carried out with the oligonuGeotide 5'-GGC-AGC-TGT-GGC-TT_r,~AG-AGT-GGC-GGC-GGC-TCT-GGT-3', which introduces a ~[ site (underlined) and an amber stop colon (TAG) foNowing Phe-19t of hGH. In the resulting construct, pS0643, a portion of gene III was deleted, and two silent mutations (underlined) occurred, yielding the folbwing junction between hGH and gene III:
__ ~ _______.__________.> geae » >
2 5 1B7 188 18B 190 181 am' 249 2!!0 261 2:3~ 2S3 264 t9Q Gars G19 P>'e (;fin tsa Cdr G~ Gf;Y ~' ~9 GGC AOC TGT GGA ThC TAG ~IGT O0~ (ifs'T' C1GC TCT GiG1' This shortens the total size of tire fusion protein firom 401 residues ~
pS0132 to 350 residues in 3 0 pS0643. Experiments using monoclonal antibodies against hGH have demonstrated that the hGH portion of the new fusion protein, assemded on a phage particle, is more acoesside than was the previous, longer fusion.
For propagation of hormone-displaying phage, pS0643 and derivatives can be grown in a amber-suppressor strain of ~, such as JM101 or XL1-Blue (Bullock et al., BioTecbpj~
5, 376-379 [1987j). Shown above is substitution of Glu at the amt~er colon which occurs in ;~ suppressor strains. Suppression with other 3 5 amino acids is also possible in various available sUair~s of ~,,~ well known and publicalty available.
To express hGH (or mutants) tree of the gene III portion of the fusion, pS0643 and derivatives can simply be groHm in a non-suppressor strain such as 16C9. ~ ihis case, the amber colon (TAG) leads to termination of translation, which yields free hormone, without the need for an independent DNA construction.
To create sites for cassette mutagenesis, pS0643 was mutated with the oligonucJeotides (1 ) 5'-CGG-40 ACT-GGG-CAG-ATA-TTC-AAG-CAG-ACC-3', which destroys the unique $q(1[ site of pS0643; (2) 5'-CTC-AAG-AAC-TAC-GGG-TTA-CCC-TGA-CTG-CTT-CAG-GAA-GG-3', which inserts a unique ~j site, a single-base (rameshift, and a non-amber stop colon (TGA); and (3) 5'-CGC-ATC-GTG-CAG-TGC-AGA-TCT-GTG-GAG-GGC-3', which introduces a new ~ site, to yield the starting vector, pH0509. The addition of a frameshift along with a TGA stop colon insures that no genelll-fusion can be produced from the startirg vector.
WO 92/09690 ~ Q ~ PCT/LJS91/09133 The ~[[ - ~[[1 segment is cut out of pH0509 and replaced with a DNA cassette, mutated at the colons of interest. Other restriction sites for cassette mutagenesis at other locatans in hGH have also been introduced into the hormone-phage vector.
Colons 172,174, 176 and 178 of hGH were targeted for random mutagenesis because they all lie on or near the surface of hGH and contribute significantly to receptor-binding (Cunningham and Wells, 244, 1081-1085 (1989]); they all we within a well-defined structure, occupying 2'tums' on the same side of helix 4;
and they are each substituted by at least one amino aad among krawn evolutionary variants of hGH.
We chose to s~stitute NNS (N=A/G/C/T; S=G/C) at each of the target residues.
The choice of the NNS degenerate sequence yields 32 possible codor~s (including at least one colon for each amino aad) at 4 sites, for a total of (32)4= 1,048,576 possible nucleotide sequences, or (20)4=
160,000 possible polypeptide sequences. Only one stop colon, amber (TAG), is albwed by this choice of colons, and this colon is suppressible as Glu in ~ strains of ~.
Two degenerate oligonudeotides, with NNS at colons 172,174,176, and 178, were synthesized, phosphorylated, and annealed to construct the mutagenic cassette: 5'-GT-TAC-TCT-ACT-GCT-TTC-AGG-AAG-GAC-ATG-GAC-NNS-GTC-NNS-ACA-NNS-CTG-NNS-ATC-GTG-CAG-TGC-A-3', and 5'-GA-TCT-GCA-CTG-CAC-GAT-SNN-CAG-SNN-TGT-SNN-GAC-SNN-GTC-CAT-GTC-CTT-CCT-GAA-GCA-GTA-GA-3'.
The vector was prepared by digesting pH0509 with followed by ~[[j. The products were run on a 1% agarose gel and the large fragment exased, phenol-extracted, and ethanol precipitated. This fragment was treated with calf intestinal phosphatase (Boehringer), then phenol:chloroform extracted, ethanol preapitated, and resuspended for ligatan with the mutagenic cassette.
rr~~umn uu: nnu~ nu~~r m w~rw~ ma Following ligation, the reaction products were again digested with , then phenol:chloroform extracted, ethanol precipitated and resuspended in water. (A g~j1 recognition site (GGTNACC) is created within cassettes which contain a ~ at position 3 of colon 172 and an ~ (Thr) colon at 174. However, treatment with ~stEll at this step should not select against any of the possible mutagenic cassettes, because virtually all cassettes will be heteroduplexes, which cannot be Geaved by the enzyme.) Approximately 150 ng (45 fmols) of DNA was electroporated into XL1-Blue cells (1.8 x 109 cells in 0.045 mL) in a 0.2 an cuvette at a voltage setting of 2.49 kV with a single pulse (time constant = 4.7 msec.).
The cells were allowed to recover 1 hour at 37oC in S.O.C meda with shaking, then mixed with 25 mL
2YT medium,100 mg/mL carbenicillin, and M13-K07 (moi= 100). After 10' at 23oC, the culture was incubated overnight (15 hours) at 37oC with shaking. Plating of serial dilutions from this culture onto carbenicillin-containing media indicated that 3.9 x 107 electrotransformants were obtained.
After overnight incubation, the cells were pelleted, and double-strarxied DNA
(dsDNA), designated pH0529E (the initial library), was prepared by the alkaline lysis method. The supernatant was spun again to remove any remaining cells, and the phage, designated phage pool ~H0529E (the initial lilxary of phage), were PEG-precipitated and resuspended in 1 mL STE buffer (10 mM Tris, pH 7.6, 1 mM
EDTA, 50 mM NaCI). Phage WO 92/09690 ~ j ~ ~ ~ PCT/US91/09133 titers were measured as cobny-forming units (CFU) for the recombinant phagemid containing hGH-gap.
Approximately 4.5 x 1013 CFU were obtained from the starting library.
From the pool of electrotransformants, 58 doves were sequenced in the region of the ~-gq(j[
cassette. Of these, 17% corresponded to the starting vector,17% contained at least one frame shift, and 7°~6 contained a non-silent (non-terminating) mutation outside the four target colons. We conclude that 41°~ of the doves were defective by one of the above measures, leaving a botat functional pool of 2.0 x 107 initial transfortnants. This number stiN exceeds the possible number of DNA sequences by nearly 20-fold. Therefore, we are confident of having all possible sequences represented in the starting litxary.
We examined the sequences of non-selected phage to evaluate the degree of colon bias in the mutager~esis (Table V). The results indicated that, although some colons (and amino adds) are under- or over-represented relative to the random expectation, the library is extremely diverse, with no evidence of large-scale 'sibling' degeneracy (Table VI).
Table V.
Colon distributan (per 188 colons) of non-selected hormone phage. Cbnes were sequenced from the starting library (pFt0529E). All colons were tabulated, inducting those from Bones which contained spurious mutations andlor frameshifts. ' Note: the amber stop colon (TAG) is suppressed as Glu in XLt-Blue cells. Highlighted colons were ovedunder-represented by 50% or more.
leu 17.6 18 1.0 Ser 17.6 26 1.5 A r g 17.6 10 0.57 Pro 11.8 16 1.4 Thr 11.8 14 1.2 Ala 11.8 13 1.1 Gly 11.8 16 1.4 Val 11.8 4 0.3 1e 5.9 2 0.3 Met 5.9 1 0.2 Ty r 5.9 1 0.2 Ws 5.9 2 0.3 Trp 5.9 2 0.3 Phe 5.9 5 0.9 4 Cys 5.9 5 0.9 Gln 5.9 7 1.2 Asn 5.9 14 2.4 Lys 5.9 11 1.9 Asp 5.9 9 1.5 Glu 5.9 6 1.0 amber' 5.9 6 1.0 WO 92/09690 ~ ~ ~ ~ ~ PCT/US91/09133 Table VI.
Non-selected (pH0529E) clones with an open reading frame.
The notation, e.g. TWGS, denotes the hGH mutant 172TI174WI176G/178S. Amber (TAG) colons, translated as GIu in XL1-Blue cells are shown as E.
Ke NT KTEQ CVLQ
TWGS NNCR EASL
Pe ER FPCL SSKE
LPPS NSDF ALLL
SLDP HRPS PSHP
OQSN LSLE SYAP
GSKT NGSK ASNG
TPVT LTTE EANN
RSRA PSGG KNAK
LCGL LWFP SRGK
TGRL PAGS GLDG
AKAS GRAK NDPI
GNDD GTNG
Immobilized hGHbp ('hGHbp-beads') was prepared as described (Bass et al., Proteins 8, 309-314 [1990]), except that wild-type hGHbp (Fuh et al., ~, Biol. Chem. 265, 3111-3115 [1990]) was used. Competitive binding experiments with [1251] hGH indicated that 58 fmols of turxtional hGHbp were coupled per uL of bead Immobilized hPRLbp ('hPRlbp-beads') was prepared as above, using the 211-residue extraoelluiar domain of the prolactin receptor (Cunningham et al., ~jg~ 250,1709-1712 [1990]). Competitive binding experiments with [1251] hGH in the presence of 50 l,t~ zinc indicated that 2.1 fmols of functional hPRLbp were 3 0 coupled per N.L of bead suspension.
'Blank beads' were prepared by treating the oxirane-acrylamide beads with 0.6 M etharalamine (pH
9.2) for 15 hours at 4oC.
Binding of hormone-phage to beads was carried out ~ one of the following buffers: Buffer A (PBS, 0.5% BSA, 0.05°~ Tween 20, 0.01°~ thimerosal) for selections using hGHbp and blank beads; Buffer B (50 mM
tris pH 7.5,10 mM MgCl2, 0.5% BSA, 0.05°~ Tween 20,100 mm ZnCl2) for selections using hPRLbp in the presence of zinc (+ Zn2+); or Buffer C (PBS, 0.5% BSA, 0.05% Tween 20, 0.01%
thimerosal, 10 m~ EDTA) for selections using hPRLbp in the absence of zinc (+ EDTA). Binding selections were carried out according to each of tt~e following paths: (1) binding to blank beads, (2) binding to hGHbp-beads, (3) binding to hPRLbp-beads (+
Zn2+), (4) binding to hPRLbp-beads (+ EDTA), (5) pre-adsorbing twice with hGHbp beads then binding the non-adsorbed fraction to hPRLbp-beads ('-hGHbp, +hPRLbp' selection), or (6) pre-adsorbing twice with hPRLbp-beads then binding the non-adsorbed fraction to hGHbp-beads ('-hPRLbp, +hGHbp' selection). The latter two procedures are expected to enrich for mutants binding hPRLbp but not hGHbp, or for mutants binding hGHbp but not hPRLbp, respectively.
4 5 Binding and elution of phage was carried out in each cycle as follows:
1. BINDING: M aliquot of hormone phage (typically 10S -1010 CFU) was mixed with an equal amount of non-hormone phage (pCAT), diluted into the appropriate buffer (A, B, or C), and mixed with a 10 mL suspension of hGHbp, hPRLbp or blank beads in a total volune of 200m1 in a t.5 ml pdypropylene tube. The phage were allowed b bind b the beads by incubating t hour at room temperature (23oC) with slow rotation (approximately 7 RPM). S~sequent steps were carried out with a constant volume of ZOO~L and at room temperature.
2. WASHES: The beads were spun t5 sec., and the supernatant was removed. To reduce the rx~mber of 5 phage not speafically bound, the beads were washed 5 times by resuspending briefly in the appropriate buffer, then pelleting.
3. hGH ELUTION: Phage binding waaldy to the beads were by ek~tion with hGH.
The beads were rotated with the appropriate buffer containing 400 r~.hGH for 15-17 hours. The supernatant was saved as the 'hGH elution' and the beads. The beads were washed by resuspending Ixiefly in buffer and pelleting.
Binding of hormone-phage to beads was carried out ~ one of the following buffers: Buffer A (PBS, 0.5% BSA, 0.05°~ Tween 20, 0.01°~ thimerosal) for selections using hGHbp and blank beads; Buffer B (50 mM
tris pH 7.5,10 mM MgCl2, 0.5% BSA, 0.05°~ Tween 20,100 mm ZnCl2) for selections using hPRLbp in the presence of zinc (+ Zn2+); or Buffer C (PBS, 0.5% BSA, 0.05% Tween 20, 0.01%
thimerosal, 10 m~ EDTA) for selections using hPRLbp in the absence of zinc (+ EDTA). Binding selections were carried out according to each of tt~e following paths: (1) binding to blank beads, (2) binding to hGHbp-beads, (3) binding to hPRLbp-beads (+
Zn2+), (4) binding to hPRLbp-beads (+ EDTA), (5) pre-adsorbing twice with hGHbp beads then binding the non-adsorbed fraction to hPRLbp-beads ('-hGHbp, +hPRLbp' selection), or (6) pre-adsorbing twice with hPRLbp-beads then binding the non-adsorbed fraction to hGHbp-beads ('-hPRLbp, +hGHbp' selection). The latter two procedures are expected to enrich for mutants binding hPRLbp but not hGHbp, or for mutants binding hGHbp but not hPRLbp, respectively.
4 5 Binding and elution of phage was carried out in each cycle as follows:
1. BINDING: M aliquot of hormone phage (typically 10S -1010 CFU) was mixed with an equal amount of non-hormone phage (pCAT), diluted into the appropriate buffer (A, B, or C), and mixed with a 10 mL suspension of hGHbp, hPRLbp or blank beads in a total volune of 200m1 in a t.5 ml pdypropylene tube. The phage were allowed b bind b the beads by incubating t hour at room temperature (23oC) with slow rotation (approximately 7 RPM). S~sequent steps were carried out with a constant volume of ZOO~L and at room temperature.
2. WASHES: The beads were spun t5 sec., and the supernatant was removed. To reduce the rx~mber of 5 phage not speafically bound, the beads were washed 5 times by resuspending briefly in the appropriate buffer, then pelleting.
3. hGH ELUTION: Phage binding waaldy to the beads were by ek~tion with hGH.
The beads were rotated with the appropriate buffer containing 400 r~.hGH for 15-17 hours. The supernatant was saved as the 'hGH elution' and the beads. The beads were washed by resuspending Ixiefly in buffer and pelleting.
10 4. GLYCINE ELUTION: To remove the tightest-binding phage (i.e. those still bound after the hGH
wash), beads were suspended in Glycine buffer (Buffer A plus 0.2 ~Glycine, pH
2.0 with HCI), rotated t hour and pelleted. The supernatant ('Glyane elution'; ZOOR.L) was neutralized by adding 30 ml of 1 M Tris base and stored at 4o C.
5. PROPAGATION: Aliquots from the hGH elutions and from the Glyane elutions from each set of 15 beads under each set of conditions were used to infect separate cultures of log-phase XLt-Blue cells.
Transductions were carried out by mixing phage with 1 mL XLt-Blue cells, incubating 20 min. at 37oC, then adding K07 (moi= t00). Cultures (25 mL 2YT plus carbenicillin) were grown as described above and the next pool of phage was prepared as described above.
Phage binding, elution, and propagation were carried out in successive rounds, according b the cycle 20 described above. For example, ~e phage amplified from the hGH elution from hGHbp-beads were again selected on hGHbp-beads and eluted with hGH, then used to infect a new culture of XL1-Blue cells. Three to five rounds of selection and propagatan were carried out for each of fhe selection procedures described above.
From the hGH and Glyane elution steps of each cycle, an aliquot of phage was used to inoculate XLt-Btue 25 cells, which were plated on LB media containing carbenialGn and tetracyGine to obtain independent doves from each phage pool. Single-stranded DNA was prepared from isolated cobny and sequenced in the region of the mutagenic cassette. The results of DNA sequencing are summarized in terms of the deduced amino acid sequerx;es in Figures 5, 6, 7, and 8.
3 0 ~.i~B~,h~H,~
To determine the tHnding affinity of some of the selected hGH mutants for the hGHbp, we transformed DNA from sequenced clones into ~ strain 1609. As described above, this is a non-suppressor strain which terminates translation of protein after the final Phe-191 residue of hGH.
Single-stranded ONA was used for these transformations, but double-stranded DNA or even wtrole phage can be easily electroporated into a non-35 suppressor strain for expression of free hormone.
Mutants of hGH were prepared from osmotically shocked cells by ammonium sulfate precipitation as described for hGH (Olson et al., ~g 293, 408-41 t (1981)), and protein concentrations were measured by laser densitomoetry of Coomassie-stained SDS-polyacrylamide gel electrophoresis gels, using hGH as standard (Cunningham and Wells, 244, 1081-1085 (1989)).
The binding affinity of each mutant was determined by displacement of 1251 hGH
as described (Spencer et al., J. Biol. Chem. 263, 7862-7867 [1988] ; Fuh et al., J. Biol. Chem. 265, 3111-3115 [1990]), using an anti-receptor monoclonal antibody (Mab263).
The results for a numt~er of hGH mutants, selected by different pathways (Fig.
6) are shown in Table VII. Many of these mutants have a tghter binding affinity for hGHbp than wild-type hGH. The most improved mutant, KSYR, has a binding affinity 5.6 times greater than that of wed-type hGH. The weakest selected mutant, among those assayed was only about 10-fold lower in binding affinity than hGH.
Binding assays may be carried out for mutants selected for hPRlbp-binding.
Table VII.
Cotre bhdhg b tlGiibP
The selected pool in which each mutant was found is indicated as 1 G (first glyclne selection), 3G (third glycine selection), 3H (third hGH selection), 3' (third selection, not tlinding to hPRI_bp, but Minding to hGHbp).
The number of times e~h mutant ocLKrred among all sequerxed Bones is shown ().
Mutant Kd (nM) Kd(mut)/Kd(hGH) Pod KSYR (6) 0.06 + 0.01 0.18 1G,3G
RSFR 0.10 + 0.05 0.30 3G
RAYR 0.13 + 0.04 0.37 3' KTYK (2) 0.16 + 0.04 0.47 H,3G
RSYR (3) 0.20 + 0.07 0.58 ~ 1G,3H,3G
KAYR (3) 0.22 + 0.03 0.66 3G
RFFR (2) 0.26 + 0.05 0.76 3H
KQYR 0.33 + 0.03 1.0 3G
KEFR= wt (9) 0.34 + 0.05 1.0 3H,3G,3' RTYH 0.68 + 0.17 2.0 3H
QRYR 0.83 + 0.14 2.5 3' KKYK 1.1 +0.4 3.2 3' RSFS (2) 1.1 + 0.2 3.3 3G,' KSNR 3.1 + 0.4 9.2 3' At some residues, substitution of a particular amino acrd has essentially the same effect independent of surrounding residues. For example. substitution of F176Y in the background of 172Rl174S redtxes tHnding affinity by 2.0-fold (RSFR vs. RSYR). Similarly, in the background of 172KI174A the tHnding affinity of the F176Y mutant (KAYR) is 2.9-fold weaker than the corresponding 176F mutant (KAFR; Cunningham and Wells, 1989).
WO 92/09690 ~ ~ ~ ~ ~ ~ ~ PCT/US91 /09133 On the other hand, the binding constants determined for several selected mutants of hGH demonstrate ran~additive etfeds of some amino aad substitutions at residues 172,174,176, and 178. For example, in the background of 172KI176Y, the substitution E174S results in a mutant (KSYR) which binds hGHbp 3.7-fold tighter than the corresponding mutant containing E174A (KAYR). However, in the background of 172R/176Y, the effects of these E174 substitutions are reversed. Here, the E174A mutant (RAYR) binds 1.5-fold tighter than the E174S mutant (RSYR).
Such non~additive effects on binding for substitutions at proximal residues illustrate the utility of protein-phage binding selek~ion as a means of selecting optimized mutants from a library m~ndomized at several positions. ~ the absence of deta~ed swdural information, without such a selection process, many combinations of substitutions might be tried before finding the optimum mutant.
EXAMPLE IX
SELECTION OF hGH VARIANTS FROM A HELIX~1 RANDOM CASSETTE
LIBRARY OF HORMONE-PHAGE
Using the methods described in Example VIII, we targeted another region of hGH
involved in binding to the hGHbp andlor hPRLbp, helix 1 residues 10,14,18, 21, for random mutagenesis in the phGHam~3p vector (also known as pS0643; see Example VIII).
We chose to use the'amber' hGH-g3 construct (called phGHam~g3p) because it appears to make the target protein, hGH, more accessible fx binding. This is supported by data from comparative ELISA assays of monodonaJ antibody binding. Phage produced from both pS0132 (S. Bass, R.
Greene, J. A. Wells, Proteins 8, 309 (1990).) and phGHam-g3 were tested with three antibodies (Medix 2,1 B5.G2, and 5B7.C10) that are known to have binding detertninar>is near the carboxyl-terminus of hGH [B. C.
Cunningham, P. Jhurare, P. Ng, J. A. Wells, Saenee 243,1330 (1989); B. C. Cunningham and J. A. Wells, Silence 244,1081 (1989); L. Jin and J. Wells, unpublished results], and one antibody (Medix 1 ) that recognizes determinants in helices 1 and 3 ([B. C.
Cunningham, P. Jhurani, P. Ng, J. A. Wells, Saerx;e 243,1330 (1989); B. C.
Cunringham and J. A. Wells, Science 244,1081 (1989)]). Pt~agemid partides from phGHam-g3 reacted much more strongly with antibodies Medix 2, 185.62, and 5B7.C10 than did phagemid partiGes from pS0132. In particular, binding of pS0132 particles was reduced by >2000-fold for both Medix 2 and 5B7.C10 and reduced by >25-fold for 1B5.G2 compared to binding to Medix 1. On the other hand, binding of phGHam~3 phage was weaker by only about 1.5-fold,1.2-fold, and 2.3-fold for the Medix 2,1 B5.G2, and 587.C10 antibodies, respectively, compared with binding to MEDIX 1.
We mutated residues in helix 1 that were previously identified by alar>ine-scanning mutager~esis (B. C.
Cunr>rngham, P. Jhurani, P. Ng, J. A. Wells, Science 243,1330 (1989); B. C.
Cunr>ingham and J. A. Wells, Science 244, 1081 (1989),15, 16) to modulate the binding of the extracellular domains of the hGH andlor hPRL
receptors (called hGHbp and hPRLbp, respectively). Cassette mutagenesis was varied out essentially as described [J. A. Wells, M. Vasser, D. B. Powers, Gene 34, 315 (1985)]. This library was constructed by cassette mutagenesis that fully mutated four residues at a time (see Example VIII) which utilized a mutated version of phGHam-g3 into which unique Kpnl (at hGH codon 27jand Xhol (at hGH codon 6) restriction sites (underlined below) had been inserted by mutagenesis [ T. A Kunkel, J. D. Roberts, R. A
Zakour, Methods EnzymoL 154, 367-2~9~~~3 38 382] with the oligonucleotides 5'-GCC TTT GAC AGG TAC CAG GAG TTT G-3' and 5'-CCA ACT ATA CCA
CTS TCG AGG TCT ATT CGA TAA C-3', respectively. The later oligo also introduced a +1 frameshift (italidzed) to terminate translation from the starting vector and minimize wild-type background in the phagemid library. This strafing vector was designated pH0508B. The helix 1 library, which mutated hGH residues 10, 14, 18, 21, was constructed by ligating to the large Xhol-Kpnl fragment of pH0508B
a cassette made from the complementary oiigonucleotides 5'-pTCG AGG CTC NNS GAC AAC GCG NNS CTG CGT GCT
NNS CGT CTT
NNS CAG CTG GCC TTT GAC ACG TAC-3' and 5'-pGT GTC AAA GGC CAG CTG SNN AAG ACG
SNN AGC
ACG CAG SNN CGC GTT GTC SNN GAG CC-3'. The Kpnl site was destroyed in the junction of the ligation product so that restriction enzyme digestion could be used for analysis of non-mutated background.
The library contained at least 10~ indeperkient transfonnaMs so that if the library were absolutely random ( 106 different combinations of colons) we would have an average of about 10 copies of each posside mutated hGH gene. Restriction analysis using Kpni indicated that at least 80%
of helix 1 library constructs contained the inserted cassette.
Binding enrichments of hGH-phage from the libraries was carried out using hGHbp immobilized on oxirane-polyacrylamide beads (Sigma Chemical Co.) as described (Example VIII).
Four residues in helix 1 (F10, M14, H18, and H21 ) were similarly mutated and after 4 and 6 cycles a non-wild-type consensus developed (Table VIII). Position 10 on the hydrophobic face of helix 1 tended to be hydrophobic whereas positions 21 and 18 on the hydrophillic face tended were dominated by Asn; no obvaus consensus was evident for position 14 (Table IX).
The binding constants for these mutants of hGH to hGHbp was determined by expressing the free hormone variants in the non-suppressor E. coli strain 1609, purifying the protein, and assaying by competitive displacement of labelled wt-hGH irom hGHbp (see F~cample VIII). As indicated, several mutants bind tighter to hGHbp than does wt-hGH.
Table VIII.
Selection of hGli helix 1 mutants Variarns of hGH (randomly mutated at residues F10, Mt4, H18, H21) expressed on phagemid particles were selected by binding to hGHbp-beads and eluting with hGH (0.4 mIN) buffer followed by gfycine (0.2 M, pH 2) buffer (see Example VIII).
Gly elution 4 Cycles H G N N
A W D N (2) Y T V N
I N I N
L N S H
F S F G
6 Cycles H G N N (6) F S F L
Consensus:
H G N N
~~95~3~ 40 Table IX
Ca~enst8 sequels tram the selected helix 1 Nbrary Observed frequency is tn~tion of all doves sequerxed with the indicated amino aad. The nominal frequency is cabulated on the basis of NNS 32 colon degeneracy. The maximal enrichment facto varies from 11 ~ 32 depending upon the rwminal frequency value for a given residue. Values of [Kd(Ala mut)IK d(wt hGH)J for single alanine mutations ware taken from B. C. Cumingham and J. A. Wells, Sderx~e 244,1081 (1989); B. C. Cunningham, D. J. Henner, J. A. Wells, Soaves 247,1461 (1990); B. C. Cunningham and J. A.
Wells, Proc. Nail. Acad Sa. USA
88, 3407 (1991 ).
wld type Selected Kd(Ala mut) residue Kd(wt hGH) re~due observed rornir~al Enrichment F10 5.9 H 0.50 0.031 17 F 0.14 0.031 5 A 0.14 0.062 2 M14 2.2 G 0.50 0.062 8 W 0.14 0.031 5 N 0.14 0.031 5 S 0.14 0.093 2 H18 1.6 N 0.50 0.031 17 D 0.14 0.031 5 F 0.14 0.031 5 H21 0.33 N 0.79 0.031 26 H 0.07 0.031 2 Table X
t8lndnp d puri~d hGH helix 1 rt~nts b hGHbp Competition Minding experiments were performed using [l~IjhGH (wild-type), hGHbp (containing the extracellular receptor domain, residues 1-238), and Mab263 [B. C. Cumingham, P. Jhurani, P. Ng, J. A. Wells, Science 243,1330 (1989));. The number P indicates the fractional ocaxrence of each mutant among all the clones sequenced after one or more rounds of selection.
Sequence P Kd (nA~\f(Kd Kd(wt pogtion mut) hGH)) H G N N 0.50 0.14 t 0.04 0.42 A W D N 0.14 0.100.03 0.30 wt= F M H H 0 0.34 0.05 (1 ) F S F L 0.07 0.680.19 2.0 Y T V N 0.07 0.750.19 2.2 L N S H 0.07 0.82 t 0.20 2.4 I N I N 0.07 12 ~ 0.31 3.4 EXAMPLE X
SELECTION OF hGH VARIANTS FROM A HEUX-4 RAN00M CASSETTE LIBRARY CONTAINING
Our experience with reauiting non-binding homologs of hGH evolutionary variants suggests that many individual amino acid substitutions can be combined to yield cumulatively improved mutants of hGH with respect to binding a particular receptor (B. C. Cunnirgham, D. J. Henner, J. A. Wells, Scien~oe 247,1461 (1990); B. C.
Cunningham and J. A. Wells, Pros. Nad. Acad Sa. USA 88, 3407 (1991 ); H. 8.
Lowman, B. C. Cumingham, J. A.
3 5 Wells, J. 8iol. Chem. 266, in press ( 1991 )j.
The helix 4b library was constructed in an attempt to further improve the helix 4 double mutant (E174SIF176Y) selected from the helix 4a library that we found bound tighter to the hGH receptor (see Example VIII). With the E174S/F176Y hGH mutant as the background starting hormone, residues were mutated that surrounded positions 174 and 176 on the hydrophiNc face of helix 4 (R167, D171, T175 and 1179) .
Cassette mutagenesis was carried out essentially as described [J. A. Wells. M.
Vasser, D. B. Powers, Gene 34, 315 (1985)). The helix 4b library, which mutated residues 167,171,175 and 179 within the E174S/F176Y background, was constructed using cassette mutagenesis that fully mutated four residues at a time (see Example VIII) and which utilized a mutated version of phGHam~3 into which uryque BstBl and BgAI
restriction sites had been inserted prevausly (Example VIII). into the BstEll-Bglll sites of the vector was inserted a cassette made from the complementary oligonudeotides 5'-pG TTA CTC TAC TGC
TTC NNS AAG GAC ATG
NNS AAG GTC AGC NNS TAC CTG CGC NNS GTG CAG TGC A-3' and 5'-pGA TCT GCA CTG
CAC SNN
GCG CAG GTA SNN GCT GAC CTT SNN CAT GTC CTT SNN GAA GCA GTA GA-3'. The BstEfl site was eliminated in the ligated cassette. From the helix 4b litxary,15 unselectsd doves were sequenced. Of these, none lacked a cassette insert, 20% were frame-shifted, and 7% had a non-silent mutatan.
Binding enrichments of hGH-phage from the libraries was carried out using hGHbp immobilized on oxirane-polyaaylamide beads (Sigma Chemical Co.) as described (Example VIII).
After 6 cycles of binding a reasonably dear consensus developed (Table XI). Interestingly, all positions tended to contain polar residues, notably Ser, Thr and Asn (XII).
The binding constants for some of these mutants of hGH to hGHbp was determined by expressing the free hormone variants in the non-suppresser E. cell strain 16C9, purifying the protein, and assaying by competitive displacement of labelled wtfiGH from hGHbp (see Example VIII). As indicated, the binding affinities of several helix-4b mutants for hGHbp were tighter than that of wt-hGH Table XIII).
Finally, we have begun to analyze the binding affinity of several of the tghter hGHbp binding mutants for their ability to bind to the hPRLbp. The E174S/F176Y mutant binds 200-fold weaker to the hPRLbp than hGH. The E174T/F176YIR178K and R167N/D171SIE174S/FI76YII179T mutants each bind >500-fold weaker to the hPRLbp than hGH. Thus, it is possible be use the produce new receptor selective mutants of hGH by phage display tectx~ology.
Of the 12 residues mutated in three hGH-phagemid libraries (Examples VIII, lX, X), 4 showed a strong, although not exclusive, conservation of the wild-type residues (K172, T175, F176, and R178). Not surprisingly, these were residues that when converted to Ata caused the largest disruptions (4- to 60-fold) in binding affinity to the hGHbp. There was a class of 4 other residues (F10, M14, D171, and 1179) where Ala substitutions caused weaker effects on binding (2- to 7-fold) and these positions exhibited little wild-type consensus. Finally the other 4 residues (H18, H21, 8167, and E174), that promote binding to he hPRLbp but not the hGHbp, did not exhibit any consensus for the wild-type hGH sequence by selection on hGHbp-beads. In fact iwo residues (E174 and H21 ), where Ala substitutions enhance binding affinity to the hGHbp by 2- to 4-fold [B. C. Cunningham, P.
Jhurani, P. Ng, J. A. Wells, Sdenoe 243,1330 ( 1989); B. C. Cunningham and J.
A Wells, Scenes 244,1081 (1989); B. C. Cunr>ingham, D. J. Henner, J. A. Wells, Saerx;e 247,1461 (1990);
B. C. Cunningham and J. A, Wells, Proc. Natl. Acad. Sa. USA 88, 3407 (1991 )]. Thus, the alanine-scanning mutagenesis data correlates reasonably well with the flexibility to substitute each position. In fact , the reduction in binding affinity caused by alanine substitutions [B. C. Cunningham, P. Jhurani, P. Ng, J. A. Wells, Science 243,1330 (1989); B. C. Cunningham and J. A. Wells, Sdenoe244,1081 (1989)], B. C. Cunningham, D. J. Henner, J. A.
Wells, Science247, 1461 (1990); 8.
C. Cunningham and J. A. Wells, Pros. Natf. Acad. Sa. USA 88, 3407 ( 1991 )] is a reasonable predictor of the percentage that the wild-type residue is found in the phagemid pool after 3-6 rounds of selection. The alanine-WO 92/09690 ~ ~ ~ ~ PCT/US91/09133 scanning information is useful for targeting side-chains that modulate binding, and the phage selection is appropriate for optimizing them and defining the flexibility of each site (and/or combinations of sites) for substitution. The comt~ir~tion of scanr~rg mutational methods [B. C.
Cunningham, P. Jhurani, P. Ng, J. A. Wells, Science ?A3,1330 (1989); B. C. Cunningham and J. A Wells, Saenc~e ?A4,1081 ( 1989)] and phage display is a powerful approach to designing reoepta-ligand interfaces and sdrdying molecular evolution in vitro.
In cases where combined mutatans in hGH have additive effects on binding affinity bo receptor, mutations learned through hormone-phagemid enrichment to improve bindirg can be combined by simple cutting and ligation of resfiction fragments or mutagenesis to yield cumulatively optimized mutants of hGH.
On the other hand, mutations in one region of hGH which optimize receptor binding may be stn~cturally or functionally compatible witty mutations in an overlapping a another region of the molecule. In these cases, hormone phagemid enrichment can be cartied out by one of several variatans on the iterdtiHe emid~ment approach (t ) random DNA litxaries can be generated in each of two (or perhaps more) regions of the molecule by cassette or another mutagenesis method. Thereafter, a combined library can be created by ligation of restriction fragments from the two ONA libraries; (2) an hGH variant, optimized for binding by mutation in one region of the molecule, can be randomly mutated in a second region of the molecule as in the helix-4b library example; (3) two or more random libraries can be y selected for improved binding by hormone-phagemid enrichment; after this 'roughing-in' of the optimized binding site, the still-partially-diverse libraries can be recombined by ligation of restriction fragments Go generate a single library, partially diverse in iwo or more regions of the molecules, which in tum can be further selected for optimized binding using hormone-phagemid enrichment.
2Q9~~'a~
Table XI.
AAumnt pt~erNds d hGH sHecbed from helix 4b library after 4 and 6 cyGes of enrichment Selection of hGH helix 4b mutants (randomly mutated at residues 167, 171,175,179), each containing the E174SIF176Y
double mutant, by binding to hGHbp-beads and eluting with hGH (0.4 mA~ buffer followed by glyane (0.2 M, pH 2) buffer.
One mutant (+) contained the spurious mutation R178H.
8167 Di71 T175 1179 4 Cydes N S T T
K S T T
S N T T
D S T T
D S T T+
D S A T
D S A N
T D T T
N D T N
A N T N
A S T T
6 CyGes N S T T (2) N N T T
D S S T
E S T I
K S T L
Cor~r~s:
N S T T
D N
WO 92/09690 ~ ~ j1 ;~ ~ ~ ~ PGT/US91/09133 Tale )01 Cornell~s ~puerroes from the >teleaed library.
Observed frequency is traction of aA cbnes sequenced with the indicated amino aad. The nominal frequerxy is calculated on the basis of NNS 32 colon degeneracy. The maximal enrichment factor varies from 11 to 16 to 32 5 depending upon the raminal frequency value for a given residue. Values of [Kd(Ala mut)IKd(wt hGH)] for single alanine mutations were taken from refs. below; for position 175 we oNy have a value br the T175S mutant [B. C.
Cunningham, P. Jtxuani, P. Ng, J. A. Wells, Saenoe 243,1330 (1989); B. C.
Cumingham and J. A. Wells, Saence 244, 1081 (1989); B. C. Cunrungham, D. J. Henner, J. A. Wells, Saenoe 247,1461 (1990); B. C. Cunningfam and J. A Wells, Proc. Nail. Acad Sci. USA88, 3407 (1991).).
Wild type Selected residue Kd(~a mut) residue observed raminal Enrichment Kd(wt hGH) 8167 0.75 N 0.35 0.031 11 D 0.24 0.031 8 K 0.12 0.031 4 A 0.12 0.062 2 D171 7.1 S 0.76 0.093 8 N 0.18 0.031 6 2 0 D 0.12 0.031 ' 4 T175 3.5 T 0.88 0.062 14 A 0.12 0.031 4 1179 2.7 T 0.71 0.062 11 N 0.18 0.031 6 Table XIII
t3Ndirrg of purified trGH mutar>m to hGHbp.
Competition binding experiments were performed using [1251]hGH (wild-type), hGHbp (containing the extraceNular receptor domain, residues 1-238), and Mab263 (11). The number P
indicates the fractional oaxxrence of each mutant among aU the doves sequenced after one or more rods of selection. Note that the helix 4b mutations (") are in the background of hGH(E174SIF176Y). In the list of helix 4b mutants" the E174SIF176Y mutant ('), with wt residues at 167,171,175, 179, is shown in bold.
Kd(Ala m~) SequerxePosition P Kd(n d(w~ t hGH) N S T T 0.18 0.04 t 0.02 0.12 E S T I 0.06 0.04 0.02 0.12 K S T L 0.06 0.05 0.03 0.16 N N T T 0.06 0.06 0.03 0.17 R D T I 0 0.06 0.01 (0.18) N S T Q 0.06 0.26 0.11 0.77 WO 92/09690 r' PCT/US91/09133 2~~~~~3~~
Assembly d F~ ~Aolea~le on tie Pld Sur<aoe Ptasmid pDH 188 captains the DNA encoding the F~ portion of a humanized IgG
antibody, called 4D5, that recognizes the HER-2 receptor. This plasmid is contained in E. coN strain SR 101, and has been deposited with the ATCC in RodcviNe, MD.
Briefly, the plasmid was prepared as follows: the starting plasmid was pS0132, oonta~ing the alkaline phosphatase promobar as described above. The DNA encoding human growth hormone was exased and, after a series of manipulations to make the ends of the plasmid compatible for ligatbn, the DNA encoding 4D5 was inserted. The 4D5 DNA contains two genes. The first gene encodes the variable and constant regions of the light chap, and contains at its 5' end the DNA erxxxJing the st II signal sequence.
The second gene cor>tains four portions: first, at its 5' end is the DNA erxodMg the st II signal sequence.
This is followed by the DNA erxoding the variable domain of the heavy chain, which is folbwed by the DNA encoding the first domain of the heavy chain constant region, which in turn is iolbwed by the DNA encoding the M13 gene III. The salient features of this construct are shown in Fgure 10. The sequence of the DNA erxxding 4D5 is shown in Fgure 11.
Both polyethylene glycol (PEG) and electroporation were used to transform plasmids into SRlOt cells.
(PEG competent cells were prepared and transformed according to the method of Chung and Miller (Nucleic Acids Res.16:3580 [1988]). Cells that were competent for electroporatbn were prepared, and subsequently transformed via electroporation according to the method of Zabarovsky and Winberg (Nucleic Acids Res.18:5912 [1990]). After placng the cells in 1 ml of the SOC media (described in Sambrook et al., supra), they were grown for 1 hour at 37°C with shaking. At this time, the concentration of the cells was determined using light scattering at ODSpO. A titered K07 phage stock was added bo achieve an multiplicity of infection (M01) of 100, and the phage were albwed to adhere to the cells for 20 minutes at room temperature.
This mixture was then diluted into 25 mls of 2n broth (described in Sambrook et al., supra) and incubated with shaking at 37°C overnight. The next day, cells were pelleted by centrifugation at 5000 x g for 10 minutes, the supernatant was collected, and the phage partices were precipitated with 0.5 M NaCI and 4% PEG (final corxentration) at room temperature for 10 minutes. Phage partices were pelleted by centrifugatbn at 10,000 x g for 10 minutes, resuspended in 1 ml of TEN
(10 mM Tris, pH 7.6,1 mM EDTA, and 150 mM NaCI), and stored at 4°C.
Aliquots of 0.5 ml from a solution of 0.1 mg/ml of the extra~etlutar domain of the HER-2 antigen (ECD) or a solution of 0.5 mg/ml of BSA (control antigen) in 0.1 M sodium bicarbonate, pH 8.5 were used to coat one well of a Falcon 12 well tissue culture plate. Once the solution was applied to the wells, the plates were incubated at 4°C on a rocking plattortn overnight. The plates were then blocked by removing the initial solution, applying 0.5 ml of blocking buffer (30 mg/ml BSA in 0.1 M sodium bicarbonate), and incubating at room temperature for one hour.
Finally, the blocking buffer was removed, 1 ml of buffer A (PBS, 0.5% BSA, and 0.05% Tween-20) was added, and the plates were stored up to 10 days at 4°C before being used for phage selection.
a~
Approximately 109 phage particles were mixed with a 100-fold excess of K07 helper pfrage and 1 ml of buffer A . This mixhxe was divided irno two 05 ml aliquots; one of which was applied to ECD coated wells, and the other was applied b BSA coated weus. The plates were ina~batad at room temperature while shaking for one to ttxee hours, and were then washed three times over a period of 30 mirurtes wish 1 ml aliquots of buffer A.
Elution of the phage from the plates was done at room temperature by one of two methods: t ) an initial overnight incubation of 0.025 mglml purified Mu4D5 antibody (murine) folbwed by a 30 minute irxubation with 0.4 ml of the add elution buffer (0.2 M glydne, pH 2.1, 0.5% BSA, and 0.05% Tween-20), or 2) an incubation with the acid elution tx~ffer alone. Eluates were then neutralized with 1 M Tris vase, and a 0.5 ml aliquot of TEN was added.
These samples were then propagated, titered, and shred at 4°C.
Alquots of eluted phage were added to 0.4 ml of 2YT broth and mixed with approximately 108 mid-log phase male E. cbli strain SR101. Phage were allowed b adhere to the cells for 20 minutes at room temperature and then added to 5 ml of 2YT broth that contained 50 R.giml of carbenidllin and 5 ~g/ml of tetracycline. These cells were grown at 37°C for 4 to 8 hours until they reached mid-log phase. The OD6pp was determined, and the cells were superinfected with K07 helper phage for phage production. Orxe phage particles were obtained, they were titered in order to determine the number of colony forming urNts (cfu).
This was done by taking aliquots of serial dilutions of a given phage stock, allowing Ihem to infect mid-log phase SRt 01, and plating on LB plates oontaimg 50 uglml c~rbeniciuin.
2 0 ~ p8fllZd, The affinity of h4D5 Fab fragments and Fab phage for the ECD antigen was determined using a competitive receptor Minding RIA (Burt, D. R., Receptor Bending in Dnrg Research. 0'Brien, R.A. (Ed.). pp. 3-29, Dekker, New York [1986)). The ECD antigen was labeled with 125-Ipd;ne using the sequential c~loramine-T
method (De Larco, J. E. et al., J. Ceff. PhysioJ.109:143-152 [1981]) which produced a radioactive tracer with a speafic activity of l4~Cilf,ig and incorporation of 0.47 moles of Iodine per mole of receptor. A series of 0.2 ml solutions containing 0.5 ng (by ELISA) of F~ or F~ phage, 50 nCi of 1251 ECD
tracer, and a range of unlabeled ECD amounts (6.4 ng to 3277ng) were prepared and incx~bated at room temperature overnight. The labeled ECD-F~ or ECD-FaM phage complex was separated from the unbound labeled antigen by forming an aggregate complex induced by the addition of an anti-human IgG (Fitzgerald 40-GH23) and 6°~ PEG 8000. The complex was pelleted by centrifugation (15,000 x g for 20 minutes) and the amount of labeled ECD (in cpm) was determined by a gamma counter. The dissoaation constant (Kd) was cala~lated by employirg a modified version of the program LIGAND (Munson, P. and Rothbard, D., Anal. &ochem.107~20-239 [1980)) which utilizes Scatchard analysis (Scatchard, G.,Ann. N.Y. Acad. Sci. 51:66072 (1949]). The Kd values are shown in Figure 13.
Murine 4D5 antibody was labeled with 125-l to a spedfic activity of 40-50 ~Cilpg using the lodogen procedure. Solutions containing a constant amount of labeled antibody and increasing amounts of unlabeled variant Fab were prepared and added to near confluent cultures of SK-BR-3 cells grown in 96-well microtiter dishes (final concentration of labeled antibody was 0.1 nM). After an overnight incubation at 4°C, the supernatant was removed, the cells were washed and the cell assodated radioactivity was determined in a gamma counter. Kd wakres were determined by analyzing ltte data usirta a motifi9d version of the program t.IGAND (MunsorL P. end Rothbaro, D., supra?
This depOSit of pldsmid pDHt 89 ATCC no. 68683 was made und9r the provisions of tkte St~dapest Treaty or1 the International Recognition of the Deposit of Micraorgsnisms for the Purpose of 5 patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable Culture for 30 ye8rs from the date of deposit. The organisms will be made available by ATCC
under the terms of the Budapest Treaty, and subject t0 an agreement between Genentech, Inc. End AT~~, which assures permanent and unrestricted availability of the progeny of the cultures to the public upon issuance of a f $tent On the basis of the application, or the patent appllGation is refused, or i5 abandoned and no longer subject to reinstatement, or is withdrawn, whichever oomes first, and assures Q availability of the progeny t0 One determined by the Commissioner of Pntetlt5 to be entitled thereto according to Section 109 of the Patent l=lutes.
The assignee of the present application has agreed that If the cultures on deposit sttoutd d'le or be Iosi or destroyed when cultivated under suitable t>onditiats, they wiN be promptly replaced on rtotificatan wi>rt a viable 15 specimen of the same a.~ture. Availability of the deG4sibed cultures is rtot to be construed as a license to practice the invention in contravention of the rights granted under tile authority of any government in accordance with its patent laws.
The fxegdrtg written spedt'~abwt is considered to be suttident to enable one skilled in the art to practice the invention. The present ~ven>ion is not to be limited in scope by ttte cultures deposited, since the 20 deposited embodiments are Intended as separate illustrations of certain aspects at the invention and any a~tures that are ftatctionally equivalent are within fhe sa~pe of this irnrention. The deposit of material herein does not constitute an admission that the wriaen description hlereln contained is inadequate to enable the pracBce of any aspect of the invention, including the best mode thereof, nor is it to be CansUtAad as limiting the soop2 of tt"to dairns to the specific illustrations that it represents. Indeed, Parlous modifications of the irnention in addition to 25 those shown 2ind descrit~ed herein wiU become apparent to those skilled in tile an from the foregoing desaipCioh and fall within me scope of the appended Balms.
whaa ttte irrrer~tion has neoessaray been desaitied in coftjurtction wilt prelerted embodiments, one of ordinary skin, after reading the toregaing speafication, w~l be able to etrect various changes, substitutions of equivalents, and alterations de Ute sut~ed rnatter set forth herein, widtout departing lrom the spirit and scone 34 thereof. Hence, the invention can be practiced in ways outer than those speafica~y desaibed herein. ft is therefore intended that the protetdon granted by ~et4ars Patent hereon be mired artly by the appended claims and equivalents thereof.
WO 92/09690 '~ ~ ~ f; ~' j ~ PCT/US91 /09133 EXAMPLE Xll SELECTION OF hGH VAi'~ANTS FROM COMBINATIONS OF HELIX-1 AND HEUX-4 HORMONE-PHAGE
VARIANTS
According to additivity principles ~J. A. Wells, Biochemistry29, 8509 (1990)j, mutations in different parts of a protein, if they are not mutually interacting, are expected to combine to produce additive changes in the free energy of Minding to another molecule (changes are additive in terms of AOGb;~ing, or multiplicative in terms of Kd = exp[-eGIRTj ). Thus a mutation produang a 2-fold increase in binding affinity, when comtHned with a second mutation causing a 3-fold increase, would be predicted to yield a double mutant with a 6-fold increased affinity over the starting variant.
To test whether multiple mutations obtained firom hGH-phage selections would produce cumulatively favorable effects on hGHbp (hGH-binding protein; the extracellular domain of the hGH receptor) Minding, we combined mutations found in the three tightest-binding variants of hGH from the helix-1 library (Example IX:
F10AIM14WIH18DlH21N, F10H/M14G/H18N/H21N, and F10FIM14S/H18F/H21L) with those found in the three tightest binding variants found in the helix-4b library (Example X:
R167N/D171SlT175II179T, R167EID171S/T175/I179, and R167N/D171NIT17511179T).
hGH-phagemid double-stranded DNA (dsDNA) from each of the one-helix variants was isolated and digested with the restriction enzymes EcoRl and BstXl. The large fragment from each helix-4b variant was then isolated and ligated with the small fragment from each helix-1 variant to yield the r~ew two-helix variants shown in Table XIII. All of these variants also contained the mutations E174S/F176Y
obtained in earlier hGH-phage binding selections (see Example X for details).
Although additivity prindples appear to hold for a number of comt~ir~ations of mutations, some comt~inations (e.g. E174S with F176Y) are Dearly non-additive (see examples VIII and X). In order to identify with certainty the tightest binding variant with, for example, 4 mutations in helix-1 ~ 4 mutations in helix-4, one would ideally mutate all 8 residues at once and then sort the pool for the globally tightest binding variant.
However, such a pool would consist of 1.1 x 1012 DNA sequences (utilizing NNS
colon degeneracy) encoding 2.6 x 1010 different polypeptides. Obtaining a random phagemid library large enough to assure representation of all variants (pefiaps 1013 transfonnants) is not practical using current transformation technology.
We have addressed this difficulty first by utilizing successive rounds of mutagenesis, taking the tightest Minding variant from one library, then mutating other residues to further improve binding (Example X).
In a second method, we have utilized the principle of additivity to comt~ir~e the best mutations from two independently sorted libraries to create multiple mutants with improved binding (described above). Here, we further searched through the possible comtHnations of mutations at positions 10,14,18, 21,167,171,175, and 179 in hGH, by creating comt~inatorial libraries of random or partially-random mutants. We constructed three different comt~inatorial libraries of hGH-phagemids, using the pooled phagemids from the helix 1 library (independently sorted for 0, 2, or 4 cycles; Example IX) and the pool from the helix-4b library (independently sorted for 0, 2, or 4 cyGes; Example X) and sorted the combined variant pool for hGHbp binding. Since some amount of sequence diversity exists in each of these pools, the resulting combinatorial library can explore more sequence combinations than what we might constmct manually (e.g. Table XIII).
WO 92/09690 2 ~ ~ ~ ~ ~ ~ PCT/US91 /09133 hGH-phagemid double-stranded DNA (dsDNA) from each of the one-helix library pools (selected for 0, 2, or 4 rounds) was isolated and digested with the restriction enzymes Ac~cl and BstXl. The large fragment from each helix-1 variant pool was then isolated and ligated with the small fragment from each helix-4b vaunt pool to yield the three combinatorial libraries pH0707A (unselecbed helix 1 and helix 4b pools, as described in examples IX
5 and X), pH0707B (twice-selected helix-1 pool with twice-selected helix-4b pool), and pH0707C (4-times selected helix-1 pool with 4-times selected helix-4b pool). Duplicate ligations were also set up with less DNA and designated as pH0707D, pH0707E, and pH0707F, corresponding to the 0-,2-, and 4-round starting libraries respectively. All of these variant pools also contained the mutations E174SIF176Y obtained in earlier hGH-phage binding selectans (see Example X for details).
The ligation products pH0707A-F were processed and electro-transformed into XL1-Blue cells as described (Example VIII). Based on colony-forming units (CFU), the number of transformants obtained from each pool was as follows: 2.4x106 from pH0707A, 1.8x106 from pH0707B, 1.6x106 from pH0707C, 8x105 from pH0707D, 3x105 from pH0707E, and 4x105 from pH0707F. hGH-phagemid particles were prepared and selected for hGHbp-binding over 2 to 7 cycles as described in Example VIII.
In additan to sorting phagemid libraries for tight-binding protein variants, as measured by equilibrium binding affinity, it is of interest to sort for variants which are altered in either the on-rate (kon) or the off-rate (koff) of binding to a receptor or other molecule. From thermodynamics, these rates are related to the equilibrium dissodation constant, I(d = (koff/kon). We envision that certain variants of a particular protein have similar Kd's for binding while having very different kon's and ko ff's.
Conversely, d~anges in Kd trom one variant to another may be due to effects on kon, effects on ko ff, or both. The pharmacological properties of a protein may be dependent on Minding affinity or on kon or koff, depending on the detailed mechanism of action. Here, we sought to identify hGH variants with higher on-rates to investigate the effects of d~anges in kon. We envision that the selection could alternatively be weighted toward koff by increasing the binding time and increasing the wash time andlor concentration with cognate ligand (hGH).
From time-course analysis of wild-type hGH-phagemid Minding to immobilized hGHbp, it appears that, of tt~e total hGH-phagemid particles that can be eluted in the final pH 2 wash (see Example VIII for the complete Minding and elution protocol), less than 10% are bound affer 1 minute of incubation, while greater than 90% are bound affer 15 minutes of incubation.
For 'rapid-binding selection,' phagemid particles from the pH0707B pool (twice-selected for helices 1 and 4 independently) were incubated with immobilized hGHbp for only 1 minute, then washed six times with 1 mL of tHnding buffer; the hGH-wash step was omitted; and the remaining hGH-phagemid particles were eluted with a pH2 (0.2M glydne in binding buffer) wash. Enrichment of hGH-phagemid particles over non~iisplaying particles indicated that even with a short binding period and no cognate-ligand (hGH) d~allenge, hGH-phagemid binding selection sorts tight-Minding variants out of a randomized pool.
5, ~~ ~~3~
The binding constants for some of these mutants of hGH to hGHbp was determined by expressing the tree hormone variants in the non-suppressor E. colt strain 1609 or 3488, purifying the protein, and assaying by competitive displacement of labelled wt-hGH from hGHbp (see Example VIII) in a radio-immunoprecipitation assay.
In Table XIII -A below, all the variants have glutamate174 replaced by serine174 and pher~lalaninel7g replaced by tyrosine176 (E174S and F1176Y) plus the additional substitutions as indicated at hGH amino aad positions 10, 14,18, 21,167,171,175 and 179.
Table XIII-A
hGH
variaMS
from addpfon of helix-1 and helix~b mutaUons li H
li wild-type residue:F1Q e ~il,$ Jj21HlCtZ e I1Z~ 1128 ri x x nt X14 ~1Z1 Va H G N N N S T T
a In Table XIV below, hGH variants were selected from combinatorial libraries by the phagemid binding selection process. All hGH variants in Table XIV contain two background mutatans (E174SlF176Y). hGH-phagemid pools from the libraries pH0707A (Part A), pH0707B and pH0707E (Part B), or pH0707C (Part C) were sorted for 2 to 7 cycles for Minding to hGHbp. The number P indicates the fractional occurrence of each variant type among the set of Bones sequerxed from each pool.
WO PC'1'/US91/09133 ~~~~~~3 52 Table XIV
hGH variants from hOrllnor~e-pt~agemld binc9np selection Of comhlnalortal I~r~aries.
Hela Helix wild-type ~Q ~ J~$ ~ g~j residue:
Variant Part 4 cycles:
A :
0.60 H0714A.1 H G N N N S T N
0.40 H0714A.4 A N D A N N T N
' Part 8:
2 Cycles:
0.13 H0712B.1 F S F G H S T T
0.13 H0712B.2 H Q T S A D N S
0.13 H0712B.4 H G N N N A T T
0.13 H0712B.5 F S F L S D T T
0.13 H0712B.6 A S T N R D T I
0.13 H0712B.7 Q Y N N H S T T
0.13 H0712B.8 W G S S R D T I
0.13 H0712E.1 F L S S K N T V
0.13 H0712E.2 W N N S H S T T
0.13 H0712E.3 A N A S N S T T
0.13 H0712E.4 P S D N R D T I
0.13 H07t2E.5 H G N N N N T S
0.13 H0712E.6 F S T G R D T I
0.13 H0712E.7 M T S N Q S T T
0.13 H0712E.8 F S F L T S T S
4 cycles:
0.17 H0714B.1 A W D N R D T I
0.17 H0714B.2 A W D N H S T N
0.17 H0714B.3 M Q M N N S T T
0.17 H0714B.4 H Y D H R D T T
0.17 H0714B.5 L N S H R D T I
0.17 H0714B.6 L N S H T S T T
7cydes:
0.57 H0717B.1 A W D N N A T T
0.14 H0717B.2 F S T G R D T I
0.14 H07178.6 A W D N R D T I
0.14 H0717B.7 I Q E H N S T T
0.50 H0717E.1 F S L A N S T V
Part C:
4 cycles:
0.67 H0714C.2 F S F L K D T T
' = also contained the mutations L15R, K168R.
In Table XV below, hGH variants were selected from combinatorial libraries by the phagemid binding selection process. All hGH variants in Table XV contain two background mutations (E174SIF176Y). The number 5 0 P is the fractional occurrence of a given variant among all Gones sequenced after 4 cycles of rapid-binding selection.
' Table XV
hGH variants from RAPID hGHbp bindklp selection d en hGH-phagernld comblnatortel IIbrJry Helot Heluc wild-type residue: ~Q ~g ~$ )~ g~ p~j~
Yaf~t 0.14 H07BF4.2 W G S S R D T I
0.57 H078F4.3 M A D N N S T T
0.14 H07BF4.6 A W D N S S V T $
0.14 H078F4.7 H Q T S R D T I
$ = also contained the mutatan Y176F (wild-type hGH also contains F176j.
In table XVI below, binding constants were measured by competitive displacement of 1251-labelled hormone H06508D or labelled hGH using hGHbp (1-238) and either Mab5 or Mab263.
The variant H06508D
appears hind more than 30-fold tighter than wild-type hGH.
~~~~~J~ 5a Table XVI
EquIAbrium blndinp oo~ants of selected hGH wadaMs.
hGH Kd,(vanantl Kd,(variantl Variant Kd(H0650BD) Kd(hGH) Kd (per hGH 3 2 -1- 340 t H0650BD -1- 0.031 tOt 3 H0650BF 1.5 0.045 15 t 5 H07148.6 3.4 0.099 34 t 19 H0712B.7 7.4 0.22 74 t 30 H0712E.2 16 0.48 60 f 70 EXAMPLE XIII
Selectirve enrichment of hGH-phage contalnlng a pr~tesse substrate sequence versus ron-substrate phage As described in Example I, the plasmid pS0132 contains the gene for hGH fused to the residue Pro198 of the gene III protein with the insertion of an extra glyane residue. This plasmid may be used to produce hGH-phage particles in which the hGH~ene III fusion product is displayed monovalently on the phage surtace (Example IV). The fusion protein comprises the entire hGH protein fused to the carboxy terminal domain of gene III via a flexible linker sequerxe.
3 0 To investigate the feasibility of using phage display technology to select favourable substrate sequences for a given proteolytic enzyme, a genetically engineered variant of subtilisin BPN' was used. (Carter, P.
et al., Proteins: Structure, function and genetics 6:240-248 (1989)). This variant (hereafter referred to as A64SAL subtilisin) contains the following mutations: Ser24Cys, His64Ata, GIu156Ser, GIy169A1a and Tyr217Leu. Since this enzyme lacks the essential catalytic residue His64, its substrate speaficity is greatly restricted so that certain histidine-containing substrates are preferentially hyrdrolysed (Carter et al., Science 237:394-399 (1987)).
The sequence of the linker region in pS0132 was mutated to create a substrate sequence for A64SAL
subtilisin, using the oligonucleotide 5'-TTC-GGG-CCC-TTC-GCT-GCT-CAC-TAT-ACG-CGT-CAG-TCG-ACT-GAC-CTG-CCT-3'. This resulted in the introduction of the protein sequence Phe-Gly-Pro-Phe-Ala-Ala-5 His-Tyr-Thr-Arg-Gln-Ser-Thr-Asp in the linker region between hGH and the carboxy terminal domain of gene III, where the first Phe residue in the above sequence is Phe191 of hGH. The sequence Ala-Ala-His-Tyr-Thr-Agr-Gln is known to be a good substrate for A64SAL subtilisin (Carter et al (1989), supra). The resulting plasmid was designated pS0640.
Phagemid particles derived from pS0132 and pS0640 were constructed as described in Example I. In initial experiments, a 10W aliquot of each phage pool was separately mixed with 30p1 of oxirane beads (prepared as described in Example II) in 100W of buffer comprising 20mM Tris-HCI pH 8.6 and 2.5M NaCI. The binding and washing steps were performed as described in example VII. The beads were then resuspended in 400p1 of the same buffer, with or without 50nM of A64SAL subtilisin. Following incubation for 10 minutes, the supernatants were collected and the phage titres (cfu) measured. Table XVII shows that approximately 10 times more substrate-containing phagemid particles (pS0640) were eluted in the presence of enzyme than in the absence of enzyme, or than in the case of the non-substrate phagemids (pS0132) in the presence or absence of enzyme. Increasing the enzyme, phagemid or bead concentrations did not improve this ratio.
In an attempt to decrease the non-speafic elution of immobilised phagemids, a tight-bir>ding variant of hGH was introduced in place of the wild-type hGH gene in pS0132 and pS0640. The hGH variant used was as described in example XI (pH0650bd) and contains the mutations PhelOAla, Mett4Trp, Hisl8Asp, His2lAsn, Arg167Asn, Asp171Ser, GIu174Ser, Phe176Tyr and IIe179Thr. This resulted in the construction of two new phagemids: pDM0390 (containing tight-Minding hGH and no substrate sequence) and pDM0411 (containing tight-binding hGH and the substrate sequence Ala-Ala-His-Tyr-Thr-Agr-Gln). The binding washing and elution protocol was also changed as follows:
(i) Binding: COSTAR 12-well tissue culture plates were coated for 16 hours with 0.5mUwell 2ug/ml hGHbp in sodium carbonate buffer pH 10Ø The plates were then incubated with lmllwell of blocking buffer (phosphate buffered saline (PBS) containing 0.1%w/v bovine serum albumen) for 2 hours and washed in an assay buffer containing lOmM Tris-HCI pH 7.5, 1 mM EDTA and 1 OOmM NaCI. Phagemids were again prepared as described in Example I: the phage pool was diluted 1:4 in the above assay buffer and 0.5m1 of phage incubated per well for 2 hours.
WO 92/09690 ~. ~ PCT/US91/09133 ~~~~~~3 (ii) Washing: The plates were washed thoroughly with PBS + 0.05% Tween 20 and incubated for 30 minuted with 1 ml of this wash buffer. This washing step was repeated three times.
(~i) Eution: The plates were incubated for 10 minutes in an elution buffer consisting of 20mM Tris-HCI pH 8.6 + 100mM NaCI, then the phage were eluted with 0.5m1 of the above buffer with or without 500nM of A64SAL subtilisin.
Table XVII shows that there was a dramatic increase in the ratio of specifically eluted substrate-phagemid particles compared to the method previously described for pS0640 and pS0132. ft is likely that this is due to the fact that the tight-binding hGH
mutant has a significantly slower off-rate for binding to hGH binding protein compared to wild-type hGH.
Table XVII
Specific elution of substrate-phagemlds by A64SAL subtllisln Colony forming units (cfu) were estimated by plating out 10.1 of 10-fold dilutions of phage on l0pl spots of XL-1 blue cells, on LB agar plates containing 50pg/ml carbenicillinl (i) wld-type hGH gene: binding to hGHbp-oxirane beads pS0640 (substrate) 9x106cfu/l0wl 1.5x106cfu/l0pl pS0132 (non-substrate) 6x105cfu/l0pl 3x105cfu/l0pl (ii) pH0650bd mutant hGH gene: Minding to hGHbp-coated plates pDM0411 (substrate) 1.7x105cfu/l0pl 2x103cfu/l0pl pDM0390 (non-substrate) 2x103cfu/l0pl tx103cfu/l0pl Example XIV
Identification of preferred substrates for A64SAL subtllisln using selective enrichment of a library of substrate sequences.
We sought to employ the selective enrichment procedure described in Example XIII to identify good substrate sequences from a library of random substrate sequences.
We designed a vector suitable for introduction of randomised substrate cassettes. and subsequent expression of a library of substrate sequences. The starting point was the vector pS0643, described in Example VIII. Site-directed mutagenesis was carried out using the oligonucleotide 5'-AGC-TGT-GGC-TTC-GGG-CCC-GCC~CC-GCG-TCG-ACT-GGC-GGT-GGC-TCT-3', which introduces ~ (GGGCCC) and ~,[ (GTCGAC) restriction sites between hGH
and Gene III. This new construct was designated pDM0253 (The actual sequence of pDM0253 is 5'-AGC-TGT-GGC-TTC-GGG-CCC-GCC-ACC-GCG-TCG-ACT-GGC-GGT-GGC-TCT-3', where WO 92/09690 ~~ ~? ~ ~, PCT/US91 /09133 57 ~~~5~~1~5 the underlined base substitution is due to a spurious error in the mutagenic oligonucleotide).
In addition, the tight-binding hGH variant described in example was introduced by exchanging a fragment from pDM0411 (example XII I) The resurting library vector was designated pDM0454.
To introduce a library cassette, pDM0454 was digested with Apal folbwed by Sall, then precipitated with 13% PEG 8000+ lOmM MgCl2, washed twice in 70% ethanol and resuspended This effidently precipitates the vector but leaves the small Apa-Sal fragment in solution (Paithankar, K. R. and Prasad, K. S. N., Nuceic Acids Research 19:1346). The product was run on a 1% agarose gel and the Apal-Sall digested vector excised, purified using a Bandprep kit (Pharmacia) and resuspended for Ngation with the mutagenic cassette.
The cassette to be inserted contained a DNA sequence similar to that in the linker region of pS0640 and pDM0411, but with the colons for the histidine and tyrosine residues in the substrate sequence replaced by randomised colons. We chose to substitute NNS
(N=G/A/T/C; S=G/C) at each of the randomised positions as described in example VIII. The oligonucleotides used in the mutagenic cassettes were: 5'-C-TTC-GCT-GCT-NNS-NNS-ACC-CGG-CAA-3' (coding strand) and 5'-T-CGA-TTG-CCG-GGT-SNN-SNN-AGC-AGC-GAA-GGG-CC-3' (non-coding strand). This cassette also destroys the Sall site, so that digestion with Sall may be used to reduce the vector background. The oGgonucleotides were not phosphorylated before insertion into the Apa-Sal cassette site, as it was feared that subsequent oGgomerisation of a small population of the cassettes may lead to spurious results with multiple cassette inserts. Following annealing and ligation, the reaction products were phenol:chloroform extracted, ethanol precipitated and resuspended in water.
Initially, no digestion with Sall to reduce the background vector was pertormed.
Approximately 200ng was electroporated into XL-1 blue cells and a phagemid library was prepared as described in example VIII.
Selection of hlyhly cleavable substrates from the snb_c_trate Ilbrarv The selection procedure used was identical to that described for pDM0411 and pDM0390 in example XIII. After each round of selection, the eluted phage were propagated by transducing a fresh culture of Xl_-1 blue cells and propagating a new phagemid library as described for hGH-phage in example VIII. The progress of the selection procedure was monitored by measuring eluted phage titres and by sequencing individual clones after each round of selection.
Table A shows the successive phage titres for elution in the presence and absence of enzyme after 1, 2 and 3 rounds of selection.
2~~~~33 58 Clearly, the ratio of specifically eluted phage: non-specifically eluted phage (ie phage eluted with enzyme:phage eluted without enzyme) increases dramatically from round 1 to round 3, suggesting that the population of good substrates is increasing with each round of selection.
Sequencing of 10 isolates from the starting library showed them all to consist of the wild-type pDM0464 sequence. This is attributed to the fact that after digestion with Apal, the Sall site is very close to the end of the DNA fragment, thus leading to bw effiaency of digestion. Nevertheless, there are only 400 possible sequences in the library, so this population should still be well represented.
Tables B1 and B2 shows the sequences of isolates obtained after round 2 and round 3 of selection. Affer 2 rounds of selection, there is clearly a high incidence of histidine residues. This is exactly what is expelled: as described in example XIII, A64SAl_ subtilisin requires a histidine residue in the substrate as it employs a substrate-assisted catalytic mechanism. After 3 rounds of selection, each of the 10 Gones sequenced has a histidine in the randomised cassette. Note, however, that 2 of the sequences are of pDM0411, which was not present in the starting library and is therefore a contaminant.
WO 92/09690 ~ ~ ~ ~ ~ ~ ~ PCT/US91 Table A
Titration of Initialphape pools and phage from 3 rounds of eluted selective enrichment Colony forming units (cfu) were estimated by plating out 101,1.1 of 10-fold dilutions of phage on 101~J spots of XL-1 aining 501ig/ml carbenicillin blue cells, on LB
agar plates cont Starting library: 3x1012 cfu/ml LIBRARY: +500nM A64SAL : 4x103 cfu/101~I
no enzyme : 3x103 cfu/101~1 pDM0411: +500nM A64SAL : 2x106 cfu/10111 (control) no enzyme : 8x103 cfu/101~I
Round 1 library: 7x1012 cfu/ml LIBRARY: +500nM A64SAL : 3x104 cfu/l0wl no enzyme : 6x103 cfu/101~1 pDM0411: +500nM A64SAL : 3x106 cfu110111 (control) no enzyme : 1.6x104 cfu/101~I
Round 2 library: 7x1011 cfu/ml LIBRARY: +500nM A64SAL : 1x105 cfu/10111 no enzyme : <103 cfu/l0wl pDM0411: +500nM A64SAL : 5x106 cfu/101~I
(control) no enzyme : 3x104 cfu/101~1 so Table B1 Sequences of eluted phage after 2 rounds of selective enrichment.
All protein sequences should be of the form AA"TRO, where ' represents a randomised colon. In the table below, the randomised colons and amino acids are underlined and in bold.
After round 2:
A A $ Y T R Q
... GCT GCT~~~ ACC CGGCAA ... 2 TAC
A A $ j~j T R Q
... GCT GCT ACC CGGCAA ... 1 A A ji $ T R Q
... GCT GCT~ ACC CGGCAA ... 1 A A Z $ T R Q
... GCT GCT~ ACC CGGCAA ... 1 A A $ T R Q
.. . GCT~~ CGG CAA... 1 #
GCT
A A ~ $ T R Q
... GCT GCT~~~ ACC CGGCAA 1 ##
CAC
... wild-type 3 pDM0454 # - spurious deletion of 1 colon within the cassette ## - ambiguous sequence ~~~~~~3 Table B2 Seauences of eluted ohaqe after 3 rounds of selective enrichment.
All protein represents sequences should a be of the form AA"TRQ, where ' randomised colon.the table below, the randomised In colons and amino acids are underlined and in bold.
After round 3:
nce o-of Seau occurrences A A $ ~ T R Q
... GCT GCT ACG CGT CAG ... 2 ~
A A ji $ T R Q
... GCT GCT CAC ACC CGG CAA ... 2 CTC
2O A A Q $ T R Q
... GCT GCT ACC CGG CAA ... 1 ~
A A T $ T R Q
... GCT GCT ACC CGG CAA ... 1 A A $ ,~, R Q
... GCT GCT TCC CGG CAA ... 1 CAC
A A $ $ T R Q
... GCT GCT ACC CGG CAA 1 ~
A A $ $ R Q
... GCT GCT TTC CGG CAA ... 1 CAC
A A $ T R Q
... GCT GCT CGG CAA ... 1 # - contaminating sequence from pDM0411 ## - contains "illegal" colon CAT - T should the not appear in the 3rd position of a colon.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Genentech, Inc.
Garrard, Lisa J.
Henner, Dennis J.
Bass, Steven Greene, Ronald Lowman, Henry B.
Wells, James A.
Matthews, David J.
(ii) TITLE OF INVENTION: Enrichment Method For Variant Proteins With Altered Binding Properties (iii) NUMBER OF SEQUENCES: 27 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Genentech, Inc.
(B) STREET: 460 Point San Bruno Blvd (C) CITY: South San Francisco (D) STATE: California (E) COUNTRY: USA
(F) ZIP: 94080 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: patin (Genentech) (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE: 03-DEC-91 (C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/743614 (B) APPLICATION DATE: 09-Aug-91 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/715300 (B) APPLICATION DATE: 14-June-91 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/683400 (B) APPLICATION DATE: 10-Apr-91 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/621667 (B) APPLICATION DATE: 03-Dec-1990 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Benson, Robert H.
(B) REGISTRATION NUMBER: 30,446 (C) REFERENCE/DOCKET NUMBER: 645P4 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 415/266-1489 (B) TELEFAX: 415/952-9881 (C) TELEX: 910/371-7168 (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: l:
(2) INFORMATION FOR SEQ ID N0:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:2:
(2) INFORMATION FOR SEQ ID N0:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:3:
(2) INFORMATION FOR SEQ ID N0:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:4:
(2) INFORMATION FOR SEQ ID N0:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:5:
(2) INFORMATION FOR SEQ ID N0:6:
(i) SEQUENCE CHARACTERISTICS:
~a~5~~~
(A) LENGTH: 23 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:6:
(2) INFORMATION FOR SEQ ID N0:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:7:
(2) INFORMATION FOR SEQ ID N0:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 63 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:8:
(2) INFORMATION FOR SEQ ID N0:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:9:
(2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
~~'~~~~3 (2) INFORMATION FOR SEQ ID NO:11:
5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
(2) INFORMATION FOR SEQ ID N0:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:12:
(2) INFORMATION FOR SEQ ID N0:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:13:
Gly Ser Cys Gly Phe Glu Ser Gly Gly Gly Ser Gly (2) INFORMATION FOR SEQ ID N0:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:14:
(2) INFORMATION FOR SEQ ID N0:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:15:
n N ~ eJ Ey 'L
(2) INFORMATION FOR SEQ ID N0:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:16:
(2) INFORMATION FOR SEQ ID N0:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 66 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:17:
(2) INFORMATION FOR SEQ ID N0:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 64 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:18:
(2) INFORMATION FOR SEQ ID N0:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:19:
(2) INFORMATION FOR SEQ ID N0:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:20:
(2) INFORMATION
FOR
SEQ
ID
N0:21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 66 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:21:
TCGAGGCTCN NSGACAACGC GNNSCTGCGT GCTNNSCGTC TTNNSCAGCT
(2) INFORMATION
FOR
SEQ
ID
N0:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 58 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:22:
GTGTCAAAGG CCAGCTGSNN AAGACGSNNA GCACGCAGSN NCGCGTTGTC
(2) INFORMATION
FOR
SEQ
ID
N0:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 65 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:23:
GTTACTCTAC TGCTTCNNSA AGGACATGNN SAAGGTCAGC NNSTACCTGC
(2) INFORMATION
FOR
SEQ
ID
N0:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 64 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear WO 92/09690 PC1'/US91/09133 209~~~~
(xi) SEQUENCE DESCRIPTION:SEQ ID
N0:24:
(2) INFORMATION FOR SEQ
ID N0:25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2178 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION:SEQ ID
N0:25:
~J ~
~~~
~
(2) INFORMATION
FOR
SEQ
ID
N0:26:
(i) SEQUENCE
CHARACTERISTICS:
(A) acids LENGTH:
amino 20 (B) amino TYPE: acid (D) linear TOPOLOGY:
(xi) SEQID
SEQUENCE N0:26:
DESCRIPTION:
25 Met LysLysAsn IleAlaPhe LeuLeuAla SerMetPhe ValPhe Ser IleAlaThr AsnAlaTyr AlaAspIle GlnMetThr GlnSer Pro SerSerLeu SerAlaSer ValGlyAsp ArgValThr IleThr Cys ArgAlaSer GlnAspVal AsnThrAla ValAlaTrp TyrGln Gln LysProGly LysAlaPro LysLeuLeu IleTyrSer AlaSer 40 Phe LeuTyrSer GlyValPro SerArgPhe SerGlySer ArgSer Gly ThrAspPhe ThrLeuThr IleSerSer LeuGlnPro GluAsp Phe AlaThrTyr TyrCysGln GlnHisTyr ThrThrPro ProThr Phe GlyGlnGly ThrLysVal GluIleLys ArgThrVal AlaAla Pro SerValPhe IlePhePro ProSerAsp GluGlnLeu LysSer 55 Gly ThrAlaSer ValValCys LeuLeuAsn AsnPheTyr ProArg Glu AlaLysVal GlnTrpLya ValAspAsn AlaLeuGln SerGly Asn SerGlnGlu SerValThr GluGlnAsp SerLyaAsp SerThr Tyr SerLeuSer SerThrLeu ThrLeuSer LysAlaAsp TyrGlu Lys HisLysVal TyrAlaCys GluValThr HisGlnGly LeuSer Ser Pro Val Thr Lys Ser Aen ArgGly GluCys Phe (2) INFORMATION FOR SEQ
ID N0:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 461 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION:SEQ ID
N0:27:
Met Lys Lys Asn Ile Ala Leu LeuAla SerMet PheVal Phe Phe Ser Ile Ala Thr Asn Ala Ala GluVal GlnLeu ValGlu Tyr Ser Gly Gly Gly Leu Val Gln Gly GlySer LeuArg LeuSer Pro Cys Ala Ala Ser Gly Phe Asn Lys AspThr TyrIle HisTrp Ile Val Arg Gln Ala Pro Gly Lys Leu GluTrp ValAla ArgIle Gly Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lye Gly Arg Phe Thr IleSerAla AspThrSer LysAsn ThrAlaTyr LeuGln Met Asn SerLeuArg AlaGluAsp ThrAla ValTyrTyr CysSer Arg Trp GlyGlyAsp GlyPheTyr AlaMet AspTyrTrp GlyGln Gly Thr LeuValThr ValSerSer AlaSer ThrLysGly ProSer Val Phe ProLeuAla ProSerSer LysSer ThrSerGly GlyThr Ala Ala LeuGlyCys LeuValLys AspTyr PheProGlu ProVal Thr Val SerTrpAsn SerGlyAla LeuThr SerGlyVal HisThr Phe Pro AlaValLeu GlnSerSer GlyLeu TyrSerLeu SerSer Val Val ThrValPro SerSerSer LeuGly ThrGlnThr TyrIle Cys Asn ValAsnHis LysProSer AsnThr LysValAsp LysLys Val Glu ProLysSer CysAspLys ThrHis ThrGlyPro PheVal Cys Glu TyrGlnGly GlnSerSer AspLeu ProGlnPro ProVal Asn Ala GlyGlyGly SerGlyGly GlySer GlyGlyGly SerGlu Gly GlyGly SerGlu GlyGlyGly SerGluGly GlyGlySer Glu Gly GlyGly SerGly GlyGlySer GlySerGly AspPheAsp Tyr Glu LysMet AlaAsn AlaAsnLys GlyAlaMet ThrGluAsn Ala Asp GluAsn AlaLeu GlnSerAsp AlaLysGly LysLeuAap Ser Val AlaThr AspTyr GlyAlaAla IleAspGly PheIleGly Asp Val SerGly LeuAla AsnGlyAsn GlyAlaThr GlyAspPhe Ala Gly SerAsn SerGln MetAlaGln ValGlyAsp GlyAspAsn Ser Pro LeuMet AsnAsn PheArgGln TyrLeuPro SerLeuPro Gln Ser ValGlu CyaArg ProPheVal PheSerAla GlyLysPro Tyr Glu PheSer IleAsp CysAspLys IleAsnLeu PheArgGly Val Phe AlaPhe LeuLeu TyrValAla ThrPheMet TyrValPhe Ser Thr PheAla AsnIle LeuArgAsn LysGluSer
wash), beads were suspended in Glycine buffer (Buffer A plus 0.2 ~Glycine, pH
2.0 with HCI), rotated t hour and pelleted. The supernatant ('Glyane elution'; ZOOR.L) was neutralized by adding 30 ml of 1 M Tris base and stored at 4o C.
5. PROPAGATION: Aliquots from the hGH elutions and from the Glyane elutions from each set of 15 beads under each set of conditions were used to infect separate cultures of log-phase XLt-Blue cells.
Transductions were carried out by mixing phage with 1 mL XLt-Blue cells, incubating 20 min. at 37oC, then adding K07 (moi= t00). Cultures (25 mL 2YT plus carbenicillin) were grown as described above and the next pool of phage was prepared as described above.
Phage binding, elution, and propagation were carried out in successive rounds, according b the cycle 20 described above. For example, ~e phage amplified from the hGH elution from hGHbp-beads were again selected on hGHbp-beads and eluted with hGH, then used to infect a new culture of XL1-Blue cells. Three to five rounds of selection and propagatan were carried out for each of fhe selection procedures described above.
From the hGH and Glyane elution steps of each cycle, an aliquot of phage was used to inoculate XLt-Btue 25 cells, which were plated on LB media containing carbenialGn and tetracyGine to obtain independent doves from each phage pool. Single-stranded DNA was prepared from isolated cobny and sequenced in the region of the mutagenic cassette. The results of DNA sequencing are summarized in terms of the deduced amino acid sequerx;es in Figures 5, 6, 7, and 8.
3 0 ~.i~B~,h~H,~
To determine the tHnding affinity of some of the selected hGH mutants for the hGHbp, we transformed DNA from sequenced clones into ~ strain 1609. As described above, this is a non-suppressor strain which terminates translation of protein after the final Phe-191 residue of hGH.
Single-stranded ONA was used for these transformations, but double-stranded DNA or even wtrole phage can be easily electroporated into a non-35 suppressor strain for expression of free hormone.
Mutants of hGH were prepared from osmotically shocked cells by ammonium sulfate precipitation as described for hGH (Olson et al., ~g 293, 408-41 t (1981)), and protein concentrations were measured by laser densitomoetry of Coomassie-stained SDS-polyacrylamide gel electrophoresis gels, using hGH as standard (Cunningham and Wells, 244, 1081-1085 (1989)).
The binding affinity of each mutant was determined by displacement of 1251 hGH
as described (Spencer et al., J. Biol. Chem. 263, 7862-7867 [1988] ; Fuh et al., J. Biol. Chem. 265, 3111-3115 [1990]), using an anti-receptor monoclonal antibody (Mab263).
The results for a numt~er of hGH mutants, selected by different pathways (Fig.
6) are shown in Table VII. Many of these mutants have a tghter binding affinity for hGHbp than wild-type hGH. The most improved mutant, KSYR, has a binding affinity 5.6 times greater than that of wed-type hGH. The weakest selected mutant, among those assayed was only about 10-fold lower in binding affinity than hGH.
Binding assays may be carried out for mutants selected for hPRlbp-binding.
Table VII.
Cotre bhdhg b tlGiibP
The selected pool in which each mutant was found is indicated as 1 G (first glyclne selection), 3G (third glycine selection), 3H (third hGH selection), 3' (third selection, not tlinding to hPRI_bp, but Minding to hGHbp).
The number of times e~h mutant ocLKrred among all sequerxed Bones is shown ().
Mutant Kd (nM) Kd(mut)/Kd(hGH) Pod KSYR (6) 0.06 + 0.01 0.18 1G,3G
RSFR 0.10 + 0.05 0.30 3G
RAYR 0.13 + 0.04 0.37 3' KTYK (2) 0.16 + 0.04 0.47 H,3G
RSYR (3) 0.20 + 0.07 0.58 ~ 1G,3H,3G
KAYR (3) 0.22 + 0.03 0.66 3G
RFFR (2) 0.26 + 0.05 0.76 3H
KQYR 0.33 + 0.03 1.0 3G
KEFR= wt (9) 0.34 + 0.05 1.0 3H,3G,3' RTYH 0.68 + 0.17 2.0 3H
QRYR 0.83 + 0.14 2.5 3' KKYK 1.1 +0.4 3.2 3' RSFS (2) 1.1 + 0.2 3.3 3G,' KSNR 3.1 + 0.4 9.2 3' At some residues, substitution of a particular amino acrd has essentially the same effect independent of surrounding residues. For example. substitution of F176Y in the background of 172Rl174S redtxes tHnding affinity by 2.0-fold (RSFR vs. RSYR). Similarly, in the background of 172KI174A the tHnding affinity of the F176Y mutant (KAYR) is 2.9-fold weaker than the corresponding 176F mutant (KAFR; Cunningham and Wells, 1989).
WO 92/09690 ~ ~ ~ ~ ~ ~ ~ PCT/US91 /09133 On the other hand, the binding constants determined for several selected mutants of hGH demonstrate ran~additive etfeds of some amino aad substitutions at residues 172,174,176, and 178. For example, in the background of 172KI176Y, the substitution E174S results in a mutant (KSYR) which binds hGHbp 3.7-fold tighter than the corresponding mutant containing E174A (KAYR). However, in the background of 172R/176Y, the effects of these E174 substitutions are reversed. Here, the E174A mutant (RAYR) binds 1.5-fold tighter than the E174S mutant (RSYR).
Such non~additive effects on binding for substitutions at proximal residues illustrate the utility of protein-phage binding selek~ion as a means of selecting optimized mutants from a library m~ndomized at several positions. ~ the absence of deta~ed swdural information, without such a selection process, many combinations of substitutions might be tried before finding the optimum mutant.
EXAMPLE IX
SELECTION OF hGH VARIANTS FROM A HELIX~1 RANDOM CASSETTE
LIBRARY OF HORMONE-PHAGE
Using the methods described in Example VIII, we targeted another region of hGH
involved in binding to the hGHbp andlor hPRLbp, helix 1 residues 10,14,18, 21, for random mutagenesis in the phGHam~3p vector (also known as pS0643; see Example VIII).
We chose to use the'amber' hGH-g3 construct (called phGHam~g3p) because it appears to make the target protein, hGH, more accessible fx binding. This is supported by data from comparative ELISA assays of monodonaJ antibody binding. Phage produced from both pS0132 (S. Bass, R.
Greene, J. A. Wells, Proteins 8, 309 (1990).) and phGHam-g3 were tested with three antibodies (Medix 2,1 B5.G2, and 5B7.C10) that are known to have binding detertninar>is near the carboxyl-terminus of hGH [B. C.
Cunningham, P. Jhurare, P. Ng, J. A. Wells, Saenee 243,1330 (1989); B. C. Cunningham and J. A. Wells, Silence 244,1081 (1989); L. Jin and J. Wells, unpublished results], and one antibody (Medix 1 ) that recognizes determinants in helices 1 and 3 ([B. C.
Cunningham, P. Jhurani, P. Ng, J. A. Wells, Saerx;e 243,1330 (1989); B. C.
Cunringham and J. A. Wells, Science 244,1081 (1989)]). Pt~agemid partides from phGHam-g3 reacted much more strongly with antibodies Medix 2, 185.62, and 5B7.C10 than did phagemid partiGes from pS0132. In particular, binding of pS0132 particles was reduced by >2000-fold for both Medix 2 and 5B7.C10 and reduced by >25-fold for 1B5.G2 compared to binding to Medix 1. On the other hand, binding of phGHam~3 phage was weaker by only about 1.5-fold,1.2-fold, and 2.3-fold for the Medix 2,1 B5.G2, and 587.C10 antibodies, respectively, compared with binding to MEDIX 1.
We mutated residues in helix 1 that were previously identified by alar>ine-scanning mutager~esis (B. C.
Cunr>rngham, P. Jhurani, P. Ng, J. A. Wells, Science 243,1330 (1989); B. C.
Cunr>ingham and J. A. Wells, Science 244, 1081 (1989),15, 16) to modulate the binding of the extracellular domains of the hGH andlor hPRL
receptors (called hGHbp and hPRLbp, respectively). Cassette mutagenesis was varied out essentially as described [J. A. Wells, M. Vasser, D. B. Powers, Gene 34, 315 (1985)]. This library was constructed by cassette mutagenesis that fully mutated four residues at a time (see Example VIII) which utilized a mutated version of phGHam-g3 into which unique Kpnl (at hGH codon 27jand Xhol (at hGH codon 6) restriction sites (underlined below) had been inserted by mutagenesis [ T. A Kunkel, J. D. Roberts, R. A
Zakour, Methods EnzymoL 154, 367-2~9~~~3 38 382] with the oligonucleotides 5'-GCC TTT GAC AGG TAC CAG GAG TTT G-3' and 5'-CCA ACT ATA CCA
CTS TCG AGG TCT ATT CGA TAA C-3', respectively. The later oligo also introduced a +1 frameshift (italidzed) to terminate translation from the starting vector and minimize wild-type background in the phagemid library. This strafing vector was designated pH0508B. The helix 1 library, which mutated hGH residues 10, 14, 18, 21, was constructed by ligating to the large Xhol-Kpnl fragment of pH0508B
a cassette made from the complementary oiigonucleotides 5'-pTCG AGG CTC NNS GAC AAC GCG NNS CTG CGT GCT
NNS CGT CTT
NNS CAG CTG GCC TTT GAC ACG TAC-3' and 5'-pGT GTC AAA GGC CAG CTG SNN AAG ACG
SNN AGC
ACG CAG SNN CGC GTT GTC SNN GAG CC-3'. The Kpnl site was destroyed in the junction of the ligation product so that restriction enzyme digestion could be used for analysis of non-mutated background.
The library contained at least 10~ indeperkient transfonnaMs so that if the library were absolutely random ( 106 different combinations of colons) we would have an average of about 10 copies of each posside mutated hGH gene. Restriction analysis using Kpni indicated that at least 80%
of helix 1 library constructs contained the inserted cassette.
Binding enrichments of hGH-phage from the libraries was carried out using hGHbp immobilized on oxirane-polyacrylamide beads (Sigma Chemical Co.) as described (Example VIII).
Four residues in helix 1 (F10, M14, H18, and H21 ) were similarly mutated and after 4 and 6 cycles a non-wild-type consensus developed (Table VIII). Position 10 on the hydrophobic face of helix 1 tended to be hydrophobic whereas positions 21 and 18 on the hydrophillic face tended were dominated by Asn; no obvaus consensus was evident for position 14 (Table IX).
The binding constants for these mutants of hGH to hGHbp was determined by expressing the free hormone variants in the non-suppressor E. coli strain 1609, purifying the protein, and assaying by competitive displacement of labelled wt-hGH irom hGHbp (see F~cample VIII). As indicated, several mutants bind tighter to hGHbp than does wt-hGH.
Table VIII.
Selection of hGli helix 1 mutants Variarns of hGH (randomly mutated at residues F10, Mt4, H18, H21) expressed on phagemid particles were selected by binding to hGHbp-beads and eluting with hGH (0.4 mIN) buffer followed by gfycine (0.2 M, pH 2) buffer (see Example VIII).
Gly elution 4 Cycles H G N N
A W D N (2) Y T V N
I N I N
L N S H
F S F G
6 Cycles H G N N (6) F S F L
Consensus:
H G N N
~~95~3~ 40 Table IX
Ca~enst8 sequels tram the selected helix 1 Nbrary Observed frequency is tn~tion of all doves sequerxed with the indicated amino aad. The nominal frequency is cabulated on the basis of NNS 32 colon degeneracy. The maximal enrichment facto varies from 11 ~ 32 depending upon the rwminal frequency value for a given residue. Values of [Kd(Ala mut)IK d(wt hGH)J for single alanine mutations ware taken from B. C. Cumingham and J. A. Wells, Sderx~e 244,1081 (1989); B. C. Cunningham, D. J. Henner, J. A. Wells, Soaves 247,1461 (1990); B. C. Cunningham and J. A.
Wells, Proc. Nail. Acad Sa. USA
88, 3407 (1991 ).
wld type Selected Kd(Ala mut) residue Kd(wt hGH) re~due observed rornir~al Enrichment F10 5.9 H 0.50 0.031 17 F 0.14 0.031 5 A 0.14 0.062 2 M14 2.2 G 0.50 0.062 8 W 0.14 0.031 5 N 0.14 0.031 5 S 0.14 0.093 2 H18 1.6 N 0.50 0.031 17 D 0.14 0.031 5 F 0.14 0.031 5 H21 0.33 N 0.79 0.031 26 H 0.07 0.031 2 Table X
t8lndnp d puri~d hGH helix 1 rt~nts b hGHbp Competition Minding experiments were performed using [l~IjhGH (wild-type), hGHbp (containing the extracellular receptor domain, residues 1-238), and Mab263 [B. C. Cumingham, P. Jhurani, P. Ng, J. A. Wells, Science 243,1330 (1989));. The number P indicates the fractional ocaxrence of each mutant among all the clones sequenced after one or more rounds of selection.
Sequence P Kd (nA~\f(Kd Kd(wt pogtion mut) hGH)) H G N N 0.50 0.14 t 0.04 0.42 A W D N 0.14 0.100.03 0.30 wt= F M H H 0 0.34 0.05 (1 ) F S F L 0.07 0.680.19 2.0 Y T V N 0.07 0.750.19 2.2 L N S H 0.07 0.82 t 0.20 2.4 I N I N 0.07 12 ~ 0.31 3.4 EXAMPLE X
SELECTION OF hGH VARIANTS FROM A HEUX-4 RAN00M CASSETTE LIBRARY CONTAINING
Our experience with reauiting non-binding homologs of hGH evolutionary variants suggests that many individual amino acid substitutions can be combined to yield cumulatively improved mutants of hGH with respect to binding a particular receptor (B. C. Cunnirgham, D. J. Henner, J. A. Wells, Scien~oe 247,1461 (1990); B. C.
Cunningham and J. A. Wells, Pros. Nad. Acad Sa. USA 88, 3407 (1991 ); H. 8.
Lowman, B. C. Cumingham, J. A.
3 5 Wells, J. 8iol. Chem. 266, in press ( 1991 )j.
The helix 4b library was constructed in an attempt to further improve the helix 4 double mutant (E174SIF176Y) selected from the helix 4a library that we found bound tighter to the hGH receptor (see Example VIII). With the E174S/F176Y hGH mutant as the background starting hormone, residues were mutated that surrounded positions 174 and 176 on the hydrophiNc face of helix 4 (R167, D171, T175 and 1179) .
Cassette mutagenesis was carried out essentially as described [J. A. Wells. M.
Vasser, D. B. Powers, Gene 34, 315 (1985)). The helix 4b library, which mutated residues 167,171,175 and 179 within the E174S/F176Y background, was constructed using cassette mutagenesis that fully mutated four residues at a time (see Example VIII) and which utilized a mutated version of phGHam~3 into which uryque BstBl and BgAI
restriction sites had been inserted prevausly (Example VIII). into the BstEll-Bglll sites of the vector was inserted a cassette made from the complementary oligonudeotides 5'-pG TTA CTC TAC TGC
TTC NNS AAG GAC ATG
NNS AAG GTC AGC NNS TAC CTG CGC NNS GTG CAG TGC A-3' and 5'-pGA TCT GCA CTG
CAC SNN
GCG CAG GTA SNN GCT GAC CTT SNN CAT GTC CTT SNN GAA GCA GTA GA-3'. The BstEfl site was eliminated in the ligated cassette. From the helix 4b litxary,15 unselectsd doves were sequenced. Of these, none lacked a cassette insert, 20% were frame-shifted, and 7% had a non-silent mutatan.
Binding enrichments of hGH-phage from the libraries was carried out using hGHbp immobilized on oxirane-polyaaylamide beads (Sigma Chemical Co.) as described (Example VIII).
After 6 cycles of binding a reasonably dear consensus developed (Table XI). Interestingly, all positions tended to contain polar residues, notably Ser, Thr and Asn (XII).
The binding constants for some of these mutants of hGH to hGHbp was determined by expressing the free hormone variants in the non-suppresser E. cell strain 16C9, purifying the protein, and assaying by competitive displacement of labelled wtfiGH from hGHbp (see Example VIII). As indicated, the binding affinities of several helix-4b mutants for hGHbp were tighter than that of wt-hGH Table XIII).
Finally, we have begun to analyze the binding affinity of several of the tghter hGHbp binding mutants for their ability to bind to the hPRLbp. The E174S/F176Y mutant binds 200-fold weaker to the hPRLbp than hGH. The E174T/F176YIR178K and R167N/D171SIE174S/FI76YII179T mutants each bind >500-fold weaker to the hPRLbp than hGH. Thus, it is possible be use the produce new receptor selective mutants of hGH by phage display tectx~ology.
Of the 12 residues mutated in three hGH-phagemid libraries (Examples VIII, lX, X), 4 showed a strong, although not exclusive, conservation of the wild-type residues (K172, T175, F176, and R178). Not surprisingly, these were residues that when converted to Ata caused the largest disruptions (4- to 60-fold) in binding affinity to the hGHbp. There was a class of 4 other residues (F10, M14, D171, and 1179) where Ala substitutions caused weaker effects on binding (2- to 7-fold) and these positions exhibited little wild-type consensus. Finally the other 4 residues (H18, H21, 8167, and E174), that promote binding to he hPRLbp but not the hGHbp, did not exhibit any consensus for the wild-type hGH sequence by selection on hGHbp-beads. In fact iwo residues (E174 and H21 ), where Ala substitutions enhance binding affinity to the hGHbp by 2- to 4-fold [B. C. Cunningham, P.
Jhurani, P. Ng, J. A. Wells, Sdenoe 243,1330 ( 1989); B. C. Cunningham and J.
A Wells, Scenes 244,1081 (1989); B. C. Cunr>ingham, D. J. Henner, J. A. Wells, Saerx;e 247,1461 (1990);
B. C. Cunningham and J. A, Wells, Proc. Natl. Acad. Sa. USA 88, 3407 (1991 )]. Thus, the alanine-scanning mutagenesis data correlates reasonably well with the flexibility to substitute each position. In fact , the reduction in binding affinity caused by alanine substitutions [B. C. Cunningham, P. Jhurani, P. Ng, J. A. Wells, Science 243,1330 (1989); B. C. Cunningham and J. A. Wells, Sdenoe244,1081 (1989)], B. C. Cunningham, D. J. Henner, J. A.
Wells, Science247, 1461 (1990); 8.
C. Cunningham and J. A. Wells, Pros. Natf. Acad. Sa. USA 88, 3407 ( 1991 )] is a reasonable predictor of the percentage that the wild-type residue is found in the phagemid pool after 3-6 rounds of selection. The alanine-WO 92/09690 ~ ~ ~ ~ PCT/US91/09133 scanning information is useful for targeting side-chains that modulate binding, and the phage selection is appropriate for optimizing them and defining the flexibility of each site (and/or combinations of sites) for substitution. The comt~ir~tion of scanr~rg mutational methods [B. C.
Cunningham, P. Jhurani, P. Ng, J. A. Wells, Science ?A3,1330 (1989); B. C. Cunningham and J. A Wells, Saenc~e ?A4,1081 ( 1989)] and phage display is a powerful approach to designing reoepta-ligand interfaces and sdrdying molecular evolution in vitro.
In cases where combined mutatans in hGH have additive effects on binding affinity bo receptor, mutations learned through hormone-phagemid enrichment to improve bindirg can be combined by simple cutting and ligation of resfiction fragments or mutagenesis to yield cumulatively optimized mutants of hGH.
On the other hand, mutations in one region of hGH which optimize receptor binding may be stn~cturally or functionally compatible witty mutations in an overlapping a another region of the molecule. In these cases, hormone phagemid enrichment can be cartied out by one of several variatans on the iterdtiHe emid~ment approach (t ) random DNA litxaries can be generated in each of two (or perhaps more) regions of the molecule by cassette or another mutagenesis method. Thereafter, a combined library can be created by ligation of restriction fragments from the two ONA libraries; (2) an hGH variant, optimized for binding by mutation in one region of the molecule, can be randomly mutated in a second region of the molecule as in the helix-4b library example; (3) two or more random libraries can be y selected for improved binding by hormone-phagemid enrichment; after this 'roughing-in' of the optimized binding site, the still-partially-diverse libraries can be recombined by ligation of restriction fragments Go generate a single library, partially diverse in iwo or more regions of the molecules, which in tum can be further selected for optimized binding using hormone-phagemid enrichment.
2Q9~~'a~
Table XI.
AAumnt pt~erNds d hGH sHecbed from helix 4b library after 4 and 6 cyGes of enrichment Selection of hGH helix 4b mutants (randomly mutated at residues 167, 171,175,179), each containing the E174SIF176Y
double mutant, by binding to hGHbp-beads and eluting with hGH (0.4 mA~ buffer followed by glyane (0.2 M, pH 2) buffer.
One mutant (+) contained the spurious mutation R178H.
8167 Di71 T175 1179 4 Cydes N S T T
K S T T
S N T T
D S T T
D S T T+
D S A T
D S A N
T D T T
N D T N
A N T N
A S T T
6 CyGes N S T T (2) N N T T
D S S T
E S T I
K S T L
Cor~r~s:
N S T T
D N
WO 92/09690 ~ ~ j1 ;~ ~ ~ ~ PGT/US91/09133 Tale )01 Cornell~s ~puerroes from the >teleaed library.
Observed frequency is traction of aA cbnes sequenced with the indicated amino aad. The nominal frequerxy is calculated on the basis of NNS 32 colon degeneracy. The maximal enrichment factor varies from 11 to 16 to 32 5 depending upon the raminal frequency value for a given residue. Values of [Kd(Ala mut)IKd(wt hGH)] for single alanine mutations were taken from refs. below; for position 175 we oNy have a value br the T175S mutant [B. C.
Cunningham, P. Jtxuani, P. Ng, J. A. Wells, Saenoe 243,1330 (1989); B. C.
Cumingham and J. A. Wells, Saence 244, 1081 (1989); B. C. Cunrungham, D. J. Henner, J. A. Wells, Saenoe 247,1461 (1990); B. C. Cunningfam and J. A Wells, Proc. Nail. Acad Sci. USA88, 3407 (1991).).
Wild type Selected residue Kd(~a mut) residue observed raminal Enrichment Kd(wt hGH) 8167 0.75 N 0.35 0.031 11 D 0.24 0.031 8 K 0.12 0.031 4 A 0.12 0.062 2 D171 7.1 S 0.76 0.093 8 N 0.18 0.031 6 2 0 D 0.12 0.031 ' 4 T175 3.5 T 0.88 0.062 14 A 0.12 0.031 4 1179 2.7 T 0.71 0.062 11 N 0.18 0.031 6 Table XIII
t3Ndirrg of purified trGH mutar>m to hGHbp.
Competition binding experiments were performed using [1251]hGH (wild-type), hGHbp (containing the extraceNular receptor domain, residues 1-238), and Mab263 (11). The number P
indicates the fractional oaxxrence of each mutant among aU the doves sequenced after one or more rods of selection. Note that the helix 4b mutations (") are in the background of hGH(E174SIF176Y). In the list of helix 4b mutants" the E174SIF176Y mutant ('), with wt residues at 167,171,175, 179, is shown in bold.
Kd(Ala m~) SequerxePosition P Kd(n d(w~ t hGH) N S T T 0.18 0.04 t 0.02 0.12 E S T I 0.06 0.04 0.02 0.12 K S T L 0.06 0.05 0.03 0.16 N N T T 0.06 0.06 0.03 0.17 R D T I 0 0.06 0.01 (0.18) N S T Q 0.06 0.26 0.11 0.77 WO 92/09690 r' PCT/US91/09133 2~~~~~3~~
Assembly d F~ ~Aolea~le on tie Pld Sur<aoe Ptasmid pDH 188 captains the DNA encoding the F~ portion of a humanized IgG
antibody, called 4D5, that recognizes the HER-2 receptor. This plasmid is contained in E. coN strain SR 101, and has been deposited with the ATCC in RodcviNe, MD.
Briefly, the plasmid was prepared as follows: the starting plasmid was pS0132, oonta~ing the alkaline phosphatase promobar as described above. The DNA encoding human growth hormone was exased and, after a series of manipulations to make the ends of the plasmid compatible for ligatbn, the DNA encoding 4D5 was inserted. The 4D5 DNA contains two genes. The first gene encodes the variable and constant regions of the light chap, and contains at its 5' end the DNA erxxxJing the st II signal sequence.
The second gene cor>tains four portions: first, at its 5' end is the DNA erxodMg the st II signal sequence.
This is followed by the DNA erxoding the variable domain of the heavy chain, which is folbwed by the DNA encoding the first domain of the heavy chain constant region, which in turn is iolbwed by the DNA encoding the M13 gene III. The salient features of this construct are shown in Fgure 10. The sequence of the DNA erxxding 4D5 is shown in Fgure 11.
Both polyethylene glycol (PEG) and electroporation were used to transform plasmids into SRlOt cells.
(PEG competent cells were prepared and transformed according to the method of Chung and Miller (Nucleic Acids Res.16:3580 [1988]). Cells that were competent for electroporatbn were prepared, and subsequently transformed via electroporation according to the method of Zabarovsky and Winberg (Nucleic Acids Res.18:5912 [1990]). After placng the cells in 1 ml of the SOC media (described in Sambrook et al., supra), they were grown for 1 hour at 37°C with shaking. At this time, the concentration of the cells was determined using light scattering at ODSpO. A titered K07 phage stock was added bo achieve an multiplicity of infection (M01) of 100, and the phage were albwed to adhere to the cells for 20 minutes at room temperature.
This mixture was then diluted into 25 mls of 2n broth (described in Sambrook et al., supra) and incubated with shaking at 37°C overnight. The next day, cells were pelleted by centrifugation at 5000 x g for 10 minutes, the supernatant was collected, and the phage partices were precipitated with 0.5 M NaCI and 4% PEG (final corxentration) at room temperature for 10 minutes. Phage partices were pelleted by centrifugatbn at 10,000 x g for 10 minutes, resuspended in 1 ml of TEN
(10 mM Tris, pH 7.6,1 mM EDTA, and 150 mM NaCI), and stored at 4°C.
Aliquots of 0.5 ml from a solution of 0.1 mg/ml of the extra~etlutar domain of the HER-2 antigen (ECD) or a solution of 0.5 mg/ml of BSA (control antigen) in 0.1 M sodium bicarbonate, pH 8.5 were used to coat one well of a Falcon 12 well tissue culture plate. Once the solution was applied to the wells, the plates were incubated at 4°C on a rocking plattortn overnight. The plates were then blocked by removing the initial solution, applying 0.5 ml of blocking buffer (30 mg/ml BSA in 0.1 M sodium bicarbonate), and incubating at room temperature for one hour.
Finally, the blocking buffer was removed, 1 ml of buffer A (PBS, 0.5% BSA, and 0.05% Tween-20) was added, and the plates were stored up to 10 days at 4°C before being used for phage selection.
a~
Approximately 109 phage particles were mixed with a 100-fold excess of K07 helper pfrage and 1 ml of buffer A . This mixhxe was divided irno two 05 ml aliquots; one of which was applied to ECD coated wells, and the other was applied b BSA coated weus. The plates were ina~batad at room temperature while shaking for one to ttxee hours, and were then washed three times over a period of 30 mirurtes wish 1 ml aliquots of buffer A.
Elution of the phage from the plates was done at room temperature by one of two methods: t ) an initial overnight incubation of 0.025 mglml purified Mu4D5 antibody (murine) folbwed by a 30 minute irxubation with 0.4 ml of the add elution buffer (0.2 M glydne, pH 2.1, 0.5% BSA, and 0.05% Tween-20), or 2) an incubation with the acid elution tx~ffer alone. Eluates were then neutralized with 1 M Tris vase, and a 0.5 ml aliquot of TEN was added.
These samples were then propagated, titered, and shred at 4°C.
Alquots of eluted phage were added to 0.4 ml of 2YT broth and mixed with approximately 108 mid-log phase male E. cbli strain SR101. Phage were allowed b adhere to the cells for 20 minutes at room temperature and then added to 5 ml of 2YT broth that contained 50 R.giml of carbenidllin and 5 ~g/ml of tetracycline. These cells were grown at 37°C for 4 to 8 hours until they reached mid-log phase. The OD6pp was determined, and the cells were superinfected with K07 helper phage for phage production. Orxe phage particles were obtained, they were titered in order to determine the number of colony forming urNts (cfu).
This was done by taking aliquots of serial dilutions of a given phage stock, allowing Ihem to infect mid-log phase SRt 01, and plating on LB plates oontaimg 50 uglml c~rbeniciuin.
2 0 ~ p8fllZd, The affinity of h4D5 Fab fragments and Fab phage for the ECD antigen was determined using a competitive receptor Minding RIA (Burt, D. R., Receptor Bending in Dnrg Research. 0'Brien, R.A. (Ed.). pp. 3-29, Dekker, New York [1986)). The ECD antigen was labeled with 125-Ipd;ne using the sequential c~loramine-T
method (De Larco, J. E. et al., J. Ceff. PhysioJ.109:143-152 [1981]) which produced a radioactive tracer with a speafic activity of l4~Cilf,ig and incorporation of 0.47 moles of Iodine per mole of receptor. A series of 0.2 ml solutions containing 0.5 ng (by ELISA) of F~ or F~ phage, 50 nCi of 1251 ECD
tracer, and a range of unlabeled ECD amounts (6.4 ng to 3277ng) were prepared and incx~bated at room temperature overnight. The labeled ECD-F~ or ECD-FaM phage complex was separated from the unbound labeled antigen by forming an aggregate complex induced by the addition of an anti-human IgG (Fitzgerald 40-GH23) and 6°~ PEG 8000. The complex was pelleted by centrifugation (15,000 x g for 20 minutes) and the amount of labeled ECD (in cpm) was determined by a gamma counter. The dissoaation constant (Kd) was cala~lated by employirg a modified version of the program LIGAND (Munson, P. and Rothbard, D., Anal. &ochem.107~20-239 [1980)) which utilizes Scatchard analysis (Scatchard, G.,Ann. N.Y. Acad. Sci. 51:66072 (1949]). The Kd values are shown in Figure 13.
Murine 4D5 antibody was labeled with 125-l to a spedfic activity of 40-50 ~Cilpg using the lodogen procedure. Solutions containing a constant amount of labeled antibody and increasing amounts of unlabeled variant Fab were prepared and added to near confluent cultures of SK-BR-3 cells grown in 96-well microtiter dishes (final concentration of labeled antibody was 0.1 nM). After an overnight incubation at 4°C, the supernatant was removed, the cells were washed and the cell assodated radioactivity was determined in a gamma counter. Kd wakres were determined by analyzing ltte data usirta a motifi9d version of the program t.IGAND (MunsorL P. end Rothbaro, D., supra?
This depOSit of pldsmid pDHt 89 ATCC no. 68683 was made und9r the provisions of tkte St~dapest Treaty or1 the International Recognition of the Deposit of Micraorgsnisms for the Purpose of 5 patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable Culture for 30 ye8rs from the date of deposit. The organisms will be made available by ATCC
under the terms of the Budapest Treaty, and subject t0 an agreement between Genentech, Inc. End AT~~, which assures permanent and unrestricted availability of the progeny of the cultures to the public upon issuance of a f $tent On the basis of the application, or the patent appllGation is refused, or i5 abandoned and no longer subject to reinstatement, or is withdrawn, whichever oomes first, and assures Q availability of the progeny t0 One determined by the Commissioner of Pntetlt5 to be entitled thereto according to Section 109 of the Patent l=lutes.
The assignee of the present application has agreed that If the cultures on deposit sttoutd d'le or be Iosi or destroyed when cultivated under suitable t>onditiats, they wiN be promptly replaced on rtotificatan wi>rt a viable 15 specimen of the same a.~ture. Availability of the deG4sibed cultures is rtot to be construed as a license to practice the invention in contravention of the rights granted under tile authority of any government in accordance with its patent laws.
The fxegdrtg written spedt'~abwt is considered to be suttident to enable one skilled in the art to practice the invention. The present ~ven>ion is not to be limited in scope by ttte cultures deposited, since the 20 deposited embodiments are Intended as separate illustrations of certain aspects at the invention and any a~tures that are ftatctionally equivalent are within fhe sa~pe of this irnrention. The deposit of material herein does not constitute an admission that the wriaen description hlereln contained is inadequate to enable the pracBce of any aspect of the invention, including the best mode thereof, nor is it to be CansUtAad as limiting the soop2 of tt"to dairns to the specific illustrations that it represents. Indeed, Parlous modifications of the irnention in addition to 25 those shown 2ind descrit~ed herein wiU become apparent to those skilled in tile an from the foregoing desaipCioh and fall within me scope of the appended Balms.
whaa ttte irrrer~tion has neoessaray been desaitied in coftjurtction wilt prelerted embodiments, one of ordinary skin, after reading the toregaing speafication, w~l be able to etrect various changes, substitutions of equivalents, and alterations de Ute sut~ed rnatter set forth herein, widtout departing lrom the spirit and scone 34 thereof. Hence, the invention can be practiced in ways outer than those speafica~y desaibed herein. ft is therefore intended that the protetdon granted by ~et4ars Patent hereon be mired artly by the appended claims and equivalents thereof.
WO 92/09690 '~ ~ ~ f; ~' j ~ PCT/US91 /09133 EXAMPLE Xll SELECTION OF hGH VAi'~ANTS FROM COMBINATIONS OF HELIX-1 AND HEUX-4 HORMONE-PHAGE
VARIANTS
According to additivity principles ~J. A. Wells, Biochemistry29, 8509 (1990)j, mutations in different parts of a protein, if they are not mutually interacting, are expected to combine to produce additive changes in the free energy of Minding to another molecule (changes are additive in terms of AOGb;~ing, or multiplicative in terms of Kd = exp[-eGIRTj ). Thus a mutation produang a 2-fold increase in binding affinity, when comtHned with a second mutation causing a 3-fold increase, would be predicted to yield a double mutant with a 6-fold increased affinity over the starting variant.
To test whether multiple mutations obtained firom hGH-phage selections would produce cumulatively favorable effects on hGHbp (hGH-binding protein; the extracellular domain of the hGH receptor) Minding, we combined mutations found in the three tightest-binding variants of hGH from the helix-1 library (Example IX:
F10AIM14WIH18DlH21N, F10H/M14G/H18N/H21N, and F10FIM14S/H18F/H21L) with those found in the three tightest binding variants found in the helix-4b library (Example X:
R167N/D171SlT175II179T, R167EID171S/T175/I179, and R167N/D171NIT17511179T).
hGH-phagemid double-stranded DNA (dsDNA) from each of the one-helix variants was isolated and digested with the restriction enzymes EcoRl and BstXl. The large fragment from each helix-4b variant was then isolated and ligated with the small fragment from each helix-1 variant to yield the r~ew two-helix variants shown in Table XIII. All of these variants also contained the mutations E174S/F176Y
obtained in earlier hGH-phage binding selections (see Example X for details).
Although additivity prindples appear to hold for a number of comt~ir~ations of mutations, some comt~inations (e.g. E174S with F176Y) are Dearly non-additive (see examples VIII and X). In order to identify with certainty the tightest binding variant with, for example, 4 mutations in helix-1 ~ 4 mutations in helix-4, one would ideally mutate all 8 residues at once and then sort the pool for the globally tightest binding variant.
However, such a pool would consist of 1.1 x 1012 DNA sequences (utilizing NNS
colon degeneracy) encoding 2.6 x 1010 different polypeptides. Obtaining a random phagemid library large enough to assure representation of all variants (pefiaps 1013 transfonnants) is not practical using current transformation technology.
We have addressed this difficulty first by utilizing successive rounds of mutagenesis, taking the tightest Minding variant from one library, then mutating other residues to further improve binding (Example X).
In a second method, we have utilized the principle of additivity to comt~ir~e the best mutations from two independently sorted libraries to create multiple mutants with improved binding (described above). Here, we further searched through the possible comtHnations of mutations at positions 10,14,18, 21,167,171,175, and 179 in hGH, by creating comt~inatorial libraries of random or partially-random mutants. We constructed three different comt~inatorial libraries of hGH-phagemids, using the pooled phagemids from the helix 1 library (independently sorted for 0, 2, or 4 cycles; Example IX) and the pool from the helix-4b library (independently sorted for 0, 2, or 4 cyGes; Example X) and sorted the combined variant pool for hGHbp binding. Since some amount of sequence diversity exists in each of these pools, the resulting combinatorial library can explore more sequence combinations than what we might constmct manually (e.g. Table XIII).
WO 92/09690 2 ~ ~ ~ ~ ~ ~ PCT/US91 /09133 hGH-phagemid double-stranded DNA (dsDNA) from each of the one-helix library pools (selected for 0, 2, or 4 rounds) was isolated and digested with the restriction enzymes Ac~cl and BstXl. The large fragment from each helix-1 variant pool was then isolated and ligated with the small fragment from each helix-4b vaunt pool to yield the three combinatorial libraries pH0707A (unselecbed helix 1 and helix 4b pools, as described in examples IX
5 and X), pH0707B (twice-selected helix-1 pool with twice-selected helix-4b pool), and pH0707C (4-times selected helix-1 pool with 4-times selected helix-4b pool). Duplicate ligations were also set up with less DNA and designated as pH0707D, pH0707E, and pH0707F, corresponding to the 0-,2-, and 4-round starting libraries respectively. All of these variant pools also contained the mutations E174SIF176Y obtained in earlier hGH-phage binding selectans (see Example X for details).
The ligation products pH0707A-F were processed and electro-transformed into XL1-Blue cells as described (Example VIII). Based on colony-forming units (CFU), the number of transformants obtained from each pool was as follows: 2.4x106 from pH0707A, 1.8x106 from pH0707B, 1.6x106 from pH0707C, 8x105 from pH0707D, 3x105 from pH0707E, and 4x105 from pH0707F. hGH-phagemid particles were prepared and selected for hGHbp-binding over 2 to 7 cycles as described in Example VIII.
In additan to sorting phagemid libraries for tight-binding protein variants, as measured by equilibrium binding affinity, it is of interest to sort for variants which are altered in either the on-rate (kon) or the off-rate (koff) of binding to a receptor or other molecule. From thermodynamics, these rates are related to the equilibrium dissodation constant, I(d = (koff/kon). We envision that certain variants of a particular protein have similar Kd's for binding while having very different kon's and ko ff's.
Conversely, d~anges in Kd trom one variant to another may be due to effects on kon, effects on ko ff, or both. The pharmacological properties of a protein may be dependent on Minding affinity or on kon or koff, depending on the detailed mechanism of action. Here, we sought to identify hGH variants with higher on-rates to investigate the effects of d~anges in kon. We envision that the selection could alternatively be weighted toward koff by increasing the binding time and increasing the wash time andlor concentration with cognate ligand (hGH).
From time-course analysis of wild-type hGH-phagemid Minding to immobilized hGHbp, it appears that, of tt~e total hGH-phagemid particles that can be eluted in the final pH 2 wash (see Example VIII for the complete Minding and elution protocol), less than 10% are bound affer 1 minute of incubation, while greater than 90% are bound affer 15 minutes of incubation.
For 'rapid-binding selection,' phagemid particles from the pH0707B pool (twice-selected for helices 1 and 4 independently) were incubated with immobilized hGHbp for only 1 minute, then washed six times with 1 mL of tHnding buffer; the hGH-wash step was omitted; and the remaining hGH-phagemid particles were eluted with a pH2 (0.2M glydne in binding buffer) wash. Enrichment of hGH-phagemid particles over non~iisplaying particles indicated that even with a short binding period and no cognate-ligand (hGH) d~allenge, hGH-phagemid binding selection sorts tight-Minding variants out of a randomized pool.
5, ~~ ~~3~
The binding constants for some of these mutants of hGH to hGHbp was determined by expressing the tree hormone variants in the non-suppressor E. colt strain 1609 or 3488, purifying the protein, and assaying by competitive displacement of labelled wt-hGH from hGHbp (see Example VIII) in a radio-immunoprecipitation assay.
In Table XIII -A below, all the variants have glutamate174 replaced by serine174 and pher~lalaninel7g replaced by tyrosine176 (E174S and F1176Y) plus the additional substitutions as indicated at hGH amino aad positions 10, 14,18, 21,167,171,175 and 179.
Table XIII-A
hGH
variaMS
from addpfon of helix-1 and helix~b mutaUons li H
li wild-type residue:F1Q e ~il,$ Jj21HlCtZ e I1Z~ 1128 ri x x nt X14 ~1Z1 Va H G N N N S T T
a In Table XIV below, hGH variants were selected from combinatorial libraries by the phagemid binding selection process. All hGH variants in Table XIV contain two background mutatans (E174SlF176Y). hGH-phagemid pools from the libraries pH0707A (Part A), pH0707B and pH0707E (Part B), or pH0707C (Part C) were sorted for 2 to 7 cycles for Minding to hGHbp. The number P indicates the fractional occurrence of each variant type among the set of Bones sequerxed from each pool.
WO PC'1'/US91/09133 ~~~~~~3 52 Table XIV
hGH variants from hOrllnor~e-pt~agemld binc9np selection Of comhlnalortal I~r~aries.
Hela Helix wild-type ~Q ~ J~$ ~ g~j residue:
Variant Part 4 cycles:
A :
0.60 H0714A.1 H G N N N S T N
0.40 H0714A.4 A N D A N N T N
' Part 8:
2 Cycles:
0.13 H0712B.1 F S F G H S T T
0.13 H0712B.2 H Q T S A D N S
0.13 H0712B.4 H G N N N A T T
0.13 H0712B.5 F S F L S D T T
0.13 H0712B.6 A S T N R D T I
0.13 H0712B.7 Q Y N N H S T T
0.13 H0712B.8 W G S S R D T I
0.13 H0712E.1 F L S S K N T V
0.13 H0712E.2 W N N S H S T T
0.13 H0712E.3 A N A S N S T T
0.13 H0712E.4 P S D N R D T I
0.13 H07t2E.5 H G N N N N T S
0.13 H0712E.6 F S T G R D T I
0.13 H0712E.7 M T S N Q S T T
0.13 H0712E.8 F S F L T S T S
4 cycles:
0.17 H0714B.1 A W D N R D T I
0.17 H0714B.2 A W D N H S T N
0.17 H0714B.3 M Q M N N S T T
0.17 H0714B.4 H Y D H R D T T
0.17 H0714B.5 L N S H R D T I
0.17 H0714B.6 L N S H T S T T
7cydes:
0.57 H0717B.1 A W D N N A T T
0.14 H0717B.2 F S T G R D T I
0.14 H07178.6 A W D N R D T I
0.14 H0717B.7 I Q E H N S T T
0.50 H0717E.1 F S L A N S T V
Part C:
4 cycles:
0.67 H0714C.2 F S F L K D T T
' = also contained the mutations L15R, K168R.
In Table XV below, hGH variants were selected from combinatorial libraries by the phagemid binding selection process. All hGH variants in Table XV contain two background mutations (E174SIF176Y). The number 5 0 P is the fractional occurrence of a given variant among all Gones sequenced after 4 cycles of rapid-binding selection.
' Table XV
hGH variants from RAPID hGHbp bindklp selection d en hGH-phagernld comblnatortel IIbrJry Helot Heluc wild-type residue: ~Q ~g ~$ )~ g~ p~j~
Yaf~t 0.14 H07BF4.2 W G S S R D T I
0.57 H078F4.3 M A D N N S T T
0.14 H07BF4.6 A W D N S S V T $
0.14 H078F4.7 H Q T S R D T I
$ = also contained the mutatan Y176F (wild-type hGH also contains F176j.
In table XVI below, binding constants were measured by competitive displacement of 1251-labelled hormone H06508D or labelled hGH using hGHbp (1-238) and either Mab5 or Mab263.
The variant H06508D
appears hind more than 30-fold tighter than wild-type hGH.
~~~~~J~ 5a Table XVI
EquIAbrium blndinp oo~ants of selected hGH wadaMs.
hGH Kd,(vanantl Kd,(variantl Variant Kd(H0650BD) Kd(hGH) Kd (per hGH 3 2 -1- 340 t H0650BD -1- 0.031 tOt 3 H0650BF 1.5 0.045 15 t 5 H07148.6 3.4 0.099 34 t 19 H0712B.7 7.4 0.22 74 t 30 H0712E.2 16 0.48 60 f 70 EXAMPLE XIII
Selectirve enrichment of hGH-phage contalnlng a pr~tesse substrate sequence versus ron-substrate phage As described in Example I, the plasmid pS0132 contains the gene for hGH fused to the residue Pro198 of the gene III protein with the insertion of an extra glyane residue. This plasmid may be used to produce hGH-phage particles in which the hGH~ene III fusion product is displayed monovalently on the phage surtace (Example IV). The fusion protein comprises the entire hGH protein fused to the carboxy terminal domain of gene III via a flexible linker sequerxe.
3 0 To investigate the feasibility of using phage display technology to select favourable substrate sequences for a given proteolytic enzyme, a genetically engineered variant of subtilisin BPN' was used. (Carter, P.
et al., Proteins: Structure, function and genetics 6:240-248 (1989)). This variant (hereafter referred to as A64SAL subtilisin) contains the following mutations: Ser24Cys, His64Ata, GIu156Ser, GIy169A1a and Tyr217Leu. Since this enzyme lacks the essential catalytic residue His64, its substrate speaficity is greatly restricted so that certain histidine-containing substrates are preferentially hyrdrolysed (Carter et al., Science 237:394-399 (1987)).
The sequence of the linker region in pS0132 was mutated to create a substrate sequence for A64SAL
subtilisin, using the oligonucleotide 5'-TTC-GGG-CCC-TTC-GCT-GCT-CAC-TAT-ACG-CGT-CAG-TCG-ACT-GAC-CTG-CCT-3'. This resulted in the introduction of the protein sequence Phe-Gly-Pro-Phe-Ala-Ala-5 His-Tyr-Thr-Arg-Gln-Ser-Thr-Asp in the linker region between hGH and the carboxy terminal domain of gene III, where the first Phe residue in the above sequence is Phe191 of hGH. The sequence Ala-Ala-His-Tyr-Thr-Agr-Gln is known to be a good substrate for A64SAL subtilisin (Carter et al (1989), supra). The resulting plasmid was designated pS0640.
Phagemid particles derived from pS0132 and pS0640 were constructed as described in Example I. In initial experiments, a 10W aliquot of each phage pool was separately mixed with 30p1 of oxirane beads (prepared as described in Example II) in 100W of buffer comprising 20mM Tris-HCI pH 8.6 and 2.5M NaCI. The binding and washing steps were performed as described in example VII. The beads were then resuspended in 400p1 of the same buffer, with or without 50nM of A64SAL subtilisin. Following incubation for 10 minutes, the supernatants were collected and the phage titres (cfu) measured. Table XVII shows that approximately 10 times more substrate-containing phagemid particles (pS0640) were eluted in the presence of enzyme than in the absence of enzyme, or than in the case of the non-substrate phagemids (pS0132) in the presence or absence of enzyme. Increasing the enzyme, phagemid or bead concentrations did not improve this ratio.
In an attempt to decrease the non-speafic elution of immobilised phagemids, a tight-bir>ding variant of hGH was introduced in place of the wild-type hGH gene in pS0132 and pS0640. The hGH variant used was as described in example XI (pH0650bd) and contains the mutations PhelOAla, Mett4Trp, Hisl8Asp, His2lAsn, Arg167Asn, Asp171Ser, GIu174Ser, Phe176Tyr and IIe179Thr. This resulted in the construction of two new phagemids: pDM0390 (containing tight-Minding hGH and no substrate sequence) and pDM0411 (containing tight-binding hGH and the substrate sequence Ala-Ala-His-Tyr-Thr-Agr-Gln). The binding washing and elution protocol was also changed as follows:
(i) Binding: COSTAR 12-well tissue culture plates were coated for 16 hours with 0.5mUwell 2ug/ml hGHbp in sodium carbonate buffer pH 10Ø The plates were then incubated with lmllwell of blocking buffer (phosphate buffered saline (PBS) containing 0.1%w/v bovine serum albumen) for 2 hours and washed in an assay buffer containing lOmM Tris-HCI pH 7.5, 1 mM EDTA and 1 OOmM NaCI. Phagemids were again prepared as described in Example I: the phage pool was diluted 1:4 in the above assay buffer and 0.5m1 of phage incubated per well for 2 hours.
WO 92/09690 ~. ~ PCT/US91/09133 ~~~~~~3 (ii) Washing: The plates were washed thoroughly with PBS + 0.05% Tween 20 and incubated for 30 minuted with 1 ml of this wash buffer. This washing step was repeated three times.
(~i) Eution: The plates were incubated for 10 minutes in an elution buffer consisting of 20mM Tris-HCI pH 8.6 + 100mM NaCI, then the phage were eluted with 0.5m1 of the above buffer with or without 500nM of A64SAL subtilisin.
Table XVII shows that there was a dramatic increase in the ratio of specifically eluted substrate-phagemid particles compared to the method previously described for pS0640 and pS0132. ft is likely that this is due to the fact that the tight-binding hGH
mutant has a significantly slower off-rate for binding to hGH binding protein compared to wild-type hGH.
Table XVII
Specific elution of substrate-phagemlds by A64SAL subtllisln Colony forming units (cfu) were estimated by plating out 10.1 of 10-fold dilutions of phage on l0pl spots of XL-1 blue cells, on LB agar plates containing 50pg/ml carbenicillinl (i) wld-type hGH gene: binding to hGHbp-oxirane beads pS0640 (substrate) 9x106cfu/l0wl 1.5x106cfu/l0pl pS0132 (non-substrate) 6x105cfu/l0pl 3x105cfu/l0pl (ii) pH0650bd mutant hGH gene: Minding to hGHbp-coated plates pDM0411 (substrate) 1.7x105cfu/l0pl 2x103cfu/l0pl pDM0390 (non-substrate) 2x103cfu/l0pl tx103cfu/l0pl Example XIV
Identification of preferred substrates for A64SAL subtllisln using selective enrichment of a library of substrate sequences.
We sought to employ the selective enrichment procedure described in Example XIII to identify good substrate sequences from a library of random substrate sequences.
We designed a vector suitable for introduction of randomised substrate cassettes. and subsequent expression of a library of substrate sequences. The starting point was the vector pS0643, described in Example VIII. Site-directed mutagenesis was carried out using the oligonucleotide 5'-AGC-TGT-GGC-TTC-GGG-CCC-GCC~CC-GCG-TCG-ACT-GGC-GGT-GGC-TCT-3', which introduces ~ (GGGCCC) and ~,[ (GTCGAC) restriction sites between hGH
and Gene III. This new construct was designated pDM0253 (The actual sequence of pDM0253 is 5'-AGC-TGT-GGC-TTC-GGG-CCC-GCC-ACC-GCG-TCG-ACT-GGC-GGT-GGC-TCT-3', where WO 92/09690 ~~ ~? ~ ~, PCT/US91 /09133 57 ~~~5~~1~5 the underlined base substitution is due to a spurious error in the mutagenic oligonucleotide).
In addition, the tight-binding hGH variant described in example was introduced by exchanging a fragment from pDM0411 (example XII I) The resurting library vector was designated pDM0454.
To introduce a library cassette, pDM0454 was digested with Apal folbwed by Sall, then precipitated with 13% PEG 8000+ lOmM MgCl2, washed twice in 70% ethanol and resuspended This effidently precipitates the vector but leaves the small Apa-Sal fragment in solution (Paithankar, K. R. and Prasad, K. S. N., Nuceic Acids Research 19:1346). The product was run on a 1% agarose gel and the Apal-Sall digested vector excised, purified using a Bandprep kit (Pharmacia) and resuspended for Ngation with the mutagenic cassette.
The cassette to be inserted contained a DNA sequence similar to that in the linker region of pS0640 and pDM0411, but with the colons for the histidine and tyrosine residues in the substrate sequence replaced by randomised colons. We chose to substitute NNS
(N=G/A/T/C; S=G/C) at each of the randomised positions as described in example VIII. The oligonucleotides used in the mutagenic cassettes were: 5'-C-TTC-GCT-GCT-NNS-NNS-ACC-CGG-CAA-3' (coding strand) and 5'-T-CGA-TTG-CCG-GGT-SNN-SNN-AGC-AGC-GAA-GGG-CC-3' (non-coding strand). This cassette also destroys the Sall site, so that digestion with Sall may be used to reduce the vector background. The oGgonucleotides were not phosphorylated before insertion into the Apa-Sal cassette site, as it was feared that subsequent oGgomerisation of a small population of the cassettes may lead to spurious results with multiple cassette inserts. Following annealing and ligation, the reaction products were phenol:chloroform extracted, ethanol precipitated and resuspended in water.
Initially, no digestion with Sall to reduce the background vector was pertormed.
Approximately 200ng was electroporated into XL-1 blue cells and a phagemid library was prepared as described in example VIII.
Selection of hlyhly cleavable substrates from the snb_c_trate Ilbrarv The selection procedure used was identical to that described for pDM0411 and pDM0390 in example XIII. After each round of selection, the eluted phage were propagated by transducing a fresh culture of Xl_-1 blue cells and propagating a new phagemid library as described for hGH-phage in example VIII. The progress of the selection procedure was monitored by measuring eluted phage titres and by sequencing individual clones after each round of selection.
Table A shows the successive phage titres for elution in the presence and absence of enzyme after 1, 2 and 3 rounds of selection.
2~~~~33 58 Clearly, the ratio of specifically eluted phage: non-specifically eluted phage (ie phage eluted with enzyme:phage eluted without enzyme) increases dramatically from round 1 to round 3, suggesting that the population of good substrates is increasing with each round of selection.
Sequencing of 10 isolates from the starting library showed them all to consist of the wild-type pDM0464 sequence. This is attributed to the fact that after digestion with Apal, the Sall site is very close to the end of the DNA fragment, thus leading to bw effiaency of digestion. Nevertheless, there are only 400 possible sequences in the library, so this population should still be well represented.
Tables B1 and B2 shows the sequences of isolates obtained after round 2 and round 3 of selection. Affer 2 rounds of selection, there is clearly a high incidence of histidine residues. This is exactly what is expelled: as described in example XIII, A64SAl_ subtilisin requires a histidine residue in the substrate as it employs a substrate-assisted catalytic mechanism. After 3 rounds of selection, each of the 10 Gones sequenced has a histidine in the randomised cassette. Note, however, that 2 of the sequences are of pDM0411, which was not present in the starting library and is therefore a contaminant.
WO 92/09690 ~ ~ ~ ~ ~ ~ ~ PCT/US91 Table A
Titration of Initialphape pools and phage from 3 rounds of eluted selective enrichment Colony forming units (cfu) were estimated by plating out 101,1.1 of 10-fold dilutions of phage on 101~J spots of XL-1 aining 501ig/ml carbenicillin blue cells, on LB
agar plates cont Starting library: 3x1012 cfu/ml LIBRARY: +500nM A64SAL : 4x103 cfu/101~I
no enzyme : 3x103 cfu/101~1 pDM0411: +500nM A64SAL : 2x106 cfu/10111 (control) no enzyme : 8x103 cfu/101~I
Round 1 library: 7x1012 cfu/ml LIBRARY: +500nM A64SAL : 3x104 cfu/l0wl no enzyme : 6x103 cfu/101~1 pDM0411: +500nM A64SAL : 3x106 cfu110111 (control) no enzyme : 1.6x104 cfu/101~I
Round 2 library: 7x1011 cfu/ml LIBRARY: +500nM A64SAL : 1x105 cfu/10111 no enzyme : <103 cfu/l0wl pDM0411: +500nM A64SAL : 5x106 cfu/101~I
(control) no enzyme : 3x104 cfu/101~1 so Table B1 Sequences of eluted phage after 2 rounds of selective enrichment.
All protein sequences should be of the form AA"TRO, where ' represents a randomised colon. In the table below, the randomised colons and amino acids are underlined and in bold.
After round 2:
A A $ Y T R Q
... GCT GCT~~~ ACC CGGCAA ... 2 TAC
A A $ j~j T R Q
... GCT GCT ACC CGGCAA ... 1 A A ji $ T R Q
... GCT GCT~ ACC CGGCAA ... 1 A A Z $ T R Q
... GCT GCT~ ACC CGGCAA ... 1 A A $ T R Q
.. . GCT~~ CGG CAA... 1 #
GCT
A A ~ $ T R Q
... GCT GCT~~~ ACC CGGCAA 1 ##
CAC
... wild-type 3 pDM0454 # - spurious deletion of 1 colon within the cassette ## - ambiguous sequence ~~~~~~3 Table B2 Seauences of eluted ohaqe after 3 rounds of selective enrichment.
All protein represents sequences should a be of the form AA"TRQ, where ' randomised colon.the table below, the randomised In colons and amino acids are underlined and in bold.
After round 3:
nce o-of Seau occurrences A A $ ~ T R Q
... GCT GCT ACG CGT CAG ... 2 ~
A A ji $ T R Q
... GCT GCT CAC ACC CGG CAA ... 2 CTC
2O A A Q $ T R Q
... GCT GCT ACC CGG CAA ... 1 ~
A A T $ T R Q
... GCT GCT ACC CGG CAA ... 1 A A $ ,~, R Q
... GCT GCT TCC CGG CAA ... 1 CAC
A A $ $ T R Q
... GCT GCT ACC CGG CAA 1 ~
A A $ $ R Q
... GCT GCT TTC CGG CAA ... 1 CAC
A A $ T R Q
... GCT GCT CGG CAA ... 1 # - contaminating sequence from pDM0411 ## - contains "illegal" colon CAT - T should the not appear in the 3rd position of a colon.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Genentech, Inc.
Garrard, Lisa J.
Henner, Dennis J.
Bass, Steven Greene, Ronald Lowman, Henry B.
Wells, James A.
Matthews, David J.
(ii) TITLE OF INVENTION: Enrichment Method For Variant Proteins With Altered Binding Properties (iii) NUMBER OF SEQUENCES: 27 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Genentech, Inc.
(B) STREET: 460 Point San Bruno Blvd (C) CITY: South San Francisco (D) STATE: California (E) COUNTRY: USA
(F) ZIP: 94080 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: patin (Genentech) (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE: 03-DEC-91 (C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/743614 (B) APPLICATION DATE: 09-Aug-91 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/715300 (B) APPLICATION DATE: 14-June-91 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/683400 (B) APPLICATION DATE: 10-Apr-91 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 07/621667 (B) APPLICATION DATE: 03-Dec-1990 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Benson, Robert H.
(B) REGISTRATION NUMBER: 30,446 (C) REFERENCE/DOCKET NUMBER: 645P4 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 415/266-1489 (B) TELEFAX: 415/952-9881 (C) TELEX: 910/371-7168 (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: l:
(2) INFORMATION FOR SEQ ID N0:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:2:
(2) INFORMATION FOR SEQ ID N0:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:3:
(2) INFORMATION FOR SEQ ID N0:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:4:
(2) INFORMATION FOR SEQ ID N0:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:5:
(2) INFORMATION FOR SEQ ID N0:6:
(i) SEQUENCE CHARACTERISTICS:
~a~5~~~
(A) LENGTH: 23 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:6:
(2) INFORMATION FOR SEQ ID N0:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:7:
(2) INFORMATION FOR SEQ ID N0:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 63 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:8:
(2) INFORMATION FOR SEQ ID N0:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:9:
(2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
~~'~~~~3 (2) INFORMATION FOR SEQ ID NO:11:
5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
(2) INFORMATION FOR SEQ ID N0:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:12:
(2) INFORMATION FOR SEQ ID N0:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:13:
Gly Ser Cys Gly Phe Glu Ser Gly Gly Gly Ser Gly (2) INFORMATION FOR SEQ ID N0:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:14:
(2) INFORMATION FOR SEQ ID N0:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:15:
n N ~ eJ Ey 'L
(2) INFORMATION FOR SEQ ID N0:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:16:
(2) INFORMATION FOR SEQ ID N0:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 66 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:17:
(2) INFORMATION FOR SEQ ID N0:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 64 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:18:
(2) INFORMATION FOR SEQ ID N0:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:19:
(2) INFORMATION FOR SEQ ID N0:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:20:
(2) INFORMATION
FOR
SEQ
ID
N0:21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 66 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:21:
TCGAGGCTCN NSGACAACGC GNNSCTGCGT GCTNNSCGTC TTNNSCAGCT
(2) INFORMATION
FOR
SEQ
ID
N0:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 58 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:22:
GTGTCAAAGG CCAGCTGSNN AAGACGSNNA GCACGCAGSN NCGCGTTGTC
(2) INFORMATION
FOR
SEQ
ID
N0:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 65 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID N0:23:
GTTACTCTAC TGCTTCNNSA AGGACATGNN SAAGGTCAGC NNSTACCTGC
(2) INFORMATION
FOR
SEQ
ID
N0:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 64 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear WO 92/09690 PC1'/US91/09133 209~~~~
(xi) SEQUENCE DESCRIPTION:SEQ ID
N0:24:
(2) INFORMATION FOR SEQ
ID N0:25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2178 bases (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION:SEQ ID
N0:25:
~J ~
~~~
~
(2) INFORMATION
FOR
SEQ
ID
N0:26:
(i) SEQUENCE
CHARACTERISTICS:
(A) acids LENGTH:
amino 20 (B) amino TYPE: acid (D) linear TOPOLOGY:
(xi) SEQID
SEQUENCE N0:26:
DESCRIPTION:
25 Met LysLysAsn IleAlaPhe LeuLeuAla SerMetPhe ValPhe Ser IleAlaThr AsnAlaTyr AlaAspIle GlnMetThr GlnSer Pro SerSerLeu SerAlaSer ValGlyAsp ArgValThr IleThr Cys ArgAlaSer GlnAspVal AsnThrAla ValAlaTrp TyrGln Gln LysProGly LysAlaPro LysLeuLeu IleTyrSer AlaSer 40 Phe LeuTyrSer GlyValPro SerArgPhe SerGlySer ArgSer Gly ThrAspPhe ThrLeuThr IleSerSer LeuGlnPro GluAsp Phe AlaThrTyr TyrCysGln GlnHisTyr ThrThrPro ProThr Phe GlyGlnGly ThrLysVal GluIleLys ArgThrVal AlaAla Pro SerValPhe IlePhePro ProSerAsp GluGlnLeu LysSer 55 Gly ThrAlaSer ValValCys LeuLeuAsn AsnPheTyr ProArg Glu AlaLysVal GlnTrpLya ValAspAsn AlaLeuGln SerGly Asn SerGlnGlu SerValThr GluGlnAsp SerLyaAsp SerThr Tyr SerLeuSer SerThrLeu ThrLeuSer LysAlaAsp TyrGlu Lys HisLysVal TyrAlaCys GluValThr HisGlnGly LeuSer Ser Pro Val Thr Lys Ser Aen ArgGly GluCys Phe (2) INFORMATION FOR SEQ
ID N0:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 461 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION:SEQ ID
N0:27:
Met Lys Lys Asn Ile Ala Leu LeuAla SerMet PheVal Phe Phe Ser Ile Ala Thr Asn Ala Ala GluVal GlnLeu ValGlu Tyr Ser Gly Gly Gly Leu Val Gln Gly GlySer LeuArg LeuSer Pro Cys Ala Ala Ser Gly Phe Asn Lys AspThr TyrIle HisTrp Ile Val Arg Gln Ala Pro Gly Lys Leu GluTrp ValAla ArgIle Gly Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lye Gly Arg Phe Thr IleSerAla AspThrSer LysAsn ThrAlaTyr LeuGln Met Asn SerLeuArg AlaGluAsp ThrAla ValTyrTyr CysSer Arg Trp GlyGlyAsp GlyPheTyr AlaMet AspTyrTrp GlyGln Gly Thr LeuValThr ValSerSer AlaSer ThrLysGly ProSer Val Phe ProLeuAla ProSerSer LysSer ThrSerGly GlyThr Ala Ala LeuGlyCys LeuValLys AspTyr PheProGlu ProVal Thr Val SerTrpAsn SerGlyAla LeuThr SerGlyVal HisThr Phe Pro AlaValLeu GlnSerSer GlyLeu TyrSerLeu SerSer Val Val ThrValPro SerSerSer LeuGly ThrGlnThr TyrIle Cys Asn ValAsnHis LysProSer AsnThr LysValAsp LysLys Val Glu ProLysSer CysAspLys ThrHis ThrGlyPro PheVal Cys Glu TyrGlnGly GlnSerSer AspLeu ProGlnPro ProVal Asn Ala GlyGlyGly SerGlyGly GlySer GlyGlyGly SerGlu Gly GlyGly SerGlu GlyGlyGly SerGluGly GlyGlySer Glu Gly GlyGly SerGly GlyGlySer GlySerGly AspPheAsp Tyr Glu LysMet AlaAsn AlaAsnLys GlyAlaMet ThrGluAsn Ala Asp GluAsn AlaLeu GlnSerAsp AlaLysGly LysLeuAap Ser Val AlaThr AspTyr GlyAlaAla IleAspGly PheIleGly Asp Val SerGly LeuAla AsnGlyAsn GlyAlaThr GlyAspPhe Ala Gly SerAsn SerGln MetAlaGln ValGlyAsp GlyAspAsn Ser Pro LeuMet AsnAsn PheArgGln TyrLeuPro SerLeuPro Gln Ser ValGlu CyaArg ProPheVal PheSerAla GlyLysPro Tyr Glu PheSer IleAsp CysAspLys IleAsnLeu PheArgGly Val Phe AlaPhe LeuLeu TyrValAla ThrPheMet TyrValPhe Ser Thr PheAla AsnIle LeuArgAsn LysGluSer
Claims
1. A human growth hormone variant, (a) wherein hGH amino acids 172, 174, 176 and 178 respectively are as a group sequentially selected from the group consisting of: (1)R,S,F,R; (2)R,A,Y,R; (3)K,T,Y,K; (4)R,S,Y,R; (5)K,A,Y,R;
(6)R,F,F,R; (7)K,Q,Y,R; (8)R,T,Y,H; (9)Q,R,Y,R; (10)K,K,Y,K;
(11)R,S,F,S and (12)K,S,N,R;
(b) wherein hCH amino acids 10, 14, 18, and 21 respectively are as a group sequentially selected from the group consisting of: (1) H,G,N,N; (2) A,W,D,N; {3) F,S,F,L; (4) Y,T,V,N and (5) I,N,I,N;
(c) wherein hGH amino acids 174 is serine and 176 is tyrosine and hGH amino acids 167, 171, 175 and 179 respectively are as a group sequentially selected from the group consisting of: (1) N,S.T.T; (2) E.S,T,I; (3) K,S,T,L; (4) N,N,T,T; (5) R,D,I,I and (6) N,S,T,Q;
(d) wherein hGH amino acid glutamate174 is replaced by serine174 and phenylalanine176 is replaced by tyrosine176 and one ar more of the eight naturally occurring hGH amino acids F10, M14, H18, H21, R167, D171, T175 and I179 are replaced by another natural amino acid to provide a variant capable of binding to human growth hormone receptor;
(e) wherein in the hGH variant of (d) the eight naturally occurring hGH amino acids F10, M14, H18, W21, R167, D171, T175 and I179 respectively are as a group replaced with a corresponding amino acid sequentially selected from the group consisting of:
(1) H, G, N, N, N, S, T, T; (2) H, G, N, N, E, S, T, I;
(3) H. G, N, N, N, N, T, T; (4) A, W, D, N, N, S, T, T;
(5) A, W, D, N, E, S, T, I; (6) A, W, D, N, N, N, T, T;
(7) F, S, F, L, N, S, T, T; (8) F, S, F, L, E, S, T, I;
(9) F, S, F, L, N, N, T, T; (10) H, G, N, N, N, S, T, N;
(11) A, N, D, A, N, N, T, N; (12) F, S, F, G, H, S, T, T;
(13) H, Q, T, S, A, D, N, S. (14) H, G, N, N, N, A, T, T;
(15) F, S, F, L, S, D, T, T; (18) A, S, T, N, R, D, T, I;
(17) Q, Y, N, N, H, S, T, T; (18) W, G, S, S, R, D, T, I;
(19) F, L, S, S, K, N, T, V; (20) W, N, N, S, H, S, T, T;
(21) A, N, A, S, N, S, T, T; (22) P, S, D, N, R, D, T, I;
(23) H, G, N, N, N, N, T, S; (24) F, S, T, G, R, D, T, I;
(25) M, T, S, N, Q, S, T, T; (26) F, S, F, L, T, S, T, S;
(27) A, W, D, N, R, D, T, I; (28) A, W, D, N, H, S, T, N;
(29) M, Q, M, N, N, S, T, T; (30) H, Y, D, H, R, D, T, T;
(31) L, N, S, H, R, D, T, I; (32) L, N, S, H, T, S, T, T;
(33) A, W, D, N, N, A, T, T; (34) F, S, T, G, R, D, T, I;
(35) A, W, D, N, R, D, T, I; (36) I, Q, E, H, N, S, T, T;
(37) F, S, L, A, N, S, T, V; (38) F, S, F, L, K, D, T, T;
(39) M, A, D, N, N, S, T, T; (40) A, W, D, N, S, S, V, T; and (41) H, Q, Y, S, R, D, T, I;
(f) wherein in the hGH variant of (e) the human growth hormone variant further contains leucine15 replaced by arginine15 and lysine168 replaced by arginine168;
(g) wherein in the hGH variant of (e) the human growth hormone variant further contains phenylalanine176.
(6)R,F,F,R; (7)K,Q,Y,R; (8)R,T,Y,H; (9)Q,R,Y,R; (10)K,K,Y,K;
(11)R,S,F,S and (12)K,S,N,R;
(b) wherein hCH amino acids 10, 14, 18, and 21 respectively are as a group sequentially selected from the group consisting of: (1) H,G,N,N; (2) A,W,D,N; {3) F,S,F,L; (4) Y,T,V,N and (5) I,N,I,N;
(c) wherein hGH amino acids 174 is serine and 176 is tyrosine and hGH amino acids 167, 171, 175 and 179 respectively are as a group sequentially selected from the group consisting of: (1) N,S.T.T; (2) E.S,T,I; (3) K,S,T,L; (4) N,N,T,T; (5) R,D,I,I and (6) N,S,T,Q;
(d) wherein hGH amino acid glutamate174 is replaced by serine174 and phenylalanine176 is replaced by tyrosine176 and one ar more of the eight naturally occurring hGH amino acids F10, M14, H18, H21, R167, D171, T175 and I179 are replaced by another natural amino acid to provide a variant capable of binding to human growth hormone receptor;
(e) wherein in the hGH variant of (d) the eight naturally occurring hGH amino acids F10, M14, H18, W21, R167, D171, T175 and I179 respectively are as a group replaced with a corresponding amino acid sequentially selected from the group consisting of:
(1) H, G, N, N, N, S, T, T; (2) H, G, N, N, E, S, T, I;
(3) H. G, N, N, N, N, T, T; (4) A, W, D, N, N, S, T, T;
(5) A, W, D, N, E, S, T, I; (6) A, W, D, N, N, N, T, T;
(7) F, S, F, L, N, S, T, T; (8) F, S, F, L, E, S, T, I;
(9) F, S, F, L, N, N, T, T; (10) H, G, N, N, N, S, T, N;
(11) A, N, D, A, N, N, T, N; (12) F, S, F, G, H, S, T, T;
(13) H, Q, T, S, A, D, N, S. (14) H, G, N, N, N, A, T, T;
(15) F, S, F, L, S, D, T, T; (18) A, S, T, N, R, D, T, I;
(17) Q, Y, N, N, H, S, T, T; (18) W, G, S, S, R, D, T, I;
(19) F, L, S, S, K, N, T, V; (20) W, N, N, S, H, S, T, T;
(21) A, N, A, S, N, S, T, T; (22) P, S, D, N, R, D, T, I;
(23) H, G, N, N, N, N, T, S; (24) F, S, T, G, R, D, T, I;
(25) M, T, S, N, Q, S, T, T; (26) F, S, F, L, T, S, T, S;
(27) A, W, D, N, R, D, T, I; (28) A, W, D, N, H, S, T, N;
(29) M, Q, M, N, N, S, T, T; (30) H, Y, D, H, R, D, T, T;
(31) L, N, S, H, R, D, T, I; (32) L, N, S, H, T, S, T, T;
(33) A, W, D, N, N, A, T, T; (34) F, S, T, G, R, D, T, I;
(35) A, W, D, N, R, D, T, I; (36) I, Q, E, H, N, S, T, T;
(37) F, S, L, A, N, S, T, V; (38) F, S, F, L, K, D, T, T;
(39) M, A, D, N, N, S, T, T; (40) A, W, D, N, S, S, V, T; and (41) H, Q, Y, S, R, D, T, I;
(f) wherein in the hGH variant of (e) the human growth hormone variant further contains leucine15 replaced by arginine15 and lysine168 replaced by arginine168;
(g) wherein in the hGH variant of (e) the human growth hormone variant further contains phenylalanine176.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002405246A CA2405246A1 (en) | 1990-12-03 | 1991-12-03 | Enrichment method for variant proteins with alterred binding properties |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62166790A | 1990-12-03 | 1990-12-03 | |
US07/621,667 | 1990-12-03 | ||
US68340091A | 1991-04-10 | 1991-04-10 | |
US07/683,400 | 1991-04-10 | ||
US71530091A | 1991-06-14 | 1991-06-14 | |
US07/715,300 | 1991-06-14 | ||
US74361491A | 1991-08-08 | 1991-08-08 | |
US07/743,614 | 1991-08-08 | ||
PCT/US1991/009133 WO1992009690A2 (en) | 1990-12-03 | 1991-12-03 | Enrichment method for variant proteins with altered binding properties |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002405246A Division CA2405246A1 (en) | 1990-12-03 | 1991-12-03 | Enrichment method for variant proteins with alterred binding properties |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2095633A1 CA2095633A1 (en) | 1992-06-04 |
CA2095633C true CA2095633C (en) | 2003-02-04 |
Family
ID=27505166
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002095633A Expired - Lifetime CA2095633C (en) | 1990-12-03 | 1991-12-03 | Enrichment method for variant proteins with altered binding properties |
CA002405246A Abandoned CA2405246A1 (en) | 1990-12-03 | 1991-12-03 | Enrichment method for variant proteins with alterred binding properties |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002405246A Abandoned CA2405246A1 (en) | 1990-12-03 | 1991-12-03 | Enrichment method for variant proteins with alterred binding properties |
Country Status (9)
Country | Link |
---|---|
US (7) | US5750373A (en) |
EP (1) | EP0564531B1 (en) |
AT (1) | ATE164395T1 (en) |
CA (2) | CA2095633C (en) |
DE (1) | DE69129154T2 (en) |
DK (1) | DK0564531T3 (en) |
ES (1) | ES2113940T3 (en) |
GR (1) | GR3026468T3 (en) |
WO (1) | WO1992009690A2 (en) |
Families Citing this family (2185)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5688666A (en) * | 1988-10-28 | 1997-11-18 | Genentech, Inc. | Growth hormone variants with altered binding properties |
US5534617A (en) * | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
US7063943B1 (en) | 1990-07-10 | 2006-06-20 | Cambridge Antibody Technology | Methods for producing members of specific binding pairs |
US6916605B1 (en) | 1990-07-10 | 2005-07-12 | Medical Research Council | Methods for producing members of specific binding pairs |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9206318D0 (en) * | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DK0564531T3 (en) * | 1990-12-03 | 1998-09-28 | Genentech Inc | Enrichment procedure for variant proteins with altered binding properties |
IE921169A1 (en) | 1991-04-10 | 1992-10-21 | Scripps Research Inst | Heterodimeric receptor libraries using phagemids |
US5506107A (en) | 1991-05-10 | 1996-04-09 | Genentech, Inc. | Selecting ligand agonists and antagonists |
US5858657A (en) * | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
US5962255A (en) * | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
US5871907A (en) * | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
US6800738B1 (en) * | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
LU91067I2 (en) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab and its variants and immunochemical derivatives including immotoxins |
DE4122599C2 (en) * | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid for screening antibodies |
US5733731A (en) * | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
US5270170A (en) * | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
PT1024191E (en) | 1991-12-02 | 2008-12-22 | Medical Res Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US6043212A (en) | 1993-07-26 | 2000-03-28 | Cor Therapeutics, Inc. | Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor |
WO1995018856A1 (en) | 1993-12-30 | 1995-07-13 | President And Fellows Of Harvard College | Vertebrate embryonic pattern-inducing hedgehog-like proteins |
US6406855B1 (en) | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
US5837458A (en) * | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US6576236B1 (en) | 1994-07-01 | 2003-06-10 | Dana Farber Cancer Institute | Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain |
US7597886B2 (en) * | 1994-11-07 | 2009-10-06 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US7820798B2 (en) * | 1994-11-07 | 2010-10-26 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US6335319B1 (en) * | 1994-11-15 | 2002-01-01 | Metabolic Pharmaceuticals, Inc. | Treatment of obesity |
US7429646B1 (en) | 1995-06-05 | 2008-09-30 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor-like 2 |
US6475806B1 (en) | 1995-06-07 | 2002-11-05 | Praecis Pharmaceuticals, Inc. | Anchor libraries and identification of peptide binding sequences |
PT1568772E (en) * | 1995-09-21 | 2010-04-14 | Genentech Inc | Human growth hormone variants |
US7368111B2 (en) | 1995-10-06 | 2008-05-06 | Cambridge Antibody Technology Limited | Human antibodies specific for TGFβ2 |
DK0859959T3 (en) * | 1995-11-10 | 2003-11-24 | Elan Corp Plc | Peptides that enhance tissue transport and methods for identifying and using them |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
WO1997035194A2 (en) * | 1996-03-21 | 1997-09-25 | President And Fellows Of Harvard College | Enantiomeric screening process, and compositions therefor |
US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
US6361938B1 (en) | 1996-11-08 | 2002-03-26 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
US20070185032A1 (en) * | 1996-12-11 | 2007-08-09 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
US6497874B1 (en) | 1997-02-05 | 2002-12-24 | Maardh Sven | Recombinant phages |
ES2285768T5 (en) | 1997-04-16 | 2011-12-22 | Millennium Pharmaceuticals, Inc. | CRSP PROTEINS (SEGREGATED PROTEINS RICH IN CYSTEINE), NUCLEIC ACID MOLECULES CODING FOR THE SAME AND USE. |
US6306826B1 (en) | 1997-06-04 | 2001-10-23 | The Regents Of The University Of California | Treatment of heart failure with growth hormone |
US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
US6172213B1 (en) * | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
US7378506B2 (en) | 1997-07-21 | 2008-05-27 | Ohio University | Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins |
US6639050B1 (en) | 1997-07-21 | 2003-10-28 | Ohio University | Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins |
CA2297070A1 (en) | 1997-08-01 | 1999-02-11 | Morphosys Ag | Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex |
GB2375765B (en) * | 1997-11-14 | 2003-02-26 | Kymed Gb Ltd | Tagged growth hormone molecules |
GB9723955D0 (en) | 1997-11-14 | 1998-01-07 | Generic Biolog Limited | Improvements in or relating to detection of molecules in samples |
US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
ES2316175T3 (en) | 1997-11-21 | 2009-04-01 | Genentech, Inc. | SPECIFIC ANTIGENS OF PLATQUETS AND THEIR PHARMACOLOGICAL USES. |
EP1093457B8 (en) | 1998-03-19 | 2011-02-02 | Human Genome Sciences, Inc. | Cytokine receptor common gamma chain like |
US7163682B2 (en) | 1998-04-13 | 2007-01-16 | The Forsyth Institute | Glucan binding protein and glucosyltransferase immunogens |
US7056517B2 (en) | 1998-04-13 | 2006-06-06 | The Forsyth Institute | Glucosyltransferase immunogens |
CA2334170A1 (en) * | 1998-07-27 | 2000-02-10 | Genentech, Inc. | Improved transformation efficiency in phage display through modification of a coat protein |
US6387888B1 (en) | 1998-09-30 | 2002-05-14 | American Foundation For Biological Research, Inc. | Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen |
US6485972B1 (en) | 1998-10-15 | 2002-11-26 | President And Fellows Of Harvard College | WNT signalling in reproductive organs |
US6420110B1 (en) | 1998-10-19 | 2002-07-16 | Gpc Biotech, Inc. | Methods and reagents for isolating biologically active peptides |
WO2000024415A2 (en) * | 1998-10-28 | 2000-05-04 | Cornell Research Foundation, Inc. | Methods for regulating angiogenesis and vascular integrity using trk receptor ligands |
US6927024B2 (en) | 1998-11-30 | 2005-08-09 | Genentech, Inc. | PCR assay |
US6696063B1 (en) * | 1998-12-30 | 2004-02-24 | Applied Research Systems Ars Holding N.V. | Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy |
EP1141313A2 (en) | 1998-12-31 | 2001-10-10 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
US20030194800A1 (en) * | 2001-08-31 | 2003-10-16 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
AU2487300A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
AU2596600A (en) * | 1998-12-31 | 2000-07-31 | Chiron Corporation | Modified hiv env polypeptides |
PT1141015E (en) | 1999-01-06 | 2009-10-13 | Genentech Inc | Insulin-like growth factor (igf) i mutant variants |
PT1141014E (en) | 1999-01-06 | 2005-04-29 | Genentech Inc | VARIATION OF THE INSULIN-LIKELY GROWTH FACTOR (IGF-I) |
EP2357192A1 (en) | 1999-02-26 | 2011-08-17 | Human Genome Sciences, Inc. | Human endokine alpha and methods of use |
WO2000050443A2 (en) | 1999-02-26 | 2000-08-31 | Millennium Pharmaceutcals, Inc. | Secreted proteins and uses thereof |
JP2002538167A (en) | 1999-03-03 | 2002-11-12 | バイオジェン インコーポレイテッド | Methods for regulating lipid metabolism and storage |
AR043274A1 (en) | 1999-03-25 | 2005-07-27 | Abbott Gmbh & Co Kg | HUMAN ANTIBODIES LINKING TO HUMAN IL-12 AND METHODS TO PRODUCE THEM |
US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
WO2000058521A2 (en) * | 1999-03-31 | 2000-10-05 | Rosetta Inpharmatics, Inc. | Methods for the identification of reporter and target molecules using comprehensive gene expression profiles |
DE19915057A1 (en) | 1999-04-01 | 2000-10-19 | Forschungszentrum Borstel | Monoclonal antibodies to the human Mcm3 protein, process for their preparation and their use |
US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
US7270969B2 (en) * | 1999-05-05 | 2007-09-18 | Phylogica Limited | Methods of constructing and screening diverse expression libraries |
US7803765B2 (en) * | 1999-05-05 | 2010-09-28 | Phylogica Limited | Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom |
CA2721199A1 (en) | 1999-05-05 | 2000-11-16 | Phylogica Limited | Isolating biological modulators from biodiverse gene fragment libraries |
US6221597B1 (en) | 1999-05-21 | 2001-04-24 | Rosetta Inpharmatics, Inc. | Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs |
US6200803B1 (en) | 1999-05-21 | 2001-03-13 | Rosetta Inpharmatics, Inc. | Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs |
US7396905B1 (en) | 1999-05-21 | 2008-07-08 | Mckeon Frank | Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto |
US6197517B1 (en) | 1999-05-21 | 2001-03-06 | Rosetta Inpharmatics, Inc. | Essential genes of yeast as targets for antifungal agents, herbicides, insecticides and anti-proliferative drugs |
US20030166003A1 (en) * | 1999-06-14 | 2003-09-04 | Cochran Andrea G. | Structured peptide scaffold for displaying turn libraries on phage |
JP2003502304A (en) * | 1999-06-14 | 2003-01-21 | ジェネンテック・インコーポレーテッド | Structured peptide scaffolds for displaying turn libraries on phage |
US7291714B1 (en) | 1999-06-30 | 2007-11-06 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
US20040001826A1 (en) | 1999-06-30 | 2004-01-01 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
CA2347973C (en) | 1999-07-20 | 2010-06-22 | Morphosys Ag | Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds |
WO2001014557A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
DE19943743C2 (en) * | 1999-09-03 | 2002-02-07 | Jerini Biotools Gmbh | Procedure for the identification of binding partners with position-specific arrays |
NZ531141A (en) | 1999-10-20 | 2005-07-29 | Genentech Inc | Modulation of T cell differentiation for the treatment of T helper cell mediated diseases |
US20060073509A1 (en) * | 1999-11-18 | 2006-04-06 | Michael Kilpatrick | Method for detecting and quantitating multiple subcellular components |
US8168178B2 (en) | 1999-11-30 | 2012-05-01 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
US6951839B1 (en) | 1999-11-30 | 2005-10-04 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
EP1240319A1 (en) * | 1999-12-15 | 2002-09-18 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
US20020004247A1 (en) * | 1999-12-23 | 2002-01-10 | Genentech, Inc. | Assay method |
ES2283340T3 (en) | 1999-12-30 | 2007-11-01 | President And Fellows Of Harvard College | METHODS CONCERNING THE MODULATION OF THE ACTIVITY OF THE TH2 CELL SUBCONJUNCT BY MODULATION OF THE ACTIVITY OF XBP-1. |
CN1461310B (en) | 2000-02-10 | 2013-06-12 | 雅培制药有限公司 | ANtibodies that bind human interleukin-18 and methods of making and using |
US6632645B1 (en) | 2000-03-02 | 2003-10-14 | Promega Corporation | Thermophilic DNA polymerases from Thermoactinomyces vulgaris |
US6436677B1 (en) | 2000-03-02 | 2002-08-20 | Promega Corporation | Method of reverse transcription |
US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
CN101289511A (en) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | Multivalent antibodies and uses therefore |
EP1274720A4 (en) | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | Albumin fusion proteins |
ES2393535T3 (en) * | 2000-04-17 | 2012-12-26 | Dyax Corp. | New methods to build libraries of genetic packages that collectively present members of a diverse family of peptides, polypeptides or proteins |
US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
US7495070B2 (en) * | 2000-04-24 | 2009-02-24 | Yale University | Protein binding miniature proteins |
WO2001081375A2 (en) * | 2000-04-24 | 2001-11-01 | Yale University | Dna & protein binding miniature proteins |
ES2301547T3 (en) | 2000-05-16 | 2008-07-01 | Genentech, Inc. | TREATMENT OF CARTILAGO DISORDERS. |
EP1714661A3 (en) | 2000-05-19 | 2012-03-14 | The Center for Blood Research, INC. | Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity |
US6573370B1 (en) | 2000-05-19 | 2003-06-03 | Regents Of The University Of Michigan | PON3 and uses thereof |
US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
JP2004502412A (en) | 2000-06-08 | 2004-01-29 | ザ センター フォー ブラッド リサーチ インコーポレーティッド | Methods and compositions for inhibiting immunoglobulin-mediated reperfusion injury |
EP2431054A3 (en) | 2000-06-15 | 2013-03-06 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
AU6842701A (en) | 2000-06-16 | 2002-01-14 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to blys |
CA2414331C (en) | 2000-06-28 | 2011-11-29 | Genetics Institute, Llc. | Pd-l2 molecules: novel pd-1 ligands and uses therefor |
JP2004509072A (en) * | 2000-06-28 | 2004-03-25 | ブリストル−マイヤーズ スクイブ カンパニー | Selective androgen receptor modulators and methods for their identification, design and use |
UY26807A1 (en) | 2000-06-29 | 2002-01-31 | Abbott Lab | DOUBLE SPECIFICITY ANTIBODIES AND METHODS FOR THE ELABORATION AND USE OF THE SAME |
US7176037B2 (en) * | 2000-07-13 | 2007-02-13 | The Scripps Research Institute | Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation |
US6951947B2 (en) * | 2000-07-13 | 2005-10-04 | The Scripps Research Institute | Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation |
WO2002028893A2 (en) | 2000-07-14 | 2002-04-11 | Cropdesign N.V. | Plant cyclin-dependent kinase inhibitors |
US6878861B2 (en) | 2000-07-21 | 2005-04-12 | Washington State University Research Foundation | Acyl coenzyme A thioesterases |
DK1303293T3 (en) | 2000-07-27 | 2009-03-30 | Genentech Inc | Sequential administration of CPT-11 and APO-2L polypeptide |
US20080194022A1 (en) * | 2000-08-03 | 2008-08-14 | Clarke Michael F | Isolation and use of solid tumor stem cells |
US6984522B2 (en) * | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
CN1446077A (en) * | 2000-08-07 | 2003-10-01 | 耐科塔医药公司 | Inhaleable spray dried 4-holix bundle protein powders having minimized aggregation |
US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
UA81743C2 (en) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS |
JP2004508411A (en) * | 2000-09-13 | 2004-03-18 | プラエシス ファーマシューティカルズ インコーポレーテッド | Pharmaceutical compositions for sustained drug delivery |
GB0022978D0 (en) | 2000-09-19 | 2000-11-01 | Oxford Glycosciences Uk Ltd | Detection of peptides |
JP2004517816A (en) | 2000-09-26 | 2004-06-17 | ジェネンテック・インコーポレーテッド | IGE receptor antagonist |
US7393532B1 (en) | 2000-10-18 | 2008-07-01 | Genentech, Inc. | Modulation of T cell differentiation for the treatment of T helper cell mediated diseases |
US6673580B2 (en) * | 2000-10-27 | 2004-01-06 | Genentech, Inc. | Identification and modification of immunodominant epitopes in polypeptides |
US6841359B2 (en) | 2000-10-31 | 2005-01-11 | The General Hospital Corporation | Streptavidin-binding peptides and uses thereof |
JP2004515233A (en) | 2000-11-01 | 2004-05-27 | イルーシス セラポーティクス,インコーポレーテッド | Method for producing bispecific molecules by protein trans-splicing |
US7037652B2 (en) | 2000-11-28 | 2006-05-02 | Wyeth | Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
EP2338512A1 (en) | 2000-11-28 | 2011-06-29 | MedImmune, LLC | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
EP2316976A1 (en) | 2000-11-28 | 2011-05-04 | Wyeth LLC | Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
US20040253242A1 (en) * | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
US7396917B2 (en) * | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
DE60136656D1 (en) | 2000-12-05 | 2009-01-02 | Alexion Pharma Inc | Rationally designed antibodies |
US20040198661A1 (en) * | 2000-12-08 | 2004-10-07 | Bowdish Katherine S. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US7408041B2 (en) | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US9249229B2 (en) * | 2000-12-08 | 2016-02-02 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
WO2002059280A2 (en) * | 2000-12-08 | 2002-08-01 | Alexion Pharmaceuticals, Inc. | Chronic lymphocytic leukemia cell line and its use for producing an antibody |
PT1355919E (en) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Molecules with extended half-lives, compositions and uses thereof |
AU2002249854B2 (en) | 2000-12-18 | 2007-09-20 | Dyax Corp. | Focused libraries of genetic packages |
JP4986370B2 (en) | 2000-12-22 | 2012-07-25 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | Uses of RGM and its modulators |
CA2447832C (en) * | 2000-12-22 | 2012-09-25 | Jamshid Tanha | Phage display libraries of human vh fragments |
ATE464322T1 (en) | 2001-01-05 | 2010-04-15 | Pfizer | ANTIBODIES AGAINST THE INSULIN-LIKE GROWTH FACTOR RECEPTOR I |
JP2005503116A (en) | 2001-02-09 | 2005-02-03 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | Human G protein chemokine receptor (CCR5) HDGNR10 |
US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
CA2438680A1 (en) | 2001-02-23 | 2002-09-06 | Dsm Ip Assets B.V. | Genes encoding proteolytic enzymes from aspargilli |
ES2360205T3 (en) | 2001-03-02 | 2011-06-01 | Agennix Ag | THREE HYBRID TEST SYSTEM. |
AU2002250236A1 (en) * | 2001-03-02 | 2002-09-19 | Medimmune, Inc. | Cd2 antagonists for treatment of autoimmune or inflammatory disease |
US8231878B2 (en) * | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
CA2342376C (en) * | 2001-03-20 | 2013-11-12 | Marco Colonna | A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
US20090081199A1 (en) * | 2001-03-20 | 2009-03-26 | Bioxell S.P.A. | Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
CA2440676A1 (en) | 2001-03-22 | 2002-10-03 | Abbott Gmbh & Co. Kg | Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
BR0208637A (en) | 2001-04-02 | 2004-12-07 | Wyeth Corp | Pd-1, a b7-4 receptor, and uses thereof |
ATE470676T1 (en) | 2001-04-13 | 2010-06-15 | Human Genome Sciences Inc | ANTI-VEGF-2 ANTIBODIES |
EP1572868A4 (en) | 2001-04-16 | 2007-04-04 | Wyeth Corp | Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
US6914123B2 (en) | 2001-04-17 | 2005-07-05 | Genentech, Inc. | Hairpin peptides with a novel structural motif and methods relating thereto |
US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
CN100594935C (en) | 2001-05-25 | 2010-03-24 | 人体基因组科学有限公司 | Antibodies that immunospecifically bind to trail receptors |
US20060239533A1 (en) * | 2001-06-04 | 2006-10-26 | Triantafyllos Tafas | Method for detecting infectious agents using computer controlled automated image analysis |
US20030148380A1 (en) * | 2001-06-05 | 2003-08-07 | Belcher Angela M. | Molecular recognition of materials |
US20030113714A1 (en) * | 2001-09-28 | 2003-06-19 | Belcher Angela M. | Biological control of nanoparticles |
US20050164515A9 (en) * | 2001-06-05 | 2005-07-28 | Belcher Angela M. | Biological control of nanoparticle nucleation, shape and crystal phase |
US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
CA2868614A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US20050107595A1 (en) * | 2001-06-20 | 2005-05-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7803915B2 (en) * | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
PT2000545E (en) | 2001-06-20 | 2011-12-21 | Genentech Inc | Compositions and methods for the diagnosis and treatment of lung tumor |
AU2002322388A1 (en) | 2001-06-22 | 2003-01-08 | E.I. Du Pont De Nemours And Company | Defensin polynucleotides and methods of use |
CA2452015C (en) | 2001-07-05 | 2012-07-03 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
EP2292772A1 (en) * | 2001-07-05 | 2011-03-09 | Novartis Vaccines and Diagnostics, Inc. | HIV vaccination with a DNA encoding a HIV polypeptide and a HIV polypeptide |
DE10135039C1 (en) * | 2001-07-18 | 2003-03-13 | Nemod Immuntherapie Ag | Method for isolating large variances of specific molecules for a target molecule from phagemid gene libraries |
US6867189B2 (en) * | 2001-07-26 | 2005-03-15 | Genset S.A. | Use of adipsin/complement factor D in the treatment of metabolic related disorders |
KR100458083B1 (en) * | 2001-08-29 | 2004-11-18 | 주식회사 아이지세라피 | Method for the construction of phage display library using helper phage variants |
US20030170614A1 (en) * | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
US20030091593A1 (en) * | 2001-09-14 | 2003-05-15 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
NZ573831A (en) | 2001-09-18 | 2010-07-30 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor, particularly breast tumor - TAT193 |
US20030073104A1 (en) * | 2001-10-02 | 2003-04-17 | Belcher Angela M. | Nanoscaling ordering of hybrid materials using genetically engineered mesoscale virus |
US20050123925A1 (en) | 2002-11-15 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
AR039067A1 (en) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
WO2003051917A2 (en) | 2001-12-18 | 2003-06-26 | Endocube Sas | Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control |
US7858297B2 (en) | 2001-12-18 | 2010-12-28 | Centre National De La Recherche Scientifique Cnrs | Chemokine-binding protein and methods of use |
AU2002359721A1 (en) | 2001-12-19 | 2003-07-09 | Bristol-Myers Squibb Company | Pichia pastoris formate dehydrogenase and uses therefor |
CA2841097A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin and g-csf fusion proteins |
CA2471431A1 (en) | 2002-01-02 | 2003-07-17 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
CN1639185A (en) * | 2002-01-03 | 2005-07-13 | 斯克里普斯研究学院 | Cancer-associated epitope |
US20060046249A1 (en) * | 2002-01-18 | 2006-03-02 | Fei Huang | Identification of polynucleotides and polypetide for predicting activity of compounds that interact with protein tyrosine kinase and or protein tyrosine kinase pathways |
US7094579B2 (en) | 2002-02-13 | 2006-08-22 | Xoma Technology Ltd. | Eukaryotic signal sequences for prokaryotic expression |
US20030180819A1 (en) * | 2002-03-01 | 2003-09-25 | Carney Walter P. | Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples |
DE60329020D1 (en) | 2002-03-01 | 2009-10-08 | Siemens Healthcare Diagnostics | ASSAYS FOR THE MONITORING OF CANCER PATIENTS BASED ON THE MIRROR OF THE EXTRACELLULAR DOMAIN (ECD) ANALYSIS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR), ALONE OR IN COMBINATION WITH OTHER ANALYTES, IN SAMPLES FROM BODY FLUIDS |
AU2003217976A1 (en) | 2002-03-07 | 2003-09-22 | The Forsyth Institute | Immunogenicity of glucan binding protein |
CA2480052A1 (en) * | 2002-04-01 | 2003-10-16 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
GB0207533D0 (en) | 2002-04-02 | 2002-05-08 | Oxford Glycosciences Uk Ltd | Protein |
US7745192B2 (en) | 2002-04-03 | 2010-06-29 | Venomics Pty Limited | Prothrombin activating protein |
EP1499352A4 (en) | 2002-04-12 | 2006-10-11 | Medimmune Inc | Recombinant anti-interleukin-9 antibodies |
NZ535925A (en) | 2002-04-16 | 2008-06-30 | Genentech Inc | An isolated antibody that binds to a particular polypeptide |
US20030206898A1 (en) | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
WO2003097825A2 (en) | 2002-05-21 | 2003-11-27 | Dsm Ip Assets B.V. | Novel phospholipases and uses thereof |
NZ556507A (en) * | 2002-06-03 | 2010-03-26 | Genentech Inc | Synthetic antibody phage libraries |
EP2305710A3 (en) | 2002-06-03 | 2013-05-29 | Genentech, Inc. | Synthetic antibody phage libraries |
AU2003274463B2 (en) * | 2002-06-10 | 2009-10-29 | University Of Rochester | Gene differentially expressed in breast and bladder cancer and encoded polypeptides |
US9321992B2 (en) * | 2002-06-14 | 2016-04-26 | Case Western Reserve University | Cell targeting methods and compositions |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
CA2490004A1 (en) | 2002-06-20 | 2003-12-31 | Board Of Trustees Operating Michigan State University | Plastid division and related genes and proteins, and methods of use |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
ATE514717T1 (en) | 2002-07-18 | 2011-07-15 | Merus B V | RECOMBINANT PRODUCTION OF ANTIBODIES MIXTURES |
PT1944322E (en) | 2002-07-19 | 2015-07-01 | Abbvie Biotechnology Ltd | Treatment of tnf alpha related disorders |
US7250551B2 (en) | 2002-07-24 | 2007-07-31 | President And Fellows Of Harvard College | Transgenic mice expressing inducible human p25 |
PT1534736E (en) | 2002-08-10 | 2010-09-07 | Univ Yale | Nogo receptor antagonists |
US20040067532A1 (en) | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
JP4459810B2 (en) | 2002-08-14 | 2010-04-28 | マクロジェニクス,インコーポレーテッド | FcγRIIB specific antibody and method of use thereof |
WO2004018660A2 (en) | 2002-08-19 | 2004-03-04 | Dsm Ip Assets B.V. | Novel lipases and uses thereof |
DE10238846A1 (en) * | 2002-08-20 | 2004-03-04 | Nemod Immuntherapie Ag | Active fusion proteins and processes for their production |
WO2004018505A1 (en) | 2002-08-20 | 2004-03-04 | Yeda Research And Development Co. Ltd. | Akap84 and its use for visualization of biological structures |
EP2311978A1 (en) | 2002-08-20 | 2011-04-20 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
EP1575515A4 (en) * | 2002-08-29 | 2007-08-08 | Genentech Inc | Achaete-scute like-2 polypeptides and encoding nucleic acids and methods for the diagnosis and treatment of tumor |
WO2004030613A2 (en) | 2002-09-04 | 2004-04-15 | University Of Louisville Research Foundation, Inc. | Cancer therapy using beta glucan and antibodies |
WO2004022593A2 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
US20050064508A1 (en) | 2003-09-22 | 2005-03-24 | Semzyme | Peptide mediated synthesis of metallic and magnetic materials |
WO2005000194A2 (en) | 2002-10-08 | 2005-01-06 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same |
NZ539101A (en) | 2002-10-08 | 2008-08-29 | Rinat Neuroscience Corp | Methods for treating post-surgical pain by administering a nerve growth factor antagonist and compositions containing the same |
AU2003279216A1 (en) * | 2002-10-09 | 2004-05-04 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
DE60336406D1 (en) | 2002-10-16 | 2011-04-28 | Purdue Pharma Lp | ANTIBODIES BINDING TO CELL ASSOCIATED CA 125 / 0722P, AND METHOD FOR THEIR USE |
CN100434440C (en) * | 2002-12-02 | 2008-11-19 | 阿布格尼克斯公司 | Antibodies directed to tumor necrosis factor and uses thereof |
US7056702B2 (en) * | 2002-12-16 | 2006-06-06 | Kimberly Clark Co | Detecting lipocalin |
AU2003293958A1 (en) * | 2002-12-23 | 2004-07-22 | Apalexo Biotechnologie Gmbh | Purification of recombinant filamental bacteriophages by means of affinity chromatography to increase the immunogenicity and efficacy of phagic vaccines |
ATE431157T1 (en) * | 2002-12-23 | 2009-05-15 | Rinat Neuroscience Corp | METHOD FOR TREATING TAXOL-INDUCED SENSORY NEUROPATHY |
US7569364B2 (en) * | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
ATE553128T1 (en) * | 2002-12-24 | 2012-04-15 | Rinat Neuroscience Corp | ANTI-NGF ANTIBODIES AND METHOD OF USE THEREOF |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
AU2004204095B2 (en) | 2003-01-07 | 2009-07-30 | Dyax Corporation | Kunitz domain library |
AU2004205631A1 (en) * | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
JP2006518997A (en) * | 2003-01-21 | 2006-08-24 | ブリストル−マイヤーズ スクイブ カンパニー | Novel acyl coenzyme A: polynucleotide encoding monoacylglycerol acyltransferase-3 (MGAT3) and uses thereof |
US7429472B2 (en) * | 2003-01-31 | 2008-09-30 | Promega Corporation | Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule |
DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
US7238842B2 (en) * | 2003-01-31 | 2007-07-03 | Promega Corporation | Covalent tethering of functional groups to proteins |
WO2004070011A2 (en) * | 2003-02-01 | 2004-08-19 | Tanox, Inc. | HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES |
PL379983A1 (en) * | 2003-02-19 | 2006-11-27 | Rinat Neuroscience Corp. | Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same |
ES2457538T3 (en) | 2003-02-20 | 2014-04-28 | Seattle Genetics, Inc. | Anti-CD70-drug antibody conjugates and their use for the treatment of cannula and immune disorders |
US20040180387A1 (en) | 2003-03-13 | 2004-09-16 | Fujirebio Diagnostics, Inc. | Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer |
PT2248899E (en) * | 2003-03-19 | 2015-09-23 | Biogen Ma Inc | Nogo receptor binding protein |
EP1620127A4 (en) * | 2003-03-20 | 2007-04-04 | Rinat Neuroscience Corp | Methods for treating taxol-induced gut disorder |
US7294701B2 (en) * | 2003-04-02 | 2007-11-13 | Technion Research & Development Foundation Ltd. | Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same |
US7354584B2 (en) | 2003-04-11 | 2008-04-08 | Medimmune, Inc. | Recombinant IL-9 antibodies |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US20050014932A1 (en) | 2003-05-15 | 2005-01-20 | Iogenetics, Llc | Targeted biocides |
EP2395016A3 (en) | 2003-05-30 | 2012-12-19 | Merus B.V. | Design and use of paired variable regions of specific binding molecules |
CN1829741A (en) | 2003-05-30 | 2006-09-06 | 健泰科生物技术公司 | Treatment with anti-VEGF antibodies |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
US9708410B2 (en) | 2003-05-30 | 2017-07-18 | Janssen Biotech, Inc. | Anti-tissue factor antibodies and compositions |
KR20110117728A (en) | 2003-06-06 | 2011-10-27 | 제넨테크, 인크. | Modulating the interaction between hgf beta chain and c-met |
WO2005004794A2 (en) | 2003-06-09 | 2005-01-20 | Alnylam Pharmaceuticals Inc. | Method of treating neurodegenerative disease |
EP2481814A3 (en) * | 2003-06-09 | 2012-10-10 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing cancer |
EP2277908A3 (en) | 2003-07-08 | 2011-12-14 | Genentech, Inc. | IL-17A/F heterologous polypeptides, antibodies and therapeutic uses thereof |
AU2004259727A1 (en) * | 2003-07-15 | 2005-02-03 | Barros Research Institute | Compositions and methods for immunotherapy of cancer and infectious diseases. |
US20050058658A1 (en) * | 2003-07-15 | 2005-03-17 | Barros Research Institute | Compositions and methods for immunotherapy of human immunodeficiency virus (HIV) |
US7727752B2 (en) | 2003-07-29 | 2010-06-01 | Life Technologies Corporation | Kinase and phosphatase assays |
US7758859B2 (en) | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
HN2004000285A (en) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTIBODIES DIRECTED TO c-MET |
JP2007511738A (en) | 2003-08-08 | 2007-05-10 | ジーンニュース インコーポレーテッド | Biomarkers for osteoarthritis and uses thereof |
ES2458636T3 (en) | 2003-08-18 | 2014-05-06 | Medimmune, Llc | Humanization of antibodies |
JP2007504244A (en) * | 2003-09-05 | 2007-03-01 | ザ スクリプス リサーチ インスティテュート | Cholesterol ozonation products for the treatment and prevention of atherosclerosis and / or cardiovascular disease |
US20050085556A1 (en) * | 2003-09-05 | 2005-04-21 | Paul Wentworth | Detection of cholesterol ozonation products |
AR045563A1 (en) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | ANTIBODIES DIRECTED TO M-CSF |
MXPA06003402A (en) | 2003-10-07 | 2006-06-27 | Millennium Pharm Inc | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer. |
IL158287A0 (en) | 2003-10-07 | 2004-05-12 | Yeda Res & Dev | Antibodies to nik, their preparation and use |
WO2005037232A2 (en) | 2003-10-17 | 2005-04-28 | Joslin Diabetes Center, Inc. | Methods and compositions for modulating adipocyte function |
US7329725B1 (en) * | 2003-10-29 | 2008-02-12 | Nastech Pharmaceutical Company Inc. | Phage displayed Trp cage ligands |
GB0325836D0 (en) * | 2003-11-05 | 2003-12-10 | Celltech R&D Ltd | Biological products |
EP1697415A1 (en) | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
DK2161283T3 (en) | 2003-11-17 | 2014-09-01 | Genentech Inc | COMPOSITIONS CONTAINING ANTIBODIES AGAINST CD79b CONJUGED TO A GROWTH INHIBITOR OR CYTOTOXIC AGENT, AND METHODS FOR TREATING TUMOR OF HEMATOPOIETIC ORIGIN |
US20070269428A1 (en) | 2003-11-21 | 2007-11-22 | Celltech R&D Limited | Method for the Treatment of Multiple Sclerosis by Inhibiting Il-17 Activity |
AU2004296184B2 (en) * | 2003-12-04 | 2010-12-16 | Vaccinex, Inc. | Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
US20050233960A1 (en) | 2003-12-11 | 2005-10-20 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
EA200601220A1 (en) * | 2003-12-23 | 2006-12-29 | Ринат Ньюросайенс Корп. | ANTI-TRKC ANTIBODY-AGONISTS AND METHODS OF THEIR APPLICATION |
GB0329825D0 (en) * | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
US20050266425A1 (en) * | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
DK2177537T3 (en) | 2004-01-09 | 2011-12-12 | Pfizer | Antibodies to MAdCAM |
WO2005069845A2 (en) | 2004-01-14 | 2005-08-04 | Ohio University | Methods of producing peptides/proteins in plants and peptides/proteins produced thereby |
AU2005207003C1 (en) | 2004-01-20 | 2013-06-13 | Humanigen, Inc. | Antibody specificity transfer using minimal essential binding determinants |
DK1737971T3 (en) | 2004-01-20 | 2017-11-13 | Merus Nv | MIXTURES OF BINDING PROTEINS |
US20060014211A1 (en) | 2004-01-21 | 2006-01-19 | Fujirebio Diagnostics, Inc. | Detection of mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of the peritoneum and the peritoneal cavity |
EP2033662B1 (en) | 2004-01-21 | 2012-10-17 | Novo Nordisk Health Care AG | Transglutaminase mediated conjugation of peptides |
AU2005209926B2 (en) * | 2004-02-02 | 2007-09-06 | Ambrx, Inc. | Modified human four helical bundle polypeptides and their uses |
CA2554779A1 (en) * | 2004-02-03 | 2005-08-18 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
BRPI0507026A (en) | 2004-02-09 | 2007-04-17 | Human Genome Sciences Inc | albumin fusion proteins |
DE602005018325D1 (en) | 2004-02-19 | 2010-01-28 | Genentech Inc | ANTIBODIES WITH CORRECTED CDR |
ATE498010T1 (en) | 2004-03-01 | 2011-02-15 | Immune Disease Inst Inc | NATURAL IGM ANTIBODIES AND INHIBITORS THEREOF |
US7592188B2 (en) * | 2004-03-12 | 2009-09-22 | The Scripps Research Institute | Live cell biosensors |
KR100882249B1 (en) | 2004-03-24 | 2009-02-06 | 트리패스 이미징, 인코포레이티드 | Methods and compositions for the detection of cervical disease |
WO2005097184A2 (en) * | 2004-03-26 | 2005-10-20 | Human Genome Sciences, Inc. | Antibodies against nogo receptor |
CN1961003B (en) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | Humanized anti-TGF-beta antibodies |
US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
SG152226A1 (en) * | 2004-04-07 | 2009-05-29 | Rinat Neuroscience Corp | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
TWI439284B (en) | 2004-04-09 | 2014-06-01 | Abbvie Biotechnology Ltd | Multiple-variable dose regimen for treating tnfα-related disorders |
US7785903B2 (en) * | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
EP1745149A4 (en) | 2004-04-15 | 2008-08-06 | Univ Florida | Neural proteins as biomarkers for nervous system injury and other neural disorders |
AU2005250333A1 (en) * | 2004-04-16 | 2005-12-15 | Genentech, Inc. | Omi PDZ modulators |
EP1751177A4 (en) | 2004-04-19 | 2008-07-16 | Univ Ohio | Cross-linkable glycoproteins and methods of making the same |
ES2442386T3 (en) | 2004-04-23 | 2014-02-11 | Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr | Method for the treatment of conditions mediated by T cells by the decrease of positive ICOS cells in vivo. |
US20060292554A1 (en) * | 2004-05-18 | 2006-12-28 | Genentech, Inc. | Major coat protein variants for C-terminal and bi-terminal display |
EP1602928A1 (en) * | 2004-06-01 | 2005-12-07 | Universiteit Maastricht | Process and kit for determining binding parameters of bioaffinity binding reactions |
US20110218118A1 (en) * | 2004-06-03 | 2011-09-08 | Phylogica Limited | Peptide modulators of cellular phenotype and bi-nucleic acid fragment library |
NZ551782A (en) | 2004-06-03 | 2010-03-26 | Athlomics Pty Ltd | Agents and methods for diagnosing stress |
US7604947B2 (en) * | 2004-06-09 | 2009-10-20 | Cornell Research Foundation, Inc. | Detection and modulation of cancer stem cells |
EP1771205B1 (en) * | 2004-06-18 | 2016-10-26 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
PT1776136E (en) | 2004-06-24 | 2012-12-05 | Biogen Idec Inc | Treatment of conditions involving demyelination |
US6986264B1 (en) * | 2004-07-15 | 2006-01-17 | Carrier Corporation | Economized dehumidification system |
BRPI0513200A (en) | 2004-07-16 | 2008-04-29 | Pfizer Prod Inc | use of an anti-igf-1r antibody in the preparation of a medicament for combined treatment for nonhematological malignancies |
NZ552956A (en) | 2004-07-20 | 2010-03-26 | Genentech Inc | Inhibitors of angiopoietin-like 4 protein (ANGPTL4), combinations, and their use for treating cancer |
US8604185B2 (en) | 2004-07-20 | 2013-12-10 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
AU2005327906B2 (en) * | 2004-07-21 | 2010-05-13 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
US7342093B2 (en) | 2004-07-23 | 2008-03-11 | University Of Massachusetts | Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins |
US20070087400A1 (en) * | 2004-07-30 | 2007-04-19 | Aldis Darzins | Covalent tethering of functional groups to proteins and substrates therefor |
GEP20115195B (en) * | 2004-07-30 | 2011-04-11 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and use thereof |
US7425436B2 (en) | 2004-07-30 | 2008-09-16 | Promega Corporation | Covalent tethering of functional groups to proteins and substrates therefor |
US7846438B2 (en) | 2004-08-03 | 2010-12-07 | Biogen Idec Ma Inc. | Methods of promoting neurite outgrowth with soluble TAJ polypeptides |
SI2322556T1 (en) | 2004-09-03 | 2016-02-29 | Genentech, Inc. | Humanized anti-beta7 antagonists and uses therefor |
AU2005286770A1 (en) | 2004-09-21 | 2006-03-30 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
WO2006047417A2 (en) | 2004-10-21 | 2006-05-04 | University Of Florida Research Foundation, Inc. | Detection of cannabinoid receptor biomarkers and uses thereof |
AU2005299701B2 (en) | 2004-10-21 | 2011-11-17 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
CA2585717A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
US20060177436A1 (en) * | 2004-12-16 | 2006-08-10 | Genentech, Inc. | Methods for Treating Autoimmune Disorders |
EP2290088A1 (en) | 2004-12-22 | 2011-03-02 | Genentech, Inc. | Methods for producing soluble multi-menbrane-spanning proteins |
EP2284191A3 (en) | 2004-12-22 | 2011-07-20 | Ambrx, Inc. | Process for the preparation of hGH |
MX2007007591A (en) * | 2004-12-22 | 2007-07-25 | Ambrx Inc | Methods for expression and purification of recombinant human growth hormone. |
NZ555386A (en) | 2004-12-22 | 2011-01-28 | Ambrx Inc | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
ATE541934T1 (en) * | 2004-12-22 | 2012-02-15 | Ambrx Inc | AMINOACYL TRNA SYNTHETASE COMPOSITIONS AND USES THEREOF |
PT1699826E (en) | 2005-01-05 | 2009-06-17 | F Star Biotech Forsch & Entw | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
EP2311880A3 (en) | 2005-01-05 | 2011-07-27 | Biogen Idec MA Inc. | Cripto binding molecules |
GT200600031A (en) | 2005-01-28 | 2006-08-29 | ANTI-BETA ANTIBODY FORMULATION | |
US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
EP2520669A3 (en) | 2005-02-07 | 2013-02-27 | GeneNews Inc. | Mild osteoathritis biomarkers and uses thereof |
AU2006214121B9 (en) | 2005-02-15 | 2013-02-14 | Duke University | Anti-CD19 antibodies and uses in oncology |
US8211430B2 (en) * | 2005-03-04 | 2012-07-03 | Curedm Group Holdings, Llc | Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions |
US20090142338A1 (en) * | 2005-03-04 | 2009-06-04 | Curedm, Inc. | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions |
ZA200707490B (en) | 2005-03-10 | 2008-12-31 | Genentech Inc | Methods and compositions for modulatiing vascular integrity |
JP5153613B2 (en) | 2005-03-18 | 2013-02-27 | メディミューン,エルエルシー | Antibody framework shuffle |
EP1861126A4 (en) | 2005-03-22 | 2009-11-18 | Harvard College | Treatment of protein degradation disorders |
EA037929B1 (en) | 2005-03-23 | 2021-06-08 | Генмаб А/С | Antibodies against human cd38 and use thereof |
GB0506912D0 (en) | 2005-04-05 | 2005-05-11 | Celltech R&D Ltd | Biological products |
EP1868650B1 (en) | 2005-04-15 | 2018-10-03 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
US20060269556A1 (en) * | 2005-04-18 | 2006-11-30 | Karl Nocka | Mast cell activation using siglec 6 antibodies |
EP1871418B1 (en) | 2005-04-19 | 2014-03-19 | Seattle Genetics, Inc. | Humanized anti-cd70 binding agents and uses thereof |
MX2007013217A (en) | 2005-04-25 | 2008-03-11 | Pfizer | Antibodies to myostatin. |
UA95775C2 (en) | 2005-04-26 | 2011-09-12 | Пфайзер Инк. | Antibody that specifically binds to p-cadherin |
AR054260A1 (en) * | 2005-04-26 | 2007-06-13 | Rinat Neuroscience Corp | METHODS OF TREATMENT OF DISEASES OF THE LOWER MOTOR NEURONE AND COMPOSITIONS USED IN THE SAME |
US7595380B2 (en) | 2005-04-27 | 2009-09-29 | Tripath Imaging, Inc. | Monoclonal antibodies and methods for their use in the detection of cervical disease |
PE20061324A1 (en) | 2005-04-29 | 2007-01-15 | Centocor Inc | ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES |
UY29504A1 (en) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | DIRECTED ANTIBODIES AGAINST BETA AMYLOID PEPTIDE AND METHODS USING THE SAME. |
NZ627177A (en) | 2005-05-16 | 2016-02-26 | Abbvie Biotechnology Ltd | Use of tnf inhibitor for treatment of erosive polyarthritis |
NZ563263A (en) | 2005-05-17 | 2010-04-30 | Univ Connecticut | Composition and methods for immunomodulation in an organism |
CA2726759C (en) | 2005-05-25 | 2016-02-16 | Curedm Group Holdings, Llc | Human proislet peptide, derivatives and analogs thereof, and methods of using same |
DK1888113T3 (en) | 2005-05-27 | 2014-09-01 | Biogen Idec Inc | TWEAK BINDING ANTIBODIES |
CA2609205A1 (en) * | 2005-06-03 | 2006-12-14 | Ambrx, Inc. | Improved human interferon molecules and their uses |
WO2006132788A2 (en) | 2005-06-06 | 2006-12-14 | Genentech, Inc. | Transgenic models for different genes and their use for gene characterization |
US20070099209A1 (en) * | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
WO2006138553A2 (en) | 2005-06-17 | 2006-12-28 | Wyeth | Methods of purifying fc region containing proteins |
KR20080025174A (en) | 2005-06-23 | 2008-03-19 | 메디뮨 인코포레이티드 | Antibody formulations having optimized aggregation and fragmentation profiles |
PT1896073E (en) | 2005-06-30 | 2013-05-28 | Janssen Biotech Inc | Anti-il-23 antibodies, compositions, methods and uses |
CN103172739A (en) | 2005-06-30 | 2013-06-26 | Abbvie公司 | IL-12/P40 binding proteins |
US20090264305A1 (en) | 2005-07-07 | 2009-10-22 | Athlomics Pty Ltd. | Polynucleotide Marker Genes and their Expression, for Diagnosis of Endotoxemia |
SI1904104T1 (en) | 2005-07-08 | 2013-12-31 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
WO2007008604A2 (en) * | 2005-07-08 | 2007-01-18 | Bristol-Myers Squibb Company | Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof |
JP4997239B2 (en) * | 2005-07-22 | 2012-08-08 | ワイズ・エー・シー株式会社 | Anti-CD26 antibody and method of use thereof |
DE602006014691D1 (en) | 2005-08-02 | 2010-07-15 | Xbiotech Inc | DIAGNOSIS, TREATMENT AND PREVENTION OF VASCULAR DISEASES USING IL-1alpha AUTOANTIC BODIES |
EP1920057A4 (en) | 2005-08-03 | 2009-03-18 | Grains Res & Dev Corp | Polysaccharide synthases |
EP1922410A2 (en) | 2005-08-15 | 2008-05-21 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
CN103103238B (en) | 2005-08-18 | 2016-08-10 | Ambrx公司 | A kind of manufacture in cell has selected amino acid whose antibody or the method for antibody fragment polypeptide in specific location |
US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US20090215992A1 (en) * | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
KR20140053410A (en) | 2005-08-19 | 2014-05-07 | 아보트 러보러터리즈 | Dual variable domain immunoglobulin and uses thereof |
US20070202512A1 (en) * | 2005-08-19 | 2007-08-30 | Bristol-Myers Squibb Company | Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof |
US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
EP2500357A3 (en) | 2005-08-19 | 2012-10-24 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
KR101536506B1 (en) | 2005-09-07 | 2015-07-14 | 암젠 프레몬트 인코포레이티드 | Human monoclonal antibodies to activin receptor-like kinase-1 |
EP1926757B1 (en) * | 2005-09-14 | 2012-02-22 | UCB Pharma, S.A. | Antibody-comb polymer conjugate |
JP2009510002A (en) | 2005-09-30 | 2009-03-12 | アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Binding domains of proteins of the repulsion-inducing molecule (RGM) protein family, and functional fragments thereof, and uses thereof |
KR101176830B1 (en) | 2005-10-17 | 2012-08-27 | 주식회사 아이지세라피 | Novel method for phage display |
CN102260742A (en) | 2005-10-21 | 2011-11-30 | 基因信息股份有限公司 | Method and apparatus for correlating levels of biomarker products with disease |
JP5602365B2 (en) | 2005-10-25 | 2014-10-08 | ザ・ジョンズ・ホプキンス・ユニバーシティ | Methods and compositions for treating Marfan syndrome and related diseases. |
CA2628255C (en) * | 2005-10-31 | 2016-04-19 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
ES2618785T3 (en) | 2005-10-31 | 2017-06-22 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating cancer based on human FZD receptors |
BRPI0618085A2 (en) | 2005-11-01 | 2011-08-16 | Abbott Biotech Ltd | Processes and kits for diagnosis of ankylosing spondylitis using biomarkers |
EP1959979A4 (en) | 2005-11-04 | 2010-01-27 | Biogen Idec Inc | Methods for promoting neurite outgrowth and survival of dopaminergic neurons |
EP2465870A1 (en) | 2005-11-07 | 2012-06-20 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
AU2006311661B2 (en) | 2005-11-07 | 2011-05-26 | The Scripps Research Institute | Compositions and methods for controlling tissue factor signaling specificity |
PT1954710E (en) * | 2005-11-08 | 2011-06-07 | Ambrx Inc | Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides |
UA96139C2 (en) * | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Anti-neuropilin-1 (nrp1) antibody |
HUE036940T2 (en) | 2005-11-14 | 2018-08-28 | Teva Pharmaceuticals Int Gmbh | Antagonist antibody directed against calcitonin gene-related peptide |
WO2007059166A2 (en) | 2005-11-14 | 2007-05-24 | Weber Georg F | Peptide sequence that promotes tumor invasion |
WO2007059312A2 (en) * | 2005-11-16 | 2007-05-24 | Ambrx, Inc. | Methods and compositions comprising non-natural amino acids |
EP1962584A2 (en) | 2005-11-21 | 2008-09-03 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
US20070122413A1 (en) | 2005-11-28 | 2007-05-31 | Sivakumar Pallavur V | Il-21 antagonists |
JP5475994B2 (en) | 2005-11-30 | 2014-04-16 | アッヴィ・インコーポレイテッド | Anti-Aβ globulomer antibody, antigen-binding portion thereof, corresponding hybridoma, nucleic acid, vector, host cell, method for producing said antibody, composition comprising said antibody, use of said antibody and method of using said antibody. |
RS53270B2 (en) | 2005-11-30 | 2018-05-31 | Abbvie Deutschland | Monoclonal antibodies against amyloid beta protein and uses thereof |
EP2410335A1 (en) | 2005-11-30 | 2012-01-25 | Massachusetts Institute of Technology (MIT) | Pathogen detection biosensor |
RU2470941C2 (en) * | 2005-12-02 | 2012-12-27 | Дженентек, Инк. | Binding polypeptides and use thereof |
EP1973951A2 (en) * | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
US7737259B2 (en) | 2005-12-02 | 2010-06-15 | Genentech, Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling |
EP1965827B1 (en) | 2005-12-02 | 2015-02-25 | Biogen Idec MA Inc. | Treatment of conditions involving demyelination |
WO2007066082A1 (en) | 2005-12-09 | 2007-06-14 | Ucb Pharma S.A. | Antibody molecules having specificity for human il-6 |
AU2006326404B2 (en) * | 2005-12-14 | 2011-11-03 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
EP1973948B1 (en) | 2005-12-15 | 2015-02-11 | Genentech, Inc. | Methods and compositions for targeting polyubiquitin |
US20070264687A1 (en) | 2005-12-15 | 2007-11-15 | Min-Yuan Chou | Recombinant triplex scaffold-based polypeptides |
US10183986B2 (en) | 2005-12-15 | 2019-01-22 | Industrial Technology Research Institute | Trimeric collagen scaffold antibodies |
US7632498B2 (en) | 2005-12-19 | 2009-12-15 | Tripath Imaging, Inc. | MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease |
MX2008008621A (en) | 2005-12-29 | 2008-11-27 | Centocor Inc | Human anti-il-23 antibodies, compositions, methods and uses. |
CA2638785C (en) | 2006-01-05 | 2017-02-21 | Genentech, Inc. | Anti-ephb4 antibodies and methods using same |
NZ599035A (en) | 2006-01-12 | 2013-12-20 | Alexion Pharma Inc | Antibodies to ox-2/cd200 and uses thereof |
ES2550099T3 (en) | 2006-01-27 | 2015-11-04 | Biogen Ma Inc. | Nogo receptor antagonists |
EP2363711A1 (en) | 2006-01-27 | 2011-09-07 | Tripath Imaging, Inc. | Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor |
US20080038761A1 (en) * | 2006-01-30 | 2008-02-14 | Invitrogen Corporation | Compositions and methods for detecting and quantifying toxic substances in disease states |
US20070175313A1 (en) * | 2006-01-31 | 2007-08-02 | Kevin Vandervliet | MP3 player holder assembly |
EP1987064A4 (en) | 2006-02-01 | 2010-04-07 | Arana Therapeutics Ltd | Domain antibody construct |
US8222423B2 (en) | 2006-02-14 | 2012-07-17 | Dana-Farber Cancer Institute, Inc. | Bifunctional histone deacetylase inhibitors |
JP2009527227A (en) | 2006-02-17 | 2009-07-30 | ジェネンテック・インコーポレーテッド | Gene disruption and related compositions and methods |
AU2007218045B2 (en) | 2006-02-20 | 2011-11-10 | Phylogica Limited | Method of constructing and screening libraries of peptide structures |
TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
US20070243192A1 (en) * | 2006-02-21 | 2007-10-18 | Regents Of The University Of Michigan | Growth hormone receptor antagonist cancer treatment |
TWI417301B (en) | 2006-02-21 | 2013-12-01 | Wyeth Corp | Antibodies against human il-22 and uses therefor |
EP1998785A4 (en) * | 2006-02-21 | 2009-06-17 | Univ Michigan | Hedgehog signaling pathway antagonist cancer treatment |
EP2010677A4 (en) * | 2006-02-24 | 2010-04-14 | Investigen Inc | Methods and compositions for detecting polynucleotides |
EP2650306A1 (en) | 2006-03-06 | 2013-10-16 | Aeres Biomedical Limited | Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
AR059851A1 (en) | 2006-03-16 | 2008-04-30 | Genentech Inc | ANTIBODIES OF EGFL7 AND METHODS OF USE |
EP2010569A4 (en) | 2006-03-20 | 2009-09-09 | Xoma Technology Ltd | Human antibodies specific for gastrin materials and methods |
EP2007428A2 (en) | 2006-04-05 | 2008-12-31 | Genentech, Inc. | Method for using boc/cdo to modulate hedgehog signaling |
NZ596517A (en) | 2006-04-05 | 2013-06-28 | Abbott Biotech Ltd | Antibody purification |
EP2708242A3 (en) | 2006-04-10 | 2014-03-26 | Abbott Biotechnology Ltd | Uses and compositions for treatment of ankylosing spondylitis |
EP2343551B1 (en) | 2006-04-10 | 2014-05-28 | Genentech, Inc. | Dishevelled PDZ modulators |
EP2007426A4 (en) | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | Uses and compositions for treatment of psoriatic arthritis |
CA2564435A1 (en) | 2006-04-10 | 2007-10-10 | Abbott Biotechnology Ltd. | Methods for monitoring and treating intestinal disorders |
JP2009536022A (en) | 2006-04-19 | 2009-10-08 | ジェネンテック・インコーポレーテッド | Novel gene disruption and related compositions and methods |
US7702468B2 (en) | 2006-05-03 | 2010-04-20 | Population Diagnostics, Inc. | Evaluating genetic disorders |
US10522240B2 (en) | 2006-05-03 | 2019-12-31 | Population Bio, Inc. | Evaluating genetic disorders |
JP5497431B2 (en) | 2006-05-03 | 2014-05-21 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Histone deacetylase and tubulin deacetylase inhibitors |
EP2016101A2 (en) * | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
US20090142259A1 (en) * | 2006-05-12 | 2009-06-04 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors |
US8524865B2 (en) | 2006-05-30 | 2013-09-03 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
US7862812B2 (en) | 2006-05-31 | 2011-01-04 | Lpath, Inc. | Methods for decreasing immune response and treating immune conditions |
WO2010123874A1 (en) | 2009-04-20 | 2010-10-28 | Oxford Biotherapeutics Ltd. | Antibodies specific to cadherin-17 |
GB0611116D0 (en) | 2006-06-06 | 2006-07-19 | Oxford Genome Sciences Uk Ltd | Proteins |
CA2654000A1 (en) | 2006-06-06 | 2008-05-22 | Genentech, Inc. | Anti-dll4 antibodies and methods using same |
WO2007146172A2 (en) * | 2006-06-07 | 2007-12-21 | Bioalliance C.V. | Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same |
SG10201504662WA (en) | 2006-06-14 | 2015-07-30 | Macrogenics Inc | Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity |
WO2008019199A2 (en) | 2006-06-26 | 2008-02-14 | Macrogenics, Inc. | FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
DE102006030028A1 (en) * | 2006-06-29 | 2008-02-14 | Forschungszentrum Jülich GmbH | A method for finding bait-binding specific molecules and bait-binding molecules and their use |
US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
AU2007269791B2 (en) | 2006-06-30 | 2013-10-03 | Abbvie Biotechnology Ltd | Automatic injection device |
ES2372709T3 (en) * | 2006-07-05 | 2012-01-25 | Catalyst Biosciences, Inc. | PROCEDURES FOR PROTEASES AND PROTEASES IDENTIFIED BY THE SAME PROCESSES. |
AT503889B1 (en) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | MULTIVALENT IMMUNE LOBULINE |
EA020324B1 (en) * | 2006-07-18 | 2014-10-30 | Санофи-Авентис | Antibodies against epha2 receptor and use thereof |
SI2511301T1 (en) | 2006-08-04 | 2018-05-31 | MedImmune Limited, | Human antibodies to erbb 2 |
AU2007284651B2 (en) | 2006-08-09 | 2014-03-20 | Institute For Systems Biology | Organ-specific proteins and methods of their use |
SG170032A1 (en) | 2006-08-28 | 2011-04-29 | Kyowa Hakko Kirin Co Ltd | Antagonistic human light-specific human monoclonal antibodies |
CN101611318B (en) | 2006-09-07 | 2015-03-04 | 奥塔哥创新有限公司 | Biomarkers |
SG174782A1 (en) * | 2006-09-08 | 2011-10-28 | Abbott Lab | Interleukin - 13 binding proteins |
AU2007292893B2 (en) * | 2006-09-08 | 2012-03-01 | Ambrx, Inc. | Suppressor tRNA transcription in vertebrate cells |
WO2008030613A2 (en) * | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Hybrid suppressor trna for vertebrate cells |
AU2007292903B2 (en) | 2006-09-08 | 2012-03-29 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
US20100008910A1 (en) | 2006-09-12 | 2010-01-14 | John Chant | Methods and compositions for the diagnosis and treatment of cancer |
WO2008034161A1 (en) * | 2006-09-19 | 2008-03-27 | Phylogica Limited | Neuroprotective peptide inhibitors of ap-1 signaling and uses therefor |
CA2664740C (en) | 2006-09-26 | 2021-11-16 | Genmab A/S | Combination treatment of cd38-expressing tumors |
MX2009003229A (en) * | 2006-09-29 | 2009-06-18 | Oncomed Pharm Inc | Compositions and methods for diagnosing and treating cancer. |
TWI414531B (en) * | 2006-10-12 | 2013-11-11 | Genentech Inc | Antibodies to lymphotoxin-alpha |
JP2010506839A (en) | 2006-10-12 | 2010-03-04 | ワイス エルエルシー | Methods and compositions with reduced opalescence |
AU2007313300A1 (en) | 2006-10-16 | 2008-04-24 | Medimmune, Llc. | Molecules with reduced half-lives, compositions and uses thereof |
GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
US20080096193A1 (en) * | 2006-10-24 | 2008-04-24 | Charles Robert Bupp | Methods and compositions for detecting polynucleotides |
KR101541550B1 (en) | 2006-10-27 | 2015-08-04 | 제넨테크, 인크. | Antibodies and immunoconjugates and uses therefor |
WO2008054821A2 (en) | 2006-10-30 | 2008-05-08 | Promega Corporation | Mutant hydrolase proteins with enhanced kinetics and functional expression |
JP5401319B2 (en) | 2006-11-03 | 2014-01-29 | ワイス・エルエルシー | Glycolytic inhibitors in cell culture |
AU2007323799B2 (en) | 2006-11-15 | 2013-07-18 | Eli Lilly And Company | Anti-TSG101 antibodies and their uses for treatment of viral infections |
US7488807B2 (en) | 2006-11-22 | 2009-02-10 | 3M Innovative Properties Company | Antibody with protein A selectivity |
WO2008064306A2 (en) * | 2006-11-22 | 2008-05-29 | Curedm, Inc. | Methods and compositions relating to islet cell neogenesis |
US8067179B2 (en) * | 2006-11-30 | 2011-11-29 | Research Development Foundation | Immunoglobulin libraries |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US8455622B2 (en) | 2006-12-01 | 2013-06-04 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
US8637244B2 (en) | 2006-12-05 | 2014-01-28 | Decode Genetics Ehf. | Genetic markers for risk management of atrial fibrillation, atrial flutter, and stroke |
CN101678100A (en) | 2006-12-06 | 2010-03-24 | 米迪缪尼有限公司 | methods of treating systemic lupus erythematosus |
BRPI0720552A2 (en) | 2006-12-19 | 2014-01-07 | Genentech Inc | VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT AND NEOADJUVANT THERAPY AND TREATMENT OF EARLY STAGE TUMORS |
RU2554747C9 (en) | 2006-12-20 | 2015-10-20 | Ксома (Сша) Ллс | Method of treating il-1beta-dependent diseases |
EP2097448A4 (en) | 2006-12-22 | 2010-07-21 | Univ Utah Res Found | Method of detecting ocular diseases and pathologic conditions and treatment of same |
WO2008079849A2 (en) * | 2006-12-22 | 2008-07-03 | Genentech, Inc. | Antibodies to insulin-like growth factor receptor |
JP5623747B2 (en) | 2006-12-27 | 2014-11-12 | エモリー ユニバーシティ | Compositions and methods for treating infections and tumors |
US8324350B2 (en) | 2006-12-29 | 2012-12-04 | Abbott Laboratories | Dual-specific IL-1α/IL-1β antibodies |
US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
NZ577976A (en) | 2007-01-09 | 2011-12-22 | Biogen Idec Inc | Sp35 antibodies and uses thereof |
WO2008088823A2 (en) | 2007-01-16 | 2008-07-24 | Abbott Laboratories | Methods for treating psoriasis |
US8664364B2 (en) | 2007-01-24 | 2014-03-04 | Carnegie Mellon University | Optical biosensors |
EP2106439B1 (en) | 2007-01-24 | 2014-11-12 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
MX2009008461A (en) | 2007-02-07 | 2009-08-17 | Decode Genetics Ehf | Genetic variants contributing to risk of prostate cancer. |
RU2009133784A (en) | 2007-02-09 | 2011-03-20 | Дженентек, Инк. (Us) | ANTI-Robo4-ANTIBODIES AND THEIR APPLICATIONS |
US8114606B2 (en) * | 2007-02-16 | 2012-02-14 | The Board Of Trustees Of Southern Illinois University | ARL-1 specific antibodies |
US8685666B2 (en) * | 2007-02-16 | 2014-04-01 | The Board Of Trustees Of Southern Illinois University | ARL-1 specific antibodies and uses thereof |
AU2008218542B2 (en) | 2007-02-21 | 2014-06-26 | Decode Genetics Ehf. | Genetic susceptibility variants associated with cardiovascular disease |
EP2436781B1 (en) | 2007-02-22 | 2015-10-07 | Genentech, Inc. | Methods for detecting inflammatory bowel disease |
WO2008103702A2 (en) * | 2007-02-23 | 2008-08-28 | Investigen, Inc. | Methods and compositions for rapid light-activated isolation and detection of analytes |
WO2008104803A2 (en) | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Proteins |
EP2121745A2 (en) | 2007-02-26 | 2009-11-25 | Oxford Genome Sciences (UK) Limited | Proteins |
EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
BRPI0809042B1 (en) | 2007-03-22 | 2021-08-31 | Biogen Ma Inc. | ISOLATED CD154-BINDING PROTEIN, ITS USE, AND COMPOSITION |
CN103641908A (en) | 2007-03-22 | 2014-03-19 | 赫普泰雅治疗有限公司 | Mutant GPCR proteins and methods for selecting them |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
RU2476442C2 (en) | 2007-03-29 | 2013-02-27 | Эббот Лэборетриз | Crystalline human il-12 antibodies |
BRPI0809583B1 (en) | 2007-03-30 | 2022-02-22 | Ambrx, Inc | Modified fgf-21 polypeptide, composition comprising the same, method for producing said fgf-21 polypeptide, and cell comprising a polynucleotide |
WO2008121615A2 (en) | 2007-03-30 | 2008-10-09 | Medimmune, Inc. | Antibody formulation |
MX2009010765A (en) | 2007-04-02 | 2009-10-26 | Amgen Fremont Inc | Anti-ige antibodies. |
ATE501280T1 (en) * | 2007-04-04 | 2011-03-15 | Chimera Biotec Gmbh | METHOD FOR DETECTING AN ANALYTE IN A BIOLOGICAL MATRIX |
US7807168B2 (en) * | 2007-04-10 | 2010-10-05 | Vaccinex, Inc. | Selection of human TNFα specific antibodies |
NZ579985A (en) | 2007-04-13 | 2012-02-24 | Catalyst Biosciences Inc | Modified factor vii polypetides and uses thereof |
WO2008137471A2 (en) | 2007-05-02 | 2008-11-13 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
PT2164868E (en) | 2007-05-04 | 2015-08-04 | Technophage Investigaçao E Desenvolvimento Em Biotecnologia Sa | Engineered rabbit antibody variable domains and uses thereof |
EP2703011A3 (en) | 2007-05-07 | 2014-03-26 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
AU2008255027B2 (en) | 2007-05-14 | 2013-10-03 | Astrazeneca Ab | Methods of reducing eosinophil levels |
KR101523788B1 (en) | 2007-05-17 | 2015-06-26 | 제넨테크, 인크. | Crystal structures of neuropilin fragments and neuropilin-antibody complexes |
MX2009012722A (en) | 2007-05-25 | 2009-12-11 | Decode Genetics Ehf | Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment. |
US7906149B2 (en) * | 2007-05-25 | 2011-03-15 | Boval Company, L.P. | Method for treating allergic dermatitis |
US20090232801A1 (en) * | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
US20090175847A1 (en) * | 2007-05-30 | 2009-07-09 | Abbott Laboratories | Humanized antibodies to ab (20-42) globulomer and uses thereof |
US8999337B2 (en) | 2007-06-11 | 2015-04-07 | Abbvie Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis by inhibition of TNFα |
US8138313B2 (en) | 2007-06-15 | 2012-03-20 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Treatment of tumors using specific anti-L1 antibody |
WO2008154700A1 (en) * | 2007-06-20 | 2008-12-24 | Phylogica Limited | Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith |
KR101799337B1 (en) | 2007-06-21 | 2017-12-20 | 마크로제닉스, 인크. | Covalent diabodies and uses thereof |
EP2158220B1 (en) | 2007-06-26 | 2017-04-19 | F-Star Biotechnologische Forschungs- und Entwicklungsges.m.b.H | Display of binding agents |
US8158758B2 (en) | 2007-07-02 | 2012-04-17 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
KR101486615B1 (en) | 2007-07-16 | 2015-01-28 | 제넨테크, 인크. | Anti-cd79b antibodies and immunoconjugates and methods of use |
ES2528922T3 (en) | 2007-07-16 | 2015-02-13 | Genentech, Inc. | Humanized and immunoconjugate anti-CD79b antibodies and methods of use |
WO2009015063A2 (en) | 2007-07-23 | 2009-01-29 | Centocor | Methods and compositions for treating fibrosis related disorders using il-17 antagonists |
BRPI0814645A2 (en) * | 2007-07-25 | 2015-01-27 | Alexion Pharma Inc | METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASE. |
US20100273722A1 (en) * | 2007-08-06 | 2010-10-28 | Yale University | Modified miniature proteins |
ES2403904T3 (en) | 2007-08-21 | 2013-05-22 | Morphosys Ag | Methods for the formation of disulfide bonds |
SG185940A1 (en) * | 2007-08-30 | 2012-12-28 | Curedm Group Holdings Llc | Compositions and methods of using proislet peptides and analogs thereof |
GB0717337D0 (en) | 2007-09-06 | 2007-10-17 | Ucb Pharma Sa | Method of treatment |
US8877688B2 (en) * | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
DK3124497T3 (en) | 2007-09-14 | 2020-05-11 | Adimab Llc | RATIONALE DESIGNED SYNTHETIC ANTIBODY LIBRARIES AND APPLICATIONS THEREOF |
CA2700714C (en) | 2007-09-26 | 2018-09-11 | Ucb Pharma S.A. | Dual specificity antibody fusions |
PL3059246T3 (en) | 2007-09-26 | 2018-11-30 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
EP2205971A4 (en) * | 2007-10-04 | 2011-03-30 | Bionomics Ltd | Markers of endothelial cells and uses thereof |
CA2703705A1 (en) | 2007-11-05 | 2009-05-14 | Medimmune, Llc | Methods of treating scleroderma |
JP5985150B2 (en) | 2007-11-07 | 2016-09-06 | ジェネンテック, インコーポレイテッド | Compositions and methods for the treatment of microbial disorders |
EP3115469B1 (en) | 2007-11-19 | 2020-04-29 | Celera Corporation | Lung cancer markers and uses thereof |
US8946148B2 (en) * | 2007-11-20 | 2015-02-03 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
WO2009070642A1 (en) * | 2007-11-28 | 2009-06-04 | Medimmune, Llc | Protein formulation |
US8697360B2 (en) | 2007-11-30 | 2014-04-15 | Decode Genetics Ehf. | Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition |
TWI468417B (en) | 2007-11-30 | 2015-01-11 | Genentech Inc | Anti-vegf antibodies |
US8426153B2 (en) | 2007-12-03 | 2013-04-23 | Carnegie Mellon University | Linked peptides fluorogenic biosensors |
GB0724051D0 (en) | 2007-12-08 | 2008-01-16 | Medical Res Council | Mutant proteins and methods for producing them |
AU2008337100B2 (en) | 2007-12-17 | 2013-02-28 | Pfizer Limited | Treatment of interstitial cystitis |
BRPI0820452A2 (en) | 2007-12-18 | 2015-06-16 | Bioalliance Cv | Antibodies which recognize a carbohydrate-containing epitope on cd-43 and cea expressed in cancer cells and methods of using them. |
AU2008343085B2 (en) | 2007-12-20 | 2015-03-12 | Xoma (Us) Llc | Methods for the treatment of gout |
GB0724860D0 (en) | 2007-12-20 | 2008-01-30 | Heptares Therapeutics Ltd | Screening |
WO2009082485A1 (en) | 2007-12-26 | 2009-07-02 | Vaccinex, Inc. | Anti-c35 antibody combination therapies and methods |
NZ586875A (en) | 2007-12-28 | 2012-10-26 | Elan Pharm Inc | Treatment and prophylaxis of amyloidosis with an antibody that binds a specific epitope of human amyloid A peptide |
GB0800277D0 (en) | 2008-01-08 | 2008-02-13 | Imagination Tech Ltd | Video motion compensation |
AU2009203350B2 (en) | 2008-01-11 | 2014-03-13 | Gene Techno Science Co., Ltd. | Humanized anti-alpha9 integrin antibodies and the uses thereof |
CA2711736A1 (en) | 2008-01-18 | 2009-07-23 | Medimmune, Llc | Cysteine engineered antibodies for site-specific conjugation |
TWI607019B (en) | 2008-01-31 | 2017-12-01 | 建南德克公司 | Anti-cd79b antibodies and immunoconjugates and methods of use |
EP2250279B1 (en) | 2008-02-08 | 2016-04-13 | MedImmune, LLC | Anti-ifnar1 antibodies with reduced fc ligand affinity |
CN101939443B (en) | 2008-02-08 | 2014-01-29 | Ambrx公司 | Modified leptin polypeptides and their uses |
GB0802474D0 (en) | 2008-02-11 | 2008-03-19 | Heptares Therapeutics Ltd | Mutant proteins and methods for selecting them |
US8828657B2 (en) | 2008-02-14 | 2014-09-09 | Decode Genetics Ehf. | Susceptibility variants for lung cancer |
BRPI0906060A2 (en) | 2008-02-28 | 2015-12-01 | 3M Innovative Properties Co | isolated antibodies, methods of preparing an anti-clostridium difficile antibody, composition and method for detecting the presence of a clostridium difficile spore in a sample |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
WO2009109572A2 (en) * | 2008-03-03 | 2009-09-11 | Ablynx Nv | Monovalent phage display of single variable domains |
DK2265288T3 (en) | 2008-03-04 | 2016-06-06 | Labrys Biologics Inc | Methods for the treatment of inflammatory pain |
RU2522493C2 (en) | 2008-03-04 | 2014-07-20 | Пфайзер Лимитед | Methods of treating chronic pain |
WO2009111644A2 (en) * | 2008-03-05 | 2009-09-11 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating pancreatic cancer |
WO2009113879A1 (en) | 2008-03-12 | 2009-09-17 | Christopher Joseph Pemberton | Biomarkers |
JP2011516038A (en) | 2008-03-12 | 2011-05-26 | オタゴ イノベーション リミテッド | Biomarker |
US9873957B2 (en) | 2008-03-13 | 2018-01-23 | Dyax Corp. | Libraries of genetic packages comprising novel HC CDR3 designs |
TW201513883A (en) | 2008-03-18 | 2015-04-16 | Abbvie Inc | Methods for treating psoriasis |
WO2009118300A1 (en) | 2008-03-25 | 2009-10-01 | Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by down-regulating frizzled-4 and/or frizzled-1 |
MX348362B (en) * | 2008-03-31 | 2017-06-07 | Genentech Inc * | Compositions and methods for treating and diagnosing asthma. |
EP2274450A2 (en) | 2008-04-01 | 2011-01-19 | Decode Genetics EHF | Susceptibility variants for peripheral arterial disease and abdominal aortic aneurysm |
DK2247304T3 (en) | 2008-04-02 | 2016-09-26 | Macrogenics Inc | Her2 / neu-specific antibodies and methods of use thereof |
EP3045475B1 (en) | 2008-04-02 | 2017-10-04 | MacroGenics, Inc. | Bcr-complex-specific antibodies and methods of using same |
MY159553A (en) | 2008-04-11 | 2017-01-13 | Seattle Genetics Inc | Detection and treatment of pancreatic, ovarian and other cancers |
GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
AU2009238897B2 (en) | 2008-04-24 | 2015-03-19 | Gene Techno Science Co., Ltd. | Humanized antibodies specific for amino acid sequence RGD of an extracellular matrix protein and the uses thereof |
JP5780951B2 (en) | 2008-04-24 | 2015-09-16 | ダイアックス コーポレーション | A library of genetic packages containing new HCCR1, CDR2 and CDR3 designs, and new LCCR1, CDR2 and CDR3 designs |
KR102072896B1 (en) | 2008-04-25 | 2020-02-03 | 다이액스 코포레이션 | Antibodies against fcrn and use thereof |
US20090269786A1 (en) * | 2008-04-25 | 2009-10-29 | The Board Of Trustees Of The University Of Illinois | RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies |
US9029508B2 (en) | 2008-04-29 | 2015-05-12 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
ES2458541T3 (en) | 2008-05-02 | 2014-05-06 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
RU2553517C2 (en) | 2008-05-06 | 2015-06-20 | Дженентек, Инк. | Affinity-matured crig versions |
CN102089430B (en) | 2008-05-09 | 2015-02-04 | Abbvie公司 | Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof |
MX2010012368A (en) * | 2008-05-16 | 2010-12-06 | Genentech Inc | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists. |
US8093018B2 (en) | 2008-05-20 | 2012-01-10 | Otsuka Pharmaceutical Co., Ltd. | Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same |
EP2599793A1 (en) | 2008-05-29 | 2013-06-05 | Nuclea Biotechnologies, Inc. | Anti-phospho-akt antibodies |
EP3002299A1 (en) | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
CN102112494A (en) | 2008-06-03 | 2011-06-29 | 雅培制药有限公司 | Dual variable domain immunoglobulins and uses thereof |
ES2675730T3 (en) | 2008-06-04 | 2018-07-12 | Macrogenics, Inc. | Antibodies with altered FcRn binding and methods of use thereof |
WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
JP2011527565A (en) | 2008-07-07 | 2011-11-04 | ディコーデ ジェネテクス イーエイチエフ | Genetic variation for breast cancer risk assessment |
MX2011000236A (en) | 2008-07-08 | 2011-02-24 | Oncomed Pharm Inc | Notch-binding agents and antagonists and methods of use thereof. |
KR20110031369A (en) | 2008-07-08 | 2011-03-25 | 아보트 러보러터리즈 | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
EP2310049A4 (en) | 2008-07-08 | 2013-06-26 | Abbvie Inc | Prostaglandin e2 binding proteins and uses thereof |
EP2315779A2 (en) | 2008-07-09 | 2011-05-04 | Biogen Idec MA Inc. | Compositions comprising antibodies to lingo or fragments thereof |
JP5986745B2 (en) | 2008-07-15 | 2016-09-06 | アカデミア シニカAcademia Sinica | Glycan arrays on PTFE-like aluminum-coated glass slides and related methods |
JP5665740B2 (en) | 2008-07-23 | 2015-02-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Deacetylase inhibitors and uses thereof |
UA118536C2 (en) | 2008-07-23 | 2019-02-11 | Амбркс, Інк. | MODIFIED Bovine granulocyte colony-stimulating factor polypeptide and its application |
US9182406B2 (en) * | 2008-08-04 | 2015-11-10 | Biodesy, Inc. | Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability |
BRPI0917000A2 (en) | 2008-08-06 | 2016-02-16 | Novo Nordisk Healthcare Ag | protein conjugates with prolonged in vivo efficacy |
WO2010019702A2 (en) | 2008-08-12 | 2010-02-18 | Oncomed Pharmaceuticals, Inc. | Ddr1-binding agents and methods of use thereof |
MX2011001409A (en) | 2008-08-14 | 2011-03-29 | Cephalon Australia Pty Ltd | Anti-il-12/il-23 antibodies. |
WO2010028347A2 (en) | 2008-09-05 | 2010-03-11 | President & Fellows Of Harvard College | Continuous directed evolution of proteins and nucleic acids |
TWI516501B (en) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9 antagonists |
EP2352760A2 (en) * | 2008-09-22 | 2011-08-10 | Calmune Corporation | Methods and vectors for display of 2g12-derived domain exchanged antibodies |
US20100081575A1 (en) * | 2008-09-22 | 2010-04-01 | Robert Anthony Williamson | Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules |
JP2012504939A (en) | 2008-09-23 | 2012-03-01 | ワイス・エルエルシー | Method for predicting the generation of activation signals by cross-linked proteins |
CN102224254A (en) | 2008-09-23 | 2011-10-19 | 哈佛大学校长及研究员协会 | Sirt4 and uses thereof |
US8313942B2 (en) | 2008-09-26 | 2012-11-20 | Wyeth Llc | Compatible display vector systems |
HUE030807T2 (en) | 2008-09-26 | 2017-05-29 | Dana Farber Cancer Inst Inc | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof |
ES2660000T3 (en) | 2008-09-26 | 2018-03-20 | Ambrx, Inc. | Vaccines and microorganisms dependent on the replication of unnatural amino acids |
BRPI0919403A2 (en) | 2008-09-26 | 2017-09-26 | Ambrx Inc | modified animal erythropoietin polypeptides and their uses |
CN105079805A (en) | 2008-09-26 | 2015-11-25 | 昂考梅德药品有限公司 | Frizzled-binding agents and uses thereof |
DK3335728T3 (en) | 2008-10-10 | 2020-02-24 | Childrens Medical Center | BIOCHEMICALLY STABILIZED HIV-1 ENV TRIMER VACCINE |
CA2740440A1 (en) | 2008-10-14 | 2010-04-22 | Dyax Corp. | Use of igf-ii/igf-iie binding proteins for the treatment and prevention of systemic sclerosis-associated pulmonary fibrosis |
CN107011415A (en) | 2008-10-20 | 2017-08-04 | 光州科学技术院 | Bipodal peptide binder |
BRPI0920027A2 (en) | 2008-10-20 | 2015-10-06 | Abbott Lab | isolation and purification of antibodies using protein affinity chromatography |
US20120251502A1 (en) | 2008-10-24 | 2012-10-04 | The Government of the US as Represented by the Secretary of the Dept. of health | Human Ebola Virus Species and Compositions and Methods Thereof |
ES2631507T3 (en) | 2008-10-29 | 2017-08-31 | China Synthetic Rubber Corporation | Procedures and agents for the diagnosis and treatment of hepatocellular carcinoma |
MX345226B (en) | 2008-10-29 | 2017-01-20 | Ablynx Nv | Formulations of single domain antigen binding molecules. |
CA2739352C (en) | 2008-10-29 | 2021-07-13 | Wyeth Llc | Methods for purification of single domain antigen binding molecules |
DK2356269T3 (en) | 2008-10-31 | 2016-08-15 | Janssen Biotech Inc | FIBRONECTIN TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, PROCEDURES AND APPLICATIONS |
WO2010054007A1 (en) | 2008-11-07 | 2010-05-14 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
EP2894166A1 (en) | 2008-11-10 | 2015-07-15 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
RS55784B1 (en) | 2008-11-11 | 2017-07-31 | Univ Michigan Regents | Anti-cxcr1 compositions and methods |
EP2358392B1 (en) | 2008-11-12 | 2019-01-09 | MedImmune, LLC | Antibody formulation |
EP2189539B2 (en) | 2008-11-21 | 2018-06-13 | Chimera Biotec GmbH | Conjugate complexes for analyte detection |
SI2361085T2 (en) | 2008-11-22 | 2018-11-30 | F. Hoffmann-La Roche Ag | Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer |
RU2011121042A (en) | 2008-11-26 | 2013-01-10 | Файв Прайм Терапеутикс, Инк. | COMPOSITIONS AND METHODS OF REGULATING EXPRESSION OF COLLAGEN AND ACT OF SMOOTH MUSCLES BY SERPINE2 |
HUE028582T2 (en) | 2008-11-28 | 2016-12-28 | Univ Emory | Methods for determining the efficacy of pd-1 antagonists |
EP2373692A4 (en) * | 2008-12-04 | 2013-11-20 | Abbvie Inc | Dual variable domain immunoglobulins and uses thereof |
TWI686405B (en) | 2008-12-09 | 2020-03-01 | 建南德克公司 | Anti-pd-l1 antibodies and their use to enhance t-cell function |
JP5734201B2 (en) | 2008-12-19 | 2015-06-17 | マクロジェニクス,インコーポレーテッド | Covalently bonded diabody and use thereof |
ES2541925T3 (en) | 2008-12-23 | 2015-07-28 | F. Hoffmann-La Roche Ag | Methods and compositions for diagnostic use in cancer patients |
US20120003235A1 (en) | 2008-12-31 | 2012-01-05 | Biogen Idec Ma Inc. | Anti-lymphotoxin antibodies |
US9181315B2 (en) | 2009-01-08 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for induced brown fat differentiation |
GB0900425D0 (en) | 2009-01-12 | 2009-02-11 | Ucb Pharma Sa | Biological products |
CA2749572A1 (en) | 2009-01-14 | 2010-07-22 | Iq Therapeutics Bv | Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins |
EP2389195B1 (en) | 2009-01-20 | 2015-05-20 | Homayoun H. Zadeh | Antibody mediated osseous regeneration |
US20120058131A1 (en) | 2009-01-21 | 2012-03-08 | Oxford Biotherapeutics Ltd | Pta089 protein |
MX2011007736A (en) | 2009-01-22 | 2011-09-06 | Novo Nordisk Healthcare Ag | Stable growth hormone compounds. |
EP2391748A4 (en) * | 2009-01-28 | 2012-08-01 | Antigen Express Inc | Li-key hybrid peptides that modulate the immune response to influenza |
JP2012516153A (en) | 2009-01-29 | 2012-07-19 | アボット・ラボラトリーズ | IL-1 binding protein |
US20110165063A1 (en) * | 2009-01-29 | 2011-07-07 | Abbott Laboratories | Il-1 binding proteins |
WO2010086828A2 (en) | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
WO2010087927A2 (en) | 2009-02-02 | 2010-08-05 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
CA2752211C (en) | 2009-02-12 | 2020-03-24 | Janssen Biotech, Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
WO2010093993A2 (en) | 2009-02-12 | 2010-08-19 | Human Genome Sciences, Inc. | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
PL2398498T3 (en) * | 2009-02-17 | 2019-03-29 | Ucb Biopharma Sprl | Antibody molecules having specificity for human ox40 |
WO2010096388A2 (en) | 2009-02-18 | 2010-08-26 | Carnegie Mellon University | Quenched dendrimeric dyes for bright detection |
US8030026B2 (en) | 2009-02-24 | 2011-10-04 | Abbott Laboratories | Antibodies to troponin I and methods of use thereof |
EP2403880A1 (en) | 2009-03-05 | 2012-01-11 | Tripath Imaging, Inc. | Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer |
RU2015132478A (en) | 2009-03-05 | 2015-12-10 | Эббви Инк. | BINDING IL-17 PROTEINS |
US20110311521A1 (en) | 2009-03-06 | 2011-12-22 | Pico Caroni | Novel therapy for anxiety |
AU2010221188A1 (en) | 2009-03-06 | 2011-10-20 | Tripath Imaging, Inc. | Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer |
WO2010104208A1 (en) | 2009-03-10 | 2010-09-16 | Gene Techno Science Co., Ltd. | Generation, expression and characterization of the humanized k33n monoclonal antibody |
GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
JP5757534B2 (en) | 2009-03-25 | 2015-07-29 | ジェネンテック, インコーポレイテッド | Anti-FGFR3 antibody and method using the same |
AR075925A1 (en) | 2009-03-25 | 2011-05-04 | Genentech Inc | ANTI-ALFA5BETA1 ANTIBODIES (ALFA5BETA1: INTEGRINE GLICOPROTEIN) AND ITS USES |
BRPI1012676A2 (en) | 2009-04-01 | 2016-04-05 | Genentech Inc | anti-fcrh5 and immunoconjugate antibodies and methods of use |
EP2414543B1 (en) | 2009-04-03 | 2016-10-12 | Decode Genetics EHF | Genetic markers for risk management of atrial fibrillation and stroke |
EP2241323A1 (en) | 2009-04-14 | 2010-10-20 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Tenascin-W and brain cancers |
EP2424567B1 (en) * | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
ES2495367T3 (en) | 2009-04-29 | 2014-09-17 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | ERG monoclonal antibodies |
MX2011011541A (en) | 2009-04-29 | 2012-02-28 | Abbott Biotech Ltd | Automatic injection device. |
BRPI1011195B1 (en) * | 2009-05-20 | 2020-10-13 | Novimmune S.A | methods to produce a collection of nucleic acids |
KR101224468B1 (en) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | Bispecific antibody having a novel form and use thereof |
US8680055B2 (en) | 2009-06-03 | 2014-03-25 | University Of Southern California | Methods for decreasing steroidogenesis in prostate cancer cells |
US8748386B2 (en) | 2009-06-10 | 2014-06-10 | New York University | Immunological targeting of pathological Tau proteins |
EP2261242A1 (en) | 2009-06-10 | 2010-12-15 | Universite Catholique De Louvain | Aspartate-N-acetyltransferase enzyme, diagnostic method and therapeutic method |
WO2010146511A1 (en) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Treatment of overactive bladder |
GB0910725D0 (en) | 2009-06-22 | 2009-08-05 | Heptares Therapeutics Ltd | Mutant proteins and methods for producing them |
MX2012000121A (en) | 2009-06-22 | 2012-03-07 | Medimmune Llc | ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION. |
EP2272979A1 (en) | 2009-06-30 | 2011-01-12 | Centre National de la Recherche Scientifique (CNRS) | Method for testing a subject thought to be predisposed to having cancer |
EP2451487A1 (en) | 2009-07-09 | 2012-05-16 | F. Hoffmann-La Roche AG | In vivi tumor vasculature imaging |
CA2767360A1 (en) | 2009-07-10 | 2011-01-13 | Decode Genetics Ehf. | Genetic markers associated with risk of diabetes mellitus |
WO2011014457A1 (en) | 2009-07-27 | 2011-02-03 | Genentech, Inc. | Combination treatments |
CN102596220A (en) | 2009-07-31 | 2012-07-18 | 韦恩州立大学 | Monophosphorylated lipid A derivatives |
US9259476B2 (en) | 2009-07-31 | 2016-02-16 | Wayne State University | Monophosphorylated lipid A derivatives |
US20110027275A1 (en) | 2009-07-31 | 2011-02-03 | Napoleone Ferrara | Inhibition of tumor metastasis |
US8841249B2 (en) | 2009-08-06 | 2014-09-23 | Novo Nordisk A/S | Growth hormones with prolonged in-vivo efficacy |
WO2011019393A2 (en) | 2009-08-11 | 2011-02-17 | President And Fellows Of Harvard College | Class- and isoform-specific hdac inhibitors and uses thereof |
KR101822205B1 (en) | 2009-08-11 | 2018-01-25 | 제넨테크, 인크. | Production of proteins in glutamine-free cell culture media |
DK2464664T3 (en) | 2009-08-13 | 2016-01-18 | Crucell Holland Bv | ANTIBODIES AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) AND METHODS FOR USING IT |
CN102573909A (en) | 2009-08-15 | 2012-07-11 | 霍夫曼-拉罗奇有限公司 | Anti-angiogenesis therapy for the treatment of previously treated breast cancer |
EP2292266A1 (en) | 2009-08-27 | 2011-03-09 | Novartis Forschungsstiftung, Zweigniederlassung | Treating cancer by modulating copine III |
RU2535074C2 (en) | 2009-08-28 | 2014-12-10 | Лэйбрис Байолоджикс, Инк. | Method of treating visceral pain by administering antagonist antibodies against calcitonin gene-related peptide |
CN102741288B (en) | 2009-08-29 | 2015-08-19 | Abbvie公司 | DLL4 associated proteins is used in treatment |
US20110059111A1 (en) | 2009-09-01 | 2011-03-10 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Mammalian receptors as targets for antibody and active vaccination therapy against mold infections |
JP2013503607A (en) | 2009-09-01 | 2013-02-04 | アボット・ラボラトリーズ | Dual variable domain immunoglobulins and uses thereof |
EP2473522B1 (en) | 2009-09-02 | 2016-08-17 | Genentech, Inc. | Mutant smoothened and methods of using the same |
WO2011030107A1 (en) | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Multivalent antibodies |
EP2477654A4 (en) | 2009-09-14 | 2013-01-23 | Abbott Lab | Methods for treating psoriasis |
WO2011032181A2 (en) * | 2009-09-14 | 2011-03-17 | Dyax Corp. | Libraries of genetic packages comprising novel hc cdr3 designs |
ES2530732T3 (en) | 2009-09-17 | 2015-03-05 | Hoffmann La Roche | Diagnostic procedures for lung cancer |
US20110189183A1 (en) | 2009-09-18 | 2011-08-04 | Robert Anthony Williamson | Antibodies against candida, collections thereof and methods of use |
WO2011036118A1 (en) | 2009-09-22 | 2011-03-31 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating mex-3 |
WO2011038301A2 (en) | 2009-09-25 | 2011-03-31 | Xoma Technology Ltd. | Screening methods |
US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
EP2480572B1 (en) | 2009-09-25 | 2019-01-30 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Neutralizing antibodies to hiv-1 and their use |
WO2011036555A1 (en) | 2009-09-25 | 2011-03-31 | University Of Oslo | Multivalent phage display systems and methods |
GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
BR112012007160A2 (en) | 2009-09-30 | 2018-03-13 | Harvard College | methods for modulating autophagy by modulating autophagy inhibitor gene products |
UY32914A (en) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | ANTIBODIES SPECIFICALLY USED TO THE EPHA2 RECEIVER |
US20120231004A1 (en) | 2009-10-13 | 2012-09-13 | Oxford Biotherapeutic Ltd. | Antibodies |
AR078651A1 (en) | 2009-10-15 | 2011-11-23 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
WO2011045352A2 (en) | 2009-10-15 | 2011-04-21 | Novartis Forschungsstiftung | Spleen tyrosine kinase and brain cancers |
ES2895226T3 (en) | 2009-10-16 | 2022-02-18 | Mereo Biopharma 5 Inc | Therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents |
MX341136B (en) | 2009-10-20 | 2016-08-09 | Abbvie Inc | Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography. |
RU2559533C2 (en) | 2009-10-22 | 2015-08-10 | Дженентек, Инк. | Anti-hepsin antibodies and methods of application thereof |
BR112012009409A2 (en) | 2009-10-22 | 2017-02-21 | Genentech Inc | method of identifying an inhibitory substance, antagonist molecule, isolated nucleic acid, vector, host cell, method of making the molecule, composition, article of manufacture, method of inhibiting a biological activity, method of treating a pathological condition, method for detect msp in a sample and method to detect hepsin in a sample |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
GB0922435D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | Method |
CN102781963B (en) | 2009-10-27 | 2018-02-16 | Ucb医药有限公司 | Functionalized modification NAv1.7 antibody |
US9234037B2 (en) | 2009-10-27 | 2016-01-12 | Ucb Biopharma Sprl | Method to generate antibodies to ion channels |
GB0922434D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | antibodies and fragments thereof |
US20110098862A1 (en) | 2009-10-27 | 2011-04-28 | ExxonMobil Research Engineering Company Law Department | Multi-stage processes and control thereof |
UY32979A (en) | 2009-10-28 | 2011-02-28 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
US20120213801A1 (en) | 2009-10-30 | 2012-08-23 | Ekaterina Gresko | Phosphorylated Twist1 and cancer |
TW201121568A (en) | 2009-10-31 | 2011-07-01 | Abbott Lab | Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof |
US20120282177A1 (en) | 2009-11-02 | 2012-11-08 | Christian Rohlff | ROR1 as Therapeutic and Diagnostic Target |
JP2013509874A (en) | 2009-11-04 | 2013-03-21 | エラスムス ユニバーシティ メディカル センター ロッテルダム | Novel compounds for modulating angiogenesis and methods of treatment using these compounds |
SI2496601T1 (en) | 2009-11-05 | 2017-09-29 | F. Hoffmann-La Roche Ag | Methods and composition for secretion of heterologous polypeptides |
CA2780024A1 (en) | 2009-11-11 | 2011-05-19 | Gentian As | Immunoassay for assessing related analytes of different origin |
CA3061784C (en) | 2009-11-13 | 2023-09-26 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 |
GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
GB0920324D0 (en) | 2009-11-19 | 2010-01-06 | Ucb Pharma Sa | Antibodies |
CN103755809B (en) | 2009-11-30 | 2016-06-01 | 霍夫曼-拉罗奇有限公司 | The antibody of the tumour of SLC34A2 (TAT211=SEQID2) is expressed in treatment and diagnosis |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
EP2510001B1 (en) | 2009-12-08 | 2015-12-02 | AbbVie Deutschland GmbH & Co KG | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
IN2012DN04908A (en) | 2009-12-09 | 2015-09-25 | Inst Nat Sante Rech Med | |
WO2011071577A1 (en) | 2009-12-11 | 2011-06-16 | Genentech, Inc. | Anti-vegf-c antibodies and methods using same |
WO2011084496A1 (en) * | 2009-12-16 | 2011-07-14 | Abbott Biotherapeutics Corp. | Anti-her2 antibodies and their uses |
MX2012006980A (en) | 2009-12-21 | 2012-07-17 | Ambrx Inc | Modified porcine somatotropin polypeptides and their uses. |
WO2011087808A1 (en) | 2009-12-21 | 2011-07-21 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
US20110226650A1 (en) | 2009-12-21 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
CA2784385A1 (en) | 2009-12-23 | 2011-06-30 | Genentech, Inc. | Anti-bv8 antibodies and uses thereof |
US20110165161A1 (en) * | 2009-12-23 | 2011-07-07 | Shih-Yao Lin | Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same |
ES2688093T3 (en) | 2010-01-06 | 2018-10-30 | Dyax Corp. | Plasma kallikrein binding proteins |
CA2786692A1 (en) | 2010-01-11 | 2011-07-14 | Alexion Pharmaceuticals, Inc. | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
TWI535445B (en) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt antagonists and methods of treatment and screening |
MX2012008085A (en) | 2010-01-13 | 2012-09-12 | Oncomed Pharm Inc | Notch1 binding agents and methods of use thereof. |
WO2011088163A1 (en) | 2010-01-14 | 2011-07-21 | President And Fellows Of Harvard College | Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination |
AU2011207210A1 (en) | 2010-01-22 | 2012-08-16 | Dana-Farber Cancer Institute, Inc. | Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders |
TWI508737B (en) | 2010-01-22 | 2015-11-21 | 諾佛 儂迪克股份有限公司 | Growth hormones with prolonged in-vivo efficacy |
EP2525833A2 (en) | 2010-01-22 | 2012-11-28 | Novo Nordisk Health Care AG | Stable growth hormone compounds |
WO2011097301A2 (en) | 2010-02-02 | 2011-08-11 | Abbott Biotechnology Ltd. | METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR |
TWI518325B (en) | 2010-02-04 | 2016-01-21 | 自治醫科大學 | Identification, assessment, and therapy of cancers with innate or acquired resistance to alk inhibitors |
EP2533810B1 (en) | 2010-02-10 | 2016-10-12 | ImmunoGen, Inc. | Cd20 antibodies and uses thereof |
WO2011103330A2 (en) | 2010-02-17 | 2011-08-25 | The Johns Hopkins University | Novel phosphorylation of cardiac troponin i as a monitor for cardiac injury |
MY160556A (en) | 2010-02-18 | 2017-03-15 | Genentech Inc | Neuregulin antagonists and use thereof in treating cancer |
US20110200595A1 (en) | 2010-02-18 | 2011-08-18 | Roche Glycart | TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR |
TW201437228A (en) | 2010-02-23 | 2014-10-01 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
CN103237810A (en) | 2010-02-23 | 2013-08-07 | 霍夫曼-拉罗奇有限公司 | Anti-angiogenesis therapy for the treatment of ovarian cancer |
SA114360064B1 (en) | 2010-02-24 | 2016-01-05 | رينات نيوروساينس كوربوريشن | Antagonist anti-il-7 receptor antibodies and methods |
KR20190114019A (en) | 2010-02-24 | 2019-10-08 | 이뮤노젠 아이엔씨 | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
RU2016146198A (en) | 2010-03-02 | 2018-12-19 | Эббви Инк. | THERAPEUTIC DLL4-BINDING PROTEINS |
US20130004519A1 (en) | 2010-03-05 | 2013-01-03 | Ruth Chiquet-Ehrismann | Smoci, tenascin-c and brain cancers |
CN102844332B (en) | 2010-03-11 | 2015-08-19 | 瑞纳神经科学公司 | The antibody combined in pH dependence antigen |
SG183542A1 (en) | 2010-03-12 | 2012-10-30 | Immunogen Inc | Cd37-binding molecules and immunoconjugates thereof |
ES2575160T3 (en) | 2010-03-15 | 2016-06-24 | The Board Of Trustees Of The University Of Illinois | Inhibitors of the interactions that bind the alpha subunit of beta integrin-protein G |
WO2011116276A2 (en) * | 2010-03-18 | 2011-09-22 | Matthew Delisa | Engineering correctly folded antibodies using inner membrane display of twin-arginine translocation intermediates |
US10706955B2 (en) | 2010-03-23 | 2020-07-07 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
CA2791991A1 (en) | 2010-03-24 | 2011-09-29 | Genentech, Inc. | Anti-lrp6 antibodies |
GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
WO2011119920A2 (en) | 2010-03-25 | 2011-09-29 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
WO2011117653A1 (en) | 2010-03-25 | 2011-09-29 | Ucb Pharma S.A. | Disulfide stabilized dvd-lg molecules |
CN102971337B (en) | 2010-04-01 | 2016-09-21 | 昂考梅德药品有限公司 | FZ combines medicament and application thereof |
WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
CA2796339C (en) | 2010-04-15 | 2020-03-31 | Abbott Laboratories | Amyloid-beta binding proteins |
WO2011131611A1 (en) | 2010-04-19 | 2011-10-27 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Modulating xrn1 |
EP2380909A1 (en) | 2010-04-26 | 2011-10-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PTK-7 protein involved in breast cancer |
MX340696B (en) | 2010-04-30 | 2016-07-21 | Alexion Pharma Inc | Anti-c5a antibodies and methods for using the antibodies. |
WO2011140114A2 (en) | 2010-05-03 | 2011-11-10 | University Of Rochester | Anti-glucosaminidase passive immunization for staphylococcus aureus infections |
SG185027A1 (en) | 2010-05-03 | 2012-11-29 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
WO2011141823A2 (en) | 2010-05-14 | 2011-11-17 | Orega Biotech | Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists |
ES2635594T3 (en) | 2010-05-14 | 2017-10-04 | Abbvie Inc. | IL-1 binding proteins |
EP2577309B1 (en) | 2010-05-25 | 2016-11-23 | Carnegie Mellon University | Targeted probes of cellular physiology |
WO2011153243A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Anti-angiogenesis therapy for treating gastric cancer |
PT2575884T (en) | 2010-06-03 | 2018-10-31 | Abbvie Biotechnology Ltd | Uses and compositions for treatment of hidradenitis suppurativa (hs) |
RU2613886C2 (en) | 2010-06-03 | 2017-03-21 | Дженентек, Инк. | Antibodies and immunoconjugates rendered by immuno-positron emission tomography, methods of application |
US20130089538A1 (en) | 2010-06-10 | 2013-04-11 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh | Treating cancer by modulating mammalian sterile 20-like kinase 3 |
US9499813B2 (en) | 2010-06-10 | 2016-11-22 | President And Fellows Of Harvard College | Systems and methods for amplification and phage display |
MX2012014838A (en) | 2010-06-16 | 2013-02-07 | Abbvie Inc | Comparison of protein samples. |
BR112012027995A2 (en) | 2010-06-18 | 2017-01-10 | Genentech Inc | antibody and isolated nucleic acid, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, use of the antibody, method of treating an individual with cancer, an individual having an immune disorder, inhibiting angiogenesis and inhibiting the constitutive activation of axl |
WO2012006500A2 (en) | 2010-07-08 | 2012-01-12 | Abbott Laboratories | Monoclonal antibodies against hepatitis c virus core protein |
UY33492A (en) | 2010-07-09 | 2012-01-31 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
KR20130120439A (en) | 2010-07-09 | 2013-11-04 | 제넨테크, 인크. | Anti-neuropilin antibodies and methods of use |
JP5744196B2 (en) | 2010-07-09 | 2015-07-08 | クルセル ホランド ベー ヴェー | Anti-human respiratory polynuclear virus (RSV) antibodies and methods of use |
TW201217526A (en) | 2010-07-09 | 2012-05-01 | Biogen Idec Hemophilia Inc | Chimeric clotting factors |
US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
CN103119062A (en) | 2010-07-16 | 2013-05-22 | 埃博灵克斯股份有限公司 | Modified single domain antigen binding molecules and uses thereof |
JP6266343B2 (en) | 2010-07-16 | 2018-01-24 | アディマブ, エルエルシー | Antibody library |
ES2629850T3 (en) | 2010-07-19 | 2017-08-16 | Otago Innovation Limited | Signal biomarkers |
WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
WO2012010516A1 (en) | 2010-07-22 | 2012-01-26 | Novo Nordisk Health Care Ag | Growth hormone conjugates |
WO2012012750A1 (en) | 2010-07-23 | 2012-01-26 | Trustees Of Boston University | ANTI-DEsupR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY |
EP2598126A2 (en) | 2010-07-30 | 2013-06-05 | Saint Louis University | Methods of treating pain |
CA2807127C (en) | 2010-08-02 | 2019-02-12 | Leslie S. Johnson | Covalent diabodies and uses thereof |
CN103392182B (en) | 2010-08-02 | 2017-07-04 | 众有生物有限公司 | System and method for finding pathogenic mutation in genetic disease |
NZ607480A (en) | 2010-08-03 | 2014-10-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
WO2012018771A1 (en) | 2010-08-03 | 2012-02-09 | Genentech, Inc. | Chronic lymphocytic leukemia (cll) biomarkers |
WO2012019024A2 (en) | 2010-08-04 | 2012-02-09 | Immunogen, Inc. | Her3-binding molecules and immunoconjugates thereof |
WO2012019061A2 (en) | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
MX2013001305A (en) | 2010-08-05 | 2013-03-20 | Hoffmann La Roche | Anti-mhc antibody anti-viral cytokine fusion protein. |
EP2420250A1 (en) | 2010-08-13 | 2012-02-22 | Universitätsklinikum Münster | Anti-Syndecan-4 antibodies |
CN105884898B (en) | 2010-08-13 | 2022-10-11 | 罗切格利卡特公司 | Anti-fibroblast activation protein antibodies and methods of use |
BR112013002444A2 (en) | 2010-08-13 | 2016-05-24 | Roche Glycart Ag | isolated antibody, polynucleotide and polypeptide, composition, vector, host cell, antibody conjugate, pharmaceutical formulation, use of the antibody, methods of producing an antibody, treating an individual, inducing cell lysis of a tumor cell and diagnosing a disease in an individual |
JP6147665B2 (en) | 2010-08-14 | 2017-06-14 | アッヴィ・インコーポレイテッド | Amyloid beta-binding protein |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
BR112013003522B1 (en) | 2010-08-17 | 2021-05-25 | Ambrx, Inc. | modified relaxin polypeptides comprising a non-naturally encoded amino acid, their method of preparation and their use, as well as nucleic acid and host cell |
CA2802278A1 (en) | 2010-08-19 | 2012-02-23 | Veit Peter Grunert | An assay for measurement of antibodies binding to a therapeutic monoclonal antibody |
JP6121903B2 (en) | 2010-08-19 | 2017-04-26 | ゾエティス・ベルジャム・エス・アー | Anti-NGF antibodies and uses thereof |
GB201014033D0 (en) | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
EP2608803A4 (en) | 2010-08-26 | 2014-01-15 | Abbvie Inc | Dual variable domain immunoglobulins and uses thereof |
KR20140018837A (en) | 2010-08-27 | 2014-02-13 | 스템 센트알엑스 인코포레이티드 | Notum protein modulators and methods of use |
EP3264089A1 (en) | 2010-08-31 | 2018-01-03 | Genentech, Inc. | Biomarkers and methods of treatment |
US9458231B2 (en) | 2010-09-03 | 2016-10-04 | Stemcentrx, Inc. | Modulators and methods of use |
US20130171159A1 (en) | 2010-09-10 | 2013-07-04 | Brian Arthur Hemmings | Phosphorylated twist1 and metastasis |
US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
AU2011305754B2 (en) | 2010-09-20 | 2015-11-05 | Abbvie Inc. | Purification of antibodies using simulated moving bed chromatography |
TWI480288B (en) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | Formulations for bovine granulocyte colony stimulating factor and variants thereof |
EP2446898A1 (en) | 2010-09-30 | 2012-05-02 | Laboratorios Del. Dr. Esteve, S.A. | Use of growth hormone to enhance the immune response in immunosuppressed patients |
WO2012044921A1 (en) | 2010-10-01 | 2012-04-05 | St. Jude Children's Research Hospital | Methods and compositions for typing molecular subgroups of medulloblastoma |
EP2625197B1 (en) | 2010-10-05 | 2016-06-29 | Genentech, Inc. | Mutant smoothened and methods of using the same |
WO2012052391A1 (en) | 2010-10-19 | 2012-04-26 | Glaxo Group Limited | Polypeptide with jmjd3 catalytic activity |
US8790649B2 (en) | 2010-10-29 | 2014-07-29 | Immunogen, Inc. | EGFR-binding molecules and immunoconjugates thereof |
US9238690B2 (en) | 2010-10-29 | 2016-01-19 | Immunogen, Inc. | Non-antagonistic EGFR-binding molecules and immunoconjugates thereof |
EP2638070B1 (en) | 2010-11-10 | 2016-10-19 | F.Hoffmann-La Roche Ag | Methods and compositions for neural disease immunotherapy |
EP2640738A1 (en) | 2010-11-15 | 2013-09-25 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Anti-fungal agents |
US20140199682A1 (en) | 2010-11-17 | 2014-07-17 | Sea Lane Biotechnologies, Llc | Influenza neutralizing agents |
WO2012068463A2 (en) | 2010-11-18 | 2012-05-24 | Beth Israel Deaconess Medicall Center, Inc. | Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt) |
WO2012071436A1 (en) | 2010-11-24 | 2012-05-31 | Genentech, Inc. | Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US8911734B2 (en) | 2010-12-01 | 2014-12-16 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
TWI585106B (en) | 2010-12-08 | 2017-06-01 | 艾伯維史坦森特瑞斯有限責任公司 | Novel modulators and methods of use |
SG10201401746TA (en) | 2010-12-16 | 2014-10-30 | Genentech Inc | Diagnosis And Treatments Relating To TH2 Inhibition |
TWI477513B (en) | 2010-12-20 | 2015-03-21 | 建南德克公司 | Anti-mesothelin antibodies and immunoconjugates |
US9029502B2 (en) | 2010-12-20 | 2015-05-12 | The Regents Of The University Of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
TW201307388A (en) | 2010-12-21 | 2013-02-16 | Abbott Lab | IL-1 binding proteins |
WO2012121775A2 (en) | 2010-12-21 | 2012-09-13 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
JP6088438B2 (en) | 2010-12-22 | 2017-03-01 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Continuous directed evolution |
SG191219A1 (en) | 2010-12-22 | 2013-07-31 | Genentech Inc | Anti-pcsk9 antibodies and methods of use |
CN103429261A (en) | 2010-12-22 | 2013-12-04 | 塞法隆澳大利亚股份有限公司 | Modified antibody with improved half-life |
EP2658971A1 (en) | 2010-12-28 | 2013-11-06 | XOMA Technology Ltd. | Cell surface display using pdz domains |
EP2658869B1 (en) | 2010-12-30 | 2019-06-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigen binding formats for use in therapeutic treatments or diagnostic assays |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
BR112013014644A2 (en) | 2011-01-03 | 2017-03-07 | F Hoffmann - La Roche Ag | pharmaceutical composition and complex |
US10208349B2 (en) | 2011-01-07 | 2019-02-19 | Ucb Biopharma Sprl | Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy |
GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
KR101950306B1 (en) | 2011-01-14 | 2019-02-20 | 유씨비 바이오파마 에스피알엘 | Antibody molecules which bind il-17a and il-17f |
WO2012103141A1 (en) | 2011-01-24 | 2012-08-02 | Abbott Biotechnology Ltd. | Automatic injection devices having overmolded gripping surfaces |
EP2668210B1 (en) | 2011-01-26 | 2020-06-17 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
TW201244737A (en) | 2011-02-03 | 2012-11-16 | Alexion Pharma Inc | Use of an anti-CD200 antibody for prolonging the survival of allografts |
US9956236B2 (en) | 2011-02-07 | 2018-05-01 | Cornell University | Methods for increasing immune responses using agents that directly bind to and activate IRE-1 |
SA112330278B1 (en) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | Novel modulators and methods of use |
PE20140627A1 (en) | 2011-03-02 | 2014-05-30 | Berg Llc | CELL-BASED INTERROGATORY TESTS AND THE USE OF THEM |
US9383364B2 (en) | 2011-03-07 | 2016-07-05 | University Of Louisville Research Foundation, Inc. | Predictive marker of DNMT1 inhibitor therapeutic efficacy and methods of using the marker |
US20120238730A1 (en) | 2011-03-15 | 2012-09-20 | Abbott Laboratories | Integrated approach to the isolation and purification of antibodies |
WO2012129347A1 (en) | 2011-03-21 | 2012-09-27 | Biodesy, Llc | Classification of kinase inhibitors using nonlinear optical techniques |
WO2012128810A1 (en) | 2011-03-23 | 2012-09-27 | Abbott Laboratories | Methods and systems for the analysis of protein samples |
AU2012234335B2 (en) | 2011-03-29 | 2016-09-01 | Roche Glycart Ag | Antibody Fc variants |
AU2012237287B2 (en) | 2011-03-30 | 2016-09-08 | Ablynx Nv | Methods of treating immune disorders with single domain antibodies against TNF-alpha |
US9777332B2 (en) | 2011-03-31 | 2017-10-03 | St. Jude Children's Research Hospital | Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia |
CA2828890A1 (en) | 2011-04-07 | 2012-10-11 | Genentech, Inc. | Anti-fgfr4 antibodies and methods of use |
US20120328567A1 (en) | 2011-04-08 | 2012-12-27 | Steven Bushnell | Biomarkers predictive of therapeutic responsiveness to ifnb and uses thereof |
WO2012142164A1 (en) | 2011-04-12 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii |
US10352936B2 (en) | 2011-04-14 | 2019-07-16 | Apoplogic Pharmaceuticals, Inc. | Use of tumor Fas expression to determine response to anti-cancer therapy |
DK2699264T3 (en) | 2011-04-20 | 2018-06-25 | Medimmune Llc | ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 |
EP2699597B1 (en) | 2011-04-21 | 2016-06-01 | Garvan Institute of Medical Research | Modified variable domain molecules and methods for producing and using them b |
US20140141458A1 (en) | 2011-05-12 | 2014-05-22 | The Johns Hopkins University | Assay reagents for a neurogranin diagnostic kit |
MX2013013054A (en) | 2011-05-12 | 2014-02-20 | Genentech Inc | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides. |
CA2834879C (en) | 2011-05-16 | 2019-10-22 | Genentech, Inc. | Fgfr1 agonists and methods of use |
KR102030531B1 (en) | 2011-05-21 | 2019-10-10 | 마크로제닉스, 인크. | Deimmunized serum-binding domains and their use for extending serum half-life |
CN103857699B (en) | 2011-05-24 | 2016-08-31 | 泽恩格尼亚股份有限公司 | Multivalence and unit price polyspecific complex and application thereof |
AU2012262007B2 (en) | 2011-06-02 | 2017-06-22 | Takeda Pharmaceutical Company Limited | Fc receptor binding proteins |
US8569462B2 (en) | 2011-06-03 | 2013-10-29 | Xoma Technology Ltd. | Antibodies specific for TGF-beta and methods for treating thereof |
US9181553B2 (en) | 2011-06-06 | 2015-11-10 | Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Method of treatment of breast cancers over-expressing the SHP2 signature genes |
WO2012170740A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
WO2012170742A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Treatment and prevention of cancer with hmgb1 antagonists |
HUE037408T2 (en) | 2011-06-10 | 2018-08-28 | Univ Oregon Health & Science | Cmv glycoproteins and recombinant vectors |
WO2012170807A2 (en) | 2011-06-10 | 2012-12-13 | Medimmune, Llc | Anti-pseudomonas psl binding molecules and uses thereof |
JP5984919B2 (en) | 2011-06-15 | 2016-09-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Anti-human EPO receptor antibody and method of use |
WO2013003625A2 (en) | 2011-06-28 | 2013-01-03 | Oxford Biotherapeutics Ltd. | Antibodies |
WO2013001369A2 (en) | 2011-06-28 | 2013-01-03 | Oxford Biotherapeutics Ltd. | Therapeutic and diagnostic target |
TW201306866A (en) | 2011-06-30 | 2013-02-16 | Genentech Inc | Anti-c-met antibody formulations |
AU2012283039A1 (en) | 2011-07-13 | 2014-01-30 | Abbvie Inc. | Methods and compositions for treating asthma using anti-IL-13 antibodies |
CA2840482C (en) | 2011-07-14 | 2018-10-16 | Pfizer Inc. | Treatment with anti-pcsk9 antibodies |
GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
WO2013012733A1 (en) | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
MX349198B (en) | 2011-07-15 | 2017-07-18 | Oncomed Pharmaceuticals Inc * | Rspo binding agents and uses thereof. |
US20130022551A1 (en) | 2011-07-22 | 2013-01-24 | Trustees Of Boston University | DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS |
EA026924B1 (en) | 2011-08-01 | 2017-05-31 | Дженентек, Инк. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
US9676854B2 (en) | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses |
BR112014003431A2 (en) | 2011-08-17 | 2017-06-13 | Genentech Inc | antibody, nucleic acid, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, pharmaceutical agent, use of the antibody, method of treating an individual who has cancer, and time-lapse method for tumor recurrence |
BR112014004168A2 (en) | 2011-08-23 | 2017-12-12 | Roche Glycart Ag | bispecific antibody, pharmaceutical composition, use of bispecific antibody, prokaryotic or eukaryotic host cell, antibody production method and invention |
BR112014004213A2 (en) | 2011-08-23 | 2017-06-20 | Found Medicine Inc | new kif5b-ret fusion molecules and their uses |
MX2014002053A (en) | 2011-08-23 | 2014-04-25 | Roche Glycart Ag | Anti-mcsp antibodies. |
WO2013026835A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Fc-free antibodies comprising two fab fragments and methods of use |
US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
EP2753697A1 (en) | 2011-09-05 | 2014-07-16 | ETH Zürich | Biosynthetic gene cluster for the production of peptide/protein analogues |
CA2848074A1 (en) | 2011-09-09 | 2013-03-14 | Medimmune Limited | Anti-siglec-15 antibodies and uses thereof |
CA2789539A1 (en) | 2011-09-12 | 2013-03-12 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
US8969519B2 (en) | 2011-09-13 | 2015-03-03 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for brown fat induction and activity using FNDC5 |
KR20140068062A (en) | 2011-09-15 | 2014-06-05 | 제넨테크, 인크. | Methods of promoting differentiation |
EP2771349B1 (en) | 2011-09-16 | 2020-02-26 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
RU2014114617A (en) | 2011-09-19 | 2015-10-27 | Дженентек, Инк. | COMBINED TREATMENTS CONTAINING C-MET ANTAGONISTS AND B-RAF ANTAGONISTS |
HUE061002T2 (en) | 2011-09-23 | 2023-04-28 | Mereo Biopharma 5 Inc | Vegf/dll4 binding agents and uses thereof |
SG11201401287SA (en) | 2011-10-05 | 2014-05-29 | Genentech Inc | Methods of treating liver conditions using notch2 antagonists |
EP2764370B1 (en) | 2011-10-06 | 2017-09-13 | The Board of Trustees of the University of Illionis | Myosin binding protein-c for use in methods relating to diastolic heart failure |
US10221454B2 (en) | 2011-10-10 | 2019-03-05 | The Hospital For Sick Children | Methods and compositions for screening and treating developmental disorders |
WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
US8623821B2 (en) | 2011-10-14 | 2014-01-07 | Genentech, Inc. | Zymogen activators |
KR20140082796A (en) | 2011-10-14 | 2014-07-02 | 제넨테크, 인크. | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE |
EP2766028B1 (en) | 2011-10-14 | 2017-08-16 | F. Hoffmann-La Roche AG | Peptide inhibitors of bace1 |
EP2766000A2 (en) | 2011-10-15 | 2014-08-20 | F.Hoffmann-La Roche Ag | Scd1 antagonists for treating cancer |
WO2013059531A1 (en) | 2011-10-20 | 2013-04-25 | Genentech, Inc. | Anti-gcgr antibodies and uses thereof |
TW201323440A (en) | 2011-10-24 | 2013-06-16 | Abbvie Inc | Immunobinders directed against sclerostin |
WO2013063114A1 (en) | 2011-10-24 | 2013-05-02 | Abbvie Inc. | Immunobinders directed against tnf |
EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
AU2012328980A1 (en) | 2011-10-28 | 2014-04-24 | Genentech, Inc. | Therapeutic combinations and methods of treating melanoma |
WO2013067060A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Anti-gpr49 antibodies |
AU2012332588B2 (en) | 2011-11-01 | 2017-09-07 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
JP2014533247A (en) | 2011-11-01 | 2014-12-11 | バイオノミクス インコーポレイテッド | Antibodies and methods of treating cancer |
WO2013067057A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Anti-gpr49 antibodies |
EP3643323A1 (en) | 2011-11-02 | 2020-04-29 | University Of Rochester | Anti-glucosaminidase passive immunization for staphylococcus aureus infections |
US10527526B2 (en) | 2011-11-03 | 2020-01-07 | Tripath Imaging, Inc. | Methods and compositions for preparing samples for immunostaining |
EP2773779B1 (en) | 2011-11-04 | 2020-10-14 | Population Bio, Inc. | Methods and compositions for diagnosing, prognosing, and treating neurological conditions |
EP2776065B1 (en) | 2011-11-07 | 2020-08-05 | MedImmune Limited | Combination therapies using anti- pseudomonas psl and pcrv binding molecules |
US20140294732A1 (en) | 2011-11-08 | 2014-10-02 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute | Early diagnostic of neurodegenerative diseases |
WO2013068902A1 (en) | 2011-11-08 | 2013-05-16 | Pfizer Inc. | Methods of treating inflammatory disorders using anti-m-csf antibodies |
WO2013068431A1 (en) | 2011-11-08 | 2013-05-16 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | New treatment for neurodegenerative diseases |
WO2013071233A1 (en) | 2011-11-10 | 2013-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for detecting infectious agents and a novel virus detected thereby |
BR112014011331A2 (en) | 2011-11-11 | 2017-04-25 | Rinat Neuroscience Corp | trop-2 specific antibodies and their uses |
EP2776466B1 (en) | 2011-11-11 | 2017-08-23 | UCB Biopharma SPRL | Albumin binding antibodies and binding fragments thereof |
RU2014121820A (en) | 2011-11-21 | 2015-12-27 | Иммьюноджен, Инк. | METHOD FOR TREATING TUMORS RESISTANT TO ANTI-EGFR THERAPIES USING AN EGFR ANTIBODY CONJUGATE WITH CYTOTOXIC AGENT |
RU2014124842A (en) | 2011-11-21 | 2015-12-27 | Дженентек, Инк. | CLEANING ANTI-C-MET ANTIBODIES |
JP2015501639A (en) | 2011-11-23 | 2015-01-19 | アイジェニカ バイオセラピューティクス インコーポレイテッド | Anti-CD98 antibody and method of use thereof |
EP2797957B1 (en) | 2011-11-23 | 2019-06-19 | MedImmune, LLC | Binding molecules specific for her3 and uses thereof |
AU2012346861A1 (en) | 2011-11-30 | 2014-06-19 | AbbVie Deutschland GmbH & Co. KG | Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor |
US20140335084A1 (en) | 2011-12-06 | 2014-11-13 | Hoffmann-La Roche Inc. | Antibody formulation |
AU2012352168C1 (en) | 2011-12-14 | 2018-01-25 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
US9636398B2 (en) | 2011-12-14 | 2017-05-02 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
US20150017157A1 (en) | 2011-12-19 | 2015-01-15 | Xoma (Us) Llc | Methods for treating acne |
SG11201403443WA (en) | 2011-12-22 | 2014-07-30 | Hoffmann La Roche | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides |
BR112014013035A2 (en) | 2011-12-22 | 2018-10-09 | Hoffmann La Roche | cell selection methods, bicistronic expression sets, eukaryotic cells, lentiviral vectors, lentiviral vector use, lentiviral and eukaryotic cell libraries, cell selection methods, workflows, and cell use |
EP2794878B1 (en) | 2011-12-22 | 2020-03-18 | F.Hoffmann-La Roche Ag | Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides |
EP2794653B1 (en) | 2011-12-23 | 2019-03-13 | Pfizer Inc | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
WO2013096791A1 (en) | 2011-12-23 | 2013-06-27 | Genentech, Inc. | Process for making high concentration protein formulations |
EP2797955A2 (en) | 2011-12-30 | 2014-11-05 | AbbVie Inc. | Dual variable domain immunoglobulins against il-13 and/or il-17 |
EP2800583A1 (en) | 2012-01-02 | 2014-11-12 | Novartis AG | Cdcp1 and breast cancer |
US20150011431A1 (en) | 2012-01-09 | 2015-01-08 | The Scripps Research Institute | Humanized antibodies |
US20140050720A1 (en) | 2012-01-09 | 2014-02-20 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
JP6247226B2 (en) | 2012-01-10 | 2017-12-13 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Improved transport of therapeutic molecules across the blood brain barrier |
WO2013109856A2 (en) | 2012-01-18 | 2013-07-25 | Genentech, Inc. | Methods of using fgf19 modulators |
IN2014DN05885A (en) | 2012-01-18 | 2015-06-05 | Hoffmann La Roche | |
GB201201332D0 (en) | 2012-01-26 | 2012-03-14 | Imp Innovations Ltd | Method |
PL2807192T3 (en) | 2012-01-27 | 2019-02-28 | Abbvie Deutschland | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
WO2013162654A1 (en) | 2012-04-25 | 2013-10-31 | Biodesy, Llc | Methods for detecting allosteric modulators of proteins |
DK2812452T3 (en) | 2012-02-09 | 2020-06-29 | Population Bio Inc | METHODS AND COMPOSITIONS FOR SCREENING AND TREATING DEVELOPMENT DISORDERS |
CA2864092C (en) | 2012-02-10 | 2021-06-29 | Seattle Genetics, Inc. | Detection and treatment of cd30+ cancers |
CN113398268A (en) | 2012-02-11 | 2021-09-17 | 霍夫曼-拉罗奇有限公司 | R-spondin translocations and methods of use thereof |
DK2814842T3 (en) | 2012-02-15 | 2018-12-10 | Novo Nordisk As | ANTIBODIES BINDING PEPTIDOGLYCAN RECOGNITION PROTEIN 1 |
US20150018241A1 (en) | 2012-02-15 | 2015-01-15 | Hoffmann-La Roche Inc. | Fc-receptor based affinity chromatography |
WO2013120553A1 (en) | 2012-02-15 | 2013-08-22 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1) |
US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
GB201203051D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
GB201203071D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
EP2817338B1 (en) | 2012-02-24 | 2017-07-26 | AbbVie Stemcentrx LLC | Dll3 modulators and methods of use |
ES2736030T3 (en) | 2012-03-13 | 2019-12-23 | Hoffmann La Roche | Polytherapy for the treatment of ovarian cancer |
US9139863B2 (en) | 2012-03-16 | 2015-09-22 | Genentech, Inc. | Engineered conformationally-stabilized proteins |
WO2013135745A1 (en) | 2012-03-16 | 2013-09-19 | F. Hoffmann-La Roche Ag | Methods of treating melanoma with pak1 inhibitors |
MX2014010943A (en) | 2012-03-16 | 2014-11-26 | Genentech Inc | Engineered conformationally-stabilized proteins. |
CN104470942B (en) | 2012-03-20 | 2018-12-14 | 奥塔哥创新有限公司 | Biomarker |
WO2013139956A1 (en) | 2012-03-22 | 2013-09-26 | Thrombogenics Nv | Antibodies abrogating cell binding to lactadherin |
CA2866185C (en) | 2012-03-23 | 2021-04-06 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pathogenic phlebovirus isolates and compositions and methods of use |
JP2015514710A (en) | 2012-03-27 | 2015-05-21 | ジェネンテック, インコーポレイテッド | Diagnosis and treatment of HER3 inhibitors |
JP2015518471A (en) | 2012-03-28 | 2015-07-02 | ジェネンテック, インコーポレイテッド | Anti-HCMV idiotype antibodies and their use |
US20150266961A1 (en) | 2012-03-29 | 2015-09-24 | Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute | Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer |
AR090549A1 (en) | 2012-03-30 | 2014-11-19 | Genentech Inc | ANTI-LGR5 AND IMMUNOCATE PLAYERS |
BR112014024537A2 (en) | 2012-04-02 | 2017-08-08 | Berg Llc | methods to identify modulators of a biological system, a disease process, and angiogenesis |
WO2013151649A1 (en) | 2012-04-04 | 2013-10-10 | Sialix Inc | Glycan-interacting compounds |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
WO2013158275A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Cell culture methods to reduce acidic species |
US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
NZ700274A (en) | 2012-04-24 | 2016-10-28 | Thrombogenics Nv | Anti-pdgf-c antibodies |
AR090903A1 (en) | 2012-05-01 | 2014-12-17 | Genentech Inc | ANTI-PMEL ANTIBODIES AND IMMUNOCADES17 |
WO2013170191A1 (en) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Methods of using antagonists of nad biosynthesis from nicotinamide |
WO2013173364A2 (en) | 2012-05-14 | 2013-11-21 | Biogen Idec Ma Inc. | Lingo-2 antagonists for treatment of conditions involving motor neurons |
MX362497B (en) | 2012-05-15 | 2019-01-21 | Eisai Inc | Methods for treatment of gastric cancer. |
WO2013177118A2 (en) | 2012-05-21 | 2013-11-28 | Abbvie Inc. | Novel purification of non-human antibodies using protein a affinity chromatography |
JP6294311B2 (en) | 2012-05-23 | 2018-03-14 | ジェネンテック, インコーポレイテッド | How to select a treatment |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
BR112014029887A8 (en) | 2012-05-31 | 2021-09-14 | Genentech Inc | Method to treat or slow the progression of cancer, kits and use of a pd-1 axis binding antagonist, oxaliplatin, leucovorin and 5-fu |
JP6629069B2 (en) | 2012-06-06 | 2020-01-15 | ゾエティス・エルエルシー | Canine anti-NGF antibody and method thereof |
KR20150018604A (en) | 2012-06-06 | 2015-02-23 | 온코메드 파마슈티칼스, 인크. | Binding agents that modulate the hippo pathway and uses thereof |
AR091462A1 (en) | 2012-06-15 | 2015-02-04 | Genentech Inc | ANTI-PCSK9 ANTIBODIES, FORMULATIONS, DOSAGE AND METHODS OF USE |
ES2631608T3 (en) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Env-glycoprotein variant of HIV-1 |
WO2014001557A1 (en) | 2012-06-28 | 2014-01-03 | Ucb Pharma S.A. | A method for identifying compounds of therapeutic interest |
EP2866831A1 (en) | 2012-06-29 | 2015-05-06 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating diseases by modulating a specific isoform of mkl1 |
JP6247287B2 (en) | 2012-07-04 | 2017-12-13 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Anti-biotin antibodies and methods of use |
PL2869837T3 (en) | 2012-07-04 | 2017-03-31 | F.Hoffmann-La Roche Ag | Anti-theophylline antibodies and methods of use |
AU2013285422B2 (en) | 2012-07-04 | 2017-04-27 | F. Hoffmann-La Roche Ag | Covalently linked antigen-antibody conjugates |
KR20150030693A (en) | 2012-07-05 | 2015-03-20 | 제넨테크, 인크. | Expression and secretion system |
US20150184154A1 (en) | 2012-07-05 | 2015-07-02 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear | New treatment for neurodegenerative diseases |
WO2014006115A1 (en) | 2012-07-06 | 2014-01-09 | Novartis Ag | Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction |
TW201408696A (en) | 2012-07-09 | 2014-03-01 | Genentech Inc | Anti-CD22 antibodies and immunoconjugates |
EA201590174A1 (en) | 2012-07-09 | 2015-09-30 | Дженентек, Инк. | IMMUNOCONGATES CONTAINING ANTI-CD22 ANTIBODIES |
IN2014DN10652A (en) | 2012-07-09 | 2015-09-11 | Genentech Inc | |
KR20150030698A (en) | 2012-07-09 | 2015-03-20 | 제넨테크, 인크. | Immunoconjugates comprising anti-cd79b antibodies |
UY34905A (en) | 2012-07-12 | 2014-01-31 | Abbvie Inc | IL-1 UNION PROTEINS |
EP3495387B1 (en) | 2012-07-13 | 2021-09-01 | Roche Glycart AG | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
GB201213652D0 (en) | 2012-08-01 | 2012-09-12 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
US9297806B2 (en) | 2012-08-01 | 2016-03-29 | The Johns Hopkins University | 5-hydroxymethylcytosine in human cancer |
EP3613765A1 (en) | 2012-08-03 | 2020-02-26 | Dana-Farber Cancer Institute, Inc. | Antibody against repulsive guidance molecule b (rgmb) |
BR112015002681A2 (en) | 2012-08-07 | 2018-08-28 | Genentech Inc | method to treat a patient and kit |
US9914956B2 (en) | 2012-08-18 | 2018-03-13 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
SG11201500938XA (en) | 2012-08-31 | 2015-04-29 | Immunogen Inc | Diagnostic assays and kits for detection of folate receptor 1 |
US9737493B2 (en) | 2012-09-07 | 2017-08-22 | University Of Louisville Research Foundation, Inc. | Compositions and methods for modulating DNMT1 inhibitor activity |
DK2895621T3 (en) | 2012-09-14 | 2020-11-30 | Population Bio Inc | METHODS AND COMPOSITION FOR DIAGNOSIS, FORECAST AND TREATMENT OF NEUROLOGICAL CONDITIONS |
CA2922005A1 (en) | 2012-09-27 | 2014-04-03 | Population Diagnostics, Inc. | Methods and compositions for screening and treating developmental disorders |
WO2014055442A2 (en) | 2012-10-01 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
KR20150064068A (en) | 2012-10-08 | 2015-06-10 | 로슈 글리카트 아게 | FC-FREE ANTIBODIES COMPRISING TWO Fab-FRAGMENTS AND METHODS OF USE |
AU2013329421A1 (en) | 2012-10-09 | 2015-04-30 | Biogen Ma Inc. | Combination therapies and uses for treatment of demyelinating disorders |
CA2887129A1 (en) | 2012-10-09 | 2014-04-17 | Igenica, Inc. | Anti-c16orf54 antibodies and methods of use thereof |
EP3679950A1 (en) | 2012-10-12 | 2020-07-15 | The Brigham and Women's Hospital, Inc. | Enhancement of the immune response |
WO2014066328A1 (en) | 2012-10-23 | 2014-05-01 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using wnt pathway-binding agents |
WO2014071018A1 (en) | 2012-10-31 | 2014-05-08 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a dll4 antagonist |
SG11201503412RA (en) | 2012-11-01 | 2015-05-28 | Abbvie Inc | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
EP2914621B1 (en) | 2012-11-05 | 2023-06-07 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
WO2014071282A1 (en) | 2012-11-05 | 2014-05-08 | Genzyme Corporation | Compositions and methods for treating proteinopathies |
WO2014074942A1 (en) | 2012-11-08 | 2014-05-15 | Illumina, Inc. | Risk variants of alzheimer's disease |
CN104903349B (en) | 2012-11-08 | 2018-10-19 | 十一生物治疗股份有限公司 | IL-6 antagonists and its application |
EP2917243B1 (en) | 2012-11-08 | 2018-03-14 | F.Hoffmann-La Roche Ag | Her3 antigen binding proteins binding to the beta-hairpin of her3 |
MA38176A1 (en) | 2012-11-13 | 2017-06-30 | Genentech Inc | Novel anti-haemagglutinin antibody, useful for the treatment, inhibition or prevention of viral influenza infection |
WO2014085821A2 (en) | 2012-11-30 | 2014-06-05 | The Regents Of The University Of California | Fully human antibodies and fragments recognizing human c-met |
DK2928923T3 (en) | 2012-12-10 | 2020-02-17 | Biogen Ma Inc | ANTIBODIES AGAINST DENDRITIC CELL ANTIGEN 2 FROM BLOOD AND APPLICATIONS THEREOF |
GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
WO2014100542A1 (en) | 2012-12-21 | 2014-06-26 | Abbvie, Inc. | High-throughput antibody humanization |
KR20150119848A (en) | 2012-12-21 | 2015-10-26 | 바이오얼라이언스 씨.브이. | Hydrophilic self-immolative linkers and conjugates thereof |
KR20150100715A (en) | 2012-12-21 | 2015-09-02 | 앰플리뮨, 인크. | Anti-h7cr antibodies |
AU2013202668B2 (en) | 2012-12-24 | 2014-12-18 | Adelaide Research & Innovation Pty Ltd | Inhibition of cancer growth and metastasis |
WO2014107739A1 (en) | 2013-01-07 | 2014-07-10 | Eleven Biotherapeutics, Inc. | Antibodies against pcsk9 |
US10717965B2 (en) | 2013-01-10 | 2020-07-21 | Gloriana Therapeutics, Inc. | Mammalian cell culture-produced neublastin antibodies |
EP3939614A1 (en) | 2013-01-18 | 2022-01-19 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
WO2014116749A1 (en) | 2013-01-23 | 2014-07-31 | Genentech, Inc. | Anti-hcv antibodies and methods of using thereof |
WO2014123696A1 (en) | 2013-01-25 | 2014-08-14 | Thymon, Llc | Compositions for selective reduction of circulating bioactive soluble tnf and methods for treating tnf-mediated disease |
CN105073195A (en) | 2013-02-04 | 2015-11-18 | 昂科梅德制药有限公司 | Methods and monitoring of treatment with a Wnt pathway inhibitor |
GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
WO2014129895A1 (en) | 2013-02-19 | 2014-08-28 | Stichting Vu-Vumc | Means and method for increasing the sensitivity of cancers for radiotherapy |
JP2016509045A (en) | 2013-02-22 | 2016-03-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | How to treat cancer and prevent drug resistance |
AU2014218730B2 (en) | 2013-02-22 | 2018-12-13 | Abbvie Stemcentrx Llc | Novel antibody conjugates and uses thereof |
MX369175B (en) | 2013-02-25 | 2019-10-30 | Genentech Inc | Methods and compositions for detecting and treating drug resistant akt mutant. |
MX2015010789A (en) | 2013-02-26 | 2015-11-26 | Roche Glycart Ag | Anti-mcsp antibodies. |
JP2016510751A (en) | 2013-03-06 | 2016-04-11 | ジェネンテック, インコーポレイテッド | Methods of treating and preventing anticancer drug resistance |
WO2014139994A1 (en) * | 2013-03-11 | 2014-09-18 | Novo Nordisk Health Care Ag | Growth hormone compounds |
CN105229035A (en) * | 2013-03-11 | 2016-01-06 | 诺和诺德保健股份有限公司 | Growth hormone compound |
AR095398A1 (en) | 2013-03-13 | 2015-10-14 | Genentech Inc | FORMULATIONS WITH REDUCED OXIDATION |
CN104968362B (en) | 2013-03-13 | 2018-12-14 | 霍夫曼-拉罗奇有限公司 | Aoxidize reduced preparaton |
AR095399A1 (en) | 2013-03-13 | 2015-10-14 | Genentech Inc | FORMULATIONS WITH REDUCED OXIDATION, METHOD |
SG10201913932VA (en) | 2013-03-13 | 2020-03-30 | Genentech Inc | Antibody formulations |
SI2968467T1 (en) | 2013-03-13 | 2020-11-30 | F. Hoffmann-La Roche Ag | Formulations with reduced oxidation |
CN105307683A (en) | 2013-03-14 | 2016-02-03 | 基因泰克公司 | Methods of treating cancer and preventing cancer drug resistance |
BR112015023212A2 (en) | 2013-03-14 | 2017-11-21 | Gill Parkash | cancer treatment using antibodies that bind to cell surface grp78 |
WO2014152358A2 (en) | 2013-03-14 | 2014-09-25 | Genentech, Inc. | Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use |
CA2899308C (en) | 2013-03-14 | 2017-04-18 | Abbvie Inc. | Low acidic species adalimumab compositions and uses thereof |
WO2014142882A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Protein purification using displacement chromatography |
US9790478B2 (en) | 2013-03-14 | 2017-10-17 | Abbott Laboratories | HCV NS3 recombinant antigens and mutants thereof for improved antibody detection |
KR20150127199A (en) | 2013-03-14 | 2015-11-16 | 제넨테크, 인크. | Anti-b7-h4 antibodies and immunoconjugates |
CN105378099B (en) | 2013-03-14 | 2021-05-11 | 雅培制药有限公司 | HCV core lipid binding domain monoclonal antibodies |
US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
CA2906421C (en) | 2013-03-14 | 2022-08-16 | George J. Dawson | Hcv antigen-antibody combination assay and methods and compositions for use therein |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
EP2970375A1 (en) | 2013-03-14 | 2016-01-20 | AbbVie Inc. | Low acidic species compositions and methods for producing the same using displacement chromatography |
CN105143264A (en) | 2013-03-15 | 2015-12-09 | 豪夫迈·罗氏有限公司 | Compositions and methods for diagnosis and treatment of hepatic cancers |
EP3424530A1 (en) | 2013-03-15 | 2019-01-09 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
WO2014151006A2 (en) | 2013-03-15 | 2014-09-25 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
CA2903587C (en) | 2013-03-15 | 2021-09-28 | Genentech, Inc. | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
AU2014236986A1 (en) | 2013-03-15 | 2015-09-03 | Biogen Ma Inc. | Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies |
EP2968589A1 (en) | 2013-03-15 | 2016-01-20 | AbbVie Inc. | Antibody drug conjugate (adc) purification |
US9469686B2 (en) | 2013-03-15 | 2016-10-18 | Abbott Laboratories | Anti-GP73 monoclonal antibodies and methods of obtaining the same |
JP2016520528A (en) | 2013-03-15 | 2016-07-14 | ジェネンテック, インコーポレイテッド | Cancer treatment and anticancer drug resistance prevention method |
EP2970452A2 (en) | 2013-03-15 | 2016-01-20 | AC Immune S.A. | Anti-tau antibodies and methods of use |
AU2014228938B2 (en) | 2013-03-15 | 2019-05-02 | Bioverativ Therapeutics Inc. | Factor IX polypeptide formulations |
KR102202476B1 (en) | 2013-03-15 | 2021-01-12 | 제넨테크, 인크. | Cell culture media and methods of antibody production |
US20140286969A1 (en) | 2013-03-15 | 2014-09-25 | Abbvie Inc. | Anti-egfr antibody drug conjugate formulations |
WO2014144292A2 (en) | 2013-03-15 | 2014-09-18 | Sanofi Pasteur Biologics , Llc | Antibodies against clostridium difficile toxins and methods of using the same |
MX2015013166A (en) | 2013-03-15 | 2015-12-11 | Abbvie Inc | Dual specific binding proteins directed against il-1 beta and il-17. |
BR112015021993A8 (en) | 2013-03-15 | 2019-12-03 | Genentech Inc | polypeptide, methods for producing it, methods for culturing a cell, pharmaceutical composition, kit, and cell culture medium |
AR095517A1 (en) | 2013-03-15 | 2015-10-21 | Genentech Inc | ANTIBODIES AGAINST THE CHEMIOATRAYENT RECEIVER EXPRESSED IN T HELPER 2 CELLS (ANTI-CRTh2) AND METHODS OF USE |
CN105120887A (en) | 2013-04-05 | 2015-12-02 | 诺和诺德保健股份有限公司 | Growth hormone compound formulation |
US9499621B2 (en) | 2013-04-08 | 2016-11-22 | Cytodyn, Inc. | Felinized antibodies and methods of treating retroviral infections in felines |
MX2015015060A (en) | 2013-04-29 | 2016-02-25 | Hoffmann La Roche | Fc-receptor binding modified asymmetric antibodies and methods of use. |
TWI653243B (en) | 2013-04-29 | 2019-03-11 | 赫孚孟拉羅股份公司 | Anti-IGF-1R antibody against FcRn binding and use thereof for treating vascular eye diseases |
CN105143262A (en) | 2013-04-29 | 2015-12-09 | 豪夫迈·罗氏有限公司 | Human fcrn-binding modified antibodies and methods of use |
WO2014176696A1 (en) | 2013-04-30 | 2014-11-06 | Université de Montréal | Novel biomarkers for acute myeloid leukemia |
EP2981822B1 (en) | 2013-05-06 | 2020-09-02 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
PL3594240T3 (en) | 2013-05-20 | 2024-04-02 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies and methods of use |
KR20160129698A (en) | 2013-05-24 | 2016-11-09 | 메디뮨 엘엘씨 | Anti-b7-h5 antibodies and their uses |
EP3293275B1 (en) | 2013-06-06 | 2021-08-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms |
AU2014274660B2 (en) | 2013-06-06 | 2019-05-16 | Pierre Fabre Médicament | Anti-C10orf54 antibodies and uses thereof |
WO2014197885A2 (en) | 2013-06-07 | 2014-12-11 | Duke University | Inhibitors of complement factor h |
JP2016521744A (en) | 2013-06-13 | 2016-07-25 | ファスト フォワード ファーマスーティカルズ ベー.フェー. | CD40 signaling inhibitor and additional compound for treating chronic inflammation and preventing digestive cancer or fibrosis, wherein the additional compound is bile acid, bile acid derivative, TGR5 receptor agonist, FXR agonist or combinations thereof |
WO2014210397A1 (en) | 2013-06-26 | 2014-12-31 | Academia Sinica | Rm2 antigens and use thereof |
WO2014210564A1 (en) | 2013-06-27 | 2014-12-31 | Academia Sinica | Glycan conjugates and use thereof |
RU2019129525A (en) | 2013-07-16 | 2019-11-05 | Дженентек, Инк. | METHODS FOR TREATING CANCER USING ANTAGONISTS BINDING THE PD-1 AXIS AND TIGIT INHIBITORS |
CA2918370A1 (en) | 2013-07-18 | 2015-01-22 | Fabrus, Inc. | Humanized antibodies with ultralong complementarity determining regions |
US20160168231A1 (en) | 2013-07-18 | 2016-06-16 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
EP3027225B1 (en) | 2013-07-31 | 2021-03-24 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating thermogenesis using transforming growth factor alpha |
CN113683695A (en) | 2013-08-02 | 2021-11-23 | 辉瑞公司 | anti-CXCR 4 antibodies and antibody-drug conjugates |
US20160178610A1 (en) | 2013-08-07 | 2016-06-23 | Friedrich Miescher Institute For Biomedical Research | New screening method for the treatment Friedreich's ataxia |
WO2015026846A1 (en) | 2013-08-19 | 2015-02-26 | Biogen Idec Ma Inc. | Control of protein glycosylation by culture medium supplementation and cell culture process parameters |
CA2922478C (en) | 2013-08-26 | 2020-09-29 | MabVax Therapeutics, Inc. | Nucleic acids encoding human antibodies to sialyl-lewisa |
WO2015031541A1 (en) | 2013-08-28 | 2015-03-05 | Stem Centrx, Inc. | Novel sez6 modulators and methods of use |
CA2922547C (en) | 2013-08-28 | 2020-03-10 | Stemcentrx, Inc. | Site-specific antibody conjugation methods and compositions |
US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
IL293871A (en) | 2013-08-30 | 2022-08-01 | Immunogen Inc | Antibodies and assays for detection of folate receptor 1 |
US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
EP3041484B1 (en) | 2013-09-06 | 2021-03-03 | Academia Sinica | Human inkt cell activation using glycolipids with altered glycosyl groups |
RU2016109247A (en) | 2013-09-17 | 2017-10-19 | Дженентек, Инк. | WAYS OF APPLICATION OF ANTIBODIES TO LGR5 |
EP3049521B1 (en) | 2013-09-25 | 2019-03-06 | Cornell University | Compounds for inducing anti-tumor immunity and methods thereof |
US10611794B2 (en) | 2013-09-25 | 2020-04-07 | Bioverativ Therapeutics Inc. | On-column viral inactivation methods |
WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
HUE047194T2 (en) | 2013-09-27 | 2020-04-28 | Hoffmann La Roche | Anti-pdl1 antibody formulations |
US10414818B2 (en) | 2013-09-27 | 2019-09-17 | Roche Diagnostics Operations, Inc. | Thermus thermophilus SlyD FKBP domain specific antibodies |
EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
MX2016004411A (en) | 2013-10-08 | 2016-07-05 | Immunogen Inc | Anti-folr1 immunoconjugate dosing regimens. |
JP2016537965A (en) | 2013-10-11 | 2016-12-08 | ジェネンテック, インコーポレイテッド | NSP4 inhibitors and methods of use |
WO2015057939A1 (en) | 2013-10-18 | 2015-04-23 | Biogen Idec Ma Inc. | Anti-s1p4 antibodies and uses thereof |
CA2925598A1 (en) | 2013-10-18 | 2015-04-23 | Genentech, Inc. | Anti-rspo antibodies and methods of use |
KR20160068802A (en) | 2013-10-23 | 2016-06-15 | 제넨테크, 인크. | Methods of diagnosing and treating eosinophilic disorders |
EP3063317B1 (en) | 2013-10-28 | 2020-06-03 | DOTS Technology Corp. | Allergen detection |
WO2015066190A1 (en) | 2013-10-29 | 2015-05-07 | President And Fellows Of Harvard College | Methods and compositions for inhibting oxidative stress |
US20160272674A1 (en) | 2013-11-07 | 2016-09-22 | Abbvie Inc. | Isolation and purification of antibodies |
EP2891722B1 (en) | 2013-11-12 | 2018-10-10 | Population Bio, Inc. | Methods and compositions for diagnosing, prognosing, and treating endometriosis |
US10900093B2 (en) | 2013-11-15 | 2021-01-26 | Institut Pasteur | Molecular marker of plasmodium falciparum artemisinin resistance |
LT3071597T (en) | 2013-11-21 | 2020-10-12 | F. Hoffmann-La Roche Ag | Anti-alpha-synuclein antibodies and methods of use |
MX2016006726A (en) | 2013-11-25 | 2016-12-16 | Ccam Biotherapeutics Ltd | Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy. |
EP3077048B1 (en) | 2013-12-07 | 2019-07-17 | Case Western Reserve University | Compositions and methods of treating thrombosis |
JP2017505756A (en) | 2013-12-13 | 2017-02-23 | ザ ジェネラル ホスピタル コーポレイション | Soluble high molecular weight (HMW) tau species and uses thereof |
ES2754209T3 (en) | 2013-12-13 | 2020-04-16 | Stora Enso Oyj | Multilayer cardboard |
SG11201604784XA (en) | 2013-12-13 | 2016-07-28 | Genentech Inc | Anti-cd33 antibodies and immunoconjugates |
US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
CA2934028A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
CN105899535A (en) | 2013-12-17 | 2016-08-24 | 豪夫迈·罗氏有限公司 | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
MX2016007972A (en) | 2013-12-17 | 2016-10-28 | Genentech Inc | Methods of treating cancers using pd-1 axis binding antagonists and taxanes. |
US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
PE20210648A1 (en) | 2013-12-17 | 2021-03-26 | Genentech Inc | ANTI-CD3 ANTIBODIES AND METHODS OF USE |
TWI672379B (en) | 2013-12-19 | 2019-09-21 | 瑞士商諾華公司 | Human mesothelin chimeric antigen receptors and uses thereof |
WO2015095868A1 (en) | 2013-12-20 | 2015-06-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
WO2015095809A1 (en) | 2013-12-20 | 2015-06-25 | Biogen Idec Ma Inc. | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
TWI670283B (en) | 2013-12-23 | 2019-09-01 | 美商建南德克公司 | Antibodies and methods of use |
EP2960252A1 (en) | 2014-06-26 | 2015-12-30 | Institut Pasteur | Phospholipase for treatment of immunosuppression |
CA2935378C (en) | 2013-12-24 | 2023-04-18 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
WO2015103549A1 (en) | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
EP3089758B1 (en) | 2014-01-03 | 2021-01-27 | F.Hoffmann-La Roche Ag | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
WO2015101586A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
BR112016014945A2 (en) | 2014-01-03 | 2018-01-23 | F. Hoffmann-La Roche Ag | conjugate, pharmaceutical formulation and use |
JP6557664B2 (en) | 2014-01-06 | 2019-08-07 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Monovalent blood-brain barrier shuttle module |
CA2931986A1 (en) | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
TW201620939A (en) | 2014-01-16 | 2016-06-16 | 中央研究院 | Compositions and methods for treatment and detection of cancers |
WO2016114819A1 (en) | 2015-01-16 | 2016-07-21 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
WO2015134121A2 (en) | 2014-01-20 | 2015-09-11 | President And Fellows Of Harvard College | Negative selection and stringency modulation in continuous evolution systems |
WO2015112909A1 (en) | 2014-01-24 | 2015-07-30 | Genentech, Inc. | Methods of using anti-steap1 antibodies and immunoconjugates |
JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
BR112016017248A8 (en) | 2014-01-24 | 2018-04-17 | Ngm Biopharmaceuticals Inc | antibody or fragment thereof, binding agent, transgenic animal, hybridoma, vector, pharmaceutical composition, fgf19 and / or fgf21-like signaling induction method, method for activating a klotho beta / fgf receptor complex, method for improving metabolism of glucose in an individual, method of detecting klotho beta, use of antibody or fragment thereof, use of pharmaceutical composition, treatment method and method for improving metabolic parameters |
US11648335B2 (en) | 2014-01-31 | 2023-05-16 | Wake Forest University Health Sciences | Organ/tissue decellularization, framework maintenance and recellularization |
JOP20200096A1 (en) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | Antibody molecules to tim-3 and uses thereof |
WO2015116902A1 (en) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | G-protein coupled receptors in hedgehog signaling |
AU2015214264B2 (en) | 2014-02-04 | 2018-12-20 | Curis, Inc. | Mutant Smoothened and methods of using the same |
WO2015120187A1 (en) | 2014-02-05 | 2015-08-13 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants |
EP3102230B1 (en) | 2014-02-08 | 2021-04-28 | F. Hoffmann-La Roche AG | Methods of treating alzheimer's disease |
JP6685912B2 (en) | 2014-02-08 | 2020-04-22 | ジェネンテック, インコーポレイテッド | Alzheimer's disease treatment method |
CA3212977A1 (en) | 2014-02-11 | 2015-08-20 | Visterra, Inc. | Antibody molecules to dengue virus and uses thereof |
AU2015217271B2 (en) | 2014-02-12 | 2018-10-25 | Genentech, Inc. | Anti-Jagged1 antibodies and methods of use |
MX2016010729A (en) | 2014-02-21 | 2016-10-26 | Genentech Inc | Anti-il-13/il-17 bispecific antibodies and uses thereof. |
EP3107576A4 (en) | 2014-02-21 | 2017-09-06 | Abbvie Stemcentrx LLC | Anti-dll3 antibodies and drug conjugates for use in melanoma |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
US9738702B2 (en) | 2014-03-14 | 2017-08-22 | Janssen Biotech, Inc. | Antibodies with improved half-life in ferrets |
JP6644717B2 (en) | 2014-03-14 | 2020-02-12 | ジェネンテック, インコーポレイテッド | Methods and compositions for secreting heterologous polypeptides |
PT3116909T (en) | 2014-03-14 | 2020-01-30 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
EA201691787A1 (en) | 2014-03-21 | 2017-02-28 | Тева Фармасьютикалз Интернэшнл Гмбх | ANTAGONISTIC ANTIBODIES DIRECTED AGAINST PEPTIDE CODED BY CALCITONIN GENE AND METHODS OF THEIR APPLICATION |
WO2015140591A1 (en) | 2014-03-21 | 2015-09-24 | Nordlandssykehuset Hf | Anti-cd14 antibodies and uses thereof |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
MX2016012285A (en) | 2014-03-24 | 2017-01-23 | Genentech Inc | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression. |
DK3122869T3 (en) | 2014-03-24 | 2019-09-09 | Biogen Ma Inc | PROCEDURES FOR REDUCING GLUTAMINE DEPRESSION IN MAMMAL CULTURE CULTURE |
CN106415244B (en) | 2014-03-27 | 2020-04-24 | 中央研究院 | Reactive marker compounds and uses thereof |
MA40682B1 (en) | 2014-03-31 | 2020-01-31 | Hoffmann La Roche | Anti-ox40 antibodies and methods of use thereof |
CN106132439A (en) | 2014-03-31 | 2016-11-16 | 豪夫迈·罗氏有限公司 | Comprise antiangiogenic agent and OX40 combines the combination treatment of agonist |
SG11201608054YA (en) | 2014-04-02 | 2016-10-28 | Hoffmann La Roche | Method for detecting multispecific antibody light chain mispairing |
AU2015240599B2 (en) | 2014-04-04 | 2020-11-19 | Bionomics, Inc. | Humanized antibodies that bind LGR5 |
HUE051676T2 (en) | 2014-04-08 | 2021-03-29 | Boston Pharmaceuticals Inc | Binding molecules specific for il-21 and uses thereof |
JP2017512765A (en) | 2014-04-11 | 2017-05-25 | メディミューン,エルエルシー | Bispecific HER2 antibody |
AP2016009549A0 (en) | 2014-04-18 | 2016-11-30 | Acceleron Pharma Inc | Methods for increasing red blood cell levels and treating sickle-cell disease |
WO2015164615A1 (en) | 2014-04-24 | 2015-10-29 | University Of Oslo | Anti-gluten antibodies and uses thereof |
US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
CR20160534A (en) | 2014-04-27 | 2017-04-25 | Ccam Biotherapeutics Ltd | HUMANIZED ANTIBODIES AGAINST THE CELLULAR ADHESION MOLECULE RELATED TO CARCINOEMBRIONIC ANTIGEN 1 (CEACAM1) |
US9753036B2 (en) | 2014-04-29 | 2017-09-05 | Edp Biotech Corporation | Methods and compositions for screening and detecting biomarkers |
RU2708075C2 (en) | 2014-04-30 | 2019-12-04 | Пфайзер Инк. | Anti-ptk7 antibody-drug conjugates |
KR102461511B1 (en) | 2014-05-05 | 2022-11-01 | 리제너론 파마슈티칼스 인코포레이티드 | Humanized c5 and c3 animals |
AU2015259516B2 (en) | 2014-05-13 | 2020-05-28 | Bavarian Nordic A/S | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against TIM-3 |
CN106413750B (en) | 2014-05-16 | 2022-04-29 | 免疫医疗有限责任公司 | Molecules with altered neonatal Fc receptor binding with enhanced therapeutic and diagnostic properties |
WO2015179658A2 (en) | 2014-05-22 | 2015-11-26 | Genentech, Inc. | Anti-gpc3 antibodies and immunoconjugates |
KR20170005016A (en) | 2014-05-23 | 2017-01-11 | 제넨테크, 인크. | Mit biomarkers and methods using the same |
KR102512592B1 (en) | 2014-05-27 | 2023-03-21 | 아카데미아 시니카 | Anti-her2 glycoantibodies and uses thereof |
EP3149036A4 (en) | 2014-05-27 | 2017-12-27 | Academia Sinica | Anti-cd20 glycoantibodies and uses thereof |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
KR102576850B1 (en) | 2014-05-27 | 2023-09-11 | 아카데미아 시니카 | Fucosidase from bacteroides and methods using the same |
NZ726513A (en) | 2014-05-28 | 2023-07-28 | Memorial Sloan Kettering Cancer Center | Anti-gitr antibodies and methods of use thereof |
AU2015267044A1 (en) | 2014-05-28 | 2016-12-15 | Academia Sinica | Anti-TNF-alpha glycoantibodies and uses thereof |
GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
RU2636780C1 (en) | 2014-06-03 | 2017-11-28 | ИксБиотеч, Инк. | Compositions and methods for treatment and prevention of infections caused by staphylococcus aureus |
NZ764877A (en) | 2014-06-04 | 2023-12-22 | Biontech Res And Development Inc | Human monoclonal antibodies to ganglioside gd2 |
CN106459202A (en) | 2014-06-11 | 2017-02-22 | 豪夫迈·罗氏有限公司 | Anti-lgR5 antibodies and uses thereof |
WO2015191986A1 (en) | 2014-06-13 | 2015-12-17 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
BR122023023170A2 (en) | 2014-06-13 | 2024-02-20 | Acceleron Pharma Inc. | USE OF AN ACTRII ANTAGONIST IN THE TREATMENT OR PREVENTION OF SKIN ULCERS ASSOCIATED WITH BETA-THALASSEMIA |
WO2015189816A1 (en) | 2014-06-13 | 2015-12-17 | Friedrich Miescher Institute For Biomedical Research | New treatment against influenza virus |
AU2015276821A1 (en) | 2014-06-20 | 2017-01-12 | Abgenomics International Inc. | Anti-folate receptor aplha (FRA) antibody-drug conjugates and methods of using thereof |
US10308935B2 (en) | 2014-06-23 | 2019-06-04 | Friedrich Miescher Institute For Biomedical Research | Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS |
GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
TW201623329A (en) | 2014-06-30 | 2016-07-01 | 亞佛瑞司股份有限公司 | Vaccines and monoclonal antibodies targeting truncated variants of osteopontin and uses thereof |
EP3164129A1 (en) | 2014-07-01 | 2017-05-10 | Friedrich Miescher Institute for Biomedical Research | Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma |
CN107074925B (en) | 2014-07-10 | 2021-08-24 | 阿费里斯股份公司 | Materials and methods for preventing and/or treating huntington's disease |
EP3166627A1 (en) | 2014-07-11 | 2017-05-17 | Genentech, Inc. | Notch pathway inhibition |
EP3169801A1 (en) | 2014-07-14 | 2017-05-24 | F. Hoffmann-La Roche AG | Diagnostic methods and compositions for treatment of glioblastoma |
US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
CA2954508A1 (en) | 2014-07-15 | 2016-01-21 | Genentech, Inc. | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
EP3172232B1 (en) | 2014-07-17 | 2023-12-27 | Novo Nordisk A/S | Site directed mutagenesis of trem-1 antibodies for decreasing viscosity. |
SG11201700416TA (en) | 2014-07-21 | 2017-02-27 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
WO2016012623A1 (en) | 2014-07-25 | 2016-01-28 | Theravectys | Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule |
WO2016020799A1 (en) | 2014-08-06 | 2016-02-11 | Rinat Neuroscience Corp. | Methods for reducing ldl-cholesterol |
WO2016020798A1 (en) | 2014-08-06 | 2016-02-11 | Rinat Neuroscience Corp. | Methods for reducing ldl-cholesterol |
WO2016025880A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
EP3712171A1 (en) | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
WO2016037157A2 (en) | 2014-09-05 | 2016-03-10 | The Johns Hopkins University | Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies |
CA2996445A1 (en) | 2014-09-05 | 2016-03-10 | Eli Hatchwell | Methods and compositions for inhibiting and treating neurological conditions |
CN107001404B (en) | 2014-09-08 | 2021-06-29 | 中央研究院 | Activation of human iNKT cells using glycolipids |
EP3693391A1 (en) | 2014-09-12 | 2020-08-12 | Genentech, Inc. | Anti-cll-1 antibodies and immunoconjugates |
EP3191518B1 (en) | 2014-09-12 | 2020-01-15 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
DK3191135T3 (en) | 2014-09-12 | 2020-10-12 | Genentech Inc | Anti-HER2 antibodies and immunoconjugates |
WO2016040880A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of alk inhibitors |
EP3193932B1 (en) | 2014-09-15 | 2023-04-26 | F. Hoffmann-La Roche AG | Antibody formulations |
AU2015316522B2 (en) | 2014-09-16 | 2021-01-21 | Symphogen A/S | Anti-met antibodies and compositions |
CN107124870A (en) | 2014-09-17 | 2017-09-01 | 基因泰克公司 | Immunoconjugates comprising Anti-HER 2 and Pyrrolobenzodiazepines * |
US10222386B2 (en) | 2014-09-19 | 2019-03-05 | The Johns Hopkins University | Biomarkers of congnitive dysfunction |
EP3197492A1 (en) | 2014-09-23 | 2017-08-02 | Pfizer Inc | Treatment with anti-pcsk9 antibodies |
US20160082120A1 (en) | 2014-09-23 | 2016-03-24 | Genentech, Inc. | METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES |
WO2016046768A1 (en) | 2014-09-24 | 2016-03-31 | Friedrich Miescher Institute For Biomedical Research | Lats and breast cancer |
US10400037B2 (en) | 2014-09-30 | 2019-09-03 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Binding molecules, especially antibodies, binding to L1CAM (CD171) |
KR20230153495A (en) | 2014-10-01 | 2023-11-06 | 메디뮨 리미티드 | Antibodies to ticagrelor and methods of use |
BR112017006664A2 (en) | 2014-10-03 | 2017-12-26 | Novartis Ag | combination therapies |
TN2017000129A1 (en) | 2014-10-14 | 2018-10-19 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-l1 and uses thereof |
EP3207057A2 (en) | 2014-10-16 | 2017-08-23 | F. Hoffmann-La Roche AG | Anti-alpha-synuclein antibodies and methods of use |
MA41685A (en) | 2014-10-17 | 2017-08-22 | Biogen Ma Inc | COPPER SUPPLEMENT FOR THE REGULATION OF GLYCOSYLATION IN A MAMMAL CELL CULTURE PROCESS |
US11124822B2 (en) | 2014-10-17 | 2021-09-21 | Carnegie Mellon University | Enhanced biomolecule detection assays based on tyramide signal amplification and gammaPNA probes |
US10920208B2 (en) | 2014-10-22 | 2021-02-16 | President And Fellows Of Harvard College | Evolution of proteases |
EP3209697A4 (en) | 2014-10-23 | 2018-05-30 | La Trobe University | Fn14-binding proteins and uses thereof |
US9434778B2 (en) | 2014-10-24 | 2016-09-06 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
WO2016070051A2 (en) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
MA40864A (en) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | HYPOTAURINE, GABA, BETA-ALANINE AND CHOLINE FOR THE REGULATION OF THE ACCUMULATION OF RESIDUAL BY-PRODUCTS IN MAMMAL CELL CULTURE PROCESSES |
US10626176B2 (en) | 2014-10-31 | 2020-04-21 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind B7-H4 |
MX2017005751A (en) | 2014-11-03 | 2018-04-10 | Genentech Inc | Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment. |
WO2016073378A1 (en) | 2014-11-03 | 2016-05-12 | Genentech, Inc. | Assays for detecting t cell immune subsets and methods of use thereof |
CN108064308B (en) | 2014-11-05 | 2023-06-09 | 豪夫迈·罗氏有限公司 | Method for producing double-stranded protein in bacteria |
WO2016073685A1 (en) | 2014-11-05 | 2016-05-12 | Annexon, Inc. | Humanized anti-complement factor c1q antibodies and uses thereof |
EP3215533A2 (en) | 2014-11-05 | 2017-09-13 | F. Hoffmann-La Roche AG | Anti-fgfr2/3 antibodies and methods using same |
KR102544705B1 (en) | 2014-11-05 | 2023-06-15 | 제넨테크, 인크. | Methods of producing two chain proteins in bacteria |
KR20170078677A (en) | 2014-11-06 | 2017-07-07 | 에프. 호프만-라 로슈 아게 | Fc-region variants with modified fcrn-binding and methods of use |
WO2016071377A1 (en) | 2014-11-06 | 2016-05-12 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and protein a-binding properties |
WO2016073157A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Anti-ang2 antibodies and methods of use thereof |
AU2015343494A1 (en) | 2014-11-06 | 2017-04-27 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and TIGIT inhibitors |
WO2016073894A1 (en) | 2014-11-07 | 2016-05-12 | Eleven Biotherapeutics, Inc. | Therapeutic agents with increased ocular retention |
SG10202103420PA (en) | 2014-11-07 | 2021-05-28 | Eleven Biotherapeutics Inc | Improved il-6 antibodies |
JP6929771B2 (en) | 2014-11-10 | 2021-09-01 | ジェネンテック, インコーポレイテッド | Anti-interleukin-33 antibody and its use |
EP3217787B1 (en) | 2014-11-10 | 2019-04-17 | F.Hoffmann-La Roche Ag | Animal model for nephropathy and agents for treating the same |
LT3218406T (en) | 2014-11-10 | 2021-06-25 | Medimmune Limited | Binding molecules specific for cd73 and uses thereof |
EP3789403A1 (en) | 2014-11-11 | 2021-03-10 | MedImmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof |
EP3218005B1 (en) | 2014-11-12 | 2023-01-04 | Seagen Inc. | Glycan-interacting compounds and methods of use |
US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
EP3875481A1 (en) | 2014-11-14 | 2021-09-08 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
WO2016081384A1 (en) | 2014-11-17 | 2016-05-26 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
CN107429075B (en) | 2014-11-17 | 2022-11-01 | 卡内基梅隆大学 | Activatable two-component photosensitizer |
CN107108745B (en) | 2014-11-19 | 2021-01-12 | 基因泰克公司 | Antibodies against BACE1 and their use for immunotherapy of neurological diseases |
EP3221362B1 (en) | 2014-11-19 | 2019-07-24 | F.Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies and methods of use |
CN107250158B (en) | 2014-11-19 | 2022-03-25 | 基因泰克公司 | Anti-transferrin receptor/anti-BACE 1 multispecific antibodies and methods of use |
KR20240024318A (en) | 2014-11-20 | 2024-02-23 | 에프. 호프만-라 로슈 아게 | Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists |
EP3220900B1 (en) | 2014-11-21 | 2020-09-23 | University of Maryland, Baltimore | Targeted structure-specific particulate delivery systems |
MA41119A (en) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | METHODS OF TREATMENT OF MYELODYSPLASIC SYNDROMES AND SIDEROBLASTIC ANEMIA |
ES2744540T3 (en) | 2014-12-05 | 2020-02-25 | Hoffmann La Roche | Anti-CD79b antibodies and usage procedures |
JP2017537929A (en) | 2014-12-05 | 2017-12-21 | ジェネンテック, インコーポレイテッド | Methods and compositions for cancer treatment using PD-1 axis antagonists and HPK1 antagonists |
WO2016094273A1 (en) | 2014-12-08 | 2016-06-16 | Dana-Farber Cancer Institute, Inc. | Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents |
BR112017011234A2 (en) | 2014-12-10 | 2018-03-27 | Genentech Inc | antibodies to the blood-brain barrier receptor and methods of use |
WO2016094837A2 (en) | 2014-12-11 | 2016-06-16 | Igenica Biotherapeutics, Inc. | Anti-c10orf54 antibodies and uses thereof |
WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
US9765135B2 (en) | 2014-12-19 | 2017-09-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-C5 antibodies |
US20170340733A1 (en) | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
JP7211703B2 (en) | 2014-12-22 | 2023-01-24 | ザ ロックフェラー ユニバーシティー | Anti-MERTK agonist antibody and use thereof |
WO2016106286A1 (en) | 2014-12-23 | 2016-06-30 | Biodesy, Inc. | Attachment of proteins to interfaces for use in nonlinear optical detection |
US20160200815A1 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
US10435467B2 (en) | 2015-01-08 | 2019-10-08 | Biogen Ma Inc. | LINGO-1 antagonists and uses for treatment of demyelinating disorders |
SG10202111844VA (en) | 2015-01-09 | 2021-12-30 | Adalta Ltd | Cxcr4 binding molecules |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
CN113956354A (en) | 2015-01-22 | 2022-01-21 | 中外制药株式会社 | Combinations and methods of use of two or more anti-C5 antibodies |
AU2015378564A1 (en) | 2015-01-24 | 2017-07-13 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
JP2018510844A (en) | 2015-01-24 | 2018-04-19 | アカデミア シニカAcademia Sinica | Cancer marker and method of use thereof |
US20180170992A1 (en) | 2015-01-26 | 2018-06-21 | The University Of Chicago | CAR T CELLS RECOGNIZING CANCER-SPECIFIC IL 13Ra2 |
EP3250609A4 (en) | 2015-01-26 | 2018-07-11 | The University of Chicago | Il13ra alpha 2 binding agents and use thereof in cancer treatment |
DK3250590T3 (en) | 2015-01-30 | 2021-10-18 | Academia Sinica | Compositions and Methods relating to universal glycoforms for enhanced anti-SSEA4 antibody efficacy |
CA2975346A1 (en) | 2015-02-02 | 2016-08-11 | I2 Pharmaceuticals, Inc. | Anti-surrogate light chain antibodies |
JP6772156B2 (en) | 2015-02-04 | 2020-10-21 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | How to choose a therapeutic molecule |
SG11201706293XA (en) | 2015-02-04 | 2017-09-28 | Hoffmann La Roche | Tau antisense oligomers and uses thereof |
JP2018512597A (en) | 2015-02-04 | 2018-05-17 | ジェネンテック, インコーポレイテッド | Mutant smoothened and method of using the same |
WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
DE112016001013T5 (en) | 2015-03-03 | 2017-12-21 | Kymab Limited | ANTIBODIES, USES AND METHODS |
US10711067B2 (en) | 2015-03-03 | 2020-07-14 | Xoma (Us) Llc | Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery |
EP3735982A1 (en) | 2015-03-10 | 2020-11-11 | The University of Massachusetts | Targeting gdf6 and bmp signaling for anti-melanoma therapy |
AR103935A1 (en) | 2015-03-16 | 2017-06-14 | Genentech Inc | METHODS OF DETECTION AND QUANTIFICATION OF IL-13 AND ITS USES IN THE DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH TH-2 |
WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
HUE049081T2 (en) | 2015-03-20 | 2020-09-28 | The United States Of America As | Neutralizing antibodies to gp120 and their use |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
BR112017020054A2 (en) | 2015-03-23 | 2018-06-05 | Jounce Therapeutics Inc | antibodies to icos |
CA2981068C (en) | 2015-03-26 | 2021-12-14 | Women & Infants Hospital Of Rhode Island | Therapy for malignant disease comprising the inhibition of human epididymal secretory protein e4 and immune checkpoint inhibitors |
ES2904573T3 (en) | 2015-03-27 | 2022-04-05 | Univ Southern California | LHR-directed T cell therapy for the treatment of solid tumors |
CA2979732A1 (en) | 2015-04-03 | 2016-10-06 | Eureka Therapeutics, Inc. | Constructs targeting afp peptide/mhc complexes and uses thereof |
CN108136001B (en) | 2015-04-03 | 2022-07-29 | 佐马技术有限公司 | Treatment of cancer using TGF-beta inhibitors and PD-1 inhibitors |
MA53400A (en) | 2015-04-06 | 2021-08-04 | Acceleron Pharma Inc | ALK7 HETEROMULTIMERS: ACTRIIB AND THEIR USES |
MA41919A (en) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | ALK4 HETEROMULTIMERS: ACTRIIB AND THEIR USES |
CA2982115A1 (en) | 2015-04-06 | 2016-10-13 | President And Fellows Of Harvard College | Compositions and methods for non-myeloablative conditioning |
CA2981183A1 (en) | 2015-04-07 | 2016-10-13 | Greg Lazar | Antigen binding complex having agonistic activity and methods of use |
SI3280441T1 (en) | 2015-04-07 | 2022-01-31 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
CA2925329C (en) | 2015-04-13 | 2024-01-02 | Pfizer Inc. | Anti-bcma antibodies, anti-cd3 antibodies and bi-specific antibodies binding to bcma and cd3 |
KR102349475B1 (en) | 2015-04-13 | 2022-01-11 | 화이자 인코포레이티드 | Chimeric antigen receptors targeting b-cell maturation antigen |
WO2016168631A1 (en) | 2015-04-17 | 2016-10-20 | President And Fellows Of Harvard College | Vector-based mutagenesis system |
EP3875477A1 (en) | 2015-04-17 | 2021-09-08 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
WO2016170022A1 (en) | 2015-04-21 | 2016-10-27 | Institut Gustave Roussy | Therapeutic methods, products and compositions inhibiting znf555 |
GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
WO2016172551A2 (en) | 2015-04-24 | 2016-10-27 | Genentech, Inc. | Methods of identifying bacteria comprising binding polypeptides |
AU2016256486B2 (en) | 2015-04-29 | 2021-09-23 | University Of South Australia | Compositions and methods for administering antibodies |
JP2018520642A (en) | 2015-05-01 | 2018-08-02 | ジェネンテック, インコーポレイテッド | Mask anti-CD3 antibody and method of use thereof |
WO2016179194A1 (en) | 2015-05-04 | 2016-11-10 | Jounce Therapeutics, Inc. | Lilra3 and method of using the same |
WO2016179518A2 (en) | 2015-05-06 | 2016-11-10 | Janssen Biotech, Inc. | Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof |
TWI820377B (en) | 2015-05-07 | 2023-11-01 | 美商艾吉納斯公司 | Anti-ox40 antibodies and methods of use thereof |
EP3936524A3 (en) | 2015-05-11 | 2022-06-15 | F. Hoffmann-La Roche AG | Compositions and methods of treating lupus nephritis |
EP3736287A1 (en) | 2015-05-11 | 2020-11-11 | The Johns Hopkins University | Autoimmune antibodies for use in inhibiting cancer cell growth |
AU2016262074A1 (en) | 2015-05-12 | 2017-11-09 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
EP3297674B1 (en) | 2015-05-22 | 2023-01-04 | Translational Drug Development Llc | Benzamide and active compound compositions and methods of use |
EA039951B1 (en) | 2015-05-27 | 2022-03-31 | Юсб Биофарма Спрл | Inhibitor of csf-1r activity for use in the treatment or prophylaxis of epilepsy or parkinson's disease and pharmaceutical composition thereof |
JP2018520658A (en) | 2015-05-29 | 2018-08-02 | ジェネンテック, インコーポレイテッド | Humanized anti-Ebola virus glycoprotein antibodies and uses thereof |
MA44594B1 (en) | 2015-05-29 | 2020-09-30 | Memorial Sloan Kettering Cancer Center | Anti-ctla-4 Antibodies and Methods of Use thereof |
PE20180193A1 (en) | 2015-05-29 | 2018-01-26 | Abbvie Inc | ANTI-CD40 ANTIBODIES AND THEIR USES |
KR20180013881A (en) | 2015-05-29 | 2018-02-07 | 제넨테크, 인크. | PD-L1 promoter methylation in cancer |
ES2789500T5 (en) | 2015-05-29 | 2023-09-20 | Hoffmann La Roche | Therapeutic and diagnostic procedures for cancer |
WO2016196679A1 (en) | 2015-06-02 | 2016-12-08 | Genentech, Inc. | Compositions and methods for using anti-il-34 antibodies to treat neurological diseases |
EP3303380B1 (en) | 2015-06-02 | 2020-01-15 | Novo Nordisk A/S | Insulins with polar recombinant extensions |
WO2016196975A1 (en) | 2015-06-03 | 2016-12-08 | The United States Of America, As Represented By The Secretary Department Of Health & Human Services | Neutralizing antibodies to hiv-1 env and their use |
US10711064B2 (en) | 2015-06-04 | 2020-07-14 | University Of Southern California | Lym-1 and Lym-2 targeted CAR cell immunotherapy |
SG10201911349YA (en) | 2015-06-05 | 2020-01-30 | Genentech Inc | Anti-tau antibodies and methods of use |
US20170000885A1 (en) | 2015-06-08 | 2017-01-05 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
CN107810011A (en) | 2015-06-08 | 2018-03-16 | 豪夫迈·罗氏有限公司 | Use the method for anti-OX40 antibodies for treating cancer |
AU2016276981B2 (en) | 2015-06-12 | 2022-10-06 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
JP2018518491A (en) | 2015-06-12 | 2018-07-12 | アレクトル エルエルシー | Anti-CD33 antibody and method of use thereof |
TW201710286A (en) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | Binding proteins against VEGF, PDGF, and/or their receptors |
EP3307780A1 (en) | 2015-06-15 | 2018-04-18 | Genentech, Inc. | Antibodies and immunoconjugates |
CN107847568B (en) | 2015-06-16 | 2022-12-20 | 豪夫迈·罗氏有限公司 | anti-CLL-1 antibodies and methods of use |
EP3310811B1 (en) | 2015-06-16 | 2021-06-16 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
SI3310814T1 (en) | 2015-06-16 | 2023-11-30 | F. Hoffmann - La Roche Ag | Humanized and affinity matured antibodies to fcrh5 and methods of use |
JP6896650B2 (en) | 2015-06-17 | 2021-06-30 | ジェネンテック, インコーポレイテッド | Treatment of Locally Advanced or Metastatic Breast Cancer Using PD-1 Axle Antagonists and Taxanes |
EP3310812A2 (en) | 2015-06-17 | 2018-04-25 | H. Hoffnabb-La Roche Ag | Anti-her2 antibodies and methods of use |
GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
EP3311165B1 (en) | 2015-06-19 | 2020-12-09 | University Of Rochester | Septin proteins as novel biomarkers for detection and treatment of müllerian cancers |
US11009509B2 (en) | 2015-06-24 | 2021-05-18 | Janssen Pharmaceutica Nv | Anti-VISTA antibodies and fragments |
CN108473573A (en) | 2015-06-29 | 2018-08-31 | 豪夫迈·罗氏有限公司 | II type anti-CD 20 antibodies are used in organ transplant |
DK3313884T3 (en) | 2015-06-29 | 2021-02-22 | Immunogen Inc | ANTI-CD123 ANTIBODIES AND CONJUGATES AND THEIR DERIVATIVES |
GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
US10877045B2 (en) | 2015-07-21 | 2020-12-29 | Saint Louis University | Compositions and methods for diagnosing and treating endometriosis-related infertility |
WO2017015545A1 (en) | 2015-07-22 | 2017-01-26 | President And Fellows Of Harvard College | Evolution of site-specific recombinases |
US11524983B2 (en) | 2015-07-23 | 2022-12-13 | President And Fellows Of Harvard College | Evolution of Bt toxins |
LT3317301T (en) | 2015-07-29 | 2021-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
US10612011B2 (en) | 2015-07-30 | 2020-04-07 | President And Fellows Of Harvard College | Evolution of TALENs |
AU2016301380B2 (en) | 2015-08-04 | 2021-07-01 | Acceleron Pharma Inc. | Methods for treating myeloproliferative disorders |
TW202330904A (en) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | Taurine supplemented cell culture medium and methods of use |
WO2017024285A2 (en) | 2015-08-06 | 2017-02-09 | Xoma (Us) Llc | Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia |
CN105384825B (en) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | A kind of bispecific chimeric antigen receptor and its application based on single domain antibody |
EP3341415B1 (en) | 2015-08-28 | 2021-03-24 | H. Hoffnabb-La Roche Ag | Anti-hypusine antibodies and uses thereof |
CN107949573B (en) | 2015-09-01 | 2022-05-03 | 艾吉纳斯公司 | anti-PD-1 antibodies and methods of use thereof |
JP2018532990A (en) | 2015-09-04 | 2018-11-08 | オービーアイ ファーマ,インコーポレイテッド | Glycan arrays and methods of use |
CA3036652A1 (en) | 2015-09-15 | 2017-03-23 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
JP6880006B2 (en) | 2015-09-17 | 2021-06-02 | イミュノジェン, インコーポレイテッド | A therapeutic combination that includes an anti-FOLR1 immune complex |
MX2018003005A (en) | 2015-09-18 | 2018-04-11 | Chugai Pharmaceutical Co Ltd | Il-8-binding antibodies and uses thereof. |
EP3353204B1 (en) | 2015-09-23 | 2023-10-18 | Mereo BioPharma 5, Inc. | Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer |
AU2016326721C1 (en) | 2015-09-23 | 2021-06-03 | Cytoimmune Therapeutics, Inc. | FLT3 directed car cells for immunotherapy |
SG10201911226QA (en) | 2015-09-23 | 2020-01-30 | Genentech Inc | Optimized variants of anti-vegf antibodies |
ES2768957T3 (en) | 2015-09-24 | 2020-06-24 | Abvitro Llc | HIV Antibody Compositions and Methods of Use |
MX2018003689A (en) | 2015-09-29 | 2018-04-30 | Celgene Corp | Pd-1 binding proteins and methods of use thereof. |
WO2017058780A1 (en) | 2015-09-30 | 2017-04-06 | Merck Patent Gmbh | Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer |
MA43348A (en) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | PROTEIN CONJUGATES |
MA43345A (en) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
UA123826C2 (en) | 2015-10-02 | 2021-06-09 | Ф. Хоффманн-Ля Рош Аг | Anti-pd1 antibodies and methods of use |
EP3362093A4 (en) | 2015-10-13 | 2019-05-08 | Technion Research & Development Foundation Limited | Heparanase-neutralizing monoclonal antibodies |
WO2017066561A2 (en) | 2015-10-16 | 2017-04-20 | President And Fellows Of Harvard College | Regulatory t cell pd-1 modulation for regulating t cell effector immune responses |
MA43354A (en) | 2015-10-16 | 2018-08-22 | Genentech Inc | CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE |
MA45326A (en) | 2015-10-20 | 2018-08-29 | Genentech Inc | CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
EP3365372A1 (en) | 2015-10-22 | 2018-08-29 | Jounce Therapeutics, Inc. | Gene signatures for determining icos expression |
AU2016342041B2 (en) | 2015-10-23 | 2021-12-02 | Eureka Therapeutics, Inc. | Antibody/T-cell receptor chimeric constructs and uses thereof |
RU2754683C2 (en) | 2015-10-27 | 2021-09-06 | Юсб Биофарма Срл | Methods for treatment using anti-il-17a antibodies |
US20180348224A1 (en) | 2015-10-28 | 2018-12-06 | Friedrich Miescher Institute For Biomedical Resear Ch | Tenascin-w and biliary tract cancers |
US20210106661A1 (en) | 2015-10-29 | 2021-04-15 | Dana-Farber Cancer Institute, Inc. | Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
KR102162324B1 (en) | 2015-10-30 | 2020-10-07 | 제넨테크, 인크. | Anti-HtrA1 antibodies and methods of use thereof |
US10407510B2 (en) | 2015-10-30 | 2019-09-10 | Genentech, Inc. | Anti-factor D antibodies and conjugates |
GB201519303D0 (en) * | 2015-11-02 | 2015-12-16 | Imp Innovations Ltd | Phagemid vector |
EP3371211A4 (en) | 2015-11-04 | 2019-08-21 | Icahn School of Medicine at Mount Sinai | Methods of treating tumors and cancer, and identifying candidate subjects for such treatment |
EP3371217A1 (en) | 2015-11-08 | 2018-09-12 | H. Hoffnabb-La Roche Ag | Methods of screening for multispecific antibodies |
SG10202103712VA (en) | 2015-11-10 | 2021-05-28 | Medimmune Llc | Binding molecules specific for asct2 and uses thereof |
CN108473559A (en) | 2015-11-10 | 2018-08-31 | 威特拉公司 | Specifically bind antibody molecule-drug conjugate and its application of lipopolysaccharides |
CA3002097A1 (en) | 2015-11-12 | 2017-05-18 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
EP3380121B1 (en) | 2015-11-23 | 2023-12-20 | Acceleron Pharma Inc. | Actrii antagonist for use in treating eye disorders |
FI3380522T3 (en) | 2015-11-25 | 2024-01-16 | Visterra Inc | Antibody molecules to april and uses thereof |
CN108925136B (en) | 2015-12-02 | 2022-02-01 | 斯特赛恩斯公司 | Antibodies specific for glycosylated BTLA (B and T lymphocyte attenuating factor) |
WO2017096051A1 (en) | 2015-12-02 | 2017-06-08 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
KR20180085740A (en) | 2015-12-09 | 2018-07-27 | 에프. 호프만-라 로슈 아게 | Type II anti-CD20 antibodies to reduce the formation of anti-drug antibodies |
EP3178848A1 (en) | 2015-12-09 | 2017-06-14 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies |
WO2017097889A1 (en) | 2015-12-10 | 2017-06-15 | Katholieke Universiteit Leuven | Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device |
CA3007671A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
KR20180094977A (en) | 2015-12-17 | 2018-08-24 | 노파르티스 아게 | Combinations of c-Met inhibitors and antibody molecules for PD-1 and uses thereof |
AU2016372930B2 (en) | 2015-12-18 | 2020-10-08 | Chugai Seiyaku Kabushiki Kaisha | Anti-C5 antibodies and methods of use |
WO2017112954A1 (en) | 2015-12-23 | 2017-06-29 | Moonshot Pharma Llc | Methods for inducing an immune response by promoting premature termination codon read-through |
MX2018008063A (en) | 2015-12-30 | 2018-11-29 | Genentech Inc | Use of tryptophan derivatives for protein formulations. |
JP7008023B2 (en) | 2015-12-30 | 2022-01-25 | ジェネンテック, インコーポレイテッド | Formulation with reduced polysorbate degradation |
CN107531795B (en) | 2016-01-05 | 2021-01-19 | 江苏恒瑞医药股份有限公司 | PCSK9 antibody, antigen-binding fragment thereof and medical application thereof |
US10596257B2 (en) | 2016-01-08 | 2020-03-24 | Hoffmann-La Roche Inc. | Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies |
US10472422B2 (en) | 2016-01-08 | 2019-11-12 | Abgenomics International Inc. | Tetravalent anti-PSGL-1 antibodies and uses thereof |
WO2017120523A2 (en) | 2016-01-08 | 2017-07-13 | Scholar Rock, Inc. | Anti-pro/latent myostatin antibodies and methods of use thereof |
WO2017127764A1 (en) | 2016-01-20 | 2017-07-27 | Genentech, Inc. | High dose treatments for alzheimer's disease |
WO2017125830A1 (en) | 2016-01-21 | 2017-07-27 | Pfizer Inc. | Chimeric antigen receptors targeting epidermal growth factor receptor variant iii |
DK3405490T3 (en) | 2016-01-21 | 2022-01-10 | Pfizer | MONO- AND BISPECIFIC ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III AND CD3 AND USES THEREOF |
EP3411396A1 (en) | 2016-02-04 | 2018-12-12 | Curis, Inc. | Mutant smoothened and methods of using the same |
GB201602413D0 (en) | 2016-02-10 | 2016-03-23 | Nascient Ltd | Method |
CN116920085A (en) | 2016-02-12 | 2023-10-24 | 詹森药业有限公司 | anti-VISTA (B7H 5) antibodies |
CN109196121B (en) | 2016-02-29 | 2022-01-04 | 基因泰克公司 | Methods for treatment and diagnosis of cancer |
EP3423488A4 (en) | 2016-02-29 | 2019-11-06 | Foundation Medicine, Inc. | Methods of treating cancer |
JP2019515876A (en) | 2016-03-08 | 2019-06-13 | アカデミア シニカAcademia Sinica | Methods for module synthesis of N-glycans and their arrays |
KR20230152153A (en) | 2016-03-10 | 2023-11-02 | 악셀레론 파마 인코포레이티드 | Activin type 2 receptor binding proteins and uses thereof |
AU2017231833B2 (en) | 2016-03-10 | 2024-03-14 | Viela Bio, Inc. | ILT7 binding molecules and methods of using the same |
SG11201807176XA (en) | 2016-03-11 | 2018-09-27 | Scholar Rock Inc | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF |
WO2017160599A1 (en) | 2016-03-14 | 2017-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of cd300b antagonists to treat sepsis and septic shock |
CN116196412A (en) | 2016-03-15 | 2023-06-02 | 中外制药株式会社 | Methods of treating cancer using PD-1 axis binding antagonists and anti-GPC 3 antibodies |
WO2017158436A1 (en) | 2016-03-17 | 2017-09-21 | Oslo Universitetssykehus Hf | Fusion proteins targeting tumour associated macrophages for treating cancer |
AU2017238172A1 (en) | 2016-03-21 | 2018-09-13 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
AU2017239038A1 (en) | 2016-03-22 | 2018-10-04 | Bionomics Inc | Administration of an anti-LGR5 monoclonal antibody |
JP6943872B2 (en) | 2016-03-25 | 2021-10-06 | ジェネンテック, インコーポレイテッド | Multiple whole antibody and antibody complex drug quantification assay |
AU2017238651A1 (en) | 2016-03-25 | 2018-10-04 | Visterra, Inc. | Formulation of antibody molecules to dengue virus |
EP3436482A4 (en) | 2016-03-29 | 2020-03-11 | OBI Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
EP3436477A2 (en) | 2016-03-29 | 2019-02-06 | Janssen Biotech, Inc. | Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody |
US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
WO2017175058A1 (en) | 2016-04-07 | 2017-10-12 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
EP3439692A4 (en) | 2016-04-08 | 2020-01-22 | ITI Health, Inc. | Plectin-1 binding antibodies and uses thereof |
EP3443004A1 (en) | 2016-04-14 | 2019-02-20 | H. Hoffnabb-La Roche Ag | Anti-rspo3 antibodies and methods of use |
PL3443350T3 (en) | 2016-04-15 | 2021-05-31 | F. Hoffmann-La Roche Ag | Methods for monitoring and treating cancer |
KR20190003957A (en) | 2016-04-15 | 2019-01-10 | 제넨테크, 인크. | Cancer monitoring and treatment methods |
WO2017181098A2 (en) | 2016-04-15 | 2017-10-19 | Visterra, Inc. | Antibody molecules to zika virus and uses thereof |
SG11201809024UA (en) | 2016-04-22 | 2018-11-29 | Obi Pharma Inc | Cancer immunotherapy by immune activation or immune modulation via globo series antigens |
US11246868B2 (en) | 2016-04-26 | 2022-02-15 | Icahn School Of Medicine At Mount Sinai | Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment |
CR20180509A (en) | 2016-05-02 | 2019-02-15 | Hoffmann La Roche | CONTORSBODY - A BIND OF DIANA MONOCATENARY |
WO2017194441A1 (en) | 2016-05-11 | 2017-11-16 | F. Hoffmann-La Roche Ag | Modified anti-tenascin antibodies and methods of use |
JP7084878B2 (en) | 2016-05-16 | 2022-06-15 | 武田薬品工業株式会社 | Anti-factor IX Padua antibody |
ES2858151T3 (en) | 2016-05-20 | 2021-09-29 | Hoffmann La Roche | PROTAC-Antibody Conjugates and Procedures for Use |
WO2017205465A2 (en) | 2016-05-24 | 2017-11-30 | Griswold Karl Edwin | Antibodies and methods of making same |
KR20230091191A (en) | 2016-05-27 | 2023-06-22 | 아게누스 인코포레이티드 | Anti-tim-3 antibodies and methods of use thereof |
WO2017205741A1 (en) | 2016-05-27 | 2017-11-30 | Genentech, Inc. | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
RU2745748C2 (en) | 2016-06-02 | 2021-03-31 | Эббви Инк. | Agonist of the glucocorticoid receptor and its immunoconjugates |
CA3059010A1 (en) | 2016-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
WO2017214024A1 (en) | 2016-06-06 | 2017-12-14 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
JP6921943B2 (en) | 2016-06-06 | 2021-08-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Ophthalmic fusion protein with increased eye retention |
CN116143918A (en) | 2016-06-24 | 2023-05-23 | 豪夫迈·罗氏有限公司 | Anti-polyubiquitin multispecific antibodies |
EP3475446A1 (en) | 2016-06-27 | 2019-05-01 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
MA45491A (en) | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES |
EP3478717B1 (en) | 2016-07-04 | 2022-01-05 | F. Hoffmann-La Roche AG | Novel antibody format |
US11292801B2 (en) | 2016-07-05 | 2022-04-05 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
EP3481864A1 (en) | 2016-07-08 | 2019-05-15 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
CN109862911A (en) | 2016-07-13 | 2019-06-07 | 比奥根Ma公司 | The dosage of LINGO-1 antagonist and purposes for treating demyelinating disorder |
CA3026757A1 (en) | 2016-07-15 | 2018-01-18 | Poseida Therapeutics, Inc. | Chimeric antigen receptors and methods for use |
WO2018013936A1 (en) | 2016-07-15 | 2018-01-18 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
CN110461315A (en) | 2016-07-15 | 2019-11-15 | 诺华股份有限公司 | Cytokines release syndrome is treated and prevented using with the Chimeric antigen receptor of kinase inhibitor combination |
AU2017296237A1 (en) | 2016-07-15 | 2019-01-03 | Poseida Therapeutics, Inc. | Chimeric antigen receptors (CARS) specific for MUC1 and methods for their use |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
US20190330318A1 (en) | 2016-07-25 | 2019-10-31 | Biogen Ma Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
BR112019001615A2 (en) | 2016-07-27 | 2019-04-30 | Acceleron Pharma Inc. | methods and compositions for treating myelofibrosis |
AU2017302038B2 (en) | 2016-07-27 | 2024-03-21 | Obi Pharma, Inc. | Immunogenic/therapeutic glycan compositions and uses thereof |
EP3491026A4 (en) | 2016-07-29 | 2020-07-29 | OBI Pharma, Inc. | Human antibodies, pharmaceutical compositions and methods |
US20190185578A1 (en) | 2016-07-29 | 2019-06-20 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity |
US10519250B2 (en) | 2016-08-01 | 2019-12-31 | Xoma (Us) Llc | Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof |
WO2018052556A1 (en) | 2016-08-02 | 2018-03-22 | Visterra, Inc. | Engineered polypeptides and uses thereof |
US11649285B2 (en) | 2016-08-03 | 2023-05-16 | Bio-Techne Corporation | Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy |
JP2019530434A (en) | 2016-08-05 | 2019-10-24 | ジェネンテック, インコーポレイテッド | Multivalent and multi-epitope antibodies with agonist activity and methods of use |
WO2018027124A1 (en) | 2016-08-05 | 2018-02-08 | Medimmune, Llc | Anti-o2 antibodies and uses thereof |
KR20230079499A (en) | 2016-08-05 | 2023-06-07 | 추가이 세이야쿠 가부시키가이샤 | Composition for prophylaxis or treatment of il-8 related diseases |
EP3497129A1 (en) | 2016-08-08 | 2019-06-19 | H. Hoffnabb-La Roche Ag | Therapeutic and diagnostic methods for cancer |
WO2018031662A1 (en) | 2016-08-11 | 2018-02-15 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
JP7213549B2 (en) | 2016-08-22 | 2023-01-27 | シーエイチオー ファーマ インコーポレイテッド | Antibodies, Binding Fragments, and Methods of Use |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
EP3515932B1 (en) | 2016-09-19 | 2023-11-22 | F. Hoffmann-La Roche AG | Complement factor based affinity chromatography |
JP2019531284A (en) | 2016-09-19 | 2019-10-31 | セルジーン コーポレイション | Methods of treating immune disorders using PD-1 binding proteins |
US10766958B2 (en) | 2016-09-19 | 2020-09-08 | Celgene Corporation | Methods of treating vitiligo using PD-1 binding antibodies |
EP3528838B1 (en) | 2016-09-23 | 2023-07-19 | F. Hoffmann-La Roche AG | Uses of il-13 antagonists for treating atopic dermatitis |
JP7274413B2 (en) | 2016-09-23 | 2023-05-16 | マレンゴ・セラピューティクス,インコーポレーテッド | Multispecific antibody molecules containing lambda and kappa light chains |
US10392434B2 (en) | 2016-09-23 | 2019-08-27 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
WO2018055573A1 (en) | 2016-09-23 | 2018-03-29 | Teva Pharmaceuticals International Gmbh | Treating cluster headache |
CA3038679A1 (en) | 2016-09-28 | 2018-04-05 | Xoma (Us) Llc | Antibodies that bind interleukin-2 and uses thereof |
AU2017336523B2 (en) | 2016-09-28 | 2022-07-21 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
GB201616596D0 (en) | 2016-09-29 | 2016-11-16 | Nascient Limited | Epitope and antibodies |
MA46366A (en) | 2016-09-30 | 2019-08-07 | Janssen Biotech Inc | SAFE AND EFFECTIVE PROCESS FOR TREATING PSORIASIS WITH A SPECIFIC ANTIBODY AGAINST IL-23 |
JP2019535015A (en) | 2016-10-03 | 2019-12-05 | アボット・ラボラトリーズAbbott Laboratories | Improved method for assessing GFAP status in patient samples |
EP3522933B1 (en) | 2016-10-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Methods for preparing antibody drug conjugates |
JP2019529509A (en) | 2016-10-05 | 2019-10-17 | アクセレロン ファーマ インコーポレーテッド | Compositions and methods for treating kidney disease |
CN110418851A (en) | 2016-10-06 | 2019-11-05 | 基因泰克公司 | The treatment of cancer and diagnostic method |
AU2017341047A1 (en) | 2016-10-07 | 2019-05-02 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
WO2018071500A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
WO2018071576A1 (en) | 2016-10-14 | 2018-04-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Treatment of tumors by inhibition of cd300f |
WO2018075408A1 (en) | 2016-10-17 | 2018-04-26 | Alexion Pharmaceuticals, Inc. | Methods of treating acute myeloid leukemia (aml) with combinations of anti-cd200 antibodies, cytarabine, and daunorubicin |
SG11201903063UA (en) | 2016-10-19 | 2019-05-30 | Medimmune Llc | Anti-o1 antibodies and uses thereof |
US11249082B2 (en) | 2016-10-29 | 2022-02-15 | University Of Miami | Zika virus assay systems |
US11555076B2 (en) | 2016-10-29 | 2023-01-17 | Genentech, Inc. | Anti-MIC antibodies and methods of use |
AU2017355401A1 (en) | 2016-11-02 | 2019-05-02 | Jounce Therapeutics, Inc. | Antibodies to PD-1 and uses thereof |
SG11201903842YA (en) | 2016-11-02 | 2019-05-30 | Immunogen Inc | Combination treatment with antibody-drug conjugates and parp inhibitors |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
US11332521B2 (en) | 2016-11-07 | 2022-05-17 | Neuracle Science Co., Ltd. | Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof |
EP3541422A4 (en) | 2016-11-16 | 2020-05-06 | Janssen Biotech, Inc. | Method of treating psoriasis with anti-il-23 specific antibody |
US11401330B2 (en) | 2016-11-17 | 2022-08-02 | Seagen Inc. | Glycan-interacting compounds and methods of use |
TW201829463A (en) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | Anti-hla-g antibodies and use thereof |
US11000601B2 (en) | 2016-11-21 | 2021-05-11 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
KR20190080949A (en) | 2016-11-23 | 2019-07-08 | 바이오버라티브 테라퓨틱스 인크. | A bispecific antibody that binds to coagulation factor IX and coagulation factor X |
CN110234319B (en) | 2016-11-23 | 2022-09-27 | 转化药物开发有限责任公司 | Compositions of benzamide and active compound and methods of use thereof |
WO2018102594A1 (en) | 2016-12-01 | 2018-06-07 | Alexion Pharmaceuticals, Inc. | Methods of treating solid tumors with anti-cd200 antibodies |
BR112019011651A2 (en) | 2016-12-07 | 2020-01-07 | Agenus Inc. | ANTI-CTTLA-4 ANTIBODIES AND METHODS OF USE OF THE SAME |
CN117820467A (en) | 2016-12-07 | 2024-04-05 | 基因泰克公司 | anti-TAU antibodies and methods of use |
CN110300599A (en) | 2016-12-07 | 2019-10-01 | 艾吉纳斯公司 | Antibody and its application method |
PE20191135A1 (en) | 2016-12-07 | 2019-09-02 | Genentech Inc | ANTITAU ANTIBODIES AND METHODS OF USE |
GB201621635D0 (en) | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
AU2017384276B9 (en) | 2016-12-21 | 2020-11-26 | F. Hoffmann-La Roche Ag | In vitro glycoengineering of antibodies |
BR112019009839A2 (en) | 2016-12-21 | 2019-09-17 | Hoffmann La Roche | method for enzymatic production of an antibody and antibody |
WO2018114879A1 (en) | 2016-12-21 | 2018-06-28 | F. Hoffmann-La Roche Ag | Method for in vitro glycoengineering of antibodies |
KR20190111036A (en) | 2016-12-23 | 2019-10-01 | 비스테라, 인크. | Binding Polypeptides and Methods for Making the Same |
PT3565592T (en) | 2017-01-06 | 2023-05-31 | Scholar Rock Inc | Methods for treating metabolic diseases by inhibiting myostatin activation |
WO2018129329A1 (en) | 2017-01-06 | 2018-07-12 | Scholar Rock, Inc. | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF |
DK3565592T3 (en) | 2017-01-06 | 2023-05-01 | Scholar Rock Inc | TREATMENT OF METABOLIC DISEASES BY INHIBITION OF MYSTATIN ACTIVATION |
WO2018132597A1 (en) | 2017-01-12 | 2018-07-19 | Eureka Therapeutics, Inc. | Constructs targeting histone h3 peptide/mhc complexes and uses thereof |
CN110290811A (en) | 2017-01-13 | 2019-09-27 | 中央研究院 | To treat the glue system of the repeatable loading of brain diseases |
TWI659750B (en) | 2017-01-13 | 2019-05-21 | 中央研究院 | Improved reloadable hydrogel system for treating myocardial infarction |
CA3049449A1 (en) | 2017-01-18 | 2018-07-26 | Visterra, Inc. | Antibody molecule-drug conjugates and uses thereof |
AU2018211064A1 (en) | 2017-01-18 | 2019-09-05 | Genentech, Inc. | Idiotypic antibodies against anti-PD-L1 antibodies and uses thereof |
AU2017396503A1 (en) | 2017-01-30 | 2019-07-11 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, and methods for the treatment of active Psoriatic arthritis |
US10240205B2 (en) | 2017-02-03 | 2019-03-26 | Population Bio, Inc. | Methods for assessing risk of developing a viral disease using a genetic test |
US11623945B2 (en) | 2017-02-06 | 2023-04-11 | The United States Of America, As Represented By The Secretary Of Agriculture | Immunostimulating compositions and uses therefore |
AU2017398101A1 (en) | 2017-02-07 | 2019-08-01 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis |
TW201837051A (en) | 2017-02-08 | 2018-10-16 | 美商必治妥美雅史谷比公司 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
PE20191548A1 (en) | 2017-02-10 | 2019-10-24 | Genentech Inc | ANTIBODIES AGAINST TRYPTASE, COMPOSITIONS OF THESE AND USES OF THEM |
US11021535B2 (en) | 2017-02-10 | 2021-06-01 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
US20200291089A1 (en) | 2017-02-16 | 2020-09-17 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
WO2018152496A1 (en) | 2017-02-17 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Compositions and methods for the diagnosis and treatment of zika virus infection |
SG11201907606XA (en) | 2017-02-27 | 2019-09-27 | Regeneron Pharma | Humanized model of kidney and liver disorders |
MX2019010295A (en) | 2017-03-01 | 2019-11-21 | Genentech Inc | Diagnostic and therapeutic methods for cancer. |
CN110382529B (en) | 2017-03-02 | 2024-03-08 | 诺华股份有限公司 | Engineered heterodimeric proteins |
JP7195262B2 (en) | 2017-03-02 | 2022-12-23 | ベス イスラエル デアコネス メディカル センター インコーポレイティッド | Method for Selecting Headache Patients Responsive to Antibodies Directed to Calcitonin Gene-Related Peptides |
SG11201907889YA (en) | 2017-03-03 | 2019-09-27 | Seattle Genetics Inc | Glycan-interacting compounds and methods of use |
EP3595682A1 (en) | 2017-03-13 | 2020-01-22 | Poseida Therapeutics, Inc. | Compositions and methods for selective elimination and replacement of hematopoietic stem cells |
AR111249A1 (en) | 2017-03-22 | 2019-06-19 | Genentech Inc | OPTIMIZED ANTIBODY COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS |
SG11201908547VA (en) | 2017-03-22 | 2019-10-30 | Genentech Inc | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods |
WO2018175942A1 (en) | 2017-03-23 | 2018-09-27 | Abbott Laboratories | Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1 |
WO2018176019A1 (en) | 2017-03-24 | 2018-09-27 | The Regents Of The University Of California | Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom |
KR20190133723A (en) | 2017-03-27 | 2019-12-03 | 에프. 호프만-라 로슈 아게 | Improved antigen binding receptors |
RU2019133199A (en) | 2017-03-27 | 2021-04-28 | Ф. Хоффманн-Ля Рош Аг | IMPROVED ANTIGEN BINDING RECEPTOR FORMATS |
PE20200010A1 (en) | 2017-04-03 | 2020-01-06 | Hoffmann La Roche | ANTIBODIES THAT JOIN STEAP-1 |
PE20191494A1 (en) | 2017-04-03 | 2019-10-21 | Hoffmann La Roche | IMMUNOCONJUGATES OF AN ANTI-PD-1 ANTIBODY WITH A MUTANT IL-2 OR IL-15 |
CN110382525B (en) | 2017-04-03 | 2023-10-20 | 豪夫迈·罗氏有限公司 | Immunoconjugates |
CA3055769A1 (en) | 2017-04-03 | 2018-10-11 | Oncologie, Inc. | Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents |
JP2020513019A (en) | 2017-04-05 | 2020-04-30 | ノヴォ ノルディスク アー/エス | Oligomer-extended insulin-Fc conjugate |
CN116375876A (en) | 2017-04-05 | 2023-07-04 | 豪夫迈·罗氏有限公司 | Bispecific antibodies that specifically bind PD1 and LAG3 |
MA49034B1 (en) | 2017-04-05 | 2022-09-30 | Hoffmann La Roche | Anti-lag3 antibody |
WO2018189611A1 (en) | 2017-04-12 | 2018-10-18 | Pfizer Inc. | Antibodies having conditional affinity and methods of use thereof |
BR112019017241A2 (en) | 2017-04-13 | 2020-04-14 | Agenus Inc | anti-cd137 antibodies and methods of using them |
EP3609918A1 (en) | 2017-04-14 | 2020-02-19 | Gamamabs Pharma | Amhrii-binding compounds for preventing or treating cancers |
WO2018189381A1 (en) | 2017-04-14 | 2018-10-18 | Gamamabs Pharma | Amhrii-binding compounds for preventing or treating lung cancers |
US10877048B2 (en) | 2017-04-15 | 2020-12-29 | Abbott Laboratories | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers |
EP3612563A1 (en) | 2017-04-19 | 2020-02-26 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
EP3612560A1 (en) | 2017-04-21 | 2020-02-26 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
MA49131A (en) | 2017-04-21 | 2020-03-25 | Hoffmann La Roche | USE OF KLK5 ANTAGONISTS FOR THE TREATMENT OF DISEASE |
GB201706451D0 (en) | 2017-04-24 | 2017-06-07 | Imp Innovations Ltd | Cancer treatment |
EP4230649A3 (en) | 2017-04-25 | 2023-10-25 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of epstein barr virus infection |
CN110741016A (en) | 2017-04-26 | 2020-01-31 | 优瑞科生物技术公司 | Chimeric antibody/T-cell receptor constructs and uses thereof |
JP7295030B2 (en) | 2017-04-26 | 2023-06-20 | ユーリカ セラピューティックス, インコーポレイテッド | Construct that specifically recognizes glypican 3 and use thereof |
CA3059468A1 (en) | 2017-04-27 | 2018-11-01 | Tesaro, Inc. | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
CA3059769A1 (en) | 2017-04-28 | 2018-11-01 | Elstar Therapeutics, Inc. | Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof |
JP7080899B2 (en) | 2017-04-28 | 2022-06-06 | アボット・ラボラトリーズ | Methods to aid in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject |
US11021537B2 (en) | 2017-05-01 | 2021-06-01 | Agenus Inc. | Anti-TIGIT antibodies and methods of use thereof |
US10865238B1 (en) | 2017-05-05 | 2020-12-15 | Duke University | Complement factor H antibodies |
JOP20190256A1 (en) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | Newcastle disease viruses and uses thereof |
EP3625251A1 (en) | 2017-05-15 | 2020-03-25 | University Of Rochester | Broadly neutralizing anti-influenza monoclonal antibody and uses thereof |
US11530273B2 (en) | 2017-05-23 | 2022-12-20 | Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing |
BR112019024701A2 (en) | 2017-05-25 | 2020-06-09 | Abbott Lab | methods to assist in determining whether an imaging test should be performed on a human individual who has suffered or may have suffered a head injury with the use of early biomarkers |
CA3059601A1 (en) | 2017-05-30 | 2018-12-06 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i and early biomarkers |
CA3065301A1 (en) | 2017-05-31 | 2018-12-06 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
WO2018222901A1 (en) | 2017-05-31 | 2018-12-06 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
US20200131266A1 (en) | 2017-05-31 | 2020-04-30 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1 |
PE20191846A1 (en) | 2017-06-02 | 2019-12-31 | Pfizer | ANTIBODIES SPECIFIC TO FLT3 AND ITS USES |
CA3062328A1 (en) | 2017-06-02 | 2018-12-06 | Pfizer Inc. | Chimeric antigen receptors targeting flt3 |
WO2018226671A1 (en) | 2017-06-06 | 2018-12-13 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands |
KR20200015717A (en) | 2017-06-09 | 2020-02-12 | 프로비던스 헬스 앤드 서비시즈 - 오레곤 | Utilization of CD39 and CD103 for Identification of Human Tumor Reactive T Cells for Cancer Treatment |
GB201709379D0 (en) | 2017-06-13 | 2017-07-26 | Univ Leuven Kath | Humanised ADAMTS13 binding antibodies |
WO2018236904A1 (en) | 2017-06-19 | 2018-12-27 | Surface Oncology, Inc. | Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof |
EP3641752A4 (en) | 2017-06-22 | 2021-03-17 | Moonshot Pharma LLC | Methods for treating cancer with compositions comprising amlexanox and immune modulators |
WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
WO2019005817A2 (en) | 2017-06-26 | 2019-01-03 | Bio-Techne Corporation | Hybridoma clones, monoclonal antibodies to vsig-4, and methods of making and using |
CA3066747A1 (en) | 2017-06-27 | 2019-01-03 | Novartis Ag | Dosage regimens for anti-tim-3 antibodies and uses thereof |
US11169159B2 (en) | 2017-07-03 | 2021-11-09 | Abbott Laboratories | Methods for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood |
WO2019010164A1 (en) | 2017-07-06 | 2019-01-10 | President And Fellows Of Harvard College | Evolution of trna synthetases |
SG10201913147WA (en) | 2017-07-11 | 2020-02-27 | Compass Therapeutics Llc | Agonist antibodies that bind human cd137 and uses thereof |
EP3652211A1 (en) | 2017-07-14 | 2020-05-20 | Pfizer Inc. | Antibodies to madcam |
WO2019018629A1 (en) | 2017-07-19 | 2019-01-24 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection |
EP3431496A1 (en) | 2017-07-19 | 2019-01-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti- isoasp7 amyloid beta antibodies and uses thereof |
US20200172617A1 (en) | 2017-07-20 | 2020-06-04 | Novartis Ag | Dosage regimens of anti-lag-3 antibodies and uses thereof |
WO2019018647A1 (en) | 2017-07-20 | 2019-01-24 | Pfizer Inc. | Anti-gd3 antibodies and antibody-drug conjugates |
CN111492245A (en) | 2017-07-21 | 2020-08-04 | 基因泰克公司 | Methods of treatment and diagnosis of cancer |
MA49690A (en) | 2017-07-28 | 2021-05-19 | Scholar Rock Inc | SPECIFIC INHIBITORS OF THE TGF-BETA 1 LTBP COMPLEX AND THEIR USES |
EP3589658A1 (en) | 2017-08-03 | 2020-01-08 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
CN111164100B (en) | 2017-08-03 | 2024-03-12 | 美国安进公司 | Interleukin-21 muteins and methods of treatment |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to bcma and uses thereof |
WO2019036605A2 (en) | 2017-08-17 | 2019-02-21 | Massachusetts Institute Of Technology | Multiple specificity binders of cxc chemokines and uses thereof |
SG11202000387YA (en) | 2017-08-25 | 2020-03-30 | Five Prime Therapeutics Inc | B7-h4 antibodies and methods of use thereof |
CN111727256A (en) | 2017-09-08 | 2020-09-29 | 波赛达治疗公司 | Compositions and methods for Chimeric Ligand Receptor (CLR) -mediated conditional gene expression |
UY37870A (en) | 2017-09-08 | 2019-03-29 | Amgen Inc | KRAS G12C INHIBITORS AND METHODS TO USE THEM FIELD OF THE INVENTION |
WO2019056002A1 (en) | 2017-09-18 | 2019-03-21 | President And Fellows Of Harvard College | Continuous evolution for stabilized proteins |
TW201922780A (en) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | Safe and effective method of treating Lupus with anti-IL12/IL23 antibody |
WO2019067499A1 (en) | 2017-09-27 | 2019-04-04 | Alexion Pharmaceuticals, Inc. | Biomarker signature for predicting tumor response to anti-cd200 therapy |
JP6496095B1 (en) | 2017-09-29 | 2019-04-03 | 中外製薬株式会社 | Multispecific antigen-binding molecule having blood coagulation factor VIII (FVIII) cofactor function alternative activity and pharmaceutical preparation containing the molecule as an active ingredient |
EP3461841B1 (en) | 2017-10-02 | 2019-09-11 | Certest Biotec, S.L. | Anti-dps antibodies and test devices for the detection of bacteria of the genus campylobacter |
CN111183157A (en) | 2017-10-02 | 2020-05-19 | 威特拉公司 | CD138 antibody molecules and uses thereof |
JP2020536115A (en) | 2017-10-04 | 2020-12-10 | オプコ ファーマシューティカルズ、エルエルシー | Articles and methods for personalized cancer therapy |
WO2019073069A1 (en) | 2017-10-13 | 2019-04-18 | Boehringer Ingelheim International Gmbh | Human antibodies to thomsen-nouvelle (tn) antigen |
US20210198365A1 (en) | 2017-10-19 | 2021-07-01 | Merck Patent Gmbh | Combination product for the treatment of cancer |
US20200331975A1 (en) | 2017-10-20 | 2020-10-22 | Institut Curie | Dap10/12 based cars adapted for rush |
TW201922294A (en) | 2017-10-31 | 2019-06-16 | 美商伊繆諾金公司 | Combination treatment with antibody-drug conjugates and cytarabine |
BR112020008514A2 (en) | 2017-10-31 | 2020-10-20 | Staten Biotechnology B.V. | anti-apoc3 antibodies and methods of using them |
JP7451410B2 (en) | 2017-10-31 | 2024-03-18 | アロジーン セラピューティクス,インコーポレイテッド | Methods and compositions for allogeneic chimeric antigen receptor T cell administration |
US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
KR102559706B1 (en) | 2017-11-01 | 2023-07-25 | 에프. 호프만-라 로슈 아게 | TRIFAB-Contols Body |
JP2021500930A (en) | 2017-11-01 | 2021-01-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | COMP Body-Multivalent Target Binding Substance |
CN111213059B (en) | 2017-11-06 | 2024-01-09 | 豪夫迈·罗氏有限公司 | Diagnostic and therapeutic methods for cancer |
WO2019094595A2 (en) | 2017-11-09 | 2019-05-16 | Pinteon Therapeutics Inc. | Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies |
CN111655288A (en) | 2017-11-16 | 2020-09-11 | 诺华股份有限公司 | Combination therapy |
WO2019100052A2 (en) | 2017-11-20 | 2019-05-23 | Compass Therapeutics Llc | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
CA3083345A1 (en) | 2017-11-27 | 2019-05-31 | Purdue Pharma L.P. | Humanized antibodies targeting human tissue factor |
CA3082442A1 (en) | 2017-11-30 | 2019-06-06 | Genentech, Inc. | Anti-pd-l1 antibodies and methods of using the same for detection of pd-l1 |
WO2019113464A1 (en) | 2017-12-08 | 2019-06-13 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
JP7379165B2 (en) | 2017-12-09 | 2023-11-14 | アボット・ラボラトリーズ | Methods for aiding in diagnosing and assessing traumatic brain injury in human subjects using a combination of GFAP and UCH-L1 |
WO2019113525A2 (en) | 2017-12-09 | 2019-06-13 | Abbott Laboratories | Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1) |
WO2019126536A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals Inc. | Humanized anti-cd200 antibodies and uses thereof |
US20210087267A1 (en) | 2017-12-20 | 2021-03-25 | Alexion Pharmaceuticals, Inc. | Liquid formulations of anti-cd200 antibodies |
PE20201149A1 (en) | 2017-12-21 | 2020-10-26 | Hoffmann La Roche | HLA-A2 / WT1 BINDING ANTIBODIES |
JP2021508246A (en) | 2017-12-21 | 2021-03-04 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | CAR-T cell assay for specificity testing of novel antigen binding moiety |
JP7394058B2 (en) | 2017-12-21 | 2023-12-07 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Universal reporter cell assay for specificity testing of novel antigen-binding moieties |
US20190211098A1 (en) | 2017-12-22 | 2019-07-11 | Genentech, Inc. | Use of pilra binding agents for treatment of a disease |
EA202091540A1 (en) | 2017-12-22 | 2021-03-22 | Джаунс Терапьютикс, Инк. | ANTIBODIES TO LILRB2 |
KR20200104333A (en) | 2017-12-28 | 2020-09-03 | 난징 레전드 바이오테크 씨오., 엘티디. | Single-domain antibodies to TIGIT and variants thereof |
CA3078849A1 (en) | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Antibodies and variants thereof against pd-l1 |
WO2019133512A1 (en) | 2017-12-29 | 2019-07-04 | Alector Llc | Anti-tmem106b antibodies and methods of use thereof |
TW201930344A (en) | 2018-01-12 | 2019-08-01 | 美商安進公司 | Anti-PD-1 antibodies and methods of treatment |
CN111770936A (en) | 2018-01-12 | 2020-10-13 | 百时美施贵宝公司 | Combination therapy of anti-IL-8 and anti-PD-1 antibodies for the treatment of cancer |
EP3740507A4 (en) | 2018-01-15 | 2022-08-24 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against pd-1 |
WO2019143636A1 (en) | 2018-01-16 | 2019-07-25 | Lakepharma, Inc. | Bispecific antibody that binds cd3 and another target |
WO2019152715A1 (en) | 2018-01-31 | 2019-08-08 | Alector Llc | Anti-ms4a4a antibodies and methods of use thereof |
MX2020008183A (en) | 2018-02-01 | 2020-09-22 | Pfizer | Antibodies specific for cd70 and their uses. |
US11396551B2 (en) | 2018-02-01 | 2022-07-26 | Pfizer Inc. | Chimeric antigen receptors targeting CD70 |
WO2019150309A1 (en) | 2018-02-02 | 2019-08-08 | Hammack Scott | Modulators of gpr68 and uses thereof for treating and preventing diseases |
CN111868082A (en) | 2018-02-02 | 2020-10-30 | 博奥泰克尼公司 | Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using the same |
CA3089279A1 (en) | 2018-02-07 | 2019-08-15 | Dana-Farber Cancer Institute, Inc. | Cell-permeable stapled peptide modules for cellular delivery |
MX2020008289A (en) | 2018-02-08 | 2020-09-25 | Genentech Inc | Bispecific antigen-binding molecules and methods of use. |
WO2019157358A1 (en) | 2018-02-09 | 2019-08-15 | Genentech, Inc. | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
TWI829667B (en) | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | Antibodies binding to gprc5d |
BR112020016400A2 (en) | 2018-02-14 | 2020-12-15 | Viela Bio, Inc. | ANTIBODIES FOR THYROSINE KINASE 3 RECEPTOR BINDER SIMILAR TO MCDONOUGH FELINE SARCOMA (FMS) (FLT3L) AND THEIR USES FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES |
GB201802486D0 (en) | 2018-02-15 | 2018-04-04 | Ucb Biopharma Sprl | Methods |
JP7391027B2 (en) | 2018-02-26 | 2023-12-04 | ジェネンテック, インコーポレイテッド | Medication for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies |
JP2021514648A (en) | 2018-03-01 | 2021-06-17 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Specificity assay for novel target antigen binding moieties |
CN111971308A (en) | 2018-03-02 | 2020-11-20 | 戊瑞治疗有限公司 | B7-H4 antibodies and methods of use thereof |
AU2019232624A1 (en) | 2018-03-05 | 2020-09-10 | Janssen Biotech, Inc. | Methods of treating Crohn's disease with anti-IL23 specific antibody |
BR112020017701A2 (en) | 2018-03-12 | 2020-12-29 | Zoetis Services Llc | ANTI-NGF ANTIBODIES AND METHODS OF THE SAME |
MX2020009568A (en) | 2018-03-14 | 2022-03-28 | Surface Oncology Inc | Antibodies that bind cd39 and uses thereof. |
US20200040103A1 (en) | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
WO2019178362A1 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
WO2019178364A2 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
KR20200132938A (en) | 2018-03-15 | 2020-11-25 | 추가이 세이야쿠 가부시키가이샤 | Anti-dengue virus antibodies with cross-reactivity against Zika virus and methods of use |
WO2019183499A1 (en) | 2018-03-22 | 2019-09-26 | Surface Oncology, Inc. | Anti-il-27 antibodies and uses thereof |
WO2019180272A1 (en) | 2018-03-23 | 2019-09-26 | Fundación Instituto De Investigación Sanitaria De Santiago De Compostela | Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases |
JP7331000B2 (en) | 2018-03-26 | 2023-08-22 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | High throughput method for measuring protease activity of complement C3 convertase |
PT3775909T (en) | 2018-03-26 | 2023-07-19 | Glycanostics S R O | Means and methods for glycoprofiling of a protein |
CA3093034A1 (en) | 2018-03-30 | 2019-10-03 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against lag-3 and uses thereof |
JP7104458B2 (en) | 2018-04-02 | 2022-07-21 | 上海博威生物医薬有限公司 | Lymphocyte activation gene-3 (LAG-3) -binding antibody and its use |
PE20201343A1 (en) | 2018-04-02 | 2020-11-25 | Bristol Myers Squibb Co | ANTI-TREM-1 ANTIBODIES AND USES OF THEM |
TW202011029A (en) | 2018-04-04 | 2020-03-16 | 美商建南德克公司 | Methods for detecting and quantifying FGF21 |
CN112424601A (en) | 2018-04-04 | 2021-02-26 | 豪夫迈·罗氏有限公司 | Diagnostic assay for detecting tumor antigens in cancer patients |
EP3775902B1 (en) | 2018-04-04 | 2023-02-22 | F. Hoffmann-La Roche AG | Diagnostic assays to detect tumor antigens in cancer patients |
WO2019200357A1 (en) | 2018-04-12 | 2019-10-17 | Surface Oncology, Inc. | Biomarker for cd47 targeting therapeutics and uses therefor |
US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
AR114789A1 (en) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | ANTI-HLA-G ANTIBODIES AND THE USE OF THEM |
AR115052A1 (en) | 2018-04-18 | 2020-11-25 | Hoffmann La Roche | MULTI-SPECIFIC ANTIBODIES AND THE USE OF THEM |
WO2019207159A1 (en) | 2018-04-27 | 2019-10-31 | Fondazione Ebri Rita Levi-Montalcini | Antibody directed against a tau-derived neurotoxic peptide and uses thereof |
WO2019213384A1 (en) | 2018-05-03 | 2019-11-07 | University Of Rochester | Anti-influenza neuraminidase monoclonal antibodies and uses thereof |
MA52590A (en) | 2018-05-11 | 2021-03-17 | Janssen Biotech Inc | METHODS OF TREATING DEPRESSION USING IL-23 ANTIBODIES |
EP4074732A1 (en) | 2018-05-11 | 2022-10-19 | Wuxi Biologics (Shanghai) Co. Ltd. | Fully human antibodies against ox40, method for preparing the same, and use thereof |
TW202003048A (en) | 2018-05-15 | 2020-01-16 | 美商伊繆諾金公司 | Combination treatment with antibody-drug conjugates and FLT3 inhibitors |
WO2019226658A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Multispecific antigen-binding compositions and methods of use |
JP2021525243A (en) | 2018-05-21 | 2021-09-24 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | Compositions and Methods for Promoting Killing of Target Cells by NK Cells |
TWI816396B (en) | 2018-05-23 | 2023-09-21 | 美商輝瑞大藥廠 | Antibodies specific for gucy2c and uses thereof |
JP7384835B2 (en) | 2018-05-23 | 2023-11-21 | ファイザー・インク | Antibodies specific to CD3 and their uses |
US11319373B2 (en) | 2018-05-25 | 2022-05-03 | Alector Llc | Anti-SIRPA antibodies and methods of use thereof |
UY38247A (en) | 2018-05-30 | 2019-12-31 | Novartis Ag | ANTIBODIES AGAINST ENTPD2, COMBINATION THERAPIES AND METHODS OF USE OF ANTIBODIES AND COMBINATION THERAPIES |
WO2019241649A1 (en) | 2018-06-14 | 2019-12-19 | President And Fellows Of Harvard College | Evolution of cytidine deaminases |
US11830582B2 (en) | 2018-06-14 | 2023-11-28 | University Of Miami | Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents |
CA3102743A1 (en) | 2018-06-18 | 2019-12-26 | UCB Biopharma SRL | Gremlin-1 antagonist for the prevention and treatment of cancer |
BR112020026033A2 (en) | 2018-06-19 | 2021-03-23 | Atarga, Llc | antibody molecules to complement component 5 and uses thereof |
EP3810189A1 (en) | 2018-06-19 | 2021-04-28 | Armo Biosciences, Inc. | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy |
US20210277118A1 (en) | 2018-06-21 | 2021-09-09 | Daiichi Sankyo Company, Limited | Compositions including cd3 antigen binding fragments and uses thereof |
TWI819011B (en) | 2018-06-23 | 2023-10-21 | 美商建南德克公司 | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
US11203645B2 (en) | 2018-06-27 | 2021-12-21 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
BR112020026819A2 (en) | 2018-06-29 | 2021-04-20 | Alector Llc | isolated antibodies, nucleic acid, vector, host cells, method of producing an antibody, pharmaceutical composition, methods for treating cancer and for treating a disease and uses of an antibody |
CN112955465A (en) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | anti-TCR antibody molecules and uses thereof |
WO2020008083A1 (en) | 2018-07-05 | 2020-01-09 | Consejo Superior De Investigaciones Científicas | Therapeutic target in chemokine receptors for the screening of compounds useful for the treatment of pathological processes involving chemokine signaling |
WO2020014460A1 (en) | 2018-07-11 | 2020-01-16 | Scholar Rock, Inc. | HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF |
WO2020014473A1 (en) | 2018-07-11 | 2020-01-16 | Scholar Rock, Inc. | TGFβ1 INHIBITORS AND USE THEREOF |
ES2905160T3 (en) | 2018-07-11 | 2022-04-07 | Scholar Rock Inc | Selective inhibitors of the TGFBeta1 isoform and their use |
TWI809147B (en) | 2018-07-13 | 2023-07-21 | 美商阿列克特有限責任公司 | Anti-sortilin antibodies and methods of use thereof |
WO2020016838A2 (en) | 2018-07-18 | 2020-01-23 | Janssen Biotech, Inc. | Sustained response predictors after treatment with anti-il23 specific antibody |
JP2021530502A (en) | 2018-07-18 | 2021-11-11 | ジェネンテック, インコーポレイテッド | How to Treat Lung Cancer with PD-1 Axial Binding Antagonists, Antimetabolites, and Platinums |
BR112021000934A2 (en) | 2018-07-20 | 2021-04-27 | Pierre Fabre Medicament | receiver for sight |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
JP2021533149A (en) | 2018-08-08 | 2021-12-02 | ジェネンテック, インコーポレイテッド | Use of tryptophan derivatives and L-methionine for protein formulations |
EP4177356A1 (en) | 2018-08-08 | 2023-05-10 | PML Screening, LLC | Methods for assessing risk of developing a viral disease using a genetic test |
WO2020033923A1 (en) | 2018-08-09 | 2020-02-13 | Compass Therapeutics Llc | Antigen binding agents that bind cd277 and uses thereof |
WO2020033925A2 (en) | 2018-08-09 | 2020-02-13 | Compass Therapeutics Llc | Antibodies that bind cd277 and uses thereof |
EP3833442A2 (en) | 2018-08-09 | 2021-06-16 | Compass Therapeutics LLC | Antibodies that bind cd277 and uses thereof |
SG11202101169PA (en) | 2018-08-10 | 2021-03-30 | Eutilex Co Ltd | Chimeric antigen receptor that binds hla-dr and car-t cell |
WO2020032230A1 (en) | 2018-08-10 | 2020-02-13 | 中外製薬株式会社 | Anti-cd137 antigen-binding molecule and utilization thereof |
WO2020041360A1 (en) | 2018-08-21 | 2020-02-27 | Quidel Corporation | Dbpa antibodies and uses thereof |
JP2021534797A (en) | 2018-08-31 | 2021-12-16 | アレクトル エルエルシー | Anti-CD33 antibody and its usage |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
US10899826B1 (en) | 2018-09-13 | 2021-01-26 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for an anti-CGRP antagonist antibody |
AU2019342099A1 (en) | 2018-09-19 | 2021-04-08 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
EP3857230B1 (en) | 2018-09-21 | 2023-06-07 | F. Hoffmann-La Roche AG | Diagnostic methods for triple-negative breast cancer |
EP3883606B9 (en) | 2018-09-24 | 2023-10-04 | Janssen Biotech, Inc. | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
JP7465272B2 (en) | 2018-09-27 | 2024-04-10 | マレンゴ・セラピューティクス,インコーポレーテッド | CSF1R/CCR2 multispecific antibodies |
AU2019349958A1 (en) | 2018-09-28 | 2021-05-06 | Kyowa Kirin Co., Ltd. | IL-36 antibodies and uses thereof |
AU2019352017A1 (en) | 2018-10-03 | 2021-05-06 | Staten Biotechnology B.V. | Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof |
CA3113818A1 (en) | 2018-10-05 | 2020-04-09 | Bavarian Nordic A/S | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist |
CA3115607A1 (en) | 2018-10-11 | 2020-04-16 | Pfizer Inc. | Dosage regimen for tfpi antagonists |
UY38407A (en) | 2018-10-15 | 2020-05-29 | Novartis Ag | TREM2 STABILIZING ANTIBODIES |
WO2020081767A1 (en) | 2018-10-18 | 2020-04-23 | Genentech, Inc. | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
EA202191122A1 (en) | 2018-10-23 | 2021-07-19 | Сколар Рок, Инк. | SELECTIVE TO RGMc INHIBITORS AND THEIR APPLICATION |
GB201817309D0 (en) | 2018-10-24 | 2018-12-05 | Ucb Biopharma Sprl | Antibodies |
GB201817311D0 (en) | 2018-10-24 | 2018-12-05 | Ucb Biopharma Sprl | Antibodies |
AU2019365238A1 (en) | 2018-10-24 | 2021-05-13 | F. Hoffmann-La Roche Ag | Conjugated chemical inducers of degradation and methods of use |
WO2020086408A1 (en) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A high-yield perfusion-based transient gene expression bioprocess |
TW202031899A (en) | 2018-11-05 | 2020-09-01 | 美商建南德克公司 | Methods of producing two chain proteins in prokaryotic host cells |
CA3119968A1 (en) | 2018-11-16 | 2020-05-22 | Memorial Sloan Kettering Cancer Center | Antibodies to mucin-16 and methods of use thereof |
CN113395979A (en) | 2018-11-20 | 2021-09-14 | 詹森生物科技公司 | Safe and effective methods for treating psoriasis with anti-IL-23 specific antibodies |
JP7463366B2 (en) | 2018-11-20 | 2024-04-08 | タケダ ワクチン,インコーポレイテッド | Novel anti-Zika virus antibodies and uses thereof |
SG11202104918PA (en) | 2018-11-20 | 2021-06-29 | Bavarian Nordic As | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
WO2020118011A1 (en) | 2018-12-06 | 2020-06-11 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
MX2021006573A (en) | 2018-12-06 | 2021-07-15 | Genentech Inc | Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody. |
JP2022513198A (en) | 2018-12-10 | 2022-02-07 | ジェネンテック, インコーポレイテッド | Photocrosslinkable peptide for site-specific conjugation to Fc-containing proteins |
EP3897722A4 (en) | 2018-12-18 | 2022-09-14 | Janssen Biotech, Inc. | Safe and effective method of treating lupus with anti-il12/il23 antibody |
AR117453A1 (en) | 2018-12-20 | 2021-08-04 | Genentech Inc | CF OF MODIFIED ANTIBODIES AND METHODS TO USE THEM |
WO2020132214A2 (en) | 2018-12-20 | 2020-06-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof |
CA3124356A1 (en) | 2018-12-20 | 2020-06-25 | Kyowa Kirin Co., Ltd. | Fn14 antibodies and uses thereof |
US20220042038A1 (en) | 2018-12-20 | 2022-02-10 | Poseida Therapeutics, Inc. | Nanotransposon compositions and methods of use |
KR20210106483A (en) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | Extended low-dose regimen for MDM2 inhibitors |
AU2019406712A1 (en) | 2018-12-21 | 2021-06-17 | F. Hoffmann-La Roche Ag | Antibody that binds to VEGF and IL-1beta and methods of use |
EP3898984A1 (en) | 2018-12-21 | 2021-10-27 | Genentech, Inc. | Methods of producing polypeptides using a cell line resistant to apoptosis |
WO2020136060A1 (en) | 2018-12-28 | 2020-07-02 | F. Hoffmann-La Roche Ag | A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response |
CN113227135A (en) | 2018-12-28 | 2021-08-06 | 斯帕克斯治疗公司 | Binding molecules specific for claudin 18.2, compositions and methods thereof for the treatment of cancer and other diseases |
WO2020148651A1 (en) | 2019-01-15 | 2020-07-23 | Janssen Biotech, Inc. | Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis |
MX2021008453A (en) | 2019-01-16 | 2021-08-19 | Compass Therapeutics Llc | Formulations of antibodies that bind human cd137 and uses thereof. |
GB201900732D0 (en) | 2019-01-18 | 2019-03-06 | Ucb Biopharma Sprl | Antibodies |
SG11202106713UA (en) | 2019-01-23 | 2021-07-29 | Genentech Inc | Methods of producing multimeric proteins in eukaryotic host cells |
MA54814A (en) | 2019-01-23 | 2021-12-01 | Janssen Biotech Inc | ANTI-TNF ANTIBODY COMPOSITIONS FOR USE IN METHODS OF TREATING PSORIATIC ARTHRITIS |
WO2020153467A1 (en) | 2019-01-24 | 2020-07-30 | 中外製薬株式会社 | Novel cancer antigens and antibodies of said antigens |
EP3917957A1 (en) | 2019-01-28 | 2021-12-08 | Maple Biotech LLC | Psmp antagonists for use in treatment of fibrotic disease of the lung, kidney or liver |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
BR112021015056A2 (en) | 2019-01-30 | 2022-01-11 | Scholar Rock Inc | Specific inhibitors of tgf-beta ltbp complexes and uses thereof |
US11738050B2 (en) | 2019-02-01 | 2023-08-29 | Regents Of The University Of Minnesota | Compounds binding to fibroblast activation protein alpha |
EP3693063A1 (en) | 2019-02-06 | 2020-08-12 | Diaccurate | Methods and compositions for treating cancer |
EP3696191A1 (en) | 2019-02-14 | 2020-08-19 | Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) | Car t-cells for the treatment of cd1a-positive cancer |
US10871640B2 (en) | 2019-02-15 | 2020-12-22 | Perkinelmer Cellular Technologies Germany Gmbh | Methods and systems for automated imaging of three-dimensional objects |
CA3131014A1 (en) | 2019-02-21 | 2020-08-27 | Andreas Loew | Anti-tcr antibody molecules and uses thereof |
CN114127112A (en) | 2019-02-21 | 2022-03-01 | 马伦戈治疗公司 | Multifunctional molecules that bind to T cells and their use to treat autoimmune disorders |
AU2020226893A1 (en) | 2019-02-21 | 2021-09-23 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
GB2597851A (en) | 2019-02-21 | 2022-02-09 | Marengo Therapeutics Inc | Antibody molecules that bind to NKP30 and uses thereof |
EP3927746A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
WO2020176497A1 (en) | 2019-02-26 | 2020-09-03 | Rgenix, Inc. | High-affinity anti-mertk antibodies and uses thereof |
CA3130695A1 (en) | 2019-02-27 | 2020-09-03 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies |
CN113474653A (en) | 2019-03-08 | 2021-10-01 | 豪夫迈·罗氏有限公司 | Method for detecting and quantifying membrane-associated proteins on extracellular vesicles |
US20200291107A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions |
WO2020183270A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Methods for producing anti-tnf antibody compositions |
US20220153829A1 (en) | 2019-03-14 | 2022-05-19 | Janssen Biotech, Inc. | Methods for Producing Anti-TNF Antibody Compositions |
MA55282A (en) | 2019-03-14 | 2022-01-19 | Janssen Biotech Inc | MANUFACTURING METHODS FOR THE PRODUCTION OF ANTI-TNF ANTIBODY COMPOSITIONS |
CN113853385A (en) | 2019-03-18 | 2021-12-28 | 詹森生物科技公司 | Methods of treating psoriasis in pediatric subjects with anti-IL 12/IL23 antibodies |
US20220169706A1 (en) | 2019-03-28 | 2022-06-02 | Danisco Us Inc | Engineered antibodies |
CA3130862A1 (en) | 2019-03-29 | 2020-10-08 | Genentech, Inc. | Modulators of cell surface protein interactions and methods and compositions related to same |
CN113950355A (en) | 2019-03-29 | 2022-01-18 | 阿塔盖有限责任公司 | Antibody molecules to FGF23 and uses thereof |
CN114364703A (en) | 2019-04-19 | 2022-04-15 | 豪夫迈·罗氏有限公司 | Anti-merk antibodies and methods of use thereof |
MX2021012506A (en) | 2019-04-19 | 2022-01-24 | Chugai Pharmaceutical Co Ltd | Chimeric receptor recognizing modification site of antibody. |
US20220227853A1 (en) | 2019-05-03 | 2022-07-21 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
MX2021013825A (en) | 2019-05-14 | 2022-01-18 | Genentech Inc | Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma. |
US20230085439A1 (en) | 2019-05-21 | 2023-03-16 | University Of Georgia Research Foundation, Inc. | Antibodies that bind human metapneumovirus fusion protein and their use |
JP2022534020A (en) | 2019-05-23 | 2022-07-27 | ヤンセン バイオテツク,インコーポレーテツド | Methods of treating inflammatory bowel disease with combination therapy of antibodies against IL-23 and TNF-alpha |
JP2022534889A (en) | 2019-05-24 | 2022-08-04 | ファイザー・インコーポレイテッド | Combination therapy using CDK inhibitors |
WO2020245677A1 (en) | 2019-06-03 | 2020-12-10 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
WO2020245676A1 (en) | 2019-06-03 | 2020-12-10 | Janssen Biotech, Inc. | Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis |
US20200392229A1 (en) | 2019-06-11 | 2020-12-17 | Alector Llc | Methods of use of anti-sortilin antibodies |
US20200392241A1 (en) | 2019-06-17 | 2020-12-17 | Visterra, Inc. | Humanized antibody molecules to cd138 and uses thereof |
EP3994169A1 (en) | 2019-07-02 | 2022-05-11 | F. Hoffmann-La Roche AG | Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody |
US20220267452A1 (en) | 2019-07-12 | 2022-08-25 | Chugai Seiyaku Kabushiki Kaisha | Anti-mutation type fgfr3 antibody and use therefor |
AR119393A1 (en) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | ANTIBODIES THAT BIND NKG2D |
CN114144436A (en) | 2019-07-24 | 2022-03-04 | H.隆德贝克有限公司 | anti-mGluR 5 antibodies and uses thereof |
WO2021021606A1 (en) | 2019-07-26 | 2021-02-04 | Visterra, Inc. | Interleukin-2 agents and uses thereof |
US11667699B2 (en) | 2019-07-31 | 2023-06-06 | Alector Llc | Anti-MS4A4A antibodies and methods of use thereof |
EP4004045A1 (en) | 2019-07-31 | 2022-06-01 | F. Hoffmann-La Roche AG | Antibodies binding to gprc5d |
SG11202112491WA (en) | 2019-07-31 | 2021-12-30 | Hoffmann La Roche | Antibodies binding to gprc5d |
LT4007777T (en) | 2019-08-02 | 2024-02-12 | Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS) | Car t-cells against bcma for the treatment of multiple myeloma |
TWI780464B (en) | 2019-08-06 | 2022-10-11 | 香港商新旭生技股份有限公司 | Antibodies that bind to pathological tau species and uses thereof |
EP4031658A1 (en) | 2019-08-07 | 2022-07-27 | DB Biotech, AS | Improved horseradish peroxidase polypeptides |
AU2020328507A1 (en) | 2019-08-12 | 2022-03-17 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells |
AU2020329217A1 (en) | 2019-08-12 | 2022-07-28 | Aptevo Research And Development Llc | 4-1BB and OX40 binding proteins and related compositions and methods, antibodies against 4-1BB, antibodies against OX40 |
WO2021028752A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
BR112022003740A2 (en) | 2019-08-30 | 2022-05-31 | Agenus Inc | Anti-cd96 antibodies and methods of using them |
EP4025303A1 (en) | 2019-09-04 | 2022-07-13 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) | Herv inhibitors for use in treating tauopathies |
CN114641501A (en) | 2019-09-04 | 2022-06-17 | Y生物股份有限公司 | anti-VSIG 4 antibodies or antigen binding fragments and uses thereof |
JP2022547866A (en) | 2019-09-05 | 2022-11-16 | ポセイダ セラピューティクス,インコーポレイティド | Allogeneic Cell Compositions and Methods of Use |
CN114340675A (en) | 2019-09-12 | 2022-04-12 | 豪夫迈·罗氏有限公司 | Compositions and methods for treating lupus nephritis |
CN114450024A (en) | 2019-09-16 | 2022-05-06 | 表面肿瘤学公司 | anti-CD 39 antibody compositions and methods |
EP4031578A1 (en) | 2019-09-18 | 2022-07-27 | Novartis AG | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
BR112022004972A2 (en) | 2019-09-18 | 2022-06-28 | Genentech Inc | ANTIBODIES, ISOLATED NUCLEIC ACIDS, ISOLATED HOST CELLS, METHODS OF PRODUCTION OF AN ANTIBODY, OF PRODUCTION OF A BIESPECIFIC ANTIBODY, AND OF TREATMENT OF AN INDIVIDUAL, BIESPECIFIC ANTIBODIES, PHARMACEUTICAL COMPOSITION, ANTIBODY, BIESPECIFIC ANTIBODY OR PHARMACEUTICAL COMPOSITION OF THE ANTIBODY, USE OF A COMBINATION OF THE ANTIBODY AND METHODS TO REDUCE INFLAMMATION AND TO IMPROVE SCALING AND/OR SKIN ERUPTION AND COMBINATION FOR USE |
TW202124446A (en) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | Combination therapies with entpd2 antibodies |
JP2022549218A (en) | 2019-09-20 | 2022-11-24 | ジェネンテック, インコーポレイテッド | Anti-tryptase antibody medication |
US20210115127A1 (en) | 2019-09-25 | 2021-04-22 | Surface Oncology, Inc. | Anti-il-27 antibodies and uses thereof |
JP2022549504A (en) | 2019-09-26 | 2022-11-25 | エスティーキューブ アンド カンパニー | Antibodies specific for glycosylated CTLA-4 and methods of use thereof |
WO2021062085A1 (en) | 2019-09-27 | 2021-04-01 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2021057978A1 (en) | 2019-09-27 | 2021-04-01 | 南京金斯瑞生物科技有限公司 | Anti-vhh domain antibodies and use thereof |
WO2021059075A1 (en) | 2019-09-27 | 2021-04-01 | Janssen Biotech, Inc. | Anti-ceacam antibodies and uses thereof |
WO2021072277A1 (en) | 2019-10-09 | 2021-04-15 | Stcube & Co. | Antibodies specific to glycosylated lag3 and methods of use thereof |
BR112022007216A2 (en) | 2019-10-18 | 2022-08-23 | Genentech Inc | METHODS FOR TREATMENT OF DIFFUSE LYMPHOMA, KIT AND IMMUNOCONJUGATE |
BR112022007179A2 (en) | 2019-10-21 | 2022-08-23 | Novartis Ag | TIM-3 INHIBITORS AND USES THEREOF |
TW202128166A (en) | 2019-10-21 | 2021-08-01 | 瑞士商諾華公司 | Combination therapies |
EP3812008A1 (en) | 2019-10-23 | 2021-04-28 | Gamamabs Pharma | Amh-competitive antagonist antibody |
US11459389B2 (en) | 2019-10-24 | 2022-10-04 | Massachusetts Institute Of Technology | Monoclonal antibodies that bind human CD161 |
JP2022553803A (en) | 2019-11-06 | 2022-12-26 | ジェネンテック, インコーポレイテッド | Diagnostic and therapeutic methods for the treatment of blood cancers |
JP2023503857A (en) | 2019-11-20 | 2023-02-01 | バヴァリアン・ノルディック・アクティーゼルスカブ | Recombinant MVA virus for intratumoral and/or intravenous administration to treat cancer |
GB201917480D0 (en) | 2019-11-29 | 2020-01-15 | Univ Oxford Innovation Ltd | Antibodies |
MX2022007158A (en) | 2019-12-13 | 2022-07-11 | Genentech Inc | Anti-ly6g6d antibodies and methods of use. |
IL293827A (en) | 2019-12-13 | 2022-08-01 | Alector Llc | Anti-mertk antibodies and methods of use thereof |
AU2020406085A1 (en) | 2019-12-18 | 2022-05-26 | F. Hoffmann-La Roche Ag | Antibodies binding to HLA-A2/MAGE-A4 |
AU2020408213A1 (en) | 2019-12-19 | 2022-06-23 | Quidel Corporation | Monoclonal antibody fusions |
GB201919061D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibody |
GB201919058D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibodies |
GB201919062D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
JP2023510121A (en) | 2019-12-20 | 2023-03-13 | ポセイダ セラピューティクス,インコーポレイティド | Anti-Muc1 compositions and methods of use |
CN115052662A (en) | 2019-12-20 | 2022-09-13 | 诺华股份有限公司 | Use of anti-TGF-beta antibodies and checkpoint inhibitors for treating proliferative diseases |
MX2022007840A (en) | 2019-12-27 | 2022-07-19 | Chugai Pharmaceutical Co Ltd | Anti-ctla-4 antibody and use thereof. |
TW202138388A (en) | 2019-12-30 | 2021-10-16 | 美商西根公司 | Methods of treating cancer with nonfucosylated anti-cd70 antibodies |
WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
BR112022011749A2 (en) | 2020-01-06 | 2022-08-30 | Vaccinex Inc | ANTI-CCR8 ANTIBODIES AND THEIR USES |
CN110818795B (en) | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | anti-TIGIT antibodies and methods of use |
CA3166328A1 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
EP4087649A1 (en) | 2020-01-11 | 2022-11-16 | Scholar Rock, Inc. | Tgfbeta inhibitors and use thereof |
TW202140553A (en) | 2020-01-13 | 2021-11-01 | 美商威特拉公司 | Antibody molecules to c5ar1 and uses thereof |
MX2022008772A (en) | 2020-01-14 | 2022-10-07 | Synthekine Inc | Il2 orthologs and methods of use. |
US20230058489A1 (en) | 2020-01-17 | 2023-02-23 | Novartis Ag | Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia |
WO2022050954A1 (en) | 2020-09-04 | 2022-03-10 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
US20230061973A1 (en) | 2020-02-05 | 2023-03-02 | Larimar Therapeutics, Inc. | Tat peptide binding proteins and uses thereof |
JP2023513401A (en) | 2020-02-10 | 2023-03-30 | 上海詩健生物科技有限公司 | Antibodies to claudin 18.2 and uses thereof |
KR20220139357A (en) | 2020-02-10 | 2022-10-14 | 상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드 | CLDN18.2 Antibodies and Their Uses |
TW202144395A (en) | 2020-02-12 | 2021-12-01 | 日商中外製藥股份有限公司 | Anti-CD137 antigen-binding molecule for use in cancer treatment |
WO2021160267A1 (en) | 2020-02-13 | 2021-08-19 | UCB Biopharma SRL | Bispecific antibodies against cd9 and cd7 |
EP4103611B1 (en) | 2020-02-13 | 2024-03-27 | UCB Biopharma SRL | Bispecific antibodies binding hvem and cd9 |
US20230151109A1 (en) | 2020-02-13 | 2023-05-18 | UCB Biopharma SRL | Bispecific antibodies against cd9 |
EP4103610A1 (en) | 2020-02-13 | 2022-12-21 | UCB Biopharma SRL | Anti cd44-ctla4 bispecific antibodies |
US20230151108A1 (en) | 2020-02-13 | 2023-05-18 | UCB Biopharma SRL | Bispecific antibodies against cd9 and cd137 |
BR112022014623A2 (en) | 2020-02-14 | 2022-09-13 | Jounce Therapeutics Inc | ANTIBODIES AND FUSION PROTEINS THAT BIND CCR8 AND USES THEREOF |
US20230220074A1 (en) | 2020-02-18 | 2023-07-13 | Alector Llc | Pilra antibodies and methods of use thereof |
CN115151573A (en) | 2020-02-28 | 2022-10-04 | 上海复宏汉霖生物技术股份有限公司 | anti-CD 137 constructs, multispecific antibodies, and uses thereof |
JP2023516945A (en) | 2020-02-28 | 2023-04-21 | 上海復宏漢霖生物技術股▲フン▼有限公司 | Anti-CD137 constructs and uses thereof |
WO2021176424A1 (en) | 2020-03-06 | 2021-09-10 | Ona Therapeutics, S.L. | Anti-cd36 antibodies and their use to treat cancer |
AU2021232853A1 (en) | 2020-03-10 | 2022-09-22 | Massachusetts Institute Of Technology | Compositions and methods for immunotherapy of NPM1c-positive cancer |
WO2021183795A1 (en) | 2020-03-11 | 2021-09-16 | Poseida Therapeutics, Inc. | Chimeric stimulatory receptors and methods of use in t cell activation and differentiation |
CA3174638A1 (en) | 2020-03-11 | 2021-09-16 | Fundacio Institut De Recerca Contra La Leucemia Josep Carreras | Cd22 targeting-moiety for the treatment of b-cell acute lymphoblastic leukemia (b-all) |
WO2021183849A1 (en) | 2020-03-13 | 2021-09-16 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
CR20220524A (en) | 2020-03-19 | 2022-12-02 | Genentech Inc | Isoform-selective anti-tgf-beta antibodies and methods of use |
MX2022011752A (en) | 2020-03-24 | 2022-10-18 | Genentech Inc | Tie2-binding agents and methods of use. |
EP4126940A1 (en) | 2020-03-30 | 2023-02-08 | F. Hoffmann-La Roche AG | Antibody that binds to vegf and pdgf-b and methods of use |
WO2021202473A2 (en) | 2020-03-30 | 2021-10-07 | Danisco Us Inc | Engineered antibodies |
WO2021202590A1 (en) | 2020-03-31 | 2021-10-07 | Alector Llc | Anti-mertk antibodies and methods of use thereof |
JP2023519930A (en) | 2020-04-01 | 2023-05-15 | ユニバーシティ オブ ロチェスター | Monoclonal Antibodies Against Hemagglutinin (HA) and Neuraminidase (NA) of Influenza H3N2 Virus |
EP4127724A1 (en) | 2020-04-03 | 2023-02-08 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
EP4126064A1 (en) | 2020-04-03 | 2023-02-08 | Visterra, Inc. | Antibody molecule-drug conjugates and uses thereof |
EP4136459A1 (en) | 2020-04-13 | 2023-02-22 | Abbott Laboratories | Methods, complexes and kits for detecting or determining an amount of a ss-coronavirus antibody in a sample |
CA3174777A1 (en) | 2020-04-14 | 2021-10-21 | Eric M. Ostertag | Compositions and methods for use in the treatment of cancer |
US20230192795A1 (en) | 2020-04-15 | 2023-06-22 | Hoffmann-La Roche Inc. | Immunoconjugates |
KR20230028242A (en) | 2020-04-24 | 2023-02-28 | 마렝고 테라퓨틱스, 인크. | Multifunctional molecules that bind to T cell-associated cancer cells and their uses |
IL297541A (en) | 2020-04-24 | 2022-12-01 | Genentech Inc | Methods of using anti-cd79b immunoconjugates |
CN115885050A (en) | 2020-04-28 | 2023-03-31 | 基因泰克公司 | Methods and compositions for non-small cell lung cancer immunotherapy |
US11634477B2 (en) | 2020-04-28 | 2023-04-25 | The Rockefeller University | Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof |
CR20220598A (en) | 2020-04-30 | 2023-01-17 | Genentech Inc | Kras specific antibodies and uses thereof |
JP2023523794A (en) | 2020-05-01 | 2023-06-07 | ノバルティス アーゲー | engineered immunoglobulin |
WO2021220218A1 (en) | 2020-05-01 | 2021-11-04 | Novartis Ag | Immunoglobulin variants |
CN116963782A (en) | 2020-05-03 | 2023-10-27 | 联宁(苏州)生物制药有限公司 | Antibody drug conjugates comprising anti-TROP-2 antibodies |
WO2021226290A1 (en) | 2020-05-05 | 2021-11-11 | 10X Genomics, Inc. | Methods for identification of antigen-binding molecules |
WO2021233834A1 (en) | 2020-05-17 | 2021-11-25 | Astrazeneca Uk Limited | Sars-cov-2 antibodies and methods of selecting and using the same |
WO2021239666A1 (en) | 2020-05-26 | 2021-12-02 | Diaccurate | Therapeutic methods |
US20230220057A1 (en) | 2020-05-27 | 2023-07-13 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing nerve growth factor and uses thereof |
CN116529260A (en) | 2020-06-02 | 2023-08-01 | 当康生物技术有限责任公司 | anti-CD 93 constructs and uses thereof |
JP2023529842A (en) | 2020-06-02 | 2023-07-12 | ダイナミキュア バイオテクノロジー エルエルシー | Anti-CD93 constructs and uses thereof |
EP4158058A1 (en) | 2020-06-02 | 2023-04-05 | 10X Genomics, Inc. | Enrichment of nucleic acid sequences |
WO2021247908A1 (en) | 2020-06-03 | 2021-12-09 | Bionecure Therapeutics, Inc. | Trophoblast cell-surface antigen-2 (trop-2) antibodies |
CA3184495A1 (en) | 2020-06-08 | 2021-12-16 | F. Hoffmann-La Roche Ag | Anti-hbv antibodies and methods of use |
GB202008651D0 (en) | 2020-06-09 | 2020-07-22 | Univ Newcastle | Method of identifying complement modulators |
CN115698719A (en) | 2020-06-12 | 2023-02-03 | 基因泰克公司 | Methods and compositions for cancer immunotherapy |
CN115916182A (en) | 2020-06-16 | 2023-04-04 | 基因泰克公司 | Methods and compositions for treating triple negative breast cancer |
US20210395366A1 (en) | 2020-06-18 | 2021-12-23 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
AU2021297315A1 (en) | 2020-06-24 | 2023-02-02 | Visterra, Inc. | Antibody molecules to APRIL and uses thereof |
CN116390772A (en) | 2020-07-07 | 2023-07-04 | 博泰康医药公司 | Novel maytansine analogs as ADC payloads and their use in cancer treatment |
JP2023534458A (en) | 2020-07-17 | 2023-08-09 | ジェネンテック, インコーポレイテッド | Anti-Notch2 antibody and method of use |
PE20231565A1 (en) | 2020-07-17 | 2023-10-04 | Pfizer | THERAPEUTIC ANTIBODIES AND THEIR USES |
IL299757A (en) | 2020-07-20 | 2023-03-01 | Astrazeneca Uk Ltd | Sars-cov-2 proteins, anti-sars-cov-2 antibodies, and methods of using the same |
CA3185197A1 (en) | 2020-07-21 | 2022-01-27 | Allogene Therapeutics, Inc. | Chimeric antigen receptors with enhanced signaling and activities and uses thereof |
KR20230042032A (en) | 2020-07-21 | 2023-03-27 | 제넨테크, 인크. | Antibody Conjugation Chemical Inducers of BRM Degradation and Methods Thereof |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
WO2022026592A2 (en) | 2020-07-28 | 2022-02-03 | Celltas Bio, Inc. | Antibody molecules to coronavirus and uses thereof |
IL300121A (en) | 2020-07-29 | 2023-03-01 | Dynamicure Biotechnology Llc | Anti-cd93 constructs and uses thereof |
WO2022031804A1 (en) | 2020-08-04 | 2022-02-10 | Abbott Laboratories | Improved methods and kits for detecting sars-cov-2 protein in a sample |
CN116761821A (en) | 2020-08-18 | 2023-09-15 | 赛福伦有限责任公司 | anti-PAR-2 antibodies and methods of use thereof |
CN116761818A (en) | 2020-08-26 | 2023-09-15 | 马伦戈治疗公司 | Method for detecting TRBC1 or TRBC2 |
CA3190755A1 (en) | 2020-08-26 | 2022-03-03 | Andreas Loew | Multifunctional molecules that bind to calreticulin and uses thereof |
KR20230074144A (en) | 2020-08-26 | 2023-05-26 | 마렝고 테라퓨틱스, 인크. | Antibody molecules that bind to NKp30 and uses thereof |
WO2022043558A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
US20230321285A1 (en) | 2020-08-31 | 2023-10-12 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
AU2021339953A1 (en) | 2020-09-11 | 2023-05-18 | Medimmune Limited | Therapeutic b7-h4 binding molecules |
AU2021342349A1 (en) | 2020-09-12 | 2023-05-25 | Medimmune Limited | A scoring method for an anti-b7h4 antibody-drug conjugate therapy |
EP3981789A1 (en) | 2020-10-12 | 2022-04-13 | Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives | Anti-lilrb antibodies and uses thereof |
WO2022081718A1 (en) | 2020-10-14 | 2022-04-21 | Five Prime Therapeutics, Inc. | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof |
AU2021359092A1 (en) | 2020-10-15 | 2023-06-01 | UCB Biopharma SRL | Binding molecules that multimerise cd45 |
US20230382978A1 (en) | 2020-10-15 | 2023-11-30 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods |
CA3190782A1 (en) | 2020-10-20 | 2022-04-28 | F. Hoffmann-La Roche Ag | Combination therapy of pd-1 axis binding antagonists and lrrk2 inhibitors |
WO2022087274A1 (en) | 2020-10-21 | 2022-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies that neutralize type-i interferon (ifn) activity |
JP2023547447A (en) | 2020-10-28 | 2023-11-10 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Improved antigen binding receptor |
KR20230095119A (en) | 2020-11-04 | 2023-06-28 | 제넨테크, 인크. | Dosing for Treatment with Anti-CD20/Anti-CD3 Bispecific Antibodies |
EP4240758A1 (en) | 2020-11-04 | 2023-09-13 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies |
CA3196076A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies |
CA3196191A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
EP4251647A1 (en) | 2020-11-24 | 2023-10-04 | Bio-Techne Corporation | Anti-severe acute respiratory syndrome coronavirus antibodies |
IL303328A (en) | 2020-12-01 | 2023-07-01 | Aptevo Res & Development Llc | Heterodimeric psma and cd3-binding bispecific antibodies |
CA3198161A1 (en) | 2020-12-01 | 2022-06-09 | Beth MCQUISTON | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
WO2023102384A1 (en) | 2021-11-30 | 2023-06-08 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
US20220168293A1 (en) | 2020-12-02 | 2022-06-02 | Pfizer Inc. | Time to resolution of axitinib-related adverse events |
US20240101681A1 (en) | 2020-12-02 | 2024-03-28 | Alector Llc | Methods of use of anti-sortilin antibodies |
TW202237171A (en) | 2020-12-04 | 2022-10-01 | 美商威特拉公司 | Methods of using interleukin-2 agents |
CN116802211A (en) | 2020-12-07 | 2023-09-22 | Ucb生物制药有限责任公司 | Antibodies against interleukin-22 |
US20240067758A1 (en) | 2020-12-07 | 2024-02-29 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations |
WO2022132904A1 (en) | 2020-12-17 | 2022-06-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies targeting sars-cov-2 |
IL303656A (en) | 2020-12-17 | 2023-08-01 | Hoffmann La Roche | Anti-hla-g antibodies and use thereof |
EP4263597A2 (en) | 2020-12-18 | 2023-10-25 | Kiniksa Pharmaceuticals, Ltd. | Protein compositions and methods for producing and using the same |
EP4271998A1 (en) | 2020-12-30 | 2023-11-08 | Abbott Laboratories | Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample |
JP2024502832A (en) | 2020-12-31 | 2024-01-23 | アラマー バイオサイエンシーズ, インコーポレイテッド | Binding agent molecules with high affinity and/or specificity and methods for their production and use |
WO2022148853A1 (en) | 2021-01-11 | 2022-07-14 | F. Hoffmann-La Roche Ag | Immunoconjugates |
JP2024503658A (en) | 2021-01-13 | 2024-01-26 | メモリアル スローン-ケタリング キャンサー センター | Anti-DLL3 antibody-drug conjugate |
US20240115720A1 (en) | 2021-01-13 | 2024-04-11 | Memorial Sloan Kettering Cancer Center | Antibody-pyrrolobenzodiazepine derivative conjugate |
JP2024505636A (en) | 2021-01-15 | 2024-02-07 | ザ ロックフェラー ユニバーシティー | Anti-SARS-COV-2 neutralizing antibody |
WO2022159590A1 (en) | 2021-01-20 | 2022-07-28 | Visterra, Inc. | Interleukin-2 mutants and uses thereof |
JP2024505049A (en) | 2021-01-29 | 2024-02-02 | ノバルティス アーゲー | Administration modes for anti-CD73 and anti-ENTPD2 antibodies and their uses |
US20240117019A1 (en) | 2021-02-09 | 2024-04-11 | University Of Georgia Research Foundation, Inc. | Human monoclonal antibodies against pneumococcal antigens |
JP2024506315A (en) | 2021-02-09 | 2024-02-13 | ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Antibodies that target the coronavirus spike protein |
WO2022182872A2 (en) | 2021-02-24 | 2022-09-01 | Alladapt Immunotherapeutics, Inc. | Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies |
CA3212151A1 (en) | 2021-03-02 | 2022-09-09 | Cgrp Diagnostics Gmbh | Treatment and/or reduction of occurrence of migraine |
JP2024509169A (en) | 2021-03-03 | 2024-02-29 | ソレント・セラピューティクス・インコーポレイテッド | Antibody-drug conjugates including anti-BCMA antibodies |
TW202302645A (en) | 2021-03-03 | 2023-01-16 | 法商皮爾法伯製藥公司 | Anti-vsig4 antibody or antigen binding fragment and uses thereof |
WO2022187440A1 (en) | 2021-03-03 | 2022-09-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | La protien as a novel regulator of osteoclastogenesis |
EP4301472A1 (en) | 2021-03-05 | 2024-01-10 | Dynamicure Biotechnology LLC | Anti-vista constructs and uses thereof |
CA3213278A1 (en) | 2021-03-12 | 2022-09-15 | Janssen Biotech, Inc. | Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody |
KR20230156387A (en) | 2021-03-12 | 2023-11-14 | 얀센 바이오테크 인코포레이티드 | Safe and effective method of treating psoriatic arthritis by anti-IL23 specific antibody |
AR125074A1 (en) | 2021-03-12 | 2023-06-07 | Genentech Inc | ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, ANTI-KLK5/KLK7 MULTI-SPECIFIC ANTIBODIES AND METHODS OF USE |
WO2022198192A1 (en) | 2021-03-15 | 2022-09-22 | Genentech, Inc. | Compositions and methods of treating lupus nephritis |
EP4308606A1 (en) | 2021-03-18 | 2024-01-24 | Alector LLC | Anti-tmem106b antibodies and methods of use thereof |
EP4308935A1 (en) | 2021-03-18 | 2024-01-24 | Novartis AG | Biomarkers for cancer and methods of use thereof |
AU2022236492A1 (en) | 2021-03-18 | 2023-10-26 | Medimmune Limited | Therapeutic binding molecule that binds to ccr9 |
WO2022197877A1 (en) | 2021-03-19 | 2022-09-22 | Genentech, Inc. | Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents |
EP4314063A1 (en) | 2021-03-23 | 2024-02-07 | Alector LLC | Anti-tmem106b antibodies for treating and preventing coronavirus infections |
TW202300648A (en) | 2021-03-25 | 2023-01-01 | 美商當康生物科技有限公司 | Anti-igfbp7 constructs and uses thereof |
WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
EP4067381A1 (en) | 2021-04-01 | 2022-10-05 | Julius-Maximilians-Universität Würzburg | Novel tnfr2 binding molecules |
TW202304979A (en) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
JP2024515591A (en) | 2021-04-08 | 2024-04-10 | マレンゴ・セラピューティクス,インコーポレーテッド | Multifunctional molecules that bind to TCRs and uses thereof |
AR125344A1 (en) | 2021-04-15 | 2023-07-05 | Chugai Pharmaceutical Co Ltd | ANTI-C1S ANTIBODY |
AU2021443863A1 (en) | 2021-04-30 | 2023-10-26 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
KR20240005691A (en) | 2021-04-30 | 2024-01-12 | 에프. 호프만-라 로슈 아게 | Dosage for combination therapy with anti-CD20/anti-CD3 bispecific antibody and anti-CD79B antibody drug conjugate |
JP2024516305A (en) | 2021-05-03 | 2024-04-12 | ユーシービー バイオファルマ エスアールエル | antibody |
WO2022235867A2 (en) | 2021-05-06 | 2022-11-10 | The Rockefeller University | Neutralizing anti-sars- cov-2 antibodies and methods of use thereof |
WO2022236134A1 (en) | 2021-05-07 | 2022-11-10 | Surface Oncology, Inc. | Anti-il-27 antibodies and uses thereof |
BR112023023622A2 (en) | 2021-05-12 | 2024-02-06 | Genentech Inc | METHODS TO TREAT DIFFUSE LYMPHOMA, KITS, IMMUNOCONJUGATES, POLATUZUMABE VEDOTIN AND IMMUNOCONJUGATE FOR USE |
AU2022279156A1 (en) | 2021-05-18 | 2023-11-02 | Abbott Laboratories | Methods of evaluating brain injury in a pediatric subject |
CN113278071B (en) | 2021-05-27 | 2021-12-21 | 江苏荃信生物医药股份有限公司 | Anti-human interferon alpha receptor1 monoclonal antibody and application thereof |
WO2022251446A1 (en) | 2021-05-28 | 2022-12-01 | Alexion Pharmaceuticals, Inc. | Methods for detecting cm-tma biomarkers |
WO2022256313A1 (en) | 2021-06-01 | 2022-12-08 | 10X Genomics, Inc. | Validation of a unique molecular identifier associated with a nucleic acid sequence of interest |
WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
CN117480184A (en) | 2021-06-04 | 2024-01-30 | 中外制药株式会社 | anti-DDR 2 antibodies and uses thereof |
BR112023022097A2 (en) | 2021-06-07 | 2023-12-19 | Agonox Inc | CXCR5, PD-1 AND ICOS EXPRESSING TUMOR-REACTIVE CD4 T CELLS AND THEIR USE |
WO2022261183A2 (en) | 2021-06-08 | 2022-12-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating and/or identifying an agent for treating intestinal cancers |
WO2022258600A1 (en) | 2021-06-09 | 2022-12-15 | F. Hoffmann-La Roche Ag | Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer |
WO2022263357A1 (en) | 2021-06-14 | 2022-12-22 | Argenx Iip Bv | Anti-il-9 antibodies and methods of use thereof |
AU2022293389A1 (en) | 2021-06-14 | 2024-01-04 | Abbott Laboratories | Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind |
WO2022266221A1 (en) | 2021-06-16 | 2022-12-22 | Alector Llc | Monovalent anti-mertk antibodies and methods of use thereof |
WO2022266223A1 (en) | 2021-06-16 | 2022-12-22 | Alector Llc | Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof |
WO2022266660A1 (en) | 2021-06-17 | 2022-12-22 | Amberstone Biosciences, Inc. | Anti-cd3 constructs and uses thereof |
WO2022271867A1 (en) | 2021-06-23 | 2022-12-29 | Scholar Rock, Inc. | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders |
CA3221833A1 (en) | 2021-06-25 | 2022-12-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-ctla-4 antibody |
IL308633A (en) | 2021-06-25 | 2024-01-01 | Chugai Pharmaceutical Co Ltd | Use of anti-ctla-4 antibody |
CA3221281A1 (en) | 2021-06-29 | 2023-01-05 | Seagen Inc. | Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist |
TW202317633A (en) | 2021-07-08 | 2023-05-01 | 美商舒泰神(加州)生物科技有限公司 | Antibodies specifically recognizing tnfr2 and uses thereof |
WO2023281463A1 (en) | 2021-07-09 | 2023-01-12 | Janssen Biotech, Inc. | Manufacturing methods for producing anti-tnf antibody compositions |
IL309997A (en) | 2021-07-09 | 2024-03-01 | Janssen Biotech Inc | Manufacturing methods for producing anti-tnf antibody compositions |
IL309987A (en) | 2021-07-09 | 2024-03-01 | Janssen Biotech Inc | Manufacturing methods for producing anti-il12/il23 antibody compositions |
WO2023285878A1 (en) | 2021-07-13 | 2023-01-19 | Aviation-Ophthalmology | Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions |
WO2023288267A1 (en) | 2021-07-14 | 2023-01-19 | 2Seventy Bio, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
CN115812082A (en) | 2021-07-14 | 2023-03-17 | 舒泰神(北京)生物制药股份有限公司 | Antibody specifically recognizing CD40 and application thereof |
WO2023004386A1 (en) | 2021-07-22 | 2023-01-26 | Genentech, Inc. | Brain targeting compositions and methods of use thereof |
KR20240036570A (en) | 2021-07-22 | 2024-03-20 | 에프. 호프만-라 로슈 아게 | Heterodimeric Fc domain antibodies |
CA3226281A1 (en) | 2021-07-30 | 2023-02-02 | ONA Therapeutics S.L. | Anti-cd36 antibodies and their use to treat cancer |
WO2023012147A1 (en) | 2021-08-03 | 2023-02-09 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use |
US11807685B2 (en) | 2021-08-05 | 2023-11-07 | The Uab Research Foundation | Anti-CD47 antibody and uses thereof |
CA3227511A1 (en) | 2021-08-06 | 2023-02-09 | Lætitia LINARES | Methods for the treatment of cancer |
IL310535A (en) | 2021-08-10 | 2024-03-01 | Byomass Inc | Anti-gdf15 antibodies, compositions and uses thereof |
WO2023019239A1 (en) | 2021-08-13 | 2023-02-16 | Genentech, Inc. | Dosing for anti-tryptase antibodies |
GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
WO2023026205A1 (en) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
WO2023025927A1 (en) | 2021-08-26 | 2023-03-02 | Glycanostics S.R.O | Glycoprotein biomarkers for diagnosing cancer |
TW202325727A (en) | 2021-08-30 | 2023-07-01 | 美商建南德克公司 | Anti-polyubiquitin multispecific antibodies |
WO2023034777A1 (en) | 2021-08-31 | 2023-03-09 | Abbott Laboratories | Methods and systems of diagnosing brain injury |
TW202323289A (en) | 2021-08-31 | 2023-06-16 | 日商大正製藥股份有限公司 | Anti-growth hormone antibody |
CN113683694B (en) | 2021-09-03 | 2022-05-13 | 江苏荃信生物医药股份有限公司 | Anti-human TSLP monoclonal antibody and application thereof |
WO2023031881A1 (en) | 2021-09-03 | 2023-03-09 | University Of Bern | Compositions and methods for treating long qt syndrome |
CN113603775B (en) | 2021-09-03 | 2022-05-20 | 江苏荃信生物医药股份有限公司 | Anti-human interleukin-33 monoclonal antibody and application thereof |
WO2023041565A1 (en) | 2021-09-14 | 2023-03-23 | Glycanostics S.R.O | Use of lectins to determine mammaglobin-a glycoforms in breast cancer |
CA3232420A1 (en) | 2021-09-20 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof |
WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
WO2023056268A1 (en) | 2021-09-30 | 2023-04-06 | Abbott Laboratories | Methods and systems of diagnosing brain injury |
TW202321308A (en) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
AU2022360244A1 (en) | 2021-10-04 | 2024-04-11 | Poseida Therapeutics, Inc. | Transposon compositions and methods of use thereof |
TW202327595A (en) | 2021-10-05 | 2023-07-16 | 美商輝瑞大藥廠 | Combinations of azalactam compounds for the treatment of cancer |
TW202333781A (en) | 2021-10-08 | 2023-09-01 | 日商中外製藥股份有限公司 | Anti-hla-dq2.5 antibody formulation |
WO2023062048A1 (en) | 2021-10-14 | 2023-04-20 | F. Hoffmann-La Roche Ag | Alternative pd1-il7v immunoconjugates for the treatment of cancer |
AU2022362681A1 (en) | 2021-10-14 | 2024-04-04 | F. Hoffmann-La Roche Ag | New interleukin-7 immunoconjugates |
WO2023069421A1 (en) | 2021-10-18 | 2023-04-27 | Byomass Inc. | Anti-activin a antibodies, compositions and uses thereof |
WO2023069919A1 (en) | 2021-10-19 | 2023-04-27 | Alector Llc | Anti-cd300lb antibodies and methods of use thereof |
WO2023073615A1 (en) | 2021-10-29 | 2023-05-04 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
EP4177266A1 (en) | 2021-11-05 | 2023-05-10 | Katholieke Universiteit Leuven | Neutralizing anti-sars-cov-2 human antibodies |
WO2023086807A1 (en) | 2021-11-10 | 2023-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
WO2023086824A1 (en) | 2021-11-10 | 2023-05-19 | 10X Genomics, Inc. | Methods for identification of antigen-binding molecules |
US20230151087A1 (en) | 2021-11-15 | 2023-05-18 | Janssen Biotech, Inc. | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody |
WO2023091887A1 (en) | 2021-11-16 | 2023-05-25 | Genentech, Inc. | Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
US20230159633A1 (en) | 2021-11-23 | 2023-05-25 | Janssen Biotech, Inc. | Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody |
US20230348614A1 (en) | 2021-11-24 | 2023-11-02 | Visterra, Inc. | Engineered antibody molecules to cd138 and uses thereof |
WO2023097119A2 (en) | 2021-11-29 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to modulate riok2 |
TW202333772A (en) | 2021-12-01 | 2023-09-01 | 美商威特拉公司 | Methods of using interleukin-2 agents |
WO2023114978A1 (en) | 2021-12-17 | 2023-06-22 | Abbott Laboratories | Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples |
WO2023122213A1 (en) | 2021-12-22 | 2023-06-29 | Byomass Inc. | Targeting gdf15-gfral pathway cross-reference to related applications |
WO2023118508A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
WO2023129942A1 (en) | 2021-12-28 | 2023-07-06 | Abbott Laboratories | Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan |
US20230322958A1 (en) | 2022-01-19 | 2023-10-12 | Genentech, Inc. | Anti-Notch2 Antibodies and Conjugates and Methods of Use |
WO2023141576A1 (en) | 2022-01-21 | 2023-07-27 | Poseida Therapeutics, Inc. | Compositions and methods for delivery of nucleic acids |
WO2023147399A1 (en) | 2022-01-27 | 2023-08-03 | The Rockefeller University | Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof |
WO2023147107A1 (en) | 2022-01-31 | 2023-08-03 | Byomass Inc. | Myeloproliferative conditions |
WO2023150652A1 (en) | 2022-02-04 | 2023-08-10 | Abbott Laboratories | Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample |
US20230383010A1 (en) | 2022-02-07 | 2023-11-30 | Visterra, Inc. | Anti-idiotype antibody molecules and uses thereof |
WO2023154824A1 (en) | 2022-02-10 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that broadly target coronaviruses |
TW202348252A (en) | 2022-02-16 | 2023-12-16 | 英商梅迪繆思有限公司 | Combination therapies for treatment of cancer with therapeutic binding molecules |
WO2023169896A1 (en) | 2022-03-09 | 2023-09-14 | Astrazeneca Ab | BINDING MOLECULES AGAINST FRα |
WO2023170216A1 (en) | 2022-03-11 | 2023-09-14 | Astrazeneca Ab | A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY |
WO2023175614A1 (en) | 2022-03-15 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof |
US20230414750A1 (en) | 2022-03-23 | 2023-12-28 | Hoffmann-La Roche Inc. | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
WO2023180511A1 (en) | 2022-03-25 | 2023-09-28 | F. Hoffmann-La Roche Ag | Improved chimeric receptors |
US20230312703A1 (en) | 2022-03-30 | 2023-10-05 | Janssen Biotech, Inc. | Method of Treating Psoriasis with IL-23 Specific Antibody |
WO2023192436A1 (en) | 2022-03-31 | 2023-10-05 | Alexion Pharmaceuticals, Inc. | Singleplex or multiplexed assay for complement markers in fresh biological samples |
WO2023192478A1 (en) | 2022-04-01 | 2023-10-05 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
US20230416361A1 (en) | 2022-04-06 | 2023-12-28 | Mirobio Limited | Engineered cd200r antibodies and uses thereof |
GB202205200D0 (en) | 2022-04-08 | 2022-05-25 | Ucb Biopharma Sprl | Combination with chemotherapy |
GB202205203D0 (en) | 2022-04-08 | 2022-05-25 | UCB Biopharma SRL | Combination with inhibitor |
WO2023198727A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
US20240092921A1 (en) | 2022-04-25 | 2024-03-21 | Visterra, Inc. | Antibody molecules to april and uses thereof |
WO2023209177A1 (en) | 2022-04-29 | 2023-11-02 | Astrazeneca Uk Limited | Sars-cov-2 antibodies and methods of using the same |
WO2023215737A1 (en) | 2022-05-03 | 2023-11-09 | Genentech, Inc. | Anti-ly6e antibodies, immunoconjugates, and uses thereof |
WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
WO2023223265A1 (en) | 2022-05-18 | 2023-11-23 | Janssen Biotech, Inc. | Method for evaluating and treating psoriatic arthritis with il23 antibody |
WO2023235699A1 (en) | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2023239803A1 (en) | 2022-06-08 | 2023-12-14 | Angiex, Inc. | Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same |
WO2023250402A2 (en) | 2022-06-22 | 2023-12-28 | Antlera Therapeutics Inc. | Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof |
EP4296279A1 (en) | 2022-06-23 | 2023-12-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti-transthyretin (ttr) binding proteins and uses thereof |
WO2024006876A1 (en) | 2022-06-29 | 2024-01-04 | Abbott Laboratories | Magnetic point-of-care systems and assays for determining gfap in biological samples |
WO2024013727A1 (en) | 2022-07-15 | 2024-01-18 | Janssen Biotech, Inc. | Material and methods for improved bioengineered pairing of antigen-binding variable regions |
WO2024015953A1 (en) | 2022-07-15 | 2024-01-18 | Danisco Us Inc. | Methods for producing monoclonal antibodies |
WO2024020407A1 (en) | 2022-07-19 | 2024-01-25 | Staidson Biopharma Inc. | Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof |
WO2024020564A1 (en) | 2022-07-22 | 2024-01-25 | Genentech, Inc. | Anti-steap1 antigen-binding molecules and uses thereof |
WO2024026447A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Anti-gpnmb antibodies and methods of use thereof |
WO2024026472A2 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
WO2024026471A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
WO2024030829A1 (en) | 2022-08-01 | 2024-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind to the underside of influenza viral neuraminidase |
WO2024030976A2 (en) | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | Compositions and methods for crossing the blood brain barrier |
WO2024050354A1 (en) | 2022-08-31 | 2024-03-07 | Washington University | Alphavirus antigen binding antibodies and uses thereof |
WO2024049949A1 (en) | 2022-09-01 | 2024-03-07 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
WO2024050524A1 (en) | 2022-09-01 | 2024-03-07 | University Of Georgia Research Foundation, Inc. | Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death |
WO2024050526A1 (en) | 2022-09-02 | 2024-03-07 | Biomarin Pharmaceutical Inc. | Compositions and methods for treating long qt syndrome |
WO2024054436A1 (en) | 2022-09-06 | 2024-03-14 | Alexion Pharmaceuticals, Inc. | Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) |
WO2024054929A1 (en) | 2022-09-07 | 2024-03-14 | Dynamicure Biotechnology Llc | Anti-vista constructs and uses thereof |
WO2024054822A1 (en) | 2022-09-07 | 2024-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Engineered sars-cov-2 antibodies with increased neutralization breadth |
WO2024059708A1 (en) | 2022-09-15 | 2024-03-21 | Abbott Laboratories | Biomarkers and methods for differentiating between mild and supermild traumatic brain injury |
WO2024062038A1 (en) | 2022-09-21 | 2024-03-28 | Elthera Ag | Novel binding molecules binding to l1cam |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3853832A (en) * | 1971-04-27 | 1974-12-10 | Harmone Res Foundation | Synthetic human pituitary growth hormone and method of producing it |
US3853833A (en) * | 1971-04-27 | 1974-12-10 | Hormone Res Foundation | Synthetic human growth-promoting and lactogenic hormones and method of producing same |
US4880910A (en) * | 1981-09-18 | 1989-11-14 | Genentech, Inc. | Terminal methionyl bovine growth hormone and its use |
US4593002A (en) * | 1982-01-11 | 1986-06-03 | Salk Institute Biotechnology/Industrial Associates, Inc. | Viruses with recombinant surface proteins |
US4670393A (en) * | 1982-03-22 | 1987-06-02 | Genentech, Inc. | DNA vectors encoding a novel human growth hormone-variant protein |
US4446235A (en) * | 1982-03-22 | 1984-05-01 | Genentech, Inc. | Method for cloning human growth hormone varient genes |
US4673641A (en) * | 1982-12-16 | 1987-06-16 | Molecular Genetics Research And Development Limited Partnership | Co-aggregate purification of proteins |
US4699897A (en) * | 1983-06-04 | 1987-10-13 | Amgen | Biologically active peptides structurally related to regions within growth hormones |
US4888286A (en) * | 1984-02-06 | 1989-12-19 | Creative Biomolecules, Inc. | Production of gene and protein analogs through synthetic gene design using double stranded synthetic oligonucleotides |
US4655160A (en) * | 1985-09-10 | 1987-04-07 | David R. Ligh | Deck box |
US5013653A (en) * | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
IT1223577B (en) * | 1987-12-22 | 1990-09-19 | Eniricerche Spa | IMPROVED PROCEDURE FOR THE PREPARATION OF THE NATURAL HUMAN GROWTH HORMONE IN PURE FORM |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5663143A (en) * | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
AU4308689A (en) * | 1988-09-02 | 1990-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
ATE189526T1 (en) * | 1988-10-28 | 2000-02-15 | Genentech Inc | METHOD FOR DETECTING ACTIVE DOMAIN AND AMINO ACID RESIDUE IN POLYPEPTIDES AND HORMONE VARIANTS |
US5688666A (en) * | 1988-10-28 | 1997-11-18 | Genentech, Inc. | Growth hormone variants with altered binding properties |
US5534617A (en) * | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
US5498538A (en) * | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
US5747334A (en) * | 1990-02-15 | 1998-05-05 | The University Of North Carolina At Chapel Hill | Random peptide library |
US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5723286A (en) * | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5770434A (en) * | 1990-09-28 | 1998-06-23 | Ixsys Incorporated | Soluble peptides having constrained, secondary conformation in solution and method of making same |
DK0564531T3 (en) * | 1990-12-03 | 1998-09-28 | Genentech Inc | Enrichment procedure for variant proteins with altered binding properties |
US5780279A (en) * | 1990-12-03 | 1998-07-14 | Genentech, Inc. | Method of selection of proteolytic cleavage sites by directed evolution and phagemid display |
IE921169A1 (en) * | 1991-04-10 | 1992-10-21 | Scripps Research Inst | Heterodimeric receptor libraries using phagemids |
US5955341A (en) * | 1991-04-10 | 1999-09-21 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
AU685753B2 (en) * | 1992-09-04 | 1998-01-29 | Scripps Research Institute, The | Phagemids coexpressing a surface receptor and a surface heterologous protein |
CA2115811A1 (en) * | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
SE9304060D0 (en) * | 1993-12-06 | 1993-12-06 | Bioinvent Int Ab | Methods to select specific bacteriophages |
US5811093A (en) * | 1994-04-05 | 1998-09-22 | Exponential Biotherapies, Inc. | Bacteriophage genotypically modified to delay inactivations by the host defense system |
EP0760012A4 (en) * | 1994-06-10 | 1997-07-02 | Symbiotech Inc | Method of detecting compounds utilizing genetically modified lambdoid bacteriophage |
US5516637A (en) * | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US5627024A (en) * | 1994-08-05 | 1997-05-06 | The Scripps Research Institute | Lambdoid bacteriophage vectors for expression and display of foreign proteins |
GB9500851D0 (en) * | 1995-01-17 | 1995-03-08 | Bionvent International Ab | Method of selecting specific bacteriophages |
US5702892A (en) * | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
ATE239799T1 (en) * | 1995-09-07 | 2003-05-15 | Novozymes As | DETECTION OF DETERGENT ENZYME ACTIVITY BY PHAGES. |
US5622699A (en) * | 1995-09-11 | 1997-04-22 | La Jolla Cancer Research Foundation | Method of identifying molecules that home to a selected organ in vivo |
US6084062A (en) * | 1996-03-20 | 2000-07-04 | Dyax Corp. | Polypeptides that bind to tissue plasminogen activator (tPA) |
AU3135097A (en) * | 1996-05-22 | 1997-12-09 | Johns Hopkins University, The | Methods of detection utilizing modified bacteriophage |
EP0954531A1 (en) * | 1996-06-06 | 1999-11-10 | Lajolla Pharmaceutical Company | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES |
CA2257873A1 (en) * | 1996-06-10 | 1997-12-18 | The Scripps Research Institute | Use of substrate subtraction libraries to distinguish enzyme specificities |
WO1998005344A1 (en) * | 1996-08-05 | 1998-02-12 | Brigham And Women's Hospital, Inc. | Bacteriophage-mediated gene therapy |
ATE230850T1 (en) * | 1996-10-08 | 2003-01-15 | Bisys B V U | METHOD AND MEANS FOR SELECTING PEPTIDES AND PROTEINS WITH SPECIFIC AFFINITY FOR A TARGET MOLECULE |
-
1991
- 1991-12-03 DK DK92902109T patent/DK0564531T3/en active
- 1991-12-03 WO PCT/US1991/009133 patent/WO1992009690A2/en active IP Right Grant
- 1991-12-03 US US08/050,058 patent/US5750373A/en not_active Expired - Lifetime
- 1991-12-03 ES ES92902109T patent/ES2113940T3/en not_active Expired - Lifetime
- 1991-12-03 DE DE69129154T patent/DE69129154T2/en not_active Expired - Lifetime
- 1991-12-03 EP EP92902109A patent/EP0564531B1/en not_active Expired - Lifetime
- 1991-12-03 CA CA002095633A patent/CA2095633C/en not_active Expired - Lifetime
- 1991-12-03 AT AT92902109T patent/ATE164395T1/en not_active IP Right Cessation
- 1991-12-03 CA CA002405246A patent/CA2405246A1/en not_active Abandoned
-
1995
- 1995-06-05 US US08/463,587 patent/US5821047A/en not_active Expired - Lifetime
- 1995-06-05 US US08/463,667 patent/US5834598A/en not_active Expired - Lifetime
-
1997
- 1997-09-03 US US08/923,854 patent/US6040136A/en not_active Expired - Fee Related
-
1998
- 1998-03-27 GR GR980400652T patent/GR3026468T3/en unknown
-
2005
- 2005-08-08 US US11/199,062 patent/US20060115874A1/en not_active Abandoned
-
2007
- 2007-06-11 US US11/761,180 patent/US20080038717A1/en not_active Abandoned
-
2009
- 2009-07-24 US US12/508,859 patent/US20100035236A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US5821047A (en) | 1998-10-13 |
CA2405246A1 (en) | 1992-06-11 |
ES2113940T3 (en) | 1998-05-16 |
CA2095633A1 (en) | 1992-06-04 |
WO1992009690A2 (en) | 1992-06-11 |
ATE164395T1 (en) | 1998-04-15 |
EP0564531B1 (en) | 1998-03-25 |
US5834598A (en) | 1998-11-10 |
US20060115874A1 (en) | 2006-06-01 |
EP0564531A1 (en) | 1993-10-13 |
US20080038717A1 (en) | 2008-02-14 |
US20100035236A1 (en) | 2010-02-11 |
DK0564531T3 (en) | 1998-09-28 |
DE69129154D1 (en) | 1998-04-30 |
US5750373A (en) | 1998-05-12 |
DE69129154T2 (en) | 1998-08-20 |
GR3026468T3 (en) | 1998-06-30 |
US6040136A (en) | 2000-03-21 |
WO1992009690A3 (en) | 1992-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2095633C (en) | Enrichment method for variant proteins with altered binding properties | |
US5846765A (en) | Identification of novel substrates | |
US5688666A (en) | Growth hormone variants with altered binding properties | |
Lowman et al. | Selecting high-affinity binding proteins by monovalent phage display | |
AU696293B2 (en) | Process for generating specific antibodies | |
EP0600866B1 (en) | Compositions and methods for identifying biologically active molecules | |
EP0397834B1 (en) | Method for identifying active domains and amino acid residues in polypeptides and hormone variants | |
US6214613B1 (en) | Expression screening vector | |
EP1127142B1 (en) | Modulation of polypeptide display on modified filamentous phage | |
US6013478A (en) | Method for identifying active domains and amino acid residues in polypeptides and hormone variants | |
JP4493271B2 (en) | Combinatorial library of proteins having a skeleton structure of C-type lectin-like domain | |
JP2001503131A (en) | Compositions and methods for screening pharmaceutical libraries | |
Gram et al. | Phage display as a rapid gene expression system: production of bioactive cytokine-phage and generation of neutralizing monoclonal antibodies | |
EP0760012A1 (en) | Method of detecting compounds utilizing genetically modified lambdoid bacteriophage | |
JP2006104205A (en) | Human growth hormone variant | |
Martin et al. | Coupling Protein Design andin VitroSelection Strategies: Improving Specificity and Affinity of a Designed β-protein IL-6 Antagonist | |
Wetzel et al. | Mutational analysis of the C-terminus of human interferon-γ | |
JPH08505524A (en) | Soluble peptide having a secondary conformation constrained in solution, and process for producing the same | |
JP3765959B2 (en) | Hormone variant | |
Ku | A combinatorial approach towards molecular recognition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |